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5The word stigma is derived from the Greek word for a mark or a stain. Stigma 
can be described as a dynamic process of devaluation that signi!cantly discredits 
an individual in the eyes of others. Within particular cultures or settings, certain 
attributes are de!ned by others as discreditable or unworthy. When stigma is 
acted upon, discrimination may result. 
 
Stigma related to tuberculosis (TB) is receiving well-deserved attention at 
the policy level.1 Zero suffering is one of the three aims of the WHO’s End 
TB strategy, and stigma is commonly referenced in key implementation 
documents.2–4 The Global Fund has declared it one of the most commonly 
identi!ed barriers to !ghting the TB epidemic,5 and The United Nations agencies 
have called for an end to discrimination in health care.1 People with TB are also 
making their rejection of TB stigma a cornerstone of organizing efforts.6 By 
demanding respect and dignity in health care, employment, education, and the 
justice system, TB survivors and their families are signaling a new era in power 
relations between programs and patients.
We have always acknowledged that TB stigma represented a signi!cant 
challenge, but we have traditionally framed TB stigma as either natural7 and 
intractable3, or easily overcome with a general improvement in quality or access 
to care.8
Recent studies have shown that both frames are inaccurate.9 TB stigma is not 
as unyielding as previously suggested.10 It can be reduced with well-designed 
efforts.10,11 However, stigma does not simply fade away as a result of small 
changes, nor is it a collateral result of improving the clinical standard of care or 
access.6,9
This measurement guidance was born from the deliberations of a three-day 
TB Stigma Measurement Experts meeting in May of 2016 in the Hague, the 
Netherlands, organized by the KNCV Tuberculosis Foundation and supported 
through USAID’s "agship project Challenge TB.12 Attended by over 50 Social 
Scientists, NGOs, donors, and technical partner agencies, the meeting brought 
stakeholders from across the world to debate TB stigma measurement papers 
and to grapple with the best way to de!ne, capture, and report TB stigma in a 
variety of settings and populations. 
Introduction
6Their conclusion was that, with proper guidance, TB stigma measurement can 
be carried out by community-based organizations with research backgrounds 
and national TB program staff.12 Each chapter of this guide attempts to balance 
ambition and pragmatism. It offers step-by-step instructions and limited jargon 
and intuitive graphics. This book and the accompanying curriculum will not make 
readers into TB stigma measurement experts, but will enable users to conduct 
assessments in a timely, systematic, and pragmatic manner according to well-
established research standards.
Many people default to doing surveys when they want to measure attitudes 
or behaviors, but that is not always appropriate with stigma. This manual is 
intended for National TB program staff, implementing agencies, NGOs, CBOs, 
donors, WHO, technical partners, and TB advocates to understand the range 
of options and to make appropriate methodological choices. All of these 
stakeholders may have distinct reasons to measure TB stigma. 
The goal of this manual is to help busy people generate enough information 
about stigma issues to design and monitor and evaluate (M&E) stigma reduction 
efforts. We adhere to some basic M&E principles familiar to many readers. 
This manual is not for academics or theorists, but rather for health workers, 
professional or management staff, people who advocate for those with TB, and 
all who need to understand stigma and respond to TB stigma. 
The guidance is designed to be user-friendly and appropriate for a broad 
audience, and it contains concrete examples and tools that are easy to adapt and 
use. We offer validated tools and strategies where they exist and recommend 
ways to experiment and innovate where they do not. This guide is appropriate 
for planning TB stigma baseline measurements and monitoring trends to capture 
the outcomes of TB stigma reduction efforts. 
Readers should also consult the Companion Curriculum of this manual to fortify 
their skills and core competencies in TB stigma measurement. 
The training materials include exercises and offer more in-depth coverage of 
challenging topics that require strong research skills. The Companion Curriculum 
to this guide can be downloaded here: 
http://www.challengetb.org/publications/tools/ua/TB_Stigma_Companion_
Curriculum.pdf
The curricula include ready-to-use PowerPoints, training exercises, and pre/
post-tests. Like the guidance, it can be used in a modular way (i.e., face to 
face course, webinar, or combined with an M&E workshop). We hope to have 
a training of trainers to create a pool of professionals in each region (activists, 
nurses, providers, and researchers) that can help countries implement these tools.
7How should this book be used?
It is not necessary to read the whole book. Chapters 1 and 2 are suf!cient to 
give an overview, and then read only the chapters that are relevant for the 
particular stigma problem you are measuring. The glossary provides useful 
de!nitions of core concepts. This is a technical guide to help TB programs and 
partners measure levels of TB stigma in speci!c settings and populations. The 
Companion Curriculum is designed to build the skills and core competencies 
in TB stigma measurement that you will need to successfully undertake the TB 
stigma studies recommended in this book. 
Overview of the contents
Chapter 1 introduces readers to stigma theory and some basic de!nitions of 
types of stigma. Chapter 2 (methodology) offers an overview of the scienti!c 
and operational considerations for matching your stigma measurement method 
to your question. Chapter 3 teaches formative qualitative research techniques 
to !nd out why the TB stigma takes a particular form, where the stigma 
comes from, and how stigma operates in your setting. Chapter 4 focuses on 
the measurement of TB stigma at the community level. This chapter details 
special considerations for embedding TB stigma measures in household surveys 
(e.g., scale length), and in settings with concentrated vs. generalized HIV 
epidemics. Chapter 5 focuses on measurement of TB discriminatory attitudes 
and behaviors in institutions such as prisons, schools, and health facilities, and 
has a special focus on measuring enacted TB stigma (discriminatory behaviors) 
through observational methods. The TB stigma literature has focused more 
on discrimination and disparagement of individual TB patients and less on the 
structural forms of discrimination.13–17
Chapter 6 covers the measurement of structural stigma. Chapter 7 teaches the 
basic principles of TB stigma measurement among TB patients. This is a relatively 
well-developed !eld with validated TB stigma scales robust in a variety of 
settings. Nevertheless, there are statistical and sampling challenges that require 
special consideration. Techniques for measuring secondary stigma are introduced 
in Chapter 8. This chapter describes the best practices for measuring stigma 
among healthcare workers (HCW), family members, and those in TB-affected 
industries. HCW stigma measurement is a high priority because HCW are often 
stigmatized for their vital TB care work, and yet may simultaneously mistreat TB 
patients.
Chapter 9 explores how to measure TB stigma among socially networked 
populations who are already marginalized and socially excluded for other 
reasons. It outlines the efforts required to obtain reliable and unbiased estimates. 
State-of-the-art methods for capturing self-stigma, resilience, and self-ef!cacy 
are covered in Chapter 10. It is vital to measure the strengths and forms of 
8resistance of people affected by TB. Documenting how some groups successfully 
de"ect stigma can inform interventions. Chapter 11 teaches how to deconstruct 
the language of TB programs to identify stigmatizing rhetoric and discourse. This 
chapter explores methods for policy analysis to pinpoint stigma embedded in 
norms and guidelines.
Chapter 12 describes how to engage civil society and TB patients meaningfully 
in TB stigma measurement efforts. This text provides useful tips on participatory 
strategies that prevent further stigmatization and ensure dignity. Chapter 13 lays 
out the methodological foundations for incorporating the costs of TB stigma and 
social disadvantage into a cost-effectiveness analysis. Policy and strategy debates 
in TB control may have unintended consequences that should be anticipated. 
Chapter 14 involves intersectional and compound stigmas, such as the double 
stigma of TB/HIV. It is widely understood that TB stigma can be enmeshed 
with other kinds of social exclusions and marginalities. This creates analytical 
challenges that must be managed carefully to prevent bias and confusion. 
Chapter 15 describes how to study the impact of TB on complex behaviors, such 
as health-seeking, adherence, and mortality. This is a !eld of particular interest 
to TB programs seeking to understand the impact of TB stigma on their program. 
Chapter 16 gives concrete advice for those who want to develop and validate 
their own TB stigma scales. Chapter 17 gives step-by-step instructions for 
analyzing qualitative data from formative stigma research.
Table 1. Overview of the Questions Answered in this Book
Research Questions/ Research Topics Chapter
1. How do I meaningfully engage people with TB in 
this work?
Chapters 1, 2, and 14 (Stigma theory, 
Methods, and Advocacy)
2. How does stigma operate in my setting? What are 
the underlying ideas behind this stigma?
Chapter 3 (Drivers)
3. How do I organize a TB stigma study? Chapter 2 (Methods)
4. Does stigma hamper TB screening/diagnosis? Chapter 4 (Measuring TB stigma at the 
Community level)
5. How do healthcare workers experience TB stigma 
when they provide TB services? Does this impact care?
Chapter 8 (Measuring TB stigma among 
healthcare workers)
6. Does stigma hamper the quality and completeness 
of contact and outbreak investigations? Does stigma 
reduce willingness to disclose TB disease to contacts?
Chapter 7 (Measuring TB stigma among TB 
patients) 
7. Does stigma contribute to the erosion of social 
capital and social networks (social impacts)?
Chapters 7 and 10 (Measuring stigma 
among TB patients, Measuring Self-Stigma)
8. Do our laws and policies stigmatize or discriminate? Chapters 6 and 11 (Measuring structural 
stigma and Discourse analysis)
9. How do I measure someone’s discriminatory beliefs 
or actions accurately?
Chapter 5 (Stigmatizing behaviors)
9We invite you to focus on the chapters you need and adapt the tools and 
techniques to your unique setting. There is a companion curriculum to help 
implement the techniques recommended here. In Autumn 2018, KNCV will 
launch a set of TB stigma reduction intervention packages. We invite you to 
share feedback on what you learn to strengthen the global efforts to measure 
and reduce TB stigma.
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10. How do to know if TB stigma is really the cause of 
low health service utilization by key populations?
Chapter 9 (Measuring TB stigma in 
hard-to-reach populations), Chapter 14 
(Intersectional stigma)
11. Does TB stigma contribute to poor adherence 
or treatment outcomes? Does TB stigma hamper 
treatment initiation? 
Chapter 15 (Measuring the impact of 
stigma on treatment adherence)
12. Does TB stigma(s) worsen TB outcomes, via poor 
adherence or loss to follow up? 
Chapter 15 (Measuring the impact of 
stigma on behavior)
13. Is stigma limiting the returns from other TB 
investments? 
Chapter 13 (Measuring the cost of stigma)
14. Does stigma contribute to death and disability? Chapter 15 (Measuring the impact of TB 
stigma on TB mortality)
15. Does stigma contribute to catastrophic costs for 
patients?
Chapter 13 (Measuring the cost of stigma)
16. Are we communicating in ways that stigmatize? Chapter 11 (Discourse analysis for 
measuring TB stigma)
17. Does stigma hamper recovery and long term 
wellness (mental health and quality of life)?
Chapter 10 (Measuring resilience, 
resistance, coping, and countering) 
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Chapter 1
TB Stigma Theory and Measurement
Abstract
There is a science to stigma measurement that brings TB stigma into focus. This 
book will orient the reader to the basics of TB stigma measurement. Mapping 
stigma becomes feasible once its underlying mechanisms are understood. The 
means by which bias and social exclusion are created is well understood. This 
chapter outlines the common architecture upon which different types of bias and 
hate are built by illustrating the basic process of “othering”.
Objectives
1. To explain why we must measure TB stigma, and who should be involved in 
this process. 
2. To introduce the elements of stigma theory.
3. To present a basic typology of stigma.
Target Audience
This chapter is for people intending to measure TB stigma who lack an in-depth 
understanding of stigma theory. It is for community-based organizations, TB 
program staff, M&E of!cers, and others who have not studied discrimination or 
marginalization in an academic setting. 
Introduction
Many experts believe that it will be necessary to address TB stigma in order 
to diagnose and treat the 4 million TB cases that are currently unidenti!ed.1,2 
Similarly, the life-saving potential of new multi-drug resistant TB (MDR-TB), 
pediatric, and latent TB drugs and regimens cannot be realized without !rst 
addressing TB stigma.3
“Defeating racism, tribalism, intolerance, and all forms of discrimination will liberate 
us all, victim and perpetrator alike.” Ban Ki-moon
Kate Macintyre, Ellen M.H. Mitchell, Amrita Daftary, and Gill Craig
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Increasingly, countries are attempting to reduce TB stigma and discrimination 
across and within elements of their TB programs. However, the capacity to 
measure and evaluate the success of these interventions must be fostered 
through capacity building.4–7 
This chapter introduces stigma theory and identi!es and de!nes the basic 
vocabulary of stigma. 
Why do we need to measure TB stigma?
There is increasing recognition that TB stigma continues to be a major barrier for 
some people (patients, families, caregivers, and communities).8–11 
Figure 1 exempli!es how TB stigma delays treatment, hinders recovery, and 
increases the suffering of some people with TB.
Reducing TB stigma to facilitate early diagnosis and full recovery is increasingly a 
priority of national TB programs. Patient groups and groups representing those 
who suffer from the stigma of TB, such as miners and healthcare workers, are 
also calling for concerted efforts to reduce stigma.12,13 
Stigma reduces 
or improves 
health seeking 
behavior
Stigma causes 
stress which 
contributes to 
breakdown to 
disease
Stigma lowers 
MD’s index of 
suspicion for 
some groups
Stigma reduces 
or improves 
health-seeking 
behavior
Stigma undermines 
full recovery and 
sense of self, affects 
contact tracing
Stigma obstructs 
accurate recording 
and reporting - 
impact disease and 
mortality estimatesStigma leads to 
aggressive screening 
in some groups and 
no screening in other 
at-risk communities
Stigma 
undermines the 
patient provider 
partnership
Fear of stigmatization 
reduces use of masks/
separation infection 
control contributing 
to transmission?
Figure 1. Potential Impacts of Stigma along a Person’s TB Care Itinerary or Trajectory
(Artist: Retsu Takahashi).
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Several donors and governments are asking TB programs to further reduce 
barriers to TB services. The Global Fund is asking countries to improve their 
analysis of the human rights barriers to TB services, but some TB programs lack 
the skills necessary to do this.14,15 One of the ways to help these programs is to 
demonstrate how to measure stigma and discrimination to reveal how it impairs 
health care seeking, quality of care, and recovery. 
Participatory approaches to TB Stigma measurement
Participatory research was developed in response to concerns that traditional 
forms of research conferred too much power on researchers to set research 
agendas and provide solutions.5,6 Participatory TB stigma research recognizes 
that communities have expertise in identifying the drivers of stigma and in 
creating solutions.
TB stigma knowledge should thus be co-produced with and co-owned by those 
most affected by TB.5,7 Participatory research aims to democratize the research 
process and challenges traditional power relations in the ‘smash and grab’ 
approaches to research. Historically, research was conducted without involving 
those most affected, and recommendations were made with little sensitivity 
to the impacts of implementation.5,8 Table 1 lists ways to engage people in the 
stigma measurement process.
Table 1. Ways to Engage People with TB in the Stigma Measurement Process 
Participating in Research Managing Research
t Setting the research agenda by deciding on 
topics for research. 
t Sitting on recruitment panels for the 
appointment of research staff.
tActing as researchers/peer researchers 
following training. 
tConducting !eldwork and collecting data. 
tAssisting with the analysis and interpretation 
of data. 
tDevising recommendations. 
tWriting or coauthoring research reports. 
tDisseminating !ndings. 
t Serving as interpreters or cultural ambassadors.
tActing as co-applicants on research proposals.
tChairing or participating in project advisory 
groups/ steering committees. 
tChairing or participating in research 
implementation groups and ethical review 
committees. 
tMonitoring the implementation of 
recommendations.
There are many different ways of conducting participatory research with affected 
communities that go beyond interviews or focus groups. Some have been used 
in the !eld of TB. These are described in Chapter 12. We believe that there is 
plenty of room to incorporate the full range of stakeholders, disciplines, and 
experiences. Diversity can strengthen the process and outcomes as TB stigma 
14
measures are advanced. Survivors, families, friends, caretakers, healthcare 
workers, and other TB-associated occupations also witness and suffer from 
stigma, and stigmatize. Many perspectives are needed to develop comprehensive 
tools.16,17 
Engaging communities in owning the problem of TB stigmas and crafting 
the solutions is essential. The following resources detail how to address the 
challenges associated with engaging communities in this process: 
Van der Werf, Mitchell, and Heumann. Community Engagement in TB 
Research. STOP TB Partnership Research Movement. Community involvement 
in tuberculosis care and prevention. Towards partnerships for health. Guiding 
principles and recommendations based on a WHO review WHO/HTM/
TB/2008.397.
Somesh Kumar. 2002. Methods for Community Participation: A Complete Guide 
for Practitioners London:ITDG
Parks et al. Communications for Social Change Consortium. 2005. Who 
measures change? An introduction to participatory monitoring and evaluation of 
communication for social change.
Available at: http://www.comminit/en/node/70592/347
(Document can be downloaded from a link at the bottom of the web page)
Guy Bessette. Involving the Community: A Guide to Participatory Development 
Communication. http://web.idrc.ca/en/ev-52226-201-1-DO_TOPIC.html
Conceptualizing TB stigma and its measurement
There has been considerable work on measuring TB stigma over the past 20 
years. Link and Phelan’s 2001 publication Conceptualizing Stigma helps in the 
understanding and measurement of TB stigma.18 They show that while the 
process of stigmatization (for multiple conditions or illnesses) is complex, it can 
be untangled by following a clear framework. 
TB Stigma is not natural
Understanding the way that stigma is constructed is important for its 
measurement and reduction. Once thought to be evolutionarily advantageous, 
most theorists now see stigma as a maladaptive social structure.19,20
TB stigma is neither a natural nor inevitable part of having TB.18 It needs to be 
enabled and nurtured to exist.21 Figuring out what ideas, legal, social and cultural 
norms, rhetoric, and routines fuel and sustain particular stigmas requires detailed 
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inquiry. However, there are some hallmarks of stigma production that have been 
de!ned over the years.18,20,22 These include conscious and unconscious processes 
that generate prejudice. They can be envisioned as a series of progressive, 
sequential steps, and conditions under which it may become socially permissible 
to reclassify a person as somehow less valuable.
Link & Phelan give a framework of de!ned components that make up the 
“stigmatizing process” and show that people construct categories around people 
with conditions or differences. These categories then get linked to stereotypical 
beliefs, which can lead to discrimination or other forms of behavior change that 
affect the patient or their family. The different types of stigma are described 
below. The group of sufferers (or patients) that is stereotyped with negative 
attributes either think they are going to be stigmatized, or they are made to feel 
stigmatized. Link and Phelan describe this process in the following way: 
“In our conceptualization, stigma exists when the following interrelated 
components converge. In the !rst component, people distinguish and label 
human differences. In the second, dominant cultural beliefs link labeled persons 
to undesirable characteristics—to negative stereotypes. In the third, labeled 
persons are placed in distinct categories so as to accomplish some degree of 
separation of “us” from “them.” In the fourth, labeled persons experience status 
loss and discrimination that lead to unequal outcomes. 
Effective stigmatization requires power
Finally, stigmatization is highly contingent upon access to social, economic, and 
political power that allows the identi!cation of differentness, the construction 
of stereotypes, the separation of labeled persons into distinct categories, and 
the full execution of disapproval, rejection, exclusion, and discrimination. Thus, 
we apply the term stigma when elements of labeling, stereotyping, separation, 
status loss, and discrimination co-occur in a power situation that allows the 
components of stigma to unfold.”18
Stigmatization, and the discrimination that can result from it, are only possible 
when there are differences in power between the group being stigmatized and 
the so-called mainstream group (the powerful).20 
They use politicians as an example. In many societies, people attach negative 
attributes to “politicians.” But few would consider them to be stigmatized 
because of the in"uence they wield.
Figure 2 shows how stigma creation begins innocuously with the recognition of 
difference, and the gradual insidious process of exaggerating difference to the 
point of dehumanization. Stigma theorists !nd commonalities in this process 
across countries and across stigmatized identities.
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Ghettoize, quarantine
Discriminate
Microaggressive acts
Disparage, malign
Create failure loops
Rationalize, legitimize, normalize 
disparities in access, care, empathy, 
and protection
Render unworthy of consideration, 
investment, or engagement
Blame
Shame 
Punish
Create stereotypes (e.g., dangerous, unpredictable, 
untrustworthy, noncompliant, secretive)
Link to other disparaged groups/identities OR recast 
as "victims" - without agency
Create new language and terms to connote otherness
Medicalize and pathologize difference
Dehumanize
Infantilize
Mark differences 
as "not normal"
Rhetorically
linked to
deviance,
negative traits
Establish
responsibility for 
TB to blame
Curtail rights
and other harms
Emphasize the 
peril of TB to 
normalize 
exclusion
Almost all stigma involves the social construction of dangerousness.22 The social 
creation of a different, dangerous identity creates fear. Generating fear of the 
‘marked’ person is an essential step in creating stigma. Many times this requires 
amplifying or exaggerating the risk that a disease or condition poses to society.23
Unpacking Stigma
To understand TB stigma, the !rst task is to clearly separate stigma drivers, 
domains, and consequences in your mind. This will help you to pose and answer 
the right questions.
Drivers of
TB stigma
Consequences
of TB stigma
Domains
of TB
stigma
Figure 3. Unpacking Stigma
Figure 2. A typical stigma-building Cascade (Link & Phelan)
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These seven domains may sound abstract but when explained in terms of 
TB patients they become recognizable as commonly understood parts of 
stigmatization. 
1. “Social distance” is when someone tries to avoid a person with TB (PWTB).
2. “Traditional prejudice” is when someone stereotypes people with TB believing 
all people with TB are less valuable 
3. “Exclusionary sentiments” refers to the wish to separate PWTB from everyone 
else, or deny them their rights.
4. “Negative affect” refers to emotional reactions such as disgust or hatred 
toward PWTB, 
5. “Treatment carryover” is when people are afraid of people knowing they were 
treated for TB in the past. This is the perceived need for secrecy that may 
linger after a person recovers.
6. “Disclosure carryover” is when people are afraid of the reactions they would 
get if they were known to have TB.
7. “Perceptions of dangerousness”1 is the idea that PWTB somehow represent a 
risk to society.
Domains of Stigma
If you think of stigma as a puzzle, then domains would be the individual pieces 
of the puzzle.
Pescosolido and Martin (2015) identi!ed seven domains of public stigma: 
social distance, traditional prejudice, exclusionary sentiments, negative affect, 
treatment carryover, disclosure carryover and perceptions of dangerousness.1
Figure 4. Common domains of Public Stigma2
Traditional
Prejudice
Perceptions of
Dangerousness
Treatment
Carryover
Exclusionary
Sentiments
Negative
Affect
Disclosure
Carryover
Social
Distance
TB
STIGMA
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Universal and local
Almost all stigmas are made by attaching negative ideas, labels, and behaviors, 
to a person. The process of ‘sticking’ labels onto marked people involves making 
rhetorical links and associations. This can be a conscious or an unconscious 
process. While negative labeling and linking are part of the ‘stigma backbone’ 
all over the world, the speci!c labels, links, and stereotypes vary by context. In 
some communities in Africa, TB is frequently linked to abortion or associated 
transgression of sexual mores.24,25 In Asia, TB can be linked to dependency on 
tobacco and alcohol.26 Among drug users in a treatment program in urban 
Chicago, having TB was rhetorically associated with sel!shness, greed, and a lack 
of street ethics and solidarity.27 People who used drugs who developed TB were 
said to engage in deception, cheating, and failure to uphold community norms 
around drug sharing.27 
Rural
Mozambique
Zambia
Urban
Nepal
Chicago
Being
sel!sh about
sharing drugs
Being
unprincipled
Having
HIV
Having an
abortion
Drinking
AlcoholSmoking
Tobacco
Visiting
Sex
Workers
TB
STEREOTYPES
Figure 5. Illustrative Negative TB Stereotypes by Setting
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De!nition of types of TB stigma and populations to 
measure it
Public stigma describes negative attitudes, beliefs, and behaviors held by the 
wider community or general public. This is closely related to anticipated stigma.
Anticipated stigma (perceived stigma) is the worry that one will be devalued 
after a TB diagnosis. For the person with a TB diagnosis, this is the fear that the 
stigma against the person will be so bad that it affects treatment. It may delay 
people from returning for care, or impact adherence to the prescribed drugs. 
Whether or not stigma actually occurs, anticipated stigma may interfere with 
care seeking and treatment adherence. 
Secondary stigma28 refers to the idea that caregivers, friends, family members, 
or health workers may expect negative attitudes or rejection because of their 
association with the disease and/or TB patients. (See also courtesy stigma). 
Further, this may dictate their behavior or beliefs, regardless of whether the 
stigmatizing attitudes or reactions actually occur.29
 
Internalized or self-stigma captures the idea that individuals may come to 
endorse negative stereotypes, and therefore behave or think according to these 
false portrayals and negative messages.20,30
Enacted or experienced stigma re"ects the range of stigmatizing behaviors, 
messages, and effects that are either directly experienced by the person with TB 
or their families and/or that drive others to acts of discrimination, rejection, or 
isolation. It is useful to distinguish between enacted and experienced stigma as 
two sides of the same coin, either seen from the perspective of the stigmatizer 
(enacted) or the stigmatized (experienced). 
Structural stigma describes the laws, policies, and institutional architecture that 
may be stigmatizing or alternatively protective against stigma. This includes 
“societal level conditions, cultural norms and institutional practices that constrain 
the opportunities, resources, and wellbeing of stigmatized populations.”31,32 
Table 2 highlights the fact that most research to date has focused on those 
on the receiving end of discrimination as opposed to those perpetrating it. To 
reduce stigma, it will be important to focus on understanding the attitudes and 
behaviors of those who stigmatize.
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Table 2. Matrix to Delineate Types of Stigma by Main Population Groups
Population Group Anticipated stigma
Internalized/self
stigma
Enacted or 
experienced stigma 
(≈discrimination)
General Public
(Jaramillo, 1999; Aaron 
M Kipp et al., 2011; 
Murray et al., 2013; Rood, 
Mergenthaler, Bakker, 
Redwood, & Mitchell, 
2017; Van Rie et al., 2008)
(Sagili, Satyanarayana, and 
Chadha 2016)
(Dodor and Kelly 2009; 
Møller et al. 2011)
Vulnerable groups at 
higher risk of TB
(Adams et al., 2017; 
Colvin, 2005, Godfrey-
Fausset, 2002) (Chikovore 
et al. 2017; de Vries et al. 
2017)
(Adams et al. 2017)
Members of TB-
affected families
(Arcêncio et al., 2014)
(Coreil et al. 2010)
(de Almeida Crispim 
et al. 2017; Bond et 
al. 2017; Touso et al. 
2014)
People with TB
(Cremers et al., 2016; 
Murray et al., 2013)
(Jittimanee et al., 
2009; A.M. Kipp et 
al., 2011; Macq, Solis, 
Martinez, & Martiny, 
2008; Somma, 
Gosoniu, et al., 2008)
(Bond et al., 2017; 
Somma, D., et al., 
2008)(Daftary and 
Padayatchi 2012; 
Miller et al. 2017)
Healthcare workers
(Buregyeya et al., 2012; 
Sommerland et al., 2017; 
E Wouters et al., 2017; 
Edwin Wouters et al., 
2016,(Tudor et al. 2013)
(Coreil, Lauzardo, and 
Heurtelou 2012)
(Sommerland et al., 
2017; E Wouters et al., 
2017; Edwin Wouters 
et al., 2016)
(Straetemans, Bakker, 
& Mitchell, 2017)
(Dodor, Kelly, and Neal 
2009; Nottingham and 
User 2009)
Media
(Smith, 2016; Soffer, 
2011a, 2011b)
Moreover, we will need to expand our focus beyond individual bad behavior to 
the societal structures that enable stigma to persist.33
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Conclusion
While we hope this book spurs robust measurement of TB stigma, measurement 
itself is not the goal. We hope to catalyze intervention and prompt additional 
resources to end discrimination and prejudice against people with TB. Moreover, 
only by improving the well-being and quality of life of those at risk for TB, and 
the family and caregivers that surround them, can we reach this aim. Valid 
stigma measurement is necessary to kick-start the kind of transformational work 
that is needed to end TB.
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Chapter 2
Overview of Methodological 
Considerations for Measuring TB 
Stigma 
Ellen M.H. Mitchell, Amrita Daftary, Lisa Redwood, Nadine Ferris France, and Stephen 
H-F Macdonald
Abstract
TB stigma is embedded in social structures, human behavior, and belief systems. 
In addition to a diversity of types of stigma, there are also a wide range of 
vital questions to be answered about its severity, scope, and impact. TB stigma 
measurement methods should be adapted to speci!c goals. This chapter will help 
researchers select the method best suited for their question. 
Objectives
1. To provide an overview of the general principles of TB stigma measurement.
2. To guide readers in assessing their options and selecting the methodology best 
suited to their study aims.
3. To lay out the operational steps and considerations when measuring stigma.
Target audience
This chapter is essential reading for all persons who want to measure TB 
stigma and need an overview of basic principles. TB program staff and non-
governmental organization staff will bene!t from the chapter’s pragmatic and 
stepwise approach to TB stigma measurement.
Introduction
TB stigma is embedded in law text, dialog, behavior, attitudes, and even 
in architecture.1 It includes anticipated and actual discrimination. Crucially, 
it can be measured both from the point of view of the stigmatizer or the 
stigmatized. TB stigma measurement methods should adapt to exercise goals. 
Measuring different manifestations and impacts of TB stigma involves a range 
of data collection and analysis methods, including direct and participant 
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observation, structured and unstructured interviews, discourse analysis, cost-
effectiveness analysis, and non-traditional sampling and statistical approaches. 
Stigma measurement can also be an advocacy effort where primacy is given 
to amplifying compelling narratives and authentic voices. This chapter helps 
researchers to pick the method best suited for their needs and provides general 
advice for stigma measurement efforts.
For some readers with a clinical background, an accessible analogy may be to 
compare the challenges associated with TB stigma measurement to challenges 
associated with TB diagnostics. Different types of TB stigma are analogous to 
different types of TB. Some are easier to detect than others. The challenge is to 
select the methodology that is suf!ciently accurate to assess the type of stigma 
you are looking for within a reasonable time limit and budget. 
Table 1. Analogies between the TB Stigma Studies and the Challenges of TB Diagnoses
Type of Stigma Analogous to Diagnosis of Rationale
Enacted stigma 
against patients
Pulmonary TB in adults
Methods well established, validated 
tools available.
Secondary stigma 
of families and care 
workers
Extra-pulmonary TB
Manifestations vary widely, methods 
not well standardized, few tools.
Self-stigma Childhood TB
Hard to differentiate from other health 
issues, requires skill, experience, 
methods under development.
As with TB, TB stigma tests are not always performed the same way 
in all circumstances. Methods will often require local adaptation. This 
is analogous to ‘calibration’ of laboratory or radiological equipment. 
This chapter introduces standardized operating procedures (SOPS) for 
measuring stigma, which should be adjusted for local conditions.
The methods of stigma measurement vary depending on the goal. Some 
common reasons for measuring stigma include: 
1. Because you want to know whether TB stigma is causing additional 
suffering or sequelae for people with TB (Chapters 7, 10, 15)2
2. Because you want to know if TB patients’ rights are being violated 
(Chapter 6)3
3. Because you wish to discern if TB stigma is deterring health seeking 
generally or for speci!c groups (Chapters 9, 15)4–6
4. Because you want to know if TB stigma is the biggest problem for 
patients, or do they face exclusion due to other stigmas as well. (Chapter 
14)
5. Because you want to know if stigma is causing recruitment or retention 
challenges for healthcare workers (HCW). (Chapter 8)6–8
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It is important to understand why you are measuring TB stigma. This will help 
you to identify the right tools and people to help you. Often you already know 
or suspect TB stigma is a problem, so you plan to do a baseline measurement to 
develop your intervention.
The method of TB stigma measurement should be based on the following 
criteria:
1. The rationale for stigma measurement (see examples above).
2. The inherent potential bias in a particular method.
3. The available resources (e.g., time, expertise, !nancial).
TB stigma can be dif!cult to measure because few people will openly admit 
to discriminating. TB stigma may operate at a subconscious level so typically it 
can be best captured through observations, vignettes, indirect questions, and 
thought experiments. Each method has advantages and disadvantages, which 
are discussed in the chapters that follow. One has to weigh the potential bias 
from self-report in surveys against the potential risk of reactivity (aka observer 
effect)from observational studies. These decisions are consequential and cannot 
be made on scienti!c criteria alone. Often the budgetary resources available for 
reducing stigma are competing against resources for diagnosing and treating 
TB, so feasibility and ef!ciency are critical elements in deciding methodology. 
The majority of scarce resources must go towards stigma reduction, not 
measurement.
Choosing a stigma measurement method
If you seek to measure the “footprint” or extent of stigma, use of locally 
validated scales is necessary. However, surveys seldom provide enough 
information, and may not tell you why TB stigma is a problem or what can 
be done about it. These “how” and “why” questions require a qualitative 
approach.
Figure 1 depicts the cascade of questions that a TB program manager might have 
about TB stigma. Each of these questions lends itself to a different methodology.
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What do you want 
to know about
TB stigma?
How does 'TB stigma'
operate in my setting?
How does 'TB stigma'
operate in my setting?
...across the globe?
(Ch.4,16)
What are the drivers
of TB stigma?
(Ch.3,11,17)
...in health care
settings? (Ch.5)
...in my
community? (Ch.4)
...in TB-affected
families, healthcare 
workers, and
industries? (Ch.8)
...on health-seeking?
(Ch.4)
...on people's
health? (Ch.15)
...in our laws
and policies? (Ch.6)
...in our
discourses? (Ch.11)
...on people's lived
experiences?
(Ch.3,10)
...on investment
decisions (Ch.13)
...among people with
TB (PWTB) and
survivors? ( Ch.7,10)
Why is there so
much TB stigma?
What is the impact 
of all this TB stigma...
Where and how
is TB stigma
embedded?
Qualitative (Ch.3,17)
Figure 1. Matching Method to Mission
Table 2 outlines the situations where quantitative and qualitative methods may 
be applied. It also shows some respective advantages and limitations. We do not 
recommend choosing between them, but rather combining them to leverage 
their respective strengths.
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Table 2. Comparison of Qualitative and Quantitative Methods
Measurement tools to assess TB stigma
When to use Advantages Limitations
Quantitative 
Measuring general prevalence 
and severity of stigma.
1. Easily applied to large 
groups.
2. Easy to train staff to 
administer the tools.
3. Comparisons across 
contexts.
1. Fixed outputs with 
data quality reliant 
on good question 
design.
2. Does not clarify how 
to intervene.
Assessment of stigma levels pre- 
and post-intervention.
Qualitative 
Identifying drivers and core 
beliefs underlying stigma.
1. Can feed into targeted 
survey design. 
2. Flexibility allows for 
the discovery of new 
and unpredicted 
domains.
3. Helps assess and 
design interventions.
1. Dif!cult to apply to 
large groups.
2. Skilled facilitators and 
analysts needed.
3. Comparisons across 
settings may not 
always be possible.
Build understanding of 
stigmatizing mechanism and 
ways to address them.
The full range of TB stigma measurement methods are explored in more detail 
in the chapters that follow. Qualitative techniques, structured observation, and 
participatory approaches are particularly valuable in beginning stigma-reduction 
interventions shortly after measurement.
Operational Issues in Measuring TB Stigma
Here we present an overview of activities and illustrative "ow of workshops 
to develop and implement a TB stigma study. Table 3 includes an illustrative 
timeline, with sequence and approximate duration of the respective activities. 
TB stigma measurement has two phases, a formative qualitative research phase 
and a latter phase where the structured tools and methods are developed and 
applied. A TB stigma study implementation process can be divided into 11 
sequential steps.
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Step Timeline
1. Orientation workshop - Engagement One day
2. Workshop 2: Capacity building methodologies One to two days
3. Formative research (i.e., qualitative !eld work) One to two months
4. Workshop 3: Selection of stigma domains Two to three days
5. Workshop 4: Construction of TB stigma methodology Two to !ve days
6. Protocol development Two to !ve days
7. Field testing of TB stigma measure Two weeks
8. Workshop 5: Revise method based on pilot results Two to !ve days
9. Study Implementation Two to six months
10. Workshop 6: Analysis Five to seven days
11. Workshop 7: Results dissemination and development of action plan Two days
Table 3. Overview of Activities to Develop a Valid TB Stigma Measure
STEP 1. Community engagement and stakeholder 
mobilization
The !rst step in planning involves a dialog with the national health authorities, 
research bodies, technical partners, and activists and advocates to create political 
commitment, co-ownership, and shared expectations of stigma measurement. 
It is important to involve NTP managers, Ministry of Health representatives, 
and members of affected communities in study design, measurement, and data 
analysis. Without their input, the whole process will have limited impact.
Methods of involving these partners include:
tHold a stakeholders orientation workshop.
t Establish a diverse TB stigma measurement committee. De!ne roles and 
responsibilities in writing, including its composition, terms of reference, and 
frequency of meetings.
t Include a TB stigma measurement activity in the national TB strategy, concept 
note, or project work plan.
tDevelop a costed operational plan in close collaboration with all partners.
Engaging communities in identifying TB stigma and the searching for solutions 
is very important. A participatory approach to stigma measurement is very 
helpful. For hints on how to address the challenges this entails, see the following 
resources: 
Van der Werf, Mitchell, and Heumann. Community Engagement in TB 
Research. STOP TB Partnership Research Movement .Community involvement 
in tuberculosis care and prevention. Towards partnerships for health. Guiding 
principles and recommendations based on a WHO review WHO/HTM/
TB/2008.397.
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Somesh Kumar (2002) Methods for Community Participation: A Complete Guide 
for Practitioners London:ITDG
Parks et al. Communications for Social Change Consortium. 2005. Who 
measures change? An introduction to participatory monitoring and evaluation of 
communication for social change.
Available at http://www.comminit/en/node/70592/347
(Document can be downloaded from a link at the bottom of this page)
Guy Bessette. Involving the Community: A Guide to Participatory Development 
Communication. http://web.idrc.ca/en/ev-52226-201-1-DO_TOPIC.html 
http://web.idrc.ca/en/ev-52226-201-1-DO_TOPIC.html
STEP 2. Formative research 
A formative research workshop should be held at the outset. The objectives of 
the workshop are to:
t Familiarize participants with qualitative research and methodology.
t Build skills in qualitative data collection techniques.
tDevelop topic guides for focus group discussions and in-depth interviews.
tDevelop formative SOPS and protocols. 
The study team is oriented on basic TB stigma terms, concepts, and jargon. It 
is essential to have a general consensus on what stigma is before studying it in 
depth. Study staff need basic stigma theory to be able to differentiate among:
tActionable Drivers of TB stigma.
tManifestations of TB stigma.
t Facilitators of TB Stigma.
The workshop should consist of interactive introductory sessions on qualitative 
research issues and group work to develop the proposal. The participants 
should become familiar with research ethics, in-depth interviews, focus group 
discussions, and observation methods. If participants have some social science 
background, plan a one or two-day event. If they do not, plan for a three to 
!ve-day workshop. (See Chapter 3 for formative research methods).
STEP 3. Qualitative !eldwork to study stigma drivers 
and domains 
Chapter 3 has detailed steps on ways to unpack stigma. A range of qualitative 
methods are needed to identify how stigma manifests locally, what sustains it, 
how it operates, and where it ‘lives’. Formative stages should minimally include 
the literature review and some qualitative research (focus group discussions, 
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in-depth interviews, participant observation). How much formative research is 
needed depends on how much is already known about TB stigma in the context.
STEP 4. Workshop 2 to analyze the data and select TB 
stigma domains
A thematic analysis is one in which data are sifted to identify words, themes, 
behaviors, to develop potential items for a structured instrument. Each transcript 
has to be coded and analyzed to draw out the themes, terms, framings, and 
attributions. Data analysis involves triangulation of data from different sources. 
Chapter 17 offers step-wise guidance on how to analyze speci!c types of 
qualitative data. Once the data are organized into themes and patterns, it is 
possible to interpret meanings and derive a conceptual framework of TB stigma 
for that population, and build skills in data analysis techniques.
Salient behaviors, terms, phrases, and frames from the transcripts have to be 
identi!ed and used in the analysis. The data are analyzed in a participatory 
workshop involving all members of the study teams. The results are used to 
develop a quantitative instrument to measure TB stigma. 
STEP 5. Workshop 3 to choose study methodology and 
draft instruments
The main objective of this workshop is to decide on a study methodology and 
mode of data collection (observation vs. self-report, online vs. in person, self-
administered vs. interview, digital vs. paper, etc.) 
Many people default to doing surveys when they want to measure stigma. 
However, the choices are much broader and indeed the strengths and limitations 
of each merit a thorough debate. Figure 2 provides examples of the decisions 
that must be made at this stage.
How does 'TB stigma'
operate in my setting?
...across the globe
(Ch.4,16)
...in health care
settings? (Ch.5)
...on health-seeking?
(Ch.4)
...on people's
health? (Ch.15)
...in our laws
and policies? (Ch.6)
...in our
discourses? (Ch.11)
...in our laws
and policies? (Ch.6)
...in our
discourses? (Ch.11)
Why is there so
much TB stigma?
...in our laws
and policies? (Ch.6)
...in our
discourses? (Ch.11)
Why is there so
much TB stigma?
What is the impact 
of all this TB stigma...
Where and how
is TB stigma
embedded?
Method
Observation
Self-report
Online
Individual
Group
Self-
administered
Interview
Digital
Paper
Video
Oral
Written
Mode? Means? Data? Consent?
Figure 2. Illustrative Methodological Choices 
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Issues to discuss include:
tHow reliable are self-reports of discriminatory acts, and how can they be queried 
without being accusatory or offensive?
tHow does one craft observational tools to minimize bias reactivity due to being 
observed?
tDo patients prefer to answer quantitative questionnaires in a group setting, or as 
individuals?
tDo groups increase the risk of their conferring or agreeing on responses instead 
of giving their own personal answers? Are con!dential interviews or group 
discussions more suitable?
People who have had TB have lived experience and practical knowledge of 
how stigma manifests and how it can be discussed. People from the National 
TB Program are also helpful, and they can keep the study grounded in national 
practice and policy. Often stigma researchers from other !elds (e.g., mental health, 
substance use) add value, but they should have a !rm understanding of TB. 
Developing the !rst draft of TB stigma measurement 
tools
Once a method is chosen, the TB stigma measurement tools are drafted. The 
research !ndings from the formative phase should be used to inform a !rst draft of 
TB stigma measurement. 
If you do a survey, you may combine a mix of validated sub-scales with new items 
derived from your formative research. Existing TB stigma scales and instruments are 
described in Chapters 4, 5, 7, 8, and 10. These chapters help you decide between 
the range of methodological options and questions to consider, including:
tWhat actions am I trying to measure speci!cally? How are we de!ning 
discrimination? Shaming? Blaming? Stereotyping?
tAre they more comfortable answering questions in the !rst-person or third-
person? (e.g., “I feel ashamed” may be changed to “Some people feel 
ashamed”) 
tAre questions worded appropriately to elicit the correct responses and avoid 
bias?
tHow should you take into local idiom and cultural interpretations if implementing 
across diverse regions?
tHow can you balance negatively and positively worded items?
tWhat is the best "ow of stems and items?
tHow can you best prepare a research plan for !eld testing, with an adequate 
pilot sample size and data entry templates?
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STEP 6. Writing a protocol, SOPs and undergoing ethical 
review 
For each data collection method, there are unique sampling, staf!ng, and ethical 
issues to consider. 
Statistical formulas sample size calculations for different study designs are explained 
in Chapters 4, 7, and 9. Ensure social validity by engaging TB-affected people in 
protocol development. Ensure content validity by basing the measures on thorough 
qualitative/formative research, and ensure construct validity by engaging suf!cient 
social scienti!c and statistical experts. TB stigma measurement may involve risk 
of social harms for the people observed, interviewed, or surveyed, and these risks 
should be mitigated. Informed consent processes have to be developed. A thorough 
ethical review helps ensure protection for participants and investigators alike. 
STEP 7: Piloting of TB stigma methodology and 
measurement
The research team, under the guidance of social scientists, should train research 
assistants to administer the measurement instrument. Training and SOP guidelines 
are necessary. Data collectors will need speci!c skills depending on the type of TB 
stigma and where it is being measured. They will need suf!cient training and practice 
to succeed. During this period, it is important to:
t Pre-test with cognitive interviewing to explore understanding, feasibility, and 
translation. 
t Pre-test ethics and informed consent.
t Pre-test all aspects of data collection, data management, and security.
STEP 8. Revision workshop to address pilot results 
At this stage, it is important to use the pilot data in order to:
tConduct reliability testing (scaling) and validation through correlation, factor 
analysis, and data reduction of any scales. (See Chapter 16 for more on scale 
validation).
tAdjust the instruments and SOPs.
tRe-train the data collectors if inter-rater reliability is low or ethical lapses occur.
If surveys using scales are being developed, the piloting (validation) is very formal. 
Chapter 16 explains these steps in detail. Participants who are familiar with statistical 
concepts, statistical software, and techniques such as correlation analysis, factor 
analysis and data reduction (scaling) require three to !ve-days. If experienced local 
statisticians are not available, the workshop should be !ve to seven-days, and 
external technical assistance is recommended. 
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STEP 9: Implementation 
Once the methods and tools are deemed robust, they can be applied with the 
population of interest in the chosen settings. 
STEP 10: Analysis and dissemination
Analysis should be conducted immediately, and results shared widely. Participants 
who are familiar with correlation analysis and factor analysis may require as little 
as three to !ve days to do the analysis. If the local team needs more support, 
a longer workshop of !ve to seven days (with external technical assistance) is 
recommended. Typically, an additional two-weeks is needed to write-up the 
results.
STEP 11: Action plan 
The results should be used to set priorities for stigma reduction. Dissemination 
can begin by organizing a meeting, with representation from TB patients, the TB 
program, health service providers, their managers, and community leaders, to 
discuss feedback on the interviews, set priorities, and to formulate interventions 
to address the problems.
An action plan will need to set intervention priorities. If several interventions 
have been proposed, but not all can be implemented, additional selection criteria 
can be used for further prioritization. 
The action plan needs to include the following components: 
t Intervention topic;
tReasons why this intervention is believed to be successful;
t Intervention objective; 
t Theory of change (conceptual framework, logic model);
t Strategies;
tActivities; projects;
t Team members (champions, early adopters, M&E);
t Time frame for implementation;
t Financial, material, and human resources required; and
t Indicators for monitoring and evaluating change.
All TB stakeholders can play a role in implementing the action plan. 
tCommunity members can support and monitor the implementation of the 
change process in facilities and provide feedback on local perceptions of the 
changes. 
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tActivists can hold stakeholders accountable for changes and push for scale-up 
of successful efforts.
tNational, regional, and international decision-makers support these changes 
in health delivery practices. They act as matchmakers, marrying effective 
practices for clinical and programmatic work and strategies for implementing 
change and scale-up.
tResearchers can help to resolve issues revealed by the study.
tClinicians apply effective practices to save lives and reduce the impact of 
stigma on treatment experiences. 
tMid-level managers can lead and champion changes in health delivery 
practices. 
t Senior management needs to visibly support the changes and those who are 
leading the change process.
tMembers of the legal community can push for an end to discriminatory laws 
and policies. 
Conclusion
Measuring different manifestations and impacts of TB stigma can involve a 
range of methods, including directed and participant observation, structured 
and unstructured interviews, discourse analysis, cost-effectiveness analysis, and 
non-traditional sampling and statistical approaches. The subsequent chapters 
introduce readers to these methods and help clarify how to choose among them.
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Chapter 3
Qualitative Methods for Identifying 
Domains (roots) of TB Stigma
Amrita Daftary, and Gill Craig
Abstract
This chapter offers guidance on how to do formative research using qualitative 
methods to unpack the drivers (causes) and dimensions (forms) of TB stigma. 
Formative research must be conducted prior to any survey or other structured 
stigma measurement.
Objectives
1. To understand the role and relevance of qualitative methods in TB stigma 
assessment
2. To learn how to deconstruct (unpack) the drivers (causes) and dimensions 
(forms) of TB stigma 
3. To be aware of ethical considerations, limitations, and challenges of qualitative 
methods
Target Audience
This chapter is for anyone seeking to understand how stigma operates and 
wishing to understand the ideas that nurture and sustain it in different settings. 
People without a social science background will bene!t from the comprehensive 
explanation of why and how to engage people in talking about stigma.
Introduction
Context is key to understanding, assessing and measuring TB stigma. Individual, 
patient, household, family, community, economic, historical, socio-political, 
health facility, and health systems circumstances collectively illuminate why, how 
and in what forms stigma is perceived, experienced and understood by particular 
39
populations in particular settings. Qualitative research methods can help us 
to understand these varied contexts in a more nuanced and deeper way. This 
chapter offers guidance on how to use qualitative methods to conduct formative 
studies that unpack the drivers (causes) and dimensions (forms) of TB stigma. 
 
The social dimensions of TB stigma
Although stigma is often conceived of at the individual level, tied to a particular 
immutable characteristic such as infectivity of the TB bacillus, it is important 
to recognize its mutable social dimensions. For instance, TB is stigmatized due 
to its relative deviance from that which is considered to be normal. But the 
assumptions or norms that govern what is acceptable (normal) or unacceptable 
(abnormal) are created by society and not by individuals alone.31 Stigma 
may thus be encountered in multiple ways, ways that may coexist and be 
contradictory. An act or symbol that is stigmatizing to one person or community 
may be perceived or experienced in an entirely different way by another. For 
example, healthcare workers may wear face masks to protect themselves and 
consider this action to be normal, but PWTB may perceive it to be exclusionary 
and stigmatizing. Once on treatment, people with TB usually recover, their visible 
symptoms fade and they may more easily pass as normal14 – experienced stigma 
may fade with or without commensurate changes in self or internalized stigma. 
When developing a stigma measurement scale, these contextual considerations 
are key to scale validity and analysis. A qualitative approach is the optimal way 
to deconstruct the local drivers (causes) and dimensions (forms) of TB stigma, or 
what we refer to as the TB stigma complex (see Figure 1).
Figure 1. Deconstructing the Stigma Complex
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Structural
Health System Structural
Public
Anticipated
Courtesy
Experienced
Community
Individual
METHODS DIMENSIONS
DATA COLLECTION
DATA SOURCES
Interviews, focus groups, document
reviews, participatory approaches,
observations
TB patients, community members
and gatekeepers, ex-patients,
family members, TB caregivers,
community health workers, nurses,
doctors, informal practitioners,
treatment supporters, program
managers, policy-makers
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Qualitative methods to identify the dimensions and 
drivers of TB stigma
A qualitative approach is grounded in the experience and perspectives of those 
most intimately affected, that is, the persons who perceive and experience 
stigma as well as the persons, communities, interactions, and contexts that 
produce and sustain stigma. We summarize its tenets in Table 1. We then offer 
guidance on main steps in the design and implementation of qualitative studies 
aimed to identify the drivers and dimensions of TB stigma.
Table 1. Tenets of qualitative methods
Premise
There are multiple ways of building and sustaining TB stigma and these operate 
consciously and unconsciously
Goal
To explore how TB stigma is produced and sustained (social construction); to 
understand its drivers (causes) and dimensions (forms)
Researcher(s) Situated and re"exive, fair dealing (non-judgmental)
Sample
Purposive samples (principle of maximum variation to gain diverse perspectives); 
with those who directly experience, perceive or produce TB stigma (e.g., people 
with TB, persons considered to be at risk for TB, community members, providers) 
Approach
Semi-structured, open-ended questioning and probing; "exible, spontaneous, 
iterative and analytic approaches; participatory approaches
Data collection
Interviews; focus groups; observations; document review; ethnography; 
participatory techniques (e.g., theater, diaries, photography, action-oriented 
community groups, use of visual aids, charting, ranking)
Data format Textual (audio and video transcripts, !eld notes), non-numerical
Analysis
Staying close to the data but does not accept it at face value; drawing on 
participants’ own words before developing higher order constructs; moving 
beyond descriptive (realist) summaries to in-depth (critical) interpretations
Asking a formative research question
Qualitative studies to discover the drivers and dimensions of TB stigma are 
primarily exploratory. As far as possible, the approach to deriving root causes of 
stigma should be broad and devoid of assumptions. 
Although qualitative researchers start off with a research question there is 
"exibility in tailoring the research questions, as the open-ended nature of 
qualitative inquiry allows for interesting issues to arise that had not been initially 
considered. Indeed, many qualitative studies that report on TB stigma have 
begun with research questions that were not focused on stigma (including 
studies described in Table 2). Findings related to TB stigma were incidental – 
an unanticipated discovery while addressing a distinct research problem, for 
example, to examine the lived experience of people with TB or challenges to TB 
health care seeking more broadly. 
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Selecting and recruiting samples 
The strength of qualitative data comes from its richness and ability to tap 
into new and unanticipated areas of interest through in-depth inquiry with 
“information-rich” [Patton 1990; p169] participants.40 In studies seeking to 
identify the drivers and dimensions of TB stigma, this includes a wide range 
of people with detailed knowledge of or direct experience with TB stigma, as 
well as persons who may not directly encounter TB stigma to understand its 
buffers and hidden drivers. See Chapter 1 and Chapter 12 on how to engage 
populations in the design and implementation of stigma studies.
Table 2: Samples to Consider for Unpacking Speci!c Drivers of Stigma
Types of 
Stigmas
Whom to interview
Illustrative empirical qualitative studies 
and normative papers
Structural 
Policy makers, government of!cials, 
journalists, bureaucrats, people with TB/
communities affected by TB
Coreil et al. 2010; Farmer 1996; 
Farmer 19972-4 
Public stigma 
Persons deemed to be ‘at risk’ for TB 
(e.g., migrant mine workers in sub-
Saharan Africa, slum dwellers in South 
Asia, homeless persons in North America).
Daftary et al. 2007; Macq et al. 
2005; Ngamvithyapong et al. 2000; 
Senthilingham et al. 2015; Waisbord 
20075-9
Enacted TB 
stigma against 
people with TB 
(e.g. people) 
People with TB, service providers 
(e.g., nurses, doctors, social workers, 
counsellors, community case/!eld 
workers),
Bond & Nyblade 2006; Daftary & 
Padayatchi 2012; Daftary 2015; Kelly 
1999,10-13
Self-stigma People with TB
Secondary 
stigma
Caregivers, TB care providers, persons 
deemed to be ‘at risk’ for TB service 
providers (e.g., nurses, doctors, social 
workers, counsellors, community case/
!eld workers),
Baral 2007, Buregyeya, 2012, Adams 
et al 2017
Compound 
stigmas in key 
populations 
affected by TB
People with TB, persons deemed to be ‘at 
risk’ for TB (e.g., smokers, slum dwellers 
homeless persons, HIV),
Atre et al. 2004; Atre et al. 2011; 
Chikovore et al. 2014; Craig et al. 
2007; Gosoniu et al. 2008; Hayes-
Larson et al. 2017; Moller et al. 2007; 
Moller at al. 2011; Ngamvithyapong 
et al. 200010,14-22 Daftary 2012
MDR-TB 
stigma
People with MDR-TB, Caregivers
Daftary 2014; Daftary & Padayatchi 
2016; Engel 2013; Senthilingham 
20158,12,23,24
Drivers of TB 
stigma across 
varied contexts 
and dimensions
Board members of local, national and 
international guideline/recommendation 
committees and advisory groups). 
Baral et al. 2007; Craig et al. 2016; 
Courtwright & Turner 2010; Coreil et 
al. 20102,25-27
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Qualitative sampling is purposive rather than random.1,38 Purposive sampling 
is a type of non-probability sampling where the researcher selects participants 
according to speci!c characteristics of interest at the study outset.41,42 For 
example, in order to understand why patients are failing to attend clinic 
appointments at a newly developed program, the researcher may interview 20 
women and 20 men to ascertain in"uences on attendance. Within this sample, 
the researcher may then select !ve people aged 20-30 years and another 
!ve aged 30-40 years to identify if there were certain (stigmatizing) practices 
of program arrangements that contributed to perceptions of poor care. The 
researcher may also purposively interview 5-10 people who demonstrate 
poor adherence (e.g., miss an appointment or report barriers to clinic staff) or 
represent marginalized sub-groups within a given population (e.g. people with 
HIV) to understand local drivers and dimensions of stigma. Participants of a 
purposive sample therefore need to meet speci!c criteria. This is distinct from 
convenience sampling where the researcher has no control over the type of 
participants in a study, and is often considered a weaker form of sampling. 
Maximum variation sampling is the most common form of purposive sampling 
that seeks to include the full spectrum of cases and re"ect the diversity within a 
given population by including extreme or negative cases.1 Because we want to 
learn how and why stigma is produced and sustained, or what are the possible 
drivers and dimensions in a setting, as opposed to learning how frequently or 
intensely these occur, we want to capture the widest range of perspectives 
rather than the most common perspective. Accordingly, we give equal attention 
or importance to the perspectives of people who have experienced the most 
overt forms of discrimination on account of having TB (e.g., job loss, family 
abandonment) and those who perceive no stigma.
At other times, we may be interested in how stigma is shaped and experienced 
against the axis of gender or immigration status. We would then recruit a good 
balance of men and women or refugees/immigrants and locally born participants 
to analyze the role of gender or immigration status in TB stigma. The goal would 
be to achieve qualitative rather than equal representation, where issues likely to 
affect TB stigma in the study context are adequately included. 
Theoretical sampling is an iterative form of purposive sampling that “is dictated 
by the data and the emerging theory” [Coyne 1997; p 629].41 Early interviews 
may suggest important characteristics of interest that were not unanticipated 
at the study outset but could be explored to yield a richer understanding of the 
research problem. For example, a researcher may learn that participant’s marital 
status or area of residence drives their health-seeking behaviors and perceptions 
of stigma in unanticipated ways. The researcher can explore this further through 
subsequent recruitment of participants deemed to have rich information about 
these unanticipated characteristics of interest (e.g., by proceeding to interview 
people who are married/single, or those who live in urban as well as rural areas). 
Purposive sampling 
is an iterative process. 
Participants are selected on 
the basis of characteristics 
considered to be relevant 
to the topic of study, with 
the aim of achieving data 
saturation and conceptual 
representativeness
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Sample size
Samples are generally smaller than those used in quantitative studies. Adequacy 
of the sample size is determined by the principle of theoretical saturation, 
whereby data collection ends once no new concepts or theoretical insights 
emerge following review and analysis of all data.38,43 Thus, sampling is most 
successful when done in conjunction with data collection and analysis, that 
is, an iterative approach. Although it is not possible to de!ne the number 
of participants in advance, a range of 20 to 30 interviews1,44 or 4 to 6 focus 
groups45,46 with a purposeful sample is usually suf!cient to achieve saturation. 
Collecting qualitative data
There are many methods for capturing in-depth qualitative data about the 
drivers and dimensions of TB stigma. In this chapter, we focus on two common 
methods that may be applied across most settings, interviews and focus 
groups, and brie"y discuss observations. Where feasible, these methods can be 
concurrently applied to facilitate triangulation and attain more comprehensive 
insights into the drivers and dimensions of TB stigma.
Interviews 
As discussed earlier, what it means for people to perceive, experience or 
produce TB stigma is inextricably related to their social contexts. However, 
these meanings are generally subconscious or hidden; that is, in their day-
to-day actions and interactions, people may not consciously think about the 
history, culture, medical or social structures within which their perceptions and 
experiences of stigma are shaped.47 A dynamic interaction between a researcher 
and participant can facilitate a rich account of the participant’s lived experience, 
and uncover the subjective (conscious and subconscious) meanings attached 
to it.1,48,49 Semi-structured interviews that allow for open-ended questioning 
and invite rich, narrative, explanatory responses (thick descriptions) through 
active listening and probing can offer a vivid picture of participants’ personal 
experiences and perspectives about TB stigma. They are optimal tools to identify 
and examine the drivers and dimensions of stigma among TB patients, key 
populations, community gatekeepers, and policy/program managers. 
A typical semi-structured interview49 is a guided conversation, where the 
participant is considered the expert and is given the opportunity to talk freely 
about their experiences and feelings. Because the interview is semi-structured it 
allows "exibility so that departures from the interview are permitted and even 
encouraged, to introduce important insights into participants’ experiences. 
Questions are broad, exploratory and open-ended to capture participant’s 
thoughts and perspectives based on his/her !rst-hand experience (i.e., what 
A Semi-structured 
interview is a guided 
conversation, where the 
participant is considered 
the expert and is given the 
opportunity to talk about 
his/her experiences and 
feelings. 
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happened to them) and personal interpretations of those experiences (i.e., 
how they understood this experience or event, how it made them feel).1 
Main questions may be comprised in an Interview Guide, but the wording 
and sequence of these questions would shift from interview to interview 
depending on the participants’ unique responses and circumstances. Key to 
qualitative interviewing is to learn about TB stigma without asking about 
stigma outright, so that ensuing understandings about stigma are rooted in 
participants’ own characterization of this research problem (rather than the 
researcher’s preconceived ideas). It is only through this manner of questioning 
that the continuous and dynamic discovery of new and unanticipated themes 
related to stigma drivers and dimensions will be possible. For example, a typical 
interview guide may include casual questions related to a persons’ diagnostic 
journey, experiences in treatment and care, interactions with providers, general 
perceptions about TB and how these may have changed with time, general 
experiences in their home, experiences with disclosure, relationships with 
others (e.g., family, partner, children, employer), !nancial obligations and 
circumstances, major life events concurrent with TB (e.g., job loss, change in 
residence, relationship with family, access to income or emotional support). 
Participants would be asked to describe day-to-day events and probed on how 
they navigated or responded to these events to learn about potential sources of 
stigma in their particular illness experience. See Tables 3 and 4 for a sample of 
questions that researchers may draw upon to develop interview guides (while 
listed in clusters, questions should be broken down and asked one at a time 
to avoid confusing the participant). It is in the analysis stage (see Chapter 17) 
that the researcher would compare these narratives and link them to broader 
concepts such as drivers and dimensions.
Throughout the interview, the role of the interviewer is to gently guide the 
participant to talk about the topics in the Interview Guide, and ask follow-
up questions (probes, e.g., asking: “Can you give me an example?” or “Can 
you tell me what you mean by that?”) to clarify a point, open new themes 
for discussion, or encourage elaboration49; it is not a question and answer 
session. The interviewer tries not to lead or in"uence participants via their body 
language, tone of voice, or by casting judgment or opinions according to their 
values or assumptions about the research problem49, including preconceived 
notions about stigma. Note that questions barely mention stigma overtly (Table 
3). Qualitative interviews can thus be considered active tools of data collection 
and analysis, where data are co-produced by both the participant as well as the 
researcher.
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Perceptions and attitudes about TB 
 – What are your thoughts about TB, how has this changed over time (since being diagnosed, 
starting treatment)?
 – What do you think others (your community) think or feel about TB patients?
 – Do you know other people with TB, what is your relationship with them now?
TB diagnostic journey, disclosure and contact tracing
 – What were your symptoms, how did you get diagnosed, what challenges did you have?
 – What were your support systems, who did you tell when you were diagnosed, what was the 
response, how has this changed over time?
 – Was there any follow-up for your family or household contacts, how was this handled?
Experiences in treatment and care
 – How are you coping with treatment, side effects, access to medicines?
 – Where do you receive your medicines, how do you make it to your clinic appointments (how 
often and for what – DOT/monitoring, with who, cost/time to commute)?
 – How do you take your medicines every day, who reminds you?
 – What are your experiences at the clinic, how is your relationship with providers, what do you 
think about the quality of care you receive?
 – If hospitalized, how was this experience, how were the interactions with patients and providers, 
how did you communicate with family or con!dantes?
 – What other co-morbid conditions or medical problems do you have?
 – What other medical support have you received and how have you experienced these supports 
(e.g., counseling, grant support, food or transport assistance, community health worker, social 
work, etc.)?
 – What barriers have you faced and how have you dealt with them? 
 – Probe for positive and negative experiences, always ask for examples
 – Do you have any preferences or suggestions going forward, if you could change something 
what would it be?
Social support and !nancial issues
 – Who do you live with, how is your household situation, who have you told about your illness, 
what did they say and what was the response?
 – What social and !nancial obligations/priorities do you have, how are you dealing with them, 
who helps?
 – What major life events have ensued since diagnosis (e.g., change in residence, relationship with 
family, access to income or emotional support), how has this affected you?
 – Who do you talk to for comfort or support, who do you go to for !nancial assistance, who 
looks after your dependents when you are being treated or at the clinic, who are your close 
con!dantes, what do they know, and how have those relationships changed?
Table 3. Sample topic guide for qualitative interviews with people on TB treatment
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General experiences in health care delivery 
 – What is your role, what are your day-to-day activities?
 – What types of patients do you typically see, what are the common medical issues and how has 
this changed over the time you have been working?
 – How would your peers describe your TB patients?
Perceptions and attitudes about TB 
 – What are your thoughts about TB, how has this changed over time (e.g., experience working 
with TB patients)?
 – What do you think others (your community) think or feel about TB patients? 
Patient interactions 
 – What are your experiences with patients in general, what is your relationship?
 – What has been your experience with TB patients, what do you think are your most common 
problems and needs (start with medical, as discussed earlier, and move into social)?
 – How do you respond to these needs, what dif!culties have you faced, ask for examples?
Workplace 
 – How are you supported at work, what is your relationship with colleagues, senior staff, other 
cadres of health workers, support staff?
 – How do you feel working at this site, with TB patients, what do your family and co-workers 
think?
 – How do you perceive risk for TB infection, what countermeasures (e.g., infection control 
practices) do you take and how do you feel about these measures?
 – Given your work day, described earlier, how else could you be supported, what are your 
preferences?
 – Where else have you worked and how would you compare those work experiences?
TB service delivery
 – What TB speci!c activities do you participate, what types of health care tasks are you directly 
involved in (e.g., testing, counseling, contact tracing, treatment initiation, treatment observation 
or monitoring, adherence support, outreach)?
 – How do you enjoy these activities, what challenges have you faced and how did you deal with 
them, ask for examples of speci!c interactions with patients?
 – How do you make medical decisions for each of these activities (e.g., how do you decide which 
patients to test for TB, how do you decide which medicines to prescribe, how do you go about 
performing contact tracing, ask to be walked through the decision-making process which can 
illuminate underlying assumptions and practices)?
 – How else do you think your patients can be supported?
 – How else can you be supported in accomplishing your duties, what would be your preference?
Table 4. Sample topic guide for qualitative interviews with healthcare workers on TB stigma
47
Focus Groups
Focus groups comprise a group of interacting participants convened by a 
facilitator who uses natural group interactions to learn about social and cultural 
norms, and how pervasive they may be in a given community. Participants may 
share some characteristics but the richness of a focus group discussion comes 
from the diversity of participants’ experiences; that is, the ability to capture 
points of group convergence as well as deviations from group norms (e.g., 
different experiences that may underlie participants’ shared perspectives, or 
different perspectives among those who otherwise appear to share a similar 
reality).46,51 When conducted soundly, focus groups can be highly ef!cient 
tools as rich insights may be captured from a large number of participants 
in a relatively short period of time.52 Focus groups have much in common 
with interviews, and the recommendations shared for interviews would apply 
to the implementation of focus groups. The main difference is the strength 
of interaction and exchange between participants of a focus group over a 
particular issue. As Morgan (1996) notes, “what makes the discussion in focus 
groups more than the sum of separate individual interviews is the fact that the 
participants both query each other and explain themselves to each other.”46 This 
allows participants themselves to compare experiences and offer explanations 
for those differences as opposed to the researcher hypothesizing why those 
differences exist on the basis of separate interviews. 
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Focus groups with health providers, community members or key populations can 
be optimal tools to understand community norms around TB stigma and identify 
the drivers of structural and public stigma. Focus groups may also serve as tools 
for advocacy by channeling participants (e.g., TB patients) into a collective 
dialogue about a shared reality. For this reason, focus groups are a useful 
participatory tool, where group opinions, rankings, and preferences may be used 
to develop more comprehensive insights into the drivers and dimensions of TB 
stigma (see Chapter 7 and 12).
In focus groups, the discussion is led to a greater degree by participants 
compared to in an in-depth interview.1 The facilitator’s role is to guide the 
discussion, manage group dynamics, encourage participants to share their 
thoughts, and probe group consensus to identify points of divergence, all 
without in"uencing the discussion or skewing responses a particular way.32,53 
The dif!culty with focus groups is that if participants share many of the same 
assumptions about TB patients, then they may not feel the need to make those 
links explicit to the underlying associations and mechanisms may remain hidden. 
For example, patient participants may not open up about their stigmatizing 
experiences in a group environment.46 Healthcare workers may not openly 
express negative attitudes about people with TB, fearing judgment from their 
peers or the researcher. In such instances, the burden falls heavily on the skills 
of the facilitator to encourage the articulation of underlying assumptions, and at 
times introduce leading statements (e.g., asking: “I have heard that some people 
are reluctant to work in a TB ward”, What do you think?”) that encourage the 
group to share opinions that would be otherwise embarrassing or awkward to 
voice in a group environment. 
Well-facilitated focus groups can be excellent ways to collect data on contentious 
topics, even with persons prone to give socially desirable responses, or disinclined 
to open up on socially sensitive subject matters.54 Small focus groups comprising 
4-5 participants have been successfully conducted with XDR-TB patients as well 
as TB health care providers and led to the discovery of novel dimensions and 
drivers of TB stigma.12,46
Ideally, a focus group should include 6-8 participants but the composition would 
depend highly on the research situation; for example, larger groups would be 
feasible to understand perceptions about TB stigma with community members 
but smaller groups may be optimal when recruiting patients who may not 
open up about their personal experiences with a large audience. Furthermore, 
as gender, immigration status, and severity of disease are understood to be 
critical determinants of TB stigma27, it would be ideal to stratify focus groups 
accordingly. However, there is no hard-and-fast rule about focus group 
composition. It is the role of the researcher and focus group facilitator to 
consider these issues prior to organizing the focus group and tailor them to the 
local context.
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Observations
Naming, blaming and shaming are behaviors that can be observed. Many 
aggressive acts re"ective of enacted and public stigma can take place in the 
public sphere. Field observations can provide a !rst‐hand or insider’s perspective 
on the physical and social environment in which TB stigma is produced 
and experienced.32 Observations can illuminate deep knowledge about the 
sociocultural norms and practices of a study setting and may also enhance 
analytic credibility.33,34 For example, clinic observations may allow for a witnessed 
account of the social contexts in which patients attend clinics and access TB-
related services, insight to their interactions between clinic staff and with other 
patients, and norms and actions practiced within the clinic environment that 
could affect patients’ overall experiences with health care. These observations 
may guide questions in subsequent interviews or focus groups, and allow 
researchers to situate their analysis of TB stigma more wholly in participants’ 
social contexts. For more on structured and unstructured observations, see 
Chapter 5. 
Ethical considerations. As with other studies, stigma research mandates 
abidance to procedural ethics at the study outset, or receipt of institutional 
ethics approvals, site permissions, participants’ informed consent (written or 
verbal, depending on the situation), and developing secure mechanisms for 
data protection and sharing.36 Ongoing ethical considerations, which mandate 
researchers to re"ect on ethical decisions beyond procedural ethics include: 
situational ethics or unpredictable ethically relevant moments that may arise 
during the conduct of research activities (e.g., establishing a plan to counsel 
patient participants who become emotional during an interview, or to address 
accounts of illegal practices); relational ethics where researchers are continually 
mindful of their character, actions, and in"uence on others (e.g., drawing on the 
principle of reciprocity to balance a researcher’s desire to publicize an evocative 
narrative against a participant’s preference to minimize it); and exiting ethics, 
where researchers re"ect on the manner in which they share research !ndings 
to avoid unjust or unintended consequences (e.g., representing participants who 
may be poor or marginalized in ways that do not portray them in a negative light 
and inadvertently compound their marginalization).36
Readers are encouraged to refer to Chapter 17 for approaches to qualitative 
analysis and research rigor.
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Conclusion
This chapter has laid out the rationale and fundamental considerations of using 
qualitative methods to identify and examine the drivers and dimensions of TB 
stigma. Qualitative research helps us to understand these varied contexts of TB 
stigma in a more nuanced and deeper way, and is thus essential to the process 
of developing and validating a stigma measurement scale. In-depth exploratory 
inquiry into the socio-medical environment in which TB stigma is produced, 
and with those who encounter or contribute to stigma, can result in a more 
humanistic1 conceptualization of TB stigma, and uncover its building blocks in a 
given setting.
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Chapter 4
Conducting valid surveys of TB stigma 
and health seeking
Lisa Redwood and Ellen M.H. Mitchell
Abstract
This chapter covers the main drivers and domains of TB stigma in the population. 
It outlines the considerations for measuring TB stigma in communities and 
nationwide. We introduce the available validated scales and explain the relative 
advantages of indirect questions and/or hypothetical questions to tap social 
norms. The chapter explains how to craft a high quality survey of the role of 
stigma in health seeking for TB symptoms. Finally, we discuss a comparative 
ecological analysis of anticipated stigma across settings.
Objectives
1. The typical domains and drivers of TB stigma in the general public
2. How to measure TB stigma to assess its impact on health seeking behavior
3. How to embed studies into larger national household surveys
4. How to compare stigma in the community across settings using ecological 
analysis.
Target Audience
The intended audience for this chapter is people wanting to measure TB stigma 
in their communities, regions, countrywide or among countries. This may include 
research institutions, national TB program staff, MoH or other government 
organizations, non-governmental organizations (NGOs), donors, and technical 
assistants implementing social surveys.
Introduction
Measuring TB stigma at the community level is crucial to shift societal treatment 
of people with TB. Stigma in the population is also known as social stigma, public 
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stigma or cultural stigma. Community attitudes toward people with TB in"uence 
their support for public policies designed to ease their !nancial, social, and 
physical burdens.1 People with more accepting views toward PWTB are more 
likely to support the use of public monies for TB research and anti-discrimination 
efforts.1 Societies which blame PWTB for developing TB disease are less likely 
to support the provision of public assistance, such as disability grants.1,2 This is 
important as provision of public assistance is associated with improved survival of 
TB patients.3 
Community fears and prejudices about TB can also deter health care seeking 
for TB symptoms.4–13 Programs and communities need to know how TB stigma 
operates at the community level and crucially whether it discourages health care 
seeking. Accurate measurement of TB stigma in the community is therefore a 
necessary !rst step in the development of effective social mobilization to increase 
use of TB services.
Drivers of stigma at community level
There are many potential drivers of anticipated stigma in the general population. 
Stigma in the general population can be in"uenced by social characteristics, 
knowledge, national epidemiological context and structural drivers of TB stigma. 
Some authors have argued that lack of understanding of TB transmission 
increases TB stigma.9,14 In some settings an increased understanding of the 
treatability of TB reduced stigma.15,16 However levels of TB knowledge often 
have no consistent relationship with levels of TB stigma.2,16,17 Indeed TB stigma 
can even increase with levels of education and social class.15 At the national level, 
TB stigma is correlated with incarceration rates.15 This suggests that a country’s 
general approach to blaming and punishment can also color the country’s view 
of PWTB.
Figure 1. Illustrative In#uences upon societal TB stigma.
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Domains of stigma to measure
The context in which you work will impact the items and the scales you should 
use. The aim of the study needs to be clear to allow the questionnaire content 
be tailored to the need and therefore deliver the desired data.
Formative research in your setting will reveal the domains most relevant, but 
Pescosolido and Martin (2015) identi!ed seven domains of public stigma that 
you may wish to explore. These include: social distance, traditional prejudice, 
exclusionary sentiments, negative affect, treatment carryover, disclosure 
carryover and perceptions of dangerousness.18 These domains are de!ned with 
TB examples in Chapter 1.
Traditional
Prejudice
Perceptions of
Dangerousness
Treatment
Carryover
Exclusionary
Sentiments
Negative
Affect
Disclosure
Carryover
Social
Distance
TB
STIGMA
Figure 2. Seven Domains of Public Stigma18
Corrigan adds two dimensions ”pity” and “treatment coercion” to measure 
public stigma.
Attitudinal Scales for Measuring TB Stigma at the 
Community Level
Once you have determined through formative research which domains are 
relevant in your setting, you can choose to adapt an existing scale or build a new 
one. There are several scales for community measurement, ranging in size from 5 
to 11 items. There are non-disease speci!c scales and TB scales derived from HIV 
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scales. Each has strengths and weaknesses for you to weigh.
Generic Scales for Measuring Discriminatory Attitudes
There are a variety of validated scales for measuring discriminatory attitudes that 
have been adapted for TB (See Table 1). The Bogardus Social Distance Scale is 
one of the oldest psychological attitude scales and it has been adapted many 
times and to many contexts.19 
The social distance scales from the nineteen twenties informed the development 
of the Jaramillo and Mak TB stigma scales.1,14 They have items like these:
1. Would marry a person who had had [insert stigmatized condition]
2. Would have as regular friends a person who had had [insert stigmatized 
condition]
3. Would work in an of!ce beside a person who had had [insert stigmatized 
condition]
4. Would have several families who had had [insert stigmatized condition] in 
my neighborhood
5. Would have a person who had had [insert stigmatized condition] merely as 
speaking acquaintances
6. Would prefer a person who had had [insert stigmatized condition] live 
outside my neighborhood
7. Would prefer a person who had had [insert stigmatized condition] live 
outside my country.
The Bogardus Social distance scale was !rst designed to measure racism and 
xenophobia and some of the behaviors may be setting speci!c. The Social 
Distance Scale (SDS) by Kelly and colleagues is also widely used as a basis for 
disease-speci!c stigma scales.20,21 The SDS questions are preceded by vignettes 
which is particularly effective if you want to understand how multiple types of 
prejudices (for example xenophobia) exacerbate TB stigmas. For guidance on the 
use of vignettes and the SDS items read Chapter 14. 
Probably the most well-known of these non-condition speci!c stigma scales is 
the Explanatory Model Interview Catalog (EMIC) scale which has been used 
extensively for stigma of leprosy, mental health and TB.20,22–27 The EMIC scale 
is described in more detail in Chapter 7 and its potential for gender bias is 
discussed in Chapter 14.
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Table 1: Overview of validated scales for health-related 
community stigma applied or applicable to TB
First author Country
Content 
validity
Construct 
validity
Reliability 
No. of 
items
Domains (if 
identi!ed)
Mak (2006)
Hong 
Kong
Literature
Focus 
groups
CFA
SEM _ = 0.83 14
Public stigma 
(prejudice/
discrimination)
Jaramillo 
(1999)14
Colombia Literature n/a n/a 5
Social distance- 
intimacy
Sermrittirong 
(2015)28
Thailand
FGD,(EMIC-
CSS
SEM _ = 0.87 15
Concealment, 
avoidance, pity, 
shame, being made 
fun of, respect and 
marriage (prospects)
Bogardus 
Social 
Distance 
(1925)
USA CFA
_= 0.75-
0.929
8 Social distance
Atre27 India EMIC n/a n/a 15
Concealment, 
avoidance, pity, 
shame, being made 
fun of, respect and 
marriage (prospects)
Coreil 
(2010b)30
US and 
Haiti
EMIC stigma 
scale
Local 
interviews
EFA
_= 0.80 for 
both
21 
(US) 
20 (H)
US (4 sub-scales): 
internal shame; 
external problems; 
disclosure, 
communicability
Haiti (5 sub-scales): 
internal shame; 
external problems; 
disclosure; family 
reputation; other 
illness
SEM - structural equation modeling, CFA - con!rmatory factor analysis, EFA – exploratory factor analysis, FGD – focus 
group discussion.
The Mak and Jaramillo scales are general stigma scales applied to TB. The 
Jaramillo scale is primarily a measure of the social distance domain and asks 
about !ve speci!c behaviors (i.e. kiss, share meals, have sex, work/study, 
hugging). Given the speci!city of these behaviors, it may not be appropriate 
for all settings. Scales that were speci!cally designed for TB and informed by 
formative work on TB are summarized in Table 2.
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Table 2: Validated TB Stigma Scales for Public Stigma
First author Country
Content 
validity
Construct 
validity
Reliability 
No. of 
items
Domains (if 
identi!ed)
Cramm & 
Nieboer 
(2010)31,32
South 
Africa
Kalichman 
HIV stigma 
scale, Møller 
2008
Correlation 
with HIV 
stigma 
(r=0.66)
_ = 0.74 8
Traditional 
prejudice, 
exclusionary 
intent, social 
distance, blame 
Van Rie (2008)33
Kipp (2011)34
Thailand
Van Rie TB 
stigma scale
EFA _ = 0.85 11
Social distance, 
exclusionary 
sentiments, 
treatment 
carryover, and 
negative affect
Crispim 
(2016,2017)35,36
Brazil Van Rie n/a _ = 0.70 11 See Van Rie 2008
Colvin 
(2005)37,38
Honduras
Literature, 
interviews
EFA _ = 0.71 7
Stereotypes, 
exclusionary 
sentiments, 
social distance, 
discrimination
Sagili (2016)39 India Literature N/R n/a 13
Exclusionary 
sentiments, social 
distance, intent to 
discriminate
Wu (2013)40 Taiwan AQ-S8  PCA
_= 0.80 for 
both
8
Avoidance, 
sympathy, fear
N/R= not reported
Wording of Stigma Items is Important
TB speci!c scales for use in behavioral surveys have been developed recently 
often borrowing items from HIV scales. One downside of borrowing items from 
a chronic disease is the tendency for items to implicitly assume TB disease results 
in a permanent mark.35 Researchers should be careful when drafting items to use 
transitive verbs to imply a temporary state. 
The Van Rie community TB stigma scale performs well, is validated, is self-
weighting, and has been applied in multiple countries (See Table 3). Validated 
versions exist in English, Malay, Thai and Portuguese.33,35,41,42 The Van Rie scale 
utilizes indirect items to measure TB stigma in the general community and in 
people living with TB, such as: “Some people do not want to talk to others 
with TB”. This indirect method of inquiry taps social norms rather than personal 
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positions. During the social validity testing of the initial scale indirect questions 
were found to be more culturally appropriate and allow for more truthful 
answers.43 The disadvantage of this indirect framing is that it may over-estimate 
the prevalence of stigma because it is easier to af!rm that ‘some’ proportion 
of any population will think almost anything. Moreover high scores on such 
indirect mild stigma measures are seldom predictive of behavior or outcomes.34 
Hayes-Larson et al (2017) recently tested and expanded version of the Van Rie 
community attitudes scale that used three more direct and severe items. These 
three seemed to pinpoint severe TB stigma better and were highly correlated 
with negative coping behaviors.44
The Van Rie scale phrases the items all in the negative, but Crispim et al 
rephrased 2 items positively to give the scale better balance, with good results.35 
The apparent similarity between item 2 and item 10 can be confusing to 
respondents, and some researchers have combined them.
Table 3: The Van Rie Scale for measuring TB Stigma at the 
Community level.
Strongly 
Agree
Agree
Don’t 
know
Disagree
Strongly 
disagree 
1. Some people may not want to eat or 
drink with friends who have TB
2. Some people feel uncomfortable about 
being near those with TB
3. If a person has TB, some community 
members will behave differently towards 
that person for the rest of their life
4. Some people do not want those with TB 
playing with their children
5. Some people keep their distance from 
people with TB
6. Some people think that those with TB 
are disgusting
7. Some people do not want to talk to 
others with TB
8. Some people are afraid of those with TB
9. Some people try not to touch others 
with TB
10. Some people may not want to eat or 
drink with relatives who have TB
11. Some people prefer not to have those 
with TB living in their community
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Wu (2013) developed a 8-item scale based on Corrigan’s Attribution 
Questionnaire for mental illness stigma (AQ-S8).45 This short scale predicted 
willingness to become a DOTS provider (See Chapter 5).40
Cramm and Nieboer (2011) created an 8-item TB-related stigma scale, which 
is the shortest validated TB-stigma scale for use in the general population (see 
Table 4).31 This scale is further simpli!ed by having two possible answers to each 
question, agree or disagree. Sagili et al has a 13-item scale primarily querying 
agreement with social distance and exclusion behaviors.39
Scale Item Agree Disagree
1. People who have TB are dirty 
2. People who have TB are cursed
3. People who have TB should be ashamed
4. People with TB must expect some restrictions on their freedom
5. A person with TB must have done something wrong and deserves to be 
punished
6. People who have TB should be isolated 
7. I do not want to be friends with someone who has TB
8. People who have TB should not be allowed to work 
Table 4: Cramm and Nieboer (2011) TB stigma scale31
The wording of the items in the stigma scale can have an impact on the 
responses given and what you end up measuring.43,46 These questions also 
pose their own challenges. They are very logical and direct, with the positive 
answer clearly conveying stigma. However, asking some people these strongly 
worded and speci!c questions might elicit a socially acceptable answer, rather 
than a truthful one. (see Chapter 5 for discussion on extreme questions). The 
dichotomized answer (yes or no) limits your ability to understand the intensity or 
distribution of opinions, reducing the utility for intervention planning.
The Colvin TB stigma scale covers four domains in only seven items (see 
Appendix 1.38 Its succinctness and avoidance of disclosure items makes it a 
candidate for use in national surveys. High scores were correlated with longer 
distances for healthcare seeking for chronic cough.
Challenges to valid measurement of TB stigma in 
behavioral surveys
Social desirability
Being explicitly discriminatory is considered uncivilized in most societies. 
Awareness of social norms in"uences peoples’ responses to direct questions. If 
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you ask someone if they possess a negative trait, such as stigmatizing attitudes, 
a proportion are likely to respond with a favorable, socially acceptable answer, 
rather than a truthful one.47 This is known as social desirability bias. Interviews 
conducted in person are particularly susceptible to this bias .The Marlow-Crowne 
Scale is designed to measure the degree to which social desirability bias may be 
in"uencing your sample (See Appendix 2).
Minimizing social desirability bias is a major challenge in all stigma measurement. 
To reduce the likelihood of this bias it is best to use self-administered surveys, 
ACASI or use indirect wording. Social desirability bias and strategies to mitigate it 
are covered in more detail in Chapter 5.
Literacy Levels
Another challenge in measuring community TB stigma is literacy. Valid scales for 
low literacy groups and children are absent. The use of interviewer administered 
surveys or images are possible. Semantic differentials (i.e. having respondents 
choose between positive and negative images of TB patients) is one potential 
method of measuring TB stereotypes without words.29
To ensure understanding with lower literacy samples, it may be preferable 
to apply “hybrid” modes of scale administration. For example, a respondent 
enters their answers on a computer screen or paper questionnaire while a 
trained interviewer reads the questions to maximize perceived con!dentiality 
while minimizing the risk of poor understanding or acquiescence bias (“rushing 
through”). Trained interviewers can carefully explain the instructions and answer 
questions, and read every question while still being unaware of the respondent’s 
answers.
Hypothetical questions 
The use of hypothetical questions in stigma surveys was widely used for HIV, 
especially in self-stigma scales. An issue with hypothetical questions is that you 
are obliging conjecture., i.e. you are measuring peoples’ assumptions about 
themselves rather than their stigmatizing behavior or their !rst hand experiences 
of stigma.47 Hypothetical family concealment questions are problematic for this 
reason and should be used only if alternatives are lacking. A single question on 
hypothetical family secrecy (If a member of your family got TB, would you want 
it to remain a secret or not?”) was used in 66 surveys as a TB stigma measure 
before validated stigma scales were available.15,48,49 However hypothetical 
questions are no longer recommended because of the poor potential correlation 
with behavior.
Common strategies to 
reduce social desirability 
bias include:
a) Use of self-administered 
surveys
b) Audio computer-assisted 
self-interview software 
(ACASI)78 
c) Indirect or impersonal 
wording of the survey 
items
d) On-line or anonymous 
surveys.
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Adaptation of a published scale
Even if a scale is well validated, one cannot simply choose a pre-existing scale 
or set of interview questions for measuring anticipated stigma and assume that 
it will be applicable in all settings. Stigma in each country may be slightly (or 
very) different. Items that reference marriage, sexual or gendered behaviors are 
often setting-speci!c.14,39 Ensure that a multidisciplinary team of local experts 
(including survivors of TB) are fully engaged so that all aspects of TB stigma are 
covered. (See Chapters 1 and 12 for how to engage PWTB, and Chapter 16 on 
scale validation steps).
Assessing the role of community TB stigma upon health 
care seeking for TB symptoms 
Stakeholders are not only interested in measuring levels of TB stigma in the 
community but also to gauge the extent to which these attitudes may contribute 
to delay in case detection. The impact of TB stigma on behavior is not always 
easy to !gure out.50 Stigma in the general population can be a deterrent to TB 
health seeking behaviors.32,51,52 TB stigma appears to in"uence the location and 
type of provider, with higher stigma leading clients to seek health care farther 
from home.38,53 Anticipated TB stigma may inhibit health-seeking behavior 
through fears of negative treatment, fear of being disparaged (gossip) or isolated 
by the community and fear of negative stereotypes. Care must be taken when 
studying the impact of stigma on health care behaviors. Health care seeking for 
TB symptoms is a very complex multi-step process in"uenced by diverse factors. 
There are many reasons why people with TB symptoms don’t seek care.54–56 To 
measure the effect of stigma on health seeking behavior you need to have:
1. A comprehensive causal theory to explain health seeking behaviors.57
2. A suf!ciently powered sample to measure small effects (>50,000 
respondents) and control for all the other in"uences.
3. Robust measures of all the other determinants of health seeking behavior
4. The ability to analyze the data correctly.
It is unwise to measure the role of stigma in isolation from all the other 
in"uences on health seeking. A lot of early work on TB health seeking 
behavior relied on Theory of Reasoned Action or Health Belief Model or similar 
frameworks linked to individual motivation.58,59 These narrow frames have 
not always suf!ciently accounted for all the societal, legal, and environmental 
obstacles to TB diagnosis. In the absence of a rapid point of care diagnostic, 
TB testing is now recognized as a multi-step process where access and other 
structural factors must be considered.32,60–62
To ensure social and 
content validity, all TB 
stigma measurement 
surveys should be 
thoroughly piloted to 
ensure that scales are 
culturally and linguistically 
appropriate (See Chapter 
3).
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Figure 3. Illustrative conceptual framework for study of the in#uence of stigma upon health care 
seeking63
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Often TB stigma can be present in high levels, but people with symptoms may 
de"ect or overcome anticipated TB stigma if they perceive TB to be a serious 
threat to survival or if effective treatment is thought to avert enacted stigma.37,67
When a comprehensive study of determinants of health seeking is conducted 
and all the other contributors are taken into account, TB stigma does not always 
turn out to be the main obstacle to health care seeking behavior for chronic 
cough.37,41,64–66 Chronic cough can conjure fears of lung cancer, HIV, and other 
conditions. There is evidence that the stigma of lung cancer, smoking, and HIV 
represent barriers to health seeking for chronic cough in some contexts.65,72,73 
Multiple stigmas can make determining the speci!c role of TB stigma in health 
care avoidance more complex.15 The presence of other prejudices may need 
to be measured to improve the interpretation of health seeking behavior. See 
Chapter 14 for guidance on how to measure syndemic stigma.
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An example from a community survey in South Africa (Figure 4) shows how fear 
of TB stigmatization and TB discrimination may not be the single most important 
impediments to care, but collectively stigmas constitute serious obstacles.32
Figure 4. Reasons people delay seeking care for TB-symptoms in Eastern Cape, South Africa (n= 
1020, Møller et al., 2011) 
0% 20% 40% 60% 80% 100%
They !rst wish to consult a traditional healer
They are afraid TB treatment will be long/dif!cult
They are afraid they will lose their jobs
They are afraid TB will interfere with their social life
They don’t want to cough into a specimen bottle
They are afraid people will talk about their visit to the clinic
There are long queues at the clinic
They are afraid they will be told they are HIV positive
The End TB strategy will require reaching over 4 million people with TB who 
are currently unreached and engaging them in care.68 For most countries, this 
will require a better understanding of the role of TB stigma as a deterrent to 
health seeking. To improve healthcare-seeking for TB, priority must be placed 
on addressing the speci!c fears and concerns of people most at risk for TB 
(e.g. gossip, job loss) even if these issues are not perceived as priorities by the 
program. 
Ideally any study of healthcare-seeking behavior should recruit the study sample 
from outside of health facilities. Many of the studies of healthcare-seeking delay 
recruit only from health care facilities. By de!nition this biases the study by 
excluding people who never seek care or delay for extended periods.
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When interested in stigma-related determinants on health care seeking we 
recommend to measure stigma domains that are susceptible to intervention. 
From a policy view, it makes little sense to focus on measuring TB stigma 
domains that are immutable or beyond your locus of control. For example, it is 
perhaps more important to measure negative stereotypes about people with TB 
than it is to focus on the role of air-borne transmission as a source of fear. The 
route of transmission of TB cannot be in"uenced whereas we can debunk myths 
and break down stereotypes about people. 
In some settings TB is disproportionately concentrated among people and 
communities who are already socially excluded (See Chapter 9).9,69,70 There is also 
clear variation in stigma’s deterrent effect by group (e.g. pastoralists).71 
Planning a study on the role of stigma in health care 
seeking behavior 
1. Identify and theorize all the major determinants of health seeking behavior 
in your settings ( literature review, formative interviews) and build your 
conceptual framework. (See Chapter 15)
2. Operationalize the framework (i.e. decide how best to measure the 
determinants of health care seeking).
3. Establish operational and meaningful de!nitions of health care seeking and 
‘delay’ 
4. Size the study (e.g. choose the sample size) based on your estimate of the 
relative importance of TB stigma upon health care seeking.
 
National Survey Estimates of TB Stigma
Embedding a TB stigma scale into a larger nationally representative behavioral 
survey is the most ef!cient way to generate national estimates.74 Integration 
of short TB stigma scales is preferable to stand alone measurement efforts 
because the cost and technical complexity of implementing a population-
based household survey correctly are high. Imbedding TB stigma scales into 
health or social surveys is more feasible and cost-effective because the high 
implementation costs can be spread across multiple health programs. This is 
the most ef!cient approach to gather valid estimates. Moreover it allows for 
triangulation of the stigma !ndings with other attitudes and health correlates.
Knowledge, attitude, and practice (KAP) surveys are also possible mechanisms 
for TB stigma measurement.75,76 National surveys can reveal important sub-
national differences in stigma levels (Figure 5).
If the study is intended 
as a baseline to improve 
health-care seeking we 
recommend including 
a pilot of anti-stigma 
messages
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Figure 5. Variability of TB non-disclosure attitudes within India by state in the 2005 DHS77
2.6-9.5%
9.6-10.9%
11-13.9%
14-20.7%
20.8-41.3%
A key challenge in incorporating a stigma scale into a national health survey is 
the scale length. A scale with many items is hard to incorporate in behavioral 
surveys that do not have TB stigma measurement as their sole objective. Stigma 
measurement experts do not believe that a complex construct like stigma can 
be adequately re"ected with a single item.74 The minimum number of items 
required to capture a complex construct like stigma is likely to be !ve to seven 
items. Validation studies of brief TB stigma scales are on-going.35,36
Measures of TB stigma can be integrated into nationally-representative surveys 
such as a Multiple Indicator Cluster Survey (MICS), a Demographic and Health 
survey (DHS), TB prevalence surveys if shown to be robust across contexts. 
Detailed guidance on how to conduct a national household survey is beyond 
the scope of this Guidance. But please note that these require multi-cluster 
designs and usually take at least two years to plan and execute. However the 
United Nations, the World Bank, and the Demographic and Health Survey (DHS) 
implementer all offer detailed training materials to enhance local capacity to 
carry out rigorous national surveys:
tUNSTATS provides a 29-chapter resource that lays out the key considerations 
for national household surveys. 
https://unstats.un.org/unsd/hhsurveys/
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t The World Bank also offers an on-line course with useful capacity building 
exercises for national household survey planning and implementation. 
http://go.worldbank.org/3Q7O7NBI60
t The DHS offers this Facilitator’s guide for conducting a national Demographic 
and Health Survey 
https://www.dhsprogram.com/pubs/pdf/DHSC4/Module_4_dhsc4.pdf
t The WHO Global TB Program also has a publication on TB prevalence surveys 
which describes the proper procedures of multi-cluster sampling and gives 
some practical tips on household survey planning and implementation.  
http://www.who.int/tb/advisory_bodies/impact_measurement_taskforce/
resources_documents/thelimebook/en/
tOn analysis:  
https://www.dhsprogram.com/Curriculum/index.cfm
Conclusion
Stigma in the general population can be in"uenced by social characteristics, 
knowledge, national epidemiological context and structural drivers of TB stigma. 
The context in which you work will impact the items and the scales you should 
use. The aim of the study needs to be clear to allow the questionnaire content be 
tailored to the need and therefore deliver the desired data. It is best to conduct 
a pilot study with cognitive interviews of the stigma scale chosen to ensure that 
it is appropriate for the setting. This will ensure that it is contextually appropriate 
and minimize the misinterpretation and misunderstanding of the scale items 
which will inevitably lead to unusable data. You need to be aware of social 
desirability bias in your data collection. The most cost effective and practical way 
to measure stigma in the community is to imbed a TB stigma scale into a general 
social survey. This will allow the costs to be shared across multiple organizations 
and the triangulation of data from the other health areas measured. Measuring 
TB stigma in the community is necessary to understand how TB stigma operates, 
and the extent to which it discourages health seeking behaviors and to evaluate 
the effectiveness of stigma reduction interventions.
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Appendix 1: Colvin Scale
1. People with TB are usually poor.
2. People with TB usually live in an unclean house.
3. People with TB do not have very much education.
4. If a friend of mine was diagnosed with TB, I would worry that s/he also has HIV/AIDS.
5. If a friend of mine had TB, people would avoid him/her.
6. If I knew a friend of mine had TB, I would no longer be friends with him/her.
7. If a friend of mine had TB, s/he would probably lose his/her job.
Appendix 2: Marlowe-Crowne Scale for Measuring Social Desirability 
Bias
Use of the Marlowe-Crowne Scale for measuring social desirability bias can help to make sense of the 
TB stigma self-reported results.76 Here is the scale: 
Directions: 
Read each item and decide whether it is true (T) or false (F) for you. Try to work rapidly and answer 
each question with “true” or “false”. 
1. Before voting, I thoroughly investigate the quali!cations of all the candidates.
2. I never hesitate to go out of my way to help someone in trouble.
3. It is sometimes hard for me to go on with my work if I am not encouraged.
4. I have never intensely disliked anyone. 
5. On occasions I have had doubts about my ability to succeed in life.
6. I sometimes feel resentful when I don’t get my way.
7. I am always careful about my manner of dress.
8. My table manners at home are as good as when I eat out in a restaurant.
9. If I could get into a movie without paying and be sure I was not seen, I would probably do it.
10. On a few occasions, I have given up something because I thought too little of my ability.
11. I like to gossip at times.
12. There have been times when I felt like rebelling against people in authority even though I knew 
they were right.
13. No matter who I’m talking to, I’m always a good listener.
14. I can remember “playing sick” to get out of something.
15. There have been occasions when I have taken advantage of someone.
16. I’m always willing to admit it when I make a mistake.
17. I always try to practice what I preach.
18. I don’t !nd it particularly dif!cult to get along with loudmouthed, obnoxious people.
19. I sometimes try to get even rather than forgive and forget.
20. When I don’t know something I don’t mind at all admitting it.
21. I am always courteous, even to people who are disagreeable.
22. At times I have really insisted on having things my own way.
23. There have been occasions when I felt like smashing things.
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24. I would never think of letting someone else be punished for my wrong-doings.
25. I never resent being asked to return a favor.
26. I have never been irked when people expressed ideas very different from my own.
27. I never make a long trip without checking the safety of my car.
28. There have been times when I was quite jealous of the good fortune of others.
29. I have almost never felt the urge to tell someone off.
30. I am sometimes irritated by people who ask favors of me.
31. I have never felt that I was punished without cause.
32. I sometimes think when people have a misfortune they only got what they deserved.
33. I have never deliberately said something that hurt someone’s feelings.
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Chapter 5
Measuring Stigmatizing Behaviors 
in Health Care Facilities and other 
Institutions
Ellen M.H. Mitchell, Sarah van de Berg, Julia van der Land, Amrita Daftary, Gill Craig, 
and Lisa Redwood
Abstract
Reducing stigma and discrimination in health care settings is one of most 
important projects of the Sustainable Development Agenda.1–4 This chapter 
synthesizes the techniques and guidance presented in other chapters to show 
how stigma measurement could be approached in a health facility ecosystem. 
The same approach can be used in other institutions like courts of law, mines 
or prisons. The use of participatory and structured observational techniques 
is introduced as a way to overcome biases from reliance upon self-reported 
attitudes and behaviors.
Objectives
1. To build readers’ capacity to conceptualize the drivers and domains of TB 
stigma in institutions. 
2. To make readers aware of the special challenges in measuring undesirable 
behaviors.
3. To build capacity in structured and unstructured observation skills for the 
measurement of stigma.
Target audience
This chapter is for social scientists, M&E of!cers, research staff of NGOs and TB 
programs, activists, and health facility managers. The methods and guidance in 
this chapter are geared to people who want to understand the manifestations of 
TB stigma in their institutions. 
Introduction
TB stigma measurement has historically concentrated on those who have been 
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stigmatized.5,6 Expanding the focus to document behavior of people who 
stigmatize is useful because those are the behaviors we seek to change.5 One of 
the challenges is how to measure stigmatizing behavior in unbiased ways. Few 
established measurement practices exist. This chapter expands on the survey 
scales methods described in Chapters 4,7 and 8 to explore more innovative (and 
unvalidated) approaches to measure stigmatizing behavior.
Effective TB stigma reduction requires shifts in the attitudes and behaviors of 
healthcare workers, employers, educators, religious leaders, journalists, opinion 
leaders, politicians, judges, and juries.5
Institutions are social spaces with a speci!c organizational culture, architecture, 
and sets of norms and policies. TB stigma can thrive under enabling conditions 
present in institutions and be virtually absent in others.3 
Stigma in health care settings hampers access to, and the quality and outcomes 
of health service delivery.2,4 Mistreatment of people with TB, is not only a 
violation of human rights, but also can contribute to mental health sequelae and 
other comorbidities.6 Discrediting persons with TB is counterproductive to TB 
care and elimination efforts because it negatively impacts health care seeking 
behavior, care delivery, adherence, and recovery.7–11 Indeed, perceptions about 
the way a person with TB is treated in a health care interaction in"uences the 
timing, location, and quality of care.12 They may also impact resilience and health 
outcomes.13,14 We know that when providers lack cultural competence with 
a wide array of client groups, their contact investigations are of lower quality 
and effectiveness.15–18 Discrimination in health care thrives in settings with poor 
supervision and inadequate training in TB patients’ rights and infection control 
(IC).3,19 When healthcare workers’ rights are disregarded, they tend not to 
prioritize patients’ rights.20
There may be many contributors to healthcare workers’ empathy fatigue 
(e.g., organizational hierarchies and culture, infrastructure, and policies).21 It is 
helpful to map the contributors to an environment that condones or tolerates 
stigmatizing behaviors. The following are examples of individual behaviors and 
institutional practices that are stigmatizing or discriminatory: 
Provider behavior 
tHuman rights violations as denial of care; mandatory testing and treatment 
practices or use of coercion, punishment or threats; breaches in con!dentiality; 
violence and abuse 
tNegative and disparaging behavior toward TB clients3 
tUse of value-laden terminology (see Chapters 6 and 11)
tGossiping; breaches of trust and con!dentiality
Make sure to measure 
stigma domains that are 
susceptible to intervention 
if you intend to use it as a 
baseline
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tDemeaning clients: name-calling, microaggressions
tNon-speci!c rudeness; insensitivity 
tAuthoritarian approach to treatment supervision22,23 
tUse of coercion, punishment, and threats
t Stigmatizing policies and structures
tUnnecessary, prolonged masking19
tUnnecessary separation of TB clients
tUnnecessary isolation of TB clients
t Task-shifting to unquali!ed staff 
tOver-referral to other facilities 
tDenial of services 
t Lack of safe waiting areas
t Lack of auditory and visual privacy
Rational for Studying TB Stigma from an Institutional 
Perspective
Stigma is about interactions between people. There is much to be gained from 
the study of human dyads (stigmatizer-stigmatized) as a combined unit of 
analysis.8 Examining stigma from multiple perspectives is more challenging than 
univariate measurement of the experiences of a person on the receiving end of 
harmful words and deeds. However, the additional investment is worthwhile 
because capturing aspects of TB stigma from an institutional perspective, such 
as the enabling environment that sustains TB stigma and the motives behind the 
behaviors of “perpetrators,” provide insights for the appropriate design of anti-
stigma interventions, and help to monitor and evaluate interventions intended to 
change the behavior of stigmatizers.
Drivers of TB Stigma in Health Facilities
There are an array of factors that create an enabling environment for TB 
stigma.24 Healthcare workers’ educational exposures can increase or decrease 
their stigmatizing attitudes.24–26 Healthcare workers who demonstrate a lack 
empathy and solidarity with TB clients may themselves be experiencing a heavy 
burden of TB “dirty work” stigma.27,28 Healthcare workers who stigmatize may 
be being mistreated themselves. Healthcare workers may lack safe and decent 
working conditions.29–32 TB healthcare workers often work in facilities that do 
not have adequate environmental and administrative infection controls needed 
to protect them.31,32 They may care for TB clients in public sector facilities 
where salaries are paid irregularly and commodities are insuf!cient.20,33–35 
Healthcare workers experience a higher prevalence of workplace violence.36–40 
Poorly designed policies, guidelines, and educational messages may reinforce 
stigmatizing language and ideas among workers. It important to try to map the 
drivers of stigma in health facilities if you plan to reduce it. Chapter 3 provides 
guidance on how to uncover the drivers of TB stigma.
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Identifying the drivers and facilitators of TB stigma through formative research 
makes the measurement task clearer.20 Figure 1 is an illustrative conceptual 
framework for an MDR-TB stigma study in Ethiopian health care facilities. The 
framework maps out the structural (policy and infrastructure), organizational, 
and individual drivers of MDR-TB stigma so that each of the relevant drivers can 
be measured. The framework presents an initial hypothesis about what issues 
are important to measure. Some of the issues may turn out to be irrelevant. 
Identifying and de!ning all the pieces of the stigma puzzle is the !rst step in 
designing a TB stigma study.
Figure 1. Conceptual Framework for Stigma in Health Facilities in Ethiopia 
Determining Which Domains of TB Stigma to Measure 
in an Institution
There are many manifestations of TB stigma that could be measured in a social 
space. Examples include: policies, organizational structures, management 
practices, health care facility (HCF infrastructure, organizational norms and 
culture, TB knowledge, attitudes of healthcare workers toward TB clients as well 
as other healthcare workers, and the behavior of healthcare workers. Measuring 
multiple domains and triangulating the !ndings can yield richer results. If 
resources are limited, the assessment of policies and attitudes for stigma can be 
inexpensively assessed. (See Chapter 11 for guidance.)
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Attitudes    Chapter 4
Behaviors    Chapter 5
Discourses    Chapter 11
Policies    Chapter 6
Knowledge    Chapters 4 & 8
Architectures    Chapter 5
Communication   Chapter 3
Tone     Chapter 5
Social hierarchies   Chapter 3
Social norms    Chapter 3
The choice of where to focus measurement is determined by both where you 
think the problem is and where you think opportunities for intervention lie. If 
your goal is to change behavior, you must measure behavior at baseline.
It is important to keep in mind that not all stigmatizing behavior is intentional. 
Indeed, some behaviors may be mandated. For example, standard TB 
control interventions, such as masking, separation, contact investigation, 
direct observation of treatment (DOT), can be perceived as stigmatizing and 
discrediting.41–43 Figure 2 illustrates how some behaviors that may stigmatize (the 
segments of the circle) can have as their root causes both value-based stigma 
and more structural origins (the outer boxes). 
Lack of knowledge
about the duration
of infectiousness
Neglect and
avoidance
behavior
Masking of 
non-infectious 
patients
Physical distancing 
from TB patients
Breaches of trust 
and con!dentiality
(deductive disclosure)
Cougher 
triaging
Patient
isolation
IC policies
Facility policies
Functionality of environmental controls (e.g. locked windows)
Stockouts of IC commodities (e.g. masks)
Lack of auditory/visual privacy
Mandatory name-based noti!cation
Figure 2. Indirect Causes of Stigmatizing Behaviors
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Figure 3. Components of the Health Care Facility that May Contribute to Stigma
Table 1. Diverse Interpretations of Healthcare Worker Behavior
What mask wearing means varies widely by region and by country. Wearing 
masks is normative in many Asian urban areas in response to air pollution or as 
a fashion accessory.44–46 In health care settings, there are often many different 
interpretations of infection control (IC) practices.19,41,47–49 The over-use, misuse, 
or prolonged use of personal protection has been a potent manifestation of 
stigma.19 As IC can be con"ated with stigmatization, it is important to assess the 
meanings attached to IC.19
Noé and colleagues found that 65% of healthcare workers in Mozambique 
agreed that their behavior contributed to TB stigma.50 One quarter of Ethiopian 
healthcare workers reported having a negative attitude toward MDR-TB 
patients.51 
A comprehensive study of stigma in health care institutions should explore 
structural-level stigma, such as norms and policies that may mandate masking, 
triage, and physical separation of TB clients (Chapter 6), but also how reality 
may depart from of!cial policies. The actual behaviors and interactions at a 
facility can belie deviations from stated policies. These unwritten (and often 
unspoken) norms are just as important. Observational techniques can help to 
tease out such issues. Secondary stigmatization of health workers by their peers 
should also be measured (Chapter 8). Figure 3 links the sites of stigma to the 
chapters that measure them.
Infection control Practices Stigmatizing Interpretation
Client separation Shunning of PWTB
Client masking Marking of PWTB (disclosure)
HCW masking Fear of PWTB
Discourses - Messages, Signage
Chapter 11
Laws, Policies, Rules, Registers
Chapter 6
Commodities, Physical Structures
Chapter 5
Community or Organizational
Norms and Behaviors
Chapters 4 & 5
Individual HCWs
and Patients
Chapters 7, 8, 10
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Measuring Stigmatizing Attitudes About TB Among 
Healthcare Workers
Stigmatizing attitudes can be measured either with surveys or observational 
methods. First we review the available scales and then consider the advantages 
and disadvantages of different observational methods. 
There are a variety of generic scales for measuring discriminatory attitudes that 
can be adapted to TB (See Chapters 4 and 14).
Wu et al found that answers to eight questions predicted willingness to provide 
directly observed therapy.52 Corrigan’s nine domain Attribution Questionnaire 
(AQ-9) may be more applicable to HCW because the coercion domain is closely 
linked to dignity and rights-based TB treatment.53 The scale uses a ten point 
likert scale.
First Author Country Population 
Content 
Validity
Construct 
Validity
Reliability Items Domains
Wu (2013)52 Taiwan HCWs
Attribution 
Questionnaire 
for mental 
illness stigma 
(AQ-S8)
PCA _=0.68 8
Attribution 
avoidance, 
sympathy, 
Respondent’s 
external stigma 
toward HCWs 
with TB
South 
Africa
HCWs CFA 3
Avoidance, 
fear, HIV 
link
Table 2. Stigmatizing Attitude Scales for Healthcare Workers
Table 3. Illustrative items based upon Corrigan Attribution Questionnaire Short Form 
AQ-9 Domain Illustrative Items
Fear How nervous are you treating TB patients?
Pity How much pity do you feel for TB patients?
Help How likely are you to help a TB patient?
Avoidance I would try to stay away from a TB patient
Blame I think developing TB is a person’s own fault.
Anger How angry do you feel towards TB patients?
Segregation I think it would be best for TB patients to be isolated in the intensive phase
Danger How dangerous do you feel TB patients are?
Coercion I think taking TB treatment should be forced if necessary
88
In 2016, Wouters et al. validated tools to measure different levels of TB and 
HIV stigma in the healthcare workforce.27,54 Wouter’s External TB Stigma scale 
for HCWs includes three items that re"ect the desire for social distance, fear of 
HCWs who treat TB, and linking TB care to stigmatized co-morbidities (Table 
4).27,28,54 The decision on whether to use Wouters, Wu or Corrigan may depend 
on available space and whether you plan to intervene narrowly on TB stigma or 
more broadly on a range of stigmas (e.g. TB and HIV stigma). 
Table 4. Wouter’s External TB Stigma Scale Items
Item No. Stigma Scale Item
Factor loadings (_ reliability 
estimate if item was removed)
Respondent’s external stigma toward HCWs with TB
10
I do not want to work together with co-workers who 
have TB
0.841 (0.813)
13 I am afraid of co-workers with TB 0.887 (0.795)
14 HCWs with TB probably also have HIV 0.602 (0.888)
Biases in Self-Reporting Stigma
Self-reporting has many important limitations for the measurement of 
stigmatizing attitudes and behaviors. Common ways around the problems of 
self-reporting and social desirability are:
t To ask the HCW about the behavior of other HCWs (not themselves). 
t To use computer-assisted self-interview (CASI) with highly literate, computer-
savvy respondents (see Chapter 7). 
t To phrase the questions in the least judgmental way possible.
It is not possible to eliminate social desirability bias completely from a survey. 
Therefore, the extent of social desirability among respondents should always be 
tested by using the Marlow-Crowne Scale. (See an explanation of the Marlow-
Crowne Scale in Chapter 4.55,56). 
Observations
Field observations allow researchers to understand TB stigma as it is produced 
without asking people whether, how, or why they stigmatize.34 Seeing daily 
practices can also highlight divergent interpretations of a shared reality. It is 
easier to measure gossip, voyeurism, taunting, scolding, and name-calling than 
inner thoughts. Social exclusion is quite visible and lends itself to observational 
measures. For example, clinic observations can allow for a witnessed account 
of the social contexts in which clients attend clinics and access TB-related 
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services, insight to their interactions with clinic staff and with other clients, and 
norms and actions practiced in a clinic environment that could affect clients’ 
overall experiences with health care (Table 3). Field observations can identify 
architectural features or health messaging that promotes stigma. There are 
structured and unstructured forms of observation. This chapter describes both. 
Field observations can elicit novel insights into discriminatory practices and 
norms that are less likely to be discussed by interview or focus group participants 
because they are considered socially undesirable or totally normal (Table 5). 
There are a variety of observational study designs, including studies in which the 
researcher becomes fully immersed in their research setting (assumes the role of 
a participant).51 
Table 5. Examples of What to Observe and Document at Clinics to Examine TB Stigma
Setting-architectures
Location in community/city, signposts, clinic layout, proximity between 
queue and provider of!ces, spacing/crowding, type of seating, posters/
"yers, ventilation/UV lighting
Human behavior
Frequency and types of interactions between people (patterns/types of 
communication, body language/touching between clients and clients 
and providers), masks/cough hygiene, social distance, microaggressions, 
tone, eye-contact
Social environment
People characteristics (types of people: clients, caregivers, providers, 
allied workers; gender; ethnicity/race; religion, clothing; physical 
appearance), human traf!c (numbers, entries/exits, accompanying 
persons, client intake/output, waiting times)
Clinical behavior
Clinical care provided (who receives which services, tests, treatments, 
advice, free samples, support, length of consultations, etc.)
Surprises and non-
occurrences
Observations that stand out: people or activities receiving more 
attention; unexpected activities: expected observations that are not 
observed, observations that do/do not appear congruent with the 
literature or interview/focus group responses; and/or absence of staff/
resources that are typically present 
Unstructured Observations
Participant observation allows researchers to build familiarity and rapport with 
study sites, from which interview or focus group participants may subsequently 
be recruited, to arrive at a more sensitive and re"exive analysis.34 Observations 
can inform the line of questioning during client interviews, including questions 
pertaining to the quality of care, interactions between clients in the clinic queue, 
relations between clients and providers, and a comparison of the social dynamics 
between multiple sites. 
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Non-participatory, unstructured observations identify how TB stigma may 
be produced or sustained in speci!c settings, such as health centers, prisons, 
mines, and other social spaces. Under this approach, the researcher serves as a 
bystander to the events that he or she observes, and subsequently documents 
and analyzes the !ndings through a process of re"exive practice. There is no set 
amount of time in which observations must be collected and analyzed. However, 
prolonged !eld engagement (e.g., a year) enhances the rigor of research.57 
Barriers to the use of observational methods are that they are time intensive, and 
often researchers do not have experience with or con!dence in conducting them.
Figure 4. Observations can highlight distinct social interactions and practices in TB and HIV clinics
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Structured Observations
Structured (or directed) observation is a more ef!cient way to measure stigma 
in interactions if desirable and undesirable behaviors can be pre-speci!ed.58,59 
A standardized checklist focuses the observer on discrete acts (e.g., greeting, 
naming, blaming, shaming). The checklist is applied in a pre-determined 
context or to a pre-determined group of people. The observer records the 
behavior and physical clues as an outsider, being as inconspicuous as possible. 
91
Figure 5. Stigma Measurement Metrics
MORE VISIBLE STIGMA EXTREME
STIGMA SUBTLELESS VISIBLE
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RIGHTS, DENIAL OF CARE,
SOCIAL EXCLUSION
FEAR, SOCIAL DISTANCE,
MICROAGGRESSION,
LABELING
Structured observation is particularly useful to measure the extent to which a 
particular “marker behavior” or event occurs; for example, a hand shake or a 
bow or other sign of mutual respect.59 Structured observation therefore allows 
for the collection of broad and in-depth information on behavior. Structured 
observations are often used in the !elds of medical education, water and 
sanitation, drug dispensing, and child health to study the quality of client-
provider interactions.60 
“Marker Behaviors” of Stigma That Can Be Observed 
Using Structured Tools
The ability to measure stigma through structured observation is predicated 
on the idea that there is a speci!c set of observable behaviors that everyone 
can agree are stigmatizing and that they can be reliably coded by a trained 
observer. Speci!c and obvious acts that are also clinically contraindicated are 
good “marker behaviors” for stigma measurement. An appropriate marker 
behavior should not require the observer to infer the motives of the observed. 
Some thinkers argue that TB stigma marker behaviors should be the more 
egregious ones.9,10 Some believe that tools should capture TB stigma in its most 
unambiguous aspects: discriminatory acts that are veri!ably attributable to TB 
attitudes alone. However, focusing on the extreme tip of the stigma iceberg does 
make measurement more straightforward (Figure 5). 
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However, extreme behavioral measurement may also not re"ect typical instances 
of stigmatization, in which stigma is likely to be displayed in more subtle ways. 
Measuring only the most offensive acts may not adequately capture what 
people with TB are experiencing. Moreover, as a policy matter, it may give false 
con!dence. The prevalence of such distinct or extreme stigma may be “too low” 
and therefore policy makers may erroneously conclude that urgency to reduce 
stigma is lacking.
There are three types of structured observation: continuous monitoring, spot 
checks, and rating checks.
Continuous monitoring encompasses observation and recording for an extended 
period of time, for example, a full day or several days. The observer should 
randomize the time and location of observations to avoid bias. (See Chapter 9 
for more information on Time Location Sampling). Note that this method would 
only be applicable for stigmatizing behaviors that occur frequently. Spot checks 
involve the observation of the presence or absence of a physical clue or behavior 
at the !rst moment of observation. This type of observation is especially useful 
to check physical clues. Its advantage is that the situation is as yet undisturbed 
by the presence of the observer. The third type of structured observation, rating 
checks, is similar to spot checks; however, in this case, the observed behavior 
or physical clue is given a value judgment by the observer. For example, while 
a spot check observation could be “TB client is greeted,” the rating check 
observation would be “TB client is greeted by name and with respect.” By 
directly adding a judgment about the behavior (with respect), the method 
provides an indication of behavior more quickly, as compared to waiting for the 
behavior to occur. Rating checks pose a speci!c challenge; making continuous, 
consistent judgments on behavior is demanding for observers. This method 
should be preceded by intensive training and harmonization for the observers to 
ensure inter-rater reliability.59
Developing Structured Observation Instruments
Formative research with people with TB provides data on marker behaviors that 
are locally relevant. Cognitive interviewing and other techniques should be used 
to re!ne the de!nition of each behavior and to enable it to be reliably coded in 
an observation.
The questions in Table 6 are not themselves stigma measures; rather, they allow 
for the collection of data on the enabling conditions. They are meant to be 
illustrative of the types of speci!c, unambiguous, observable phenomena that 
would need to be measured. For example, breaches in con!dentiality may be 
facilitated by a facility infrastructure that limits privacy.
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Yes No
1. Is there a space dedicated to TB consultations?
2. Can conversations in the exam room be heard outside the room?
3. Can the client be seen from outside the exam room?
4. Are there interruptions during the TB consultation?
5. Is there any physical wall or glass between client and provider?
6. Is there suf!cient air ventilation in the room (e.g., open window) to protect the   
    HCW?
7. Are there educational materials (e.g., posters, videos, pamphlets, job aids) about       
    TB in the TB clinic?
8. If yes, do images or text of materials convey fear, danger, pity, or death?
Table 6. Example of a Structured Observation Tool to Measure the Enabling Environment for TB 
Stigma
The structured observation of conversations and interactions requires clarity and 
speci!city about precisely which acts constitute an af!rmative answer to each 
question. This requires thorough observer training and harmonization. Table 7 
provides some examples that seem clear at !rst glance, but once applied, may 
be too ambiguously worded to yield reliable and valid results. For example, there 
could be different interpretations of what constitutes “listening carefully”.
Steps and Goals in the Use of Structured Observations
To implement the structured observation method, there are sequential steps to 
follow (adapted from Bentley et al.).58
1. Decide if structured observations are needed and can be done considering 
available resources
a. Determine the needs of the stigma project.
b. Determine if structured observations are necessary to meet these 
research needs.
c. Decide if available resources are suf!cient to do structured observations.
Yes No
1. Was the client greeted in a friendly manner by the HCW?
2. Was the PWTB asked by the HCW if they had any questions or concerns?
3. Did the provider listen carefully to the client? 
4. Were value-laden terms or labels used by the HCW?
5. Were negative stereotypes or motives of clients expressed or implied?
6. Was there any use of blaming or shaming by the HCW? 
7. Was there exaggeration of dangerousness or risk by the HCW?
8. Were there any threats made or coercive language used by the HCW?
9. Did HCW state that clients’ health information would be protected?
Table 7. Example of a Structured Observation of a Client-Provider Encounter
94
2. Generate a list of potential “key” or “marker” behaviors through a literature 
review and interviews with informants
a. Review the literature and brainstorm.
b. Develop a preliminary list of key behaviors.
3. Conduct formative qualitative research to identify which behaviors and how 
behaviors should be observed (See Chapter 3 for methods).
a. Develop a !eld guide.
b. Conduct the qualitative investigation. (See Chapter 17)
4. Re!ne the list of key behaviors and determine the heterogeneity of the 
population.
a. Re!ne the list of behaviors to be observed in a structured format.
b. Determine behavioral markers, if needed.
c. Ascertain gender, cultural, cadre, and role heterogeneity of the study 
population.
d. Check the work thus far and considering decisions made in Step 1.
5. Identify who to observe, where and when
a. Identify who (and what) to observe.
b. Identify locations where key behaviors occur.
c. Identify times that key behaviors occur.
6. Choose type(s) of structured observations to conduct
a. Use "ow chart to select the type(s) of structured observations.
7. Estimate the reactivity and variability of key behaviors
a. Select test sites.
b. Estimate variation in key behaviors.
8. Design instruments and data sheets
a. Operationalize and de!ne key behaviors.
b. Design continuous monitoring/spot check instruments.
c. Develop ratings checklist, if required.
d. Prepare observation summary.
9. Determine data collection schedule
a. Determine the number of days for data collection.
b. Determine the mean number of observational episodes that can be 
conducted by one observer.
c. Determine the number of observers required to conduct structured 
observations.
10. Train observers and pretest instruments
a. Involve observers in the development of structured observations.
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b. Develop !eld manual and code books and carry out the training.
c. Pretest instruments.
d. Conduct reliability tests to reduce inter- and intra-observer variability.
11. Implement data collection and data management
a. Conduct the structured observations.
b. Review data sheets and store properly.
12. Clean data set(s)
a. Conduct range checks.
b. Conduct consistency checks.
13. Process the data
a. Determine frequencies of key behaviors.
b. Determine the amount of time spent on key behaviors.
c. Create behavioral scales or scores.
14. Conduct data analysis and use study results for project planning, 
implementation, or evaluation
a. Do descriptive analysis.
b. If necessary or desirable, do further statistical analysis.
A limitation of observational methods is that while they elucidate behaviors, 
they provide limited insight into why or what prompts such behavior. 
Identifying people’s motives requires a more interactive approach. Many people 
affected by TB are managing multiple stigmatized identities (e.g., a person 
may have a history of incarceration).61 This makes measurement of enacted 
stigma additionally challenging. Asking broad, close-ended questions about 
discrimination experiences, one risks con"ating many different types of prejudice. 
Therefore, speci!city of the items is essential to make sure that what you are 
measuring is TB stigma and not other types of prejudice. (See Chapter 14 on 
measurement of intersectional stigmas.) Finally, data analysis of structured 
observations is usually complex and often requires the assistance of a statistician.
Bias from Being Observed
A major challenge in observational studies is that the people observed may 
change their behavior in response to being observed. This is known as the 
Hawthorne effect.57 Researchers do not agree on the extent of the bias that 
may be caused by the use of observation. Some experts believe that arti!cial 
socially desirable behavior is energy-intensive to maintain over long periods of 
observation and, therefore, bias can be reduced through longer observation 
intervals. It is crucial that the observer receives proper training in order to be 
neutral (structured) and/or re"exive (unstructured) toward the interactions under 
observation.
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Additional Resources:
The World Health Organization has several handbooks in multiple languages on 
observation of client interactions:
http://apps.who.int/medicinedocs/en/d/Js2289e/
Mystery Clients or Surrogate Patients for Studying 
Stigma in Institutions
Techniques such as “surrogate patients,” “standardized patients,” “simulated 
patients,” or “mystery clients” may also be appropriate for the study of 
stigmatization. These terms refer to the use of trained actors to measure the 
quality of health care.62 The actors are trained to follow a script, describing 
a series of symptoms and characteristics.63–65 They observe and describe any 
stigmatizing experiences.66 The advantage of using trained actors posing as TB 
clients is the ability to measure the variability of responses with a speci!c type of 
client, especially those who may be at more risk for stigmatization (e.g., female 
TB client who uses alcohol). Mystery clients have been used extensively in the 
!eld of family planning to measure the quality of care. 
The use of mystery clients raises a host of ethical and informed consent issues. 
Consent is often only sought from the institution and, therefore, healthcare 
workers often do not realize that they are participating in research. Healthcare 
workers therefore need to be protected from professional harm associated with 
the use of such techniques.
Exit Interviews
Exit interviews with actual TB clients is also a common approach for collecting 
data on the quality of interactions between providers and clients.67–70 Exit 
interviews are conducted as a client is leaving a health service encounter to 
explore the quality of that encounter before recall bias limits the quality of the 
information.71 Exit interviews have been used extensively in TB research. See 
Chapter 7 for a comprehensive discussion of exit interviewing people with TB 
about stigma.
Considerations When Choosing a Methodology
Each of the methods presented above has advantages and disadvantages. The 
choice of method to use depends on your study questions, the acceptability of 
the method in the target group, and the resources you have available (Table 
8). Unstructured observation is necessary for informing the development of 
structured instruments, but it is hard to operationalize across multiple settings or 
on a large scale.
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Table 8. Comparison of Different Methods for Quantitative Measurement of Stigma in Institutions
Structured Observations Exit Interviews
Simulated Client 
Interviews
Ideal for measuring
tMicroaggression
tValue-laden terms
tQuality of health 
worker-client rapport
tNon-verbal 
communication
Clients’ perceptions of 
what occurred and how 
they were treated
tHealthcare worker 
responses to speci!c 
types of clients
tMicroaggression
tValue-laden terms
tQuality of health 
worker-client rapport
tNon-verbal 
communication
Advantages
tMore reliable than oral 
communication; veri!es 
what people actually do
t Information can be 
quanti!ed
t Interactions between 
clients and health 
workers can be 
observed in the 
“natural” context
tQuick way to collect 
data
t Information can be 
quanti!ed
tCan be used in 
combination with 
observations
tVeri!es what people 
actually do
tQuick way to collect 
data
Disadvantages
tDif!cult not to in"uence 
the interaction because 
of researcher’s presence
t Ethical question: may 
be impractical to ask 
informed consent of 
each new client
tDif!cult to analyze 
because of researcher’s 
own involvement in the 
interaction
tHeavily dependent on 
the skills of the observer
tObservation may 
alter behavior of the 
observed
Clients may be 
inclined to give socially 
desirable answers 
(to please the health 
workers)
Ethical question as to 
whether it is acceptable 
to collect data with 
only institutional 
(but not individual 
healthcare worker) 
informed consent
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Sample Size Considerations
The relational nature of stigma makes considerations of sampling issues very 
important. Stigmatizing attitudes and behaviors are typically clustered.3,72 There is 
considerable intra-country, inter-facility, and intra-facility variation.3,73 This implies 
that the sample sizes for stigma surveys need to be adjusted upward by a design 
effect to account for the non-random distribution of stigma and the potential for 
selected clusters to be extreme. In practice, this means including as many facilities 
as logically feasible.
Figure 6 shows how exposure to stigma in a health setting is not usually randomly 
distributed across clients; rather, it is clustered by site and often by TB care 
provider. Stigma measurement in health care settings has found that stigma is 
clustered in facilities.74 Similarly, there is geographic clustering.74,75 This means 
that when clusters are used (i.e., speci!c districts or health facilities are chosen), 
it is vital to try to describe the nature of the speci!c exposures that clients have 
and to limit the in"uence that a single person with extreme behavior could have 
on the validity of the measurement process. For example, HCW #7 treats seven 
clients (patients “m” through “s” in Figure 6) and has more potential stigmatizing 
in"uence on patients than does HCW #1, who treats only two patients (a and 
b). Maximizing the number of clusters and decreasing their size is a good way to 
reduce the potential for bias.
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Statistical formulas for multi-stage cluster survey sample size calculations are 
explained in Chapters 4, 7, and 9. All formulas require you to input a design 
effect in the formula, which can only really be known after the survey is 
completed. In practice, this means that you should make an educated guess 
about how much clustering is going on based on previous studies.
Conclusion
The study of interactions between and among people in institutions may 
provide the most interesting unit of analysis for the study of stigma because 
changing abusive dynamics is our end goal. Standardized observational 
techniques are not yet well-developed for measuring TB stigma in health 
facilities, but we can leverage established tools from other health !elds. A 
health care facility is a complex ecosystem. In addition to the measurement 
of stigmatizing behaviors described here, one could measure TB stigma 
embedded in norms and policies (Chapter 6), discourses (Chapter 11), 
attitudes of HCWs (Chapter 8), and perspectives of people with TB 
(Chapters 7 and 10). A holistic assessment of this kind would serve as a solid 
basis for stigma reduction interventions and evaluation.
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Figure 6. Example of how stigma may be clustered within and among facilities
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Chapter 6
Measuring Structural Stigma - Human 
Rights and Legal Discrimination
Brian Citro, Assistant Clinical Professor of Law, Northwestern Pritzker School of Law
Abstract
Measuring structural stigma against people with TB is a methodological 
challenge. At its core, it involves assessing whether the legal regime respects 
the dignity, equality and autonomy of affected communities and understanding 
the relationship between stigma and discrimination. Human rights law provides 
a useful foundation for this. Structural stigma against people with TB is most 
pernicious when it manifests in enacted stigma, i.e., discriminatory laws and 
policies or the discriminatory application of otherwise neutral laws and policies 
in areas of special focus. These include, but are not limited to, health care, 
employment, education, prisons, immigration and asylum, housing, and public 
bene!ts. The absence of legal protections and the failure to protect the human 
rights of people with TB are just as harmful. In order to identify and measure 
structural stigma, it is also critical to understand the attitudes of institutional 
actors and how discriminatory laws and the absence of legal protections impact 
affected communities.
This chapter discusses methods to assess the relationship between stigma, 
discrimination and law. It addresses the primary sources of law that make-
up national legal regimes, including constitutions, legislation, policies and 
regulations, and case law. It presents a human rights-based tool to measure 
structural stigma against people with TB through assessment of these sources of 
law. Finally, it provides guidance on how to measure compliance with the legal 
regime on the ground. 
Objectives
This chapter aims to:
1. Examine and clarify the relationship between structural stigma, enacted 
stigma, and discrimination against people with TB.
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2. Develop capacity in applying human rights assessment standards for 
measuring structural stigma against people with TB.
3. Build skills in assessing national legal regimes and gauge on-the-ground 
compliance to measure structural stigma against people with TB.
Target Audience
This chapter is intended for communities, people affected by TB, national TB 
program staff, implementing agencies, NGOs, CBOs, USAID technical staff, 
WHO, and other partners and advocates. Users are not expected to be trained 
in law, although the concepts and tools developed in the chapter will be most 
easily utilized by lawyers. Familiarity researching and analyzing constitutions, 
legislation, policies and regulations, and case law is valuable, but the chapter 
provides clear guidance on how this research and analysis should be conducted. 
Introduction
This chapter aims to examine, clarify, and present tools to measure structural 
stigma against people with TB. It focuses on assessing the components of 
national legal regimes (constitutions, legislation, policies and regulation, and case 
law) in areas of special focus, with concern for key populations at high risk of TB. 
The chapter provides guidance on how to assess laws and policies using human 
rights standards based on international human rights law.
We know that stigmatized groups experience inequities in employment, 
education, and health care settings, as well as poor health outcomes and 
challenges in their interpersonal relationships.1 But what shape does this kind of 
stigma take at the societal level against people with TB?
Structural stigma refers to the “legitimatization and perpetuation of a 
stigmatized status by society’s institutions and ideological systems.”2 Another 
de!nition highlights the impact of structural stigma, de!ning the phenomenon 
as “societal-level conditions, cultural norms, and institutional practices 
that constrain the opportunities, resources, and well-being for stigmatized 
populations.”3 In both cases, structural stigma is de!ned by its operation at the 
societal level through institutions and norms. Stigmatized individuals in society 
experience constrained opportunities, reduced access to resources, and negative 
impacts on their well-being. Put simply, examining structural stigma requires us 
to consider “all manner of disadvantage [that] can result outside of a model in 
which one person does something bad to another.”4
The impact of structural stigma occurs by way of enacted stigma: the negative 
treatment of a person possessing a stigmatized condition.5 Enacted stigma 
comprises “instances of discrimination against people...on the grounds of their 
perceived unacceptability or inferiority.”6 Here we see the connection and 
How do TB control laws 
and policies mitigate or 
sustain TB stigma?
Structural stigma is 
de!ned by its operation at 
the societal level through 
institutions and norms. 
Stigmatized individuals 
in the society experience 
constrained opportunities, 
reduced access to 
resources, and negative 
impacts on their well-
being.
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transformation of stigma to discrimination. Enacted stigma can occur through 
person-to-person treatment, but it also operates through discriminatory laws and 
policies, the discriminatory application of facially neutral laws and policies, the 
absence of legal protections, and the failure to enforce the rights of stigmatized 
persons. 
In addition to explicitly discriminatory laws and policies and the intentional, 
discriminatory application of otherwise neutral laws and policies, discrimination 
of people with TB may be indirect. Indirect discrimination involves a law, policy 
or other measure that does not directly—i.e., explicitly or intentionally—
discriminate on the basis of TB, but nonetheless produces a discriminatory 
impact.7 For example, a public housing policy that requires all applicants to 
submit a full record of their medical history in order to obtain housing, may 
result in discrimination against people with TB if the information is used by 
administrators to reject their applications. There is no universal agreement on 
the boundaries between indirect and direct discrimination and structural and 
enacted stigma. Figure 1 below illustrates the overlapping relationships among 
the phenomena.
Figure 1. Relationship among discrimination and stigmatization
Indirect 
Discrimination 
against people 
with TB
Structural 
Stigmatization 
of people with 
TB
Direct 
Discrimination 
against people 
with TB
Enacted Stigma 
against people 
with TB
Importantly, enacted stigma excludes “fair or legitimate discrimination,” 
whereby people are prohibited from engaging in certain kinds of activities 
because they are, in fact, incapable of doing so. For instance, a law that prohibits 
individuals with complete vision loss from driving is not an example of enacted 
stigma. On the other hand, a law prohibiting a person with visual impairment 
from using public walkways could be a form of enacted stigma. In the context of 
TB, for example, a law that prohibits people with TB from occupations involving 
customer contact during the entire period of their treatment is overly broad and 
a form of enacted stigma. People with TB are not contagious and thus pose no 
threat to customers shortly after starting appropriate treatment. In other cases, 
legal protections needed to prevent common forms of enacted stigma against 
people with TB or to provide redress for human rights violations simply do not 
exist. For instance, employment discrimination against people with TB and TB 
survivors, including dismissal and refusal to hire on the basis of TB, is rarely 
explicitly prohibited by law, even though such discrimination is common.
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As stated in Chapter 1, enacted and structural stigma are dependent on the 
power to adopt and enforce discriminatory laws and policies and the power to 
refrain from enacting or implementing legal protections.9 It is the power of the 
law that operates through national legal regime that creates, perpetuates, and 
exacerbates structural stigma against people with TB. This chapter will focus on 
the vital social institution of the law, as manifest in the text and implementation 
of national constitutions, legislation, policy and regulations, and case law, in 
areas of special focus, with concern for key populations. For more stigma analysis 
of texts such as health communication, see Chapter 11.
Challenges 
Measuring structural stigma against people with TB is a methodological 
challenge. First, there are signi!cant research challenges. In order to identify 
and examine the sources of law, we must have access to the documents. Many 
countries make their legislation, policies and regulations, and case law available 
online, at government websites or in public databases, but some do not. Second, 
some degree of familiarity reading and interpreting legal language is very helpful. 
Otherwise, we may misunderstand or fail to identify important provisions or 
principles in the documents. Third, even when constitutions, legislation, policies 
and regulations, and case law are correctly interpreted, we must measure their 
levels of compliance and implementation to fully measure structural stigma.
Existing Tools to Measure Structural Stigma against 
People with TB
No tools currently exist to measure structural stigma against people with TB. 
Studies have been conducted to measure other forms of stigma associated 
with TB,10 but these are not helpful in developing a tool to assess legal regimes. 
A variety of tools have been developed to measure various kinds of stigma 
associated with HIV, including some examining structural stigma.11 They also 
review discriminatory laws and policies and attempt to identify gaps in legal 
protections, but they do not present comprehensive models.
The Stop TB Partnership has developed an Operational Guide to conduct a 
legal environment assessment for TB.12 The guide provides detailed direction 
on how to identify and analyze laws, policies, and practices that pose barriers 
to accessing TB services. It is founded on a human rights-based approach to 
prevention, treatment, and care of people with TB, and instructs users on how 
to advocate for TB programs to address barriers in national contexts. The guide 
does not provide a tool to measure structural stigma. The concept of structural 
stigma is not mentioned in the guide, although stigma is acknowledged as a key 
concern for the legal environment assessment.
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Human Rights and Structural Stigma: Developing 
Standards of Assessment
“Stigma, discrimination, and human rights violations form a vicious, 
regenerative circle. … Condoning human rights violations can create, legitimize, 
and reinforce stigma that can, if left to fester, lead to discriminatory action and 
further human rights violations.”13
This observation was made more than 14 years ago in an article examining 
HIV-related stigma and discrimination. Unfortunately, it applies with equal force 
today to TB. Human rights in international and regional legal instruments provide 
a foundation to build a robust set of standards to assess structural stigma against 
people with TB. Just as human rights violations create, legitimize and enable 
stigmatization, the incorporation of human rights principles in constitutions, 
legislation, policies and regulation, and case law helps protect against structural 
stigma. Human rights law therefore provides a universally accepted framework 
to develop assessment standards for measuring structural stigma, allowing us to 
identify priorities and develop baselines using speci!c legal content. 
Stigmatizing 
attitudes 
rationalize 
exclusion
Enactment of 
discriminatory 
laws and policies 
or discriminatory 
application of 
neutral laws and 
policies
Normalization 
of stigmatizing 
attitudes and 
behaviors
Exclusion of 
stigmatized 
groups
Human Dignity
The concept of human dignity acts as a nexus between human rights and 
structural stigma. Dignity is the backbone of human rights law. A legal system 
that respects and upholds human rights respects the dignity of its people. 
Two prominent concepts of human dignity are closely associated with stigma: 
dignity as the maintenance and respect of social status and dignity as the 
Figure 2. Role of legal discrimination in compounding discriminatory attitudes and behaviors 
Protection and ful!llment 
of human rights results in 
greater recognition and 
respect for the dignity, 
equality, and autonomy 
of people with TB, which 
in turn reduces structural 
stigma.
Human dignity - the 
inherent and equal 
worthiness of all human 
beings deserving of self-
respect and the respect of 
others.
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Table 1. Human Rights Assessment Standards
principle of non-instrumentalization. The latter simply means that people should 
not be used as a means or an instrument to other people’s ends. They must be 
respected and treated as autonomous, equal individuals. 
 
Stigma violates human dignity. The stigma process has been described as 
entailing a general “downward placement of a person in a status hierarchy,” 
thereby depreciating the person’s social status.14 The imposition of stigma 
through power, including structural stigma, has a signi!cant negative impact on 
the life chances and opportunities of the stigmatized group,15 thereby reducing 
their autonomy and equal status in their community.
Protection and ful!llment of human rights results in greater recognition and 
respect for the dignity, equality and autonomy of people with TB, which in turn 
reduces structural stigma.
Human Rights Assessment Standards
The content of human rights law provides standards with which to assess the 
level of structural stigma against people with TB in national legal contexts. 
Developing these standards involves three steps: (1) identify the relevant 
human rights and sources, (2) clarify their pertinent, health-related content and 
meaning, and (3) apply the rights to the context of TB as they relate to the legal 
regime. Table 1 contains this analysis for human rights of particular importance 
to people with TB and to assessing legal regimes to identify structural stigma.
The list of rights and their sources in Table 1 is not meant to be exhaustive; there 
are other rights important for people with TB, and the rights listed may appear in 
other sources. The examples of content and application are not exhaustive either, 
but rather highlight a critical issue related to each right for people with TB.
Principle of non-
instrumentalization - the 
principle that people 
should not be used as 
means or an instrument 
to other people’s ends; 
instead; they must be 
respected and treated 
as autonomous, equal 
individuals.
Human Rights (and Sources) Health-Related Content
Application to TB in Legal 
Regime
Right to life
Sources: UDHR, ICCPR, ICMW, 
ACHPR, IACHR, ECHR, 147 
constitutions.16
States must adopt positive 
measures to protect life, to 
eliminate epidemics, and ensure 
access to medical care.17
States must adopt measures 
in law and policy to protect 
the lives of people with TB, 
including ensuring access to 
testing and treatment.
112
Right to health
Sources: UDHR, ICESCR, 
ICERD, CRC, CEDAW, 
ICMW, CRPD, ACHPR, 131 
constitutions.18
States have a core obligation 
to provide essential medicines 
on the WHO Model List of 
Essential Medicines.19
Section 6.2.4 of the 19th 
WHO Model List of Essential 
Medicines includes !rst- and 
second-line anti-tuberculosis 
drugs, including bedaquiline 
and delamanid. States must 
adopt laws and/or policies 
that ensure people with TB are 
provided these medicines.
Right to be free from 
discrimination
Sources: UDHR, ICCPR, 
ICESCR, ICERD, CEDAW, 
ICMW, CRPD, ACHPR, IACHR, 
ECHR, 142 constitutions.21
Prohibition of discrimination 
based on “other status” 
includes health status and direct 
and indirect discrimination in 
the public and private spheres.22
People with TB must be 
protected by law against 
discrimination in both the public 
and private spheres, including 
employment, education, 
housing, health care settings, 
etc.
Right to be free from torture 
and other cruel, inhuman 
or degrading treatment or 
punishment
Sources: UDHR, ICCPR, CAT, 
ICMW, ACHPR, IACHR, ECHR, 
150 constitutions.23
Failure to provide adequate 
medical care to prisoners and 
other people deprived of their 
liberty constitutes inhuman and 
degrading treatment.24
Law and policy must ensure 
people with TB in prisons and 
other detention centers are 
provided testing and treatment 
services.
Right to privacy
Source: UDHR, ICCPR, ICMW, 
CRPD, ACHR, ECHR, 167 
constitutions.25
Right to privacy includes the 
right to keep information 
related to health and health 
status private.26
Law and policy must establish 
the right of people with TB to 
keep their health status and 
other health-related information 
private and con!dential, except 
from those to whom they pose 
a real risk of transmission, and 
then only for the duration of 
the risk.
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Right to liberty and security of 
person
Sources: UDHR, ICCPR, ICERD, 
ICMW, CRPD, ACHPR, IACHR, 
ECHR, 149 constitutions.27
Any deprivation of liberty 
must be necessary and 
proportionate to protecting the 
individual from serious harm or 
preventing injury to others. It 
must be applied only as a last 
resort, for the shortest period, 
accompanied by adequate 
procedural and substantive 
safeguards established by law.28
Law and policy must establish 
clear protections against 
involuntary detention or 
isolation of people with TB, 
except under exceptional 
circumstances, as a last resort, 
when a person is known to be 
or highly likely to be contagious 
but refuses treatment or testing 
and all reasonable measures to 
ensure adherence have been 
unsuccessful. In these cases, the 
least restrictive measure possible 
must be used, isolation must 
occur in an appropriate medical 
setting, and the individual must 
be provided treatment, basic 
necessities and the right to 
appeal the isolation decision.29
Right to participation (to take 
part in the conduct of public 
affairs)
Sources: UDHR, ICCPR, ICERD, 
ICMW, CRPD, ACHPR, IACHR, 
158 constitutions.30
The “conduct of public affairs” 
is a broad concept, comprising 
legislative, executive, and 
administrative powers, and all 
aspects of the formulation and 
implementation of policy at 
international, national, and local 
levels.31
The law must establish and 
facilitate the right of people 
with TB and TB survivors to 
be involved in the formulation 
and implementation of law and 
policy implicating TB at the 
international, national, and local 
levels.
Right to asylum 
Sources: UDHR, Convention 
relating to the Status of 
Refugees,32 ACHPR, ADRDM, 
IACHR, 88 constitutions.33
Everyone has the right to 
seek and enjoy asylum from 
persecution in other countries 
without discrimination.34
The law must establish the right 
of people with TB to receive 
asylum without discrimination 
based on their health status. 
It should allow for asylum 
consideration based on a 
high risk of contracting TB 
in a person’s home country, 
including when a person is likely 
to be detained in a prison with 
high rates of TB disease.
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Right to adequate housing 
(right to shelter)
Sources: UDHR, ICESCR, 
ICERD, CRC, CEDAW, ICMW, 
CRPD, 72 constitutions.35
Housing must be accessible, 
affordable, and habitable, 
providing adequate space, 
ventilation, and protection 
from threats to health and 
disease vectors, especially for 
disadvantaged groups, such 
as people living with HIV and 
those with persistent medical 
problems.36
Law and policy must ensure 
affordable housing with 
adequate ventilation is 
accessible to the urban poor to 
help prevent transmission of TB 
in overcrowded
Right to food
Sources: UDHR, ICESCR, CRC, 
CRPD, 24 constitutions.37
States must ensure everyone 
under their jurisdiction can 
access minimum essential food 
that is suf!cient, nutritious, and 
safe, with priority consideration 
given to disadvantaged 
groups.38
Law and policy must provide 
people with TB access to 
adequate, nutritious food 
during treatment, as under-
nutrition and low body mass 
index are associated with poor 
treatment outcomes.
Right to education
Sources: UDHR, ICESCR, 
ICERD, CRC, ICMW, CRPD, 
134 constitutions.39
Education must be accessible 
to all, especially the most 
vulnerable groups, in law and 
fact, without discrimination, 
including for persons with 
disabilities, children of migrants, 
and other disadvantaged 
groups.40
Children with TB must be 
protected by law against 
discrimination at school. They 
must be allowed to attend 
normal classes, unless and only 
for as long as they pose a real 
risk of transmission to their 
classmates.
Developing a Structural Stigma Measurement Tool
Measuring structural stigma against people with TB requires a careful assessment 
of a country’s legal regime to identify both discriminatory laws and policies and 
a lack of necessary legal protections. This section lays out areas of special focus, 
key populations of particular concern, and the sources of law to be examined: 
constitutions, legislation, executive policies and regulations, and case law. It 
provides guidance on how to obtain and analyze the text of the sources of 
law to identify stigmatizing language. It utilizes the human rights assessment 
standards developed above to formulate key questions in assessing the legal 
regime. Finally, it considers how to measure compliance with the legal regime 
on the ground through legal implementation, the attitudes of institutional actors 
and experiences of affected communities, and empirical indicators.
Areas of Special Focus
Stigma against people with TB manifests in a myriad of ways. It takes on a 
structural form in the laws and policies that regulate activity in certain areas of 
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special focus, i.e., areas in the lives of people with TB that intersect with and are regulated by the 
government. In these areas, people with TB are particularly vulnerable to structural stigma. Areas 
of special focus may depend on the country context, but often include health care, employment, 
education, prisons, immigration and asylum, housing, and public bene!ts. For more on this, see 
Chapter 14 on intersectional stigma.
Key Populations
Key populations include people who have increased exposure to TB due to where they live or work, 
people with limited access to good quality TB services, or people at increased risk for TB due to 
biological or behavioral factors.41 The Stop TB Partnership has identi!ed 10 key populations, although 
more may exist depending on the country context: children, health care workers, mobile populations, 
miners, people who use drugs, prisoners, people living with HIV, rural poor, urban poor, and 
indigenous populations.42 Special attention must be paid to the ways laws and policies impact these 
groups when assessing the legal regime to measure structural stigma.
Obtaining the text of sources of law
The text of sources of law can be obtained in multiple ways. Text can be obtained by requesting the 
documents from the responsible government entity, such as the legislature, government agency, or 
court. Many sources of law can be obtained online in of!cial government databases. For example, 
legislation.gov.uk, congress.gov, and indiacode.nic.in contain the texts of legislation in the United 
Kingdom, United States, and India, respectively.
The text of regulations and policies are often available on the website of the government agency 
that drafted and promulgated the regulations. For example, the regulations of the Department 
of Health of South Africa are available at health.gov.za. Sources of law can also be obtained in 
nongovernmental databases. National constitutions are available online in a free, searchable database 
at constituteproject.org.
Case law can also be obtained in government and nongovernmental databases online. Some 
countries make their case law available on their courts’ government websites.43 Several free 
nongovernmental databases provide access to case law. For example, the World Legal Information 
Institute provides free access to more than 1,000 databases covering more than 120 jurisdictions. 
Google Scholar provides a free database of U.S. cases. The Global Health and Human Rights 
Database provides free access to cases involving health and human rights from around the world. 
Case law is also available in databases accessible with a paid subscription, such as Westlaw, 
LexisNexis and Bloomberg Law.46 Case law databases provide search functions that allow users to 
search for keywords, case names, and case citations.
Analyzing the text of sources of law
The text of sources of law can be analyzed quantitatively or qualitatively. If texts are numerous 
and available in digital form, then quantitative content analysis may be possible.47 In these cases, 
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computer software can be used to reduce the amount of human reading 
required. In general, choosing an analytic approach depends on how much text 
you have, how subtle and nuanced your examination needs to be, and whether 
the texts are available in a digital form.
Table 2. Choosing an Analytic Approach to Analyze the Text of Sources of Law
Advantages Disadvantages
Quantitative Content 
Analysis
tCan be done in teams.
t Some aspects may be automated.
tOften seen as more legitimate by 
stakeholders who privilege use of 
data and numbers.
tRequires a very clear, replicable 
de!nition of stigma and training 
to ensure inter-rater reliability of 
coders.
tDif!cult to ensure suf!cient 
sample size.
(Qualitative) 
Discourse Analysis 
(Ch.11)
tAllows for unexpected forms of 
stigma to be discovered.
tCan reveal discursive frame and 
arguments.
tCan reveal what is unstated, 
implicit or absent.
t Large data sets require many 
hours to analyze.
tRequires skilled and meticulous 
analysts.
For a detailed discussion of how to conduct discourse analysis, please see 
Chapter 11.
The text of sources of law may include explicit language that marks people 
with TB as different than people without the disease, labels people with TB 
using stereotypical or denigrating terms, blames people with TB for concerns 
related to the disease, or overemphasizes the peril people with TB represent to 
their communities.48 The Stop TB Partnership “United to End TB — Every Word 
Counts: Suggested Language and Usage for Tuberculosis Communications” 
provides guidance in identifying stigmatizing terms and offering substitutes.49 
The key terms for which substitutes are provided in the guidance are presented 
in Table 3. The text of each source of law should be searched to determine if 
these or other stigmatizing terms are used, or if their non-stigmatizing substitutes 
or equivalents are used instead. Searching the text of a source of law involves 
reading it carefully and using digital search functions like CTRL-F on a computer 
keyboard for searchable !les (Word documents and most PDFs).
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Table 3. Stigmatizing and non-stigmatizing TB terms from Stop TB Partnership “United to End TB - 
Every Word Counts: Suggested Language and Usage for Tuberculosis Communications”
Stigmatizing Term Non-Stigmatizing Term
People/person suffering from or infected by TB People/person with TB
Treatment defaulter Person lost to follow-up
Treatment compliance or noncompliance Treatment adherence or non-adherence 
TB control TB prevention and care
TB suspect Person to be evaluated for TB
Stigma, however, is not always blatant or explicit. Sources of law can contribute 
to structural stigma without using explicitly stigmatizing language. The 
placement of two ideas in close proximity in a paragraph may be enough to 
have a stigmatizing effect. In the case of TB stigma, laws can be embedded with 
assumptions about the untrustworthiness, irresponsibility, or sel!shness of people 
with TB. These may not be explicit in the text, but may be revealed by discourse 
analysis. Some of the ideas that should be coded when analyzing a legal text 
include phrases that:
t Introduce new language and terms to connote otherness.
tMedicalize or pathologize difference.
tDehumanize people with TB or refer to them as objects (e.g., only referring to 
TB cases).
tCreate stereotypes (e.g., dangerous, unpredictable, untrustworthy, 
noncompliant, or secretive).
t Link people with TB to other disparaged groups or identities.
t Infantilize people with TB, or de!ne them as victims, lacking autonomy and 
agency.
t Blame people with TB.
tOver-emphasize the danger of TB to normalize exclusion or render people 
with TB unworthy of consideration, investment, or meaningful engagement.
In addition to searching for speci!c terms or phrases, the text of each source of 
law should be analyzed using questions based on the human rights assessment 
standards. The objective of developing and applying these questions is to 
determine whether the meaning or likely application of the text is stigmatizing, 
discriminatory, or fails to protect against discrimination, or, on the contrary, 
whether it protects against discrimination and promotes the human rights of 
people with TB.
The human rights assessment standards presented in Table 1 should be 
referenced to formulate effective questions to analyze the text. For example, the 
human rights assessment standard for the right to privacy establishes the right 
of people with TB to keep their health status private and con!dential, except 
from those to whom they pose a real risk of transmission, and then only for 
the duration of the risk. Figure 1 provides examples of questions based on this 
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standard. Additional examples of the questions to be used to analyze text are 
provided below for each source of law.
Figure 3. Questions to Assess Sources of Law based on Human Rights Assessment Standards
In the event that there are too many legal texts to read in full, a sampling plan 
may be used to ensure the chosen documents are representative. Techniques 
for probability sampling of legal texts are beyond the scope of this chapter, but 
instructions on how to do sampling are available in Chapter 5 of Riffe, Daniel, 
Stephen Lacy, and in Frederick G. Fico. 2005. Analyzing Media Content: Using 
Quantitative Content Analysis in Research. 2nd ed. Mahwah, New Jersey: 
Lawrence Erlbaum Associates.
Sources of Law and Assessment Questions
A country’s legal regime consists of constitutions, legislation, executive policies 
and regulations, and case law. Each source must be examined to measure 
structural stigma against people with TB. The !gures below provide a visual 
representation of the measurement tool and its application for each source, with 
examples of assessment questions in areas of special focus. The areas of special 
focus in each !gure come from the list provided above, with consideration for 
the areas most often addressed by each source of law. The assessment questions 
are based on the human rights assessment standards, taking into consideration 
concerns about key populations. For each source of law, they aim to identify 
Human Rights Assessment Standard
Application to TB in Legal Regime 
Questions for Assessment
Right to Privacy
Law and policy must establish the right of people with TB to keep their health status and other health-related 
information private and con!dential, except from those to whom they pose a real risk of transmission and only for 
the duration of the risk.
Does policy establish and provide clear 
guidelines for health workers to respect 
rights to privacy and con!dentiality of 
health information and status?
Does legalization establish rights to privacy 
and con!dentiality of health information 
and status, including for TB?
Does case law recognize employees’ right 
to privacy in health information and status, 
including for TB, vis-à-vis employers? 
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positive provisions or actions, stigmatizing or discriminatory provisions or actions, 
and gaps in legal protections. Assessment questions may be used in analysis 
and for interviewing government of!cials and other stakeholders. While a “yes” 
or “no” answer to an assessment question is an indication of the presence of 
positive or stigmatizing provisions in a law, further inquiry should be made 
to determine whether processes are ongoing to modify, amend, or repeal the 
provision in question.
Constitutions
National constitutions are the supreme law of the land. They are the highest 
source of law and rights in most countries. All legislation, policies, and 
regulations must conform to the constitution and are guided by its content. In 
countries with federal systems, sub-national governments, such as provinces and 
states, may also have constitutions. 
Although constitutions are not likely to contain speci!c references to TB, they 
are the !rst source of law to be examined because they are the highest source 
of national law and they enshrine and protect the rights of all people, including 
people with TB. In order to examine a constitution, we must obtain and analyze 
the text in line with the guidance provided above, interview judges and lawyers 
with constitutional expertise, and, if possible, those who drafted the constitution, 
and consult secondary sources, such as scholarly and other writings on the 
meaning of the constitution. 
Assessment questions developed in line with human rights assessment standards 
should be used when analyzing the text of the constitution and interviewing 
constitutional experts. Secondary sources, including legal scholarship on relevant 
constitutional issues, may be accessed using Google Search and online databases 
to provide a general context or more speci!c information about constitutional 
provisions and their meaning and practical application.
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Health Care
Are the rights to life, health and privacy explicitly 
recognized?
Does the right to health include the right to good 
quality health goods, facilities and services?
Does the right to be free from discrimination 
prohibit discrimination based on health status?
Education
Is the right to education explicitly recognized, 
including free, compulsory primary and secondary 
education?
Is discrimination in education explicitly prohibited in 
both public and private institutions?
Prisons
Is the right to be free from torture and cruel, 
inhuman or degrading treatment or punishment 
explicitly recognized?
Is the right to liberty and security of person 
explicitly recognized?
Employment
Is employment discrimination based on health 
status prohibited?
Is the right to a safe and healthy workplace 
explicitly recognized?
Is the state required to provide employment 
assistance to disadvantaged groups?
Constitutions
Figure 4. Constitutions Assessment Questions
Legislation
Legislation includes laws, acts, and statutes written and enacted by legislatures of 
national and sub-national governments. Legislation has the “force of law,” as it 
can establish rights and remedial mechanisms and is enforceable in court. Once 
enacted, legislation cannot be repealed without another act of the legislature. 
Legislation is the second highest source of law in a country and is therefore the 
second source to be examined in assessing the legal regime. In order to do so, we 
must obtain and analyze the legislation text according to the guidelines above, 
interview legislators or their staff who drafted and enacted the legislation, consult 
individuals and agencies tasked with implementing the legislation, and speak with 
stakeholders whose activities are regulated by the legislation. Questions developed 
according to human rights assessment standards, as outlined above and in Figure 5, 
should be used in text analysis of the legislation and while interviewing legislators 
and other relevant stakeholders.
Criminal law and criminal sanctions
Criminal law is a special kind of legislation because it authorizes the state to 
imprison people, depriving them of their liberty. Criminal law is also unique because 
it tends to stigmatize the behaviors it prohibits and, by extension, the people who 
engage in them. The UN Special Rapporteur on the Right to Health (2008-14), 
Mr. Anand Grover, has explained that “criminalization generates and perpetuates 
stigma” and stigma, in turn, is a “major impediment to the implementation of 
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Health Care
Is there TB-speci!c legislation establishing the 
rights of people with TB, including to free testing 
and treatment for TB and MDR-TB?
Are rights to privacy and con!dentiality of 
health information and status, including for TB, 
established in legislation?
Does legislation allow for compulsory treatment, 
isolation or detention of people with TB? If so, 
under what circumstances?
Housing
Does legislation guarantee urban poor access to 
adequate housing with good ventilation?
Is discrimination in housing based on health status, 
including TB, prohibited by legislation?
Immigration and Asylum
Does legislation prohibit the entrance of migrants 
with TB?
Does legislation allow for asylum seekers to 
remain in the country if they face a high-risk of 
contracting TB in prison or will lack access to 
TB treatment if they are returned to their home 
countries?
Employment
Is employment discrimination based on health 
status prohibited under legislation?
Does legislation prohibit people with TB from 
working in certain professions during the course of 
treatment? If so, which professions?
Does legislation establish health and safety 
standards for miners and provide for 
compensation in cases of TB disease?
Legislation
Figure 5. Legislation Assessment Questions
successful interventions” in the area of HIV/AIDS.50 In light of this, special 
attention should be paid to the use of criminal law and criminal sanctions, 
including imprisonment, in the prevention, treatment, and care of TB. Criminal 
laws and other health-related legislation should be obtained and analyzed to 
determine if people with infectious diseases, including TB, can be imprisoned 
for stopping their treatment, failing to take appropriate preventive measures, or 
unintentionally transmitting disease to another person.
Policies and regulations
Policies and regulations are written and promulgated by executive agencies, 
such as ministries of health, drug regulatory authorities, and other administrative 
bodies. They contain detailed rules and directives that control a wide spectrum 
of activities. In many countries, instructions and details related to the 
implementation of legislation are found in regulations. Policies and administrative 
regulations are the third source of law to be examined. In order to do so, we 
must obtain and analyze the text of the policies and regulations in line with 
the guidance provided above, interview members of agencies or their staff 
responsible for writing, promulgating, and implementing the regulations, 
interview stakeholders whose activities are regulated, and speak with the 
intended bene!ciaries of particular policies. Assessment questions developed 
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in line with human rights assessment standards should be used in analyzing 
regulation text and interviewing agency of!cials and other relevant stakeholders.
For analyzing stigma in the text of institutional policies, see Chapter 11.
Health Care
Does policy establish and provide clear guidelines 
for health workers to respect rights to privacy and 
con!dentiality of health information and status?
Does policy provide malnourished people with TB 
nutritional supplements during treatment?
Does policy require people with TB access 
treatment services in their home town or may they 
access treatment were they currently reside? 
Public Bene!ts
Do disability bene!ts provide compensation for TB 
survivors with physical disabilities?
Does workers’ compensation provide public and 
private health care workers who acquired TB in the 
workplace wage replacement and medical bene!ts?
Housing
Does policy establish adequate standards for 
housing of migrant workers, including suf!cient 
space and ventilation?
Does policy provide assistance to people with TB 
in accessing affordable housing?
Prisons
Does policy require and ensure hygienic, 
ventilated prison conditions?
Does policy provide for adequate and timely TB 
and MDR-TB testing and treatment services in 
prisons and detention centers?
Does policy require solitary isolation prisoners with 
TB?
Policies and 
Regulations
Figure 6. Policies and Regulations Assessment Questions
Case law
Case law comprises judicial opinions from courts of law that apply and interpret 
the constitution, legislation, common law, policies, and regulation. Judges apply 
the law, but also clarify its meaning through opinions. Most importantly, opinions 
from appellate courts, such as supreme courts, constitutional courts, and high 
courts, contribute to the interpretation and development of rights established in 
constitutions and legislation. In order to examine case law, we must obtain and 
analyze the text of relevant case law, interview judges or their staff responsible 
for deciding relevant cases, consult lawyers familiar with the areas of special 
focus, interview parties, including plaintiffs and defendants, to relevant cases, 
and consult secondary sources, such as scholarly and other writings on the 
meaning and impact of relevant court decisions. Assessment questions developed 
in line with human rights assessment standards should be used in analyzing case 
law text and while interviewing judges, lawyers, and other relevant stakeholders.
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Health Care
Have courts interpreted rights to life or health to 
include right to access life-saving medicines?
Have courts acknowledged risks faced by health 
care workers and provided compensation for TB 
contracted at their workplace? 
Have courts allowed detention of people with TB 
lost to follow-up in prisons or detention centers?
Prisons
Have courts imprisoned injecting drug users for 
personal use? 
Have courts held lack of access to TB services or 
conditions contributing to contracting TB in prisons 
constitute inhuman or degrading treatment?
Have courts upheld involuntary isolation of 
prisoners solely on basis of their TB status?
Immigration and Asylum
Have courts granted asylum to people based on 
high risk of contracting TB or lack of access to TB 
services in home country?
Have courts allowed removal or deportation of 
people facing high risk of contracting TB in prison 
or lack of access to TB services in their home 
country?
Employment
Have courts interpreted prohibited grounds of 
discrimination to include health status or disease? 
Have courts upheld dismissals of employees based 
solely on their TB status?
Have courts denied claims for compensation for 
wrongful dismissal based solely on TB status? 
Case Law
Figure 7. Case Law Assessment Questions
Measuring Compliance with the Legal Regime: What is 
the Reality on the Ground?
A legal regime assessment is incomplete without determining the level of on-
the-ground compliance and implementation of constitutions, legislation, policies 
and regulations, and case law. These sources of law are each implemented 
and complied with in different ways. Constitutional rights can be implemented 
through legislation and policy. Policies and regulations are often needed to 
implement the objectives and speci!c components of legislation. Courts apply, 
interpret, and ensure compliance with constitutions, legislation, and policies and 
regulations. Finally, legislatures, executive agencies, and private actors must 
comply with court orders to implement case law.
Implementation through Law 
The !rst step in measuring compliance is to determine if the source of law has 
been implemented through legislative, executive, or private action. Contact with 
relevant institutional actors can help to identify various kinds of implementation. 
This contact, however, is separate and distinct from understanding the attitudes 
of these actors, which is discussed below. 
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For constitutions, this means determining if legislation to implement the 
constitution has been enacted, and if courts routinely enforce individuals’ 
constitutional rights. This can be done by obtaining and analyzing relevant 
legislation, as discussed above, to determine if constitutional rights to life, 
health, privacy, and to be free from torture are explicitly referenced in legislation 
related to TB. Case law can be obtained and analyzed to determine if courts 
have interpreted constitutional rights in favor of people with TB, for example, 
by recognizing and upholding their rights against government and private 
defendants.
For legislation, we must determine if executive policies or regulations have been 
promulgated to clarify and direct implementation of the law. This can be done 
by contacting the relevant agency, such as the Ministry of Health, National 
TB Program, or Department of Labor, directly or through an online portal to 
determine what regulations have been put in place.
For policies and regulations, the activities of relevant executive agencies must 
be examined to gauge the extent to which they have raised awareness about, 
implemented and enforced their directives. The private actors and regulated 
industries must also be consulted and interviewed, including employers, health 
providers, and housing developers, to determine if their activities are in line with 
the regulations.
For case law, we must establish if court orders are obeyed and implemented 
by the various government and private parties involved in the cases. This can 
be done by contacting the parties involved, such as plaintiffs with TB and 
government and private defendants, to inquire whether court orders have been 
obeyed through, for instance, disbursements of money to plaintiffs for damages 
or changes to the law, policy, or practices of government and private defendants. 
Attitudes of Institutional Actors and Experience of 
Affected Communities 
“Attitudinal studies of actors within institutions may be indicative of a climate 
within the institution that tolerates, is complicit in, or even fosters stigmatizing 
attitudes and practices, even though the attitudes and practices are exercised at 
the individual level.”51
In order to understand the impact of the legal system at the ground level, we 
must understand the attitudes of the institutional actors that design, enact, 
implement, and enforce the sources of law. Stigmatizing attitudes reduce 
support for supportive TB public policies.1 This includes legislators, policymakers, 
regulators, health care workers, and judges. Interviews with institutional actors 
should be conducted using questions developed to reveal their knowledge of TB, 
attitudes about and experience interacting with people with TB, and familiarity 
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with challenges faced by people with TB. For detailed guidance on how to 
measure attitudes and behavior of institutional actors, see Chapters 5 and 8. 
It is also critical to understand how affected communities experience the 
constitutions, laws, policies, and regulations that impact their lives. This includes 
people with TB, TB survivors, their families, and members of key populations. 
Interviews with affected communities should be conducted using questions 
developed to reveal how they are impacted by law and policy and how they are 
treated by government and private actors, such as employers, educators, prison 
of!cials, and public and private health care providers. Chapter 7 explains more 
on measuring stigmas among PWTB.
Figure 8. Attitudes of Institutional Actors and Experience of Affected Communities Assessment 
Questions
Institutional 
Actors
Affected 
Communities
Are people aware of protective laws?
How long is a person with TB typically contagious after beginning treatment?
Are there mechanisms for citizen monitoring & accountability?
Are stakeholders aware of the negative impacts of discriminatory law on PWTB?
Do stakeholders know anyone who has TB, has survived TB, or has died from TB?
Did you tell your employer when you were diagnosed with TB?
Were you provided TB services while in prison or detention?
Did health care workers uphold patient-provider con!dentiality?
Do you believe law and policymakers want to help people with TB?
Do you believe your child has a right to go to school even though they have TB? 
Empirical Indicators
Empirical indicators provide concrete evidence about the levels of compliance 
with and implementation of sources of law. These include indicators that record 
law-related phenomenon, such as the number of cases involving claims directly 
related to TB in which plaintiffs with TB or TB survivors prevail, and health 
systems indicators, such as the number of prisoners receiving TB and MDR-TB 
services in a country. 
Empirical indicators should be developed to collect data on the implementation 
of sources of law. For example, data related to case law involving people with 
TB can be collected through case law databases to empirically assess how people 
with TB are treated by courts. Rates of dismissals and refusal to hire people 
with TB in particular industries or geographic areas can be collected through 
126
consultation with employees and employers and relevant government agencies. 
This can clarify how people with TB are treated by employers. Rates, locations, 
and methods of involuntary isolation of people with TB can be collected through 
referencing published government data and consulting prison administrators, 
government health care providers, and relevant government agencies. This can 
help gauge whether people with TB’s right to liberty and security of person is 
respected according to the human rights assessment standards.
Figure 8. Attitudes of Institutional Actors and Experience of Affected Communities Assessment 
Questions
Number of Cases 
and Outcomes
Rates of Dismissals 
and Refusals to Hire
Rate, Locations 
and Methods of 
Involuntary Isolation
Rates of involuntary isolation of people with TB and MDR-TB.
Record of locations where involuntary isolation occurs.
Record of methods used to involuntarily isolate people with TB and MDR-
TB, including settings, duration and services provided.
Rates of dismissal of people with TB compared to average rates in 
particular industries or geographic areas.
Rates of refusals to hire people with TB compared to average rates in 
particular industries or geographic areas.
Number of claims brought to court by people with TB under the 
constitution and relevant legislation.
Percentage of cases in which people with TB prevail.
Percentage of judicial orders in favor of people with TB implemented 
compared to average rates.
Conclusion
Measuring structural stigma against people with TB through the assessment of legal 
regimes is a multifaceted task. It involves using human rights assessment standards 
to examine the primary sources of law (constitutions, legislation, policies and 
regulations, and case law) in special areas of focus, with concern for key populations 
at high-risk for the disease. Next, in order to understand the impact of the legal 
regime on the ground, we must measure levels of compliance and implementation. 
This involves gauging the level of implementation through law, measuring the 
attitudes of institutional actors and experience of affected communities, and 
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developing and applying empirical indicators in areas of special focus. At its core, 
this process aims to assess the level of respect for the dignity of people with TB 
in national legal regimes to identify and measure structural stigma.
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Appendix
Sources of Human Rights Law 
Human rights are established at the international level in the Universal 
Declaration on Human Rights (UDHR) and legally binding international treaties.52 
These include, among others, the International Covenant on Civil and Political 
Rights (ICCPR),53 the International Covenant on Economic, Social and Cultural 
Rights (ICESCR),54 the International Convention on the Elimination of All Forms 
of Racial Discrimination (ICERD),55 the Convention against Torture and Other 
Cruel, Inhuman or Degrading Treatment or Punishment (CAT),56 the Convention 
on Elimination of All Forms of Discrimination Against Women (CEDAW),57 the 
Convention on the Rights of the Child (CRC),58 the International Convention 
on the Protection of the Rights of All Migrant Workers and Members of Their 
Families (ICMW),59 and the Convention on the Rights of Persons with Disabilities 
(CRPD).60 Each treaty has a body of experts that monitors state compliance, 
provides authoritative interpretations of the rights in the treaty, and, in some 
instances, hears complaints of violations from individuals. The Of!ce of the 
UN High Commissioner for Human Rights Status of Rati!cation Interactive 
Dashboard (available at http://indicators.ohchr.org/) can be used to determine 
whether a particular country has signed, rati!ed, and acceded to a treaty and is 
therefore legally bound by its provisions.
At the regional level, the African Charter on Human and Peoples Rights 
(ACHPR),61 the American Declaration on the Rights and Duties of Man 
(ADRDM),62 the American Convention on Human Rights (ACHR),63 and the 
European Convention on Human Rights (ECHR)64 all contain human rights that 
are interpreted and developed in regional commissions and courts, including 
most prominently the European Court of Human Rights. Information about 
which countries have signed, rati!ed, and acceded to these treaties is also 
available online at the African Commission on Human and People’s Rights,65 the 
Organization of American States,66 and the Council of Europe’s websites.67 
Human rights are also enshrined in national constitutions around the world. 
These rights take the form of constitutional rights, enforceable in national courts, 
but their content and scope is similar to the human rights in international and 
regional instruments.68
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Chapter 7
Measuring TB stigma among people 
with TB using scales
Lisa Redwood, Amrita Daftary, Dean Lewis and Ellen M.H. Mitchell
Abstract
This chapter explores how to measure perceived or enacted TB stigma in people 
with TB (PWTB). It aims to give an overview of validated scales and to describe 
how to analyze and interpret the TB stigma scale. It starts with a comprehensive 
guide on how to de!ne the study population and sample TB patients, which 
selection methods to use, and how to determine the sample size required, 
including adjustment for clusters. All basic formulas required are given. The focus 
then shifts to how to measure the impact of stigma. We explore how to include 
people with TB lost to follow-up and how and why to include patients during 
the diagnostic process. We also explore the TB stigma treatment trajectory, and 
how stigma may change throughout this process. The method for measuring TB 
stigma to assess if it is a treatment barrier is outlined. Next, we discuss measuring 
TB stigma in drug resistant TB (DR-TB) patients and the issues surrounding 
disease disclosure. 
Objectives
1. To familiarize readers with the literature on stigma among TB patients.
2. To convey the methodological challenges of capturing the full gamut of TB 
stigma manifestations 
3. To teach the core principles for rigorous and reliable measurement of TB 
stigma in this group.
Target Audience
Individuals or organizations who want to gauge stigma among PWTB, including 
TB survivors, advocacy organizations, national TB program staff, researchers, 
HCWs, CBO and NGO staff, volunteers, and outreach workers. This chapter is 
not for those interested in self-stigma (See Chapter 10).
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Introduction
Stigma was !rst de!ned by Goffman (1963) as “an undesirable or discrediting 
attribute that an individual possesses, thus reducing that individual’s status in 
the eyes of society.”1 This has been further de!ned in the health care context 
as “a social process or related personal experience characterized by exclusion, 
rejection, blame, or devaluation that results from experience or reasonable 
anticipation of an adverse social judgment about a person or group identi!ed 
with a particular health problem.”2 TB patients can be subjected to stigma in four 
ways. This chapter focuses upon three of the four types of stigma: anticipated 
stigma, perceived stigma and enacted stigma. The fourth type, self-stigma or 
internalized stigma, is covered in Chapter 10. 
Anticipated stigma is when a person changes their normal behaviors and 
activities of daily living for fear of stigma, judgment, and exclusion from their 
community due to their identity.3 Perceived TB stigma most commonly refers to 
the awareness of stigmatization.3 Enacted stigma is also known as experienced 
stigma. It can be demonstrated through discrimination and behaviors of others 
that harm people with TB. Enacted stigma can range from overt to very subtle –
microaggression.4,5 
Table 1. Types of Stigma
The type(s) of TB stigma you chose to measure among PWTB depends on what 
you plan to do with the information. 
The measurement of stigma in PWTB is important for identifying human rights 
violations, understanding the scope and severity of stigma affecting people’s 
lives, and in assessing the ef!cacy of efforts to eliminate stigma. 
Many studies have identi!ed a signi!cant burden of stigma in PWTB.6–13 Enacted 
stigma can lead to chronic disadvantage via loss of employment, which in turn is 
a risk factor for TB mortality.14 Stigma hinders treatment adherence, which leads 
to poor treatment outcomes and may contribute to the development of drug 
resistence.7,12 
This chapter provides practical ways to measure TB stigma in PWTB. These are 
scattered throughout the chapter, and consider the different areas of stigma that 
Anticipated stigma Enacted stigma Self-stigma
She is to be avoided because 
she has got TB.
It is your fault you have TB.
I feel guilty and useless for 
having TB.
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can be measured. To make the practical steps of measurement clearer, you can 
search for the steps as follows:
1. Study Design:
a. Study population and sampling frame
b. Set sample size and adjust for clustering
c. Choose a scale.
2. Pilot study with cognitive interviews (if the scale has not been used in that 
context)
3. Conduct the study with the (new) scale
4. Analyze data and interpret the results.
How to sample PWTB
The results of any TB stigma measurement will only be as good as the sample 
that is used. 
It is important to get a representative sample of PWTB. To ensure that your 
sample truthfully represents your patient population, you must:
tHave a well-de!ned population;
tUse the best method for selecting your sample;
tUse the correct sample size; and
tAdjust for clustering.
De!ning your population
A clearly de!ned population includes person, place, and time, based on each 
setting and which population is being evaluated. Measuring TB stigma among 
patients is best done by posing questions to PWTB, and only if that is impossible 
(e.g., for infants), query proxies.
It is vital to de!ne the type of PWTB to be measured and to decide whether you 
are interested in speci!c types of PWTB, such as those receiving treatment, those 
not receiving treatment, MDR-TB, HIV/TB, latent TB infection (LTBI) or extra-
pulmonary TB. Include the full range of clients relevant to the PWTB population 
(e.g., different socio-economic conditions, migrants, daily wage laborers, the 
homeless, urban slum dwellers, criminalized populations, and custodial settings) 
so the sample is representative.
Inclusion of clients lost to follow-up in TB 
TB stigma and similar exclusionary attitudes (racism, xenophobia, homophobia, 
etc.) represent a hurdle to treatment completion in some contexts.12,15,16 
How is stigma against 
PWTB created, manifested, 
and sustained?
What is the experience of 
living with TB in a speci!c 
country, setting, or [key] 
population?
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Therefore, study samples should always include non-adherent and clients lost to 
follow-up, as these populations may be more affected by stigma.17–20 Clients can 
be lost to follow-up either in pre-treatment or during treatment. You may wish 
to over-sample this group to capture their experiences well. See Chapter 15 for 
methods of measuring the impact of stigma on adherence. 
Inclusion of clients that are still going through or have 
not yet started the diagnostic process
The study sample should be selected from those with the diagnosis, so that 
people who are never treated are included. The use of lab registers as a sampling 
frame is preferable to a TB treatment register so that all people diagnosed with 
TB are included in the study, and not only those who receive treatment. 
This will also ensure that people all along the ‘patient pathway’ are captured, 
and stigma can be compared by treatment phase. Embedding a study of stigma 
into a national TB prevalence survey is another option of measuring TB stigma 
among PWTB without a diagnosis. This approach helps to identify if stigma was 
a factor in their delayed health-seeking behavior.
Inclusion of clients in the private sector
Often people with the highest levels of anticipated TB stigma are those who 
use health services in the private sector. Private sector services are less likely to 
participate in name-based TB disease noti!cation and are often more attuned 
to clients’ requirements for audio and visual privacy, con!dentiality, and 
discretion. Be sure to include PWTB who access private sector services to avoid 
underestimation of TB stigma.
Where to study stigma
The place refers to the study setting, for example a health care center, district/
province, or the country in which the study was undertaken. Studying stigma 
within a context where the respondent is disempowered or affected by 
stigmatization may not offer full freedom to be candid. If you must study PWTB 
stigma within a health care setting, social desirability bias should be assessed 
using the Marlow-Crowne Scale, which is discussed in more detail in Chapters 4 
and 5.21 
When to study stigma
TB stigma can be measured from the moment TB has been diagnosed, and 
throughout the TB treatment time line and beyond. TB stigma accumulates 
and (may) abate over time. Responses from a single person may differ over 
To reduce bias, include 
as many different health 
care facilities, providers, 
treatment supporters, and 
patients with different 
types of TB as possible 
when drawing a TB client 
sample.
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time. Time refers to the stage of treatment the TB patients were when they 
participated in the study. The point at which you measure stigma during the 
person’s treatment odyssey will determine how much internalized and enacted 
stigma a person reports, because the longer someone has been labeled as a “TB 
patient,” the more chance he/she has had to be exposed to stigmatization. 
Moreover, the physical and emotional states of PWTB and meanings of TB can 
vary over the course of treatment. As visible symptoms and signs of TB decline, a 
person may more easily “pass as normal”, and their experience of stigmatization 
may lessen. (Figure 1) This dynamism makes it challenging to know how to 
interpret studies with cross-sectional designs. 
It is critical to include a de!nitive time frame to ensure that the timing of 
internalized, perceived, or experienced stigma is clear (Table 2) Also, it is 
important to capture where each respondent is in their diagnostic/treatment 
process (e.g., not on treatment yet, two weeks on treatment, or three months on 
treatment) to allow for analysis of time-related variation in responses.
Table 2. Types of TB Stigma Expressed with or without a Determined Time Period
Type of stigma Undetermined Time Period Determined Time Period
Internalized “I feel ashamed to have TB.” “In the last two weeks I have felt ashamed to have TB.”
Perceived “Others would think less of you.”
“In the last two weeks others 
have thought less of you.”
Enacted “Others refuse to visit.” “In the last two weeks others have refused to visit.”
Advantages of measuring just after diagnosis and during the intensive phase
PWTB may feel more vulnerable to stigmatization just after diagnosis and in 
the intensive phase of TB treatment because of social distancing to prevent 
transmission and use of infection control methods, such as masking, that may 
lead to deductive disclosure. 
TB stigma is thought to be acute due to physical isolation, infection control 
measures, and drug reactions. Often TB stigma studies have included people 
who have taken TB therapy for less than one month.22,23 Measuring stigma 
during the intensive phase ensures that there is less recall bias if you are 
speci!cally interested in measuring stigmatization during the early stages of TB 
treatment.
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Figure 1. How TB Stigma may be Encountered
Advantages of measuring in the continuation phase
In the continuation phase, PWTB are no longer infectious and physical 
separation and masking are no longer indicated. Stigmatizing behaviors, such 
as unnecessary social distancing, that are reported in the continuation phase are 
more directly attributable to TB stigma. PWTB are experiencing fewer treatment 
side effects, improved general physical and mental health, and with additional 
understanding of TB, the potential for confounding is lower.24 People may be 
better positioned to re"ect on their experience after the acute medical crisis is 
stabilized.
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Advantages of measuring after TB treatment is 
completed
Surveying people treated for TB about stigma after their treatment ends permits 
the detection of any stigma sequelae after successful treatment. This gives an 
unambiguous TB stigma signal unclouded by social distancing for the purposes 
of infection control. To assess TB stigma at the end of treatment, you need 
to recruit drug-susceptible TB patients who have received !ve to six months 
of treatment. If your study population is MDR-TB patients, this would be 
9-12 months (with the shorter regimen) or 23-24 months of treatment (with 
standard-length regimens).
Long term sequelae of TB stigma are understudied. The disability studies !eld 
has a range of validated tools for capturing the social impacts of stigmatized 
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conditions. The Participation Scale (Van Brakel)25 is an 18-item instrument 
available in seven languages that has shown good internal consistency, with a 
Cronbach’s alpha of 0.92, intra-tester stability 0.83, and inter-tester reliability 
0.80. 
This means that the scale is measuring what it is intended to measure. A study 
by Rajeswari (2005) evaluated the health and well-being of people treated for 
TB within two months of being diagnosed and between the fourth and sixth 
months of treatment. They created a questionnaire based on a previous study 
of the socioeconomic impact on people treated for TB, and a modi!ed version 
of the SF36 questionnaire, which explores patients’ perspectives of their illness, 
recovery, well-being, and quality of life.26 At the end of treatment, 47% of 
patients still had symptoms, which interfered with them visiting friends.26 At 
treatment completion, 54% of men and 52% of women reported feeling happy 
most of the time. 
Advantages of measuring stigma at multiple time points 
(Cohort Approaches)
Given the temporal sensitivity of stigma measurement, measure stigma at least 
twice. The size and strength of a PWTB’ social network is often dynamic over 
the course of treatment.27 This can be due to self-imposed isolation and/or 
stigmatization. Social capital is highly protective and leads to better TB treatment 
outcomes.28 One way to capture the fraying/decaying of family and friendship 
ties is to ask at diagnosis and again at treatment completion how many close 
friends one has at different points in time.
Figure 2. Example of Social Network Size Variation over the Course of TB Treatment 
Social network 
size at diagnosis
Social network 
at two months
Social network 
at six months
Social network 
size at 18 months
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Sampling Methods
Next, PWTB must be selected into your survey. In theory, the best method is 
simple random sampling, as this guarantees that any variance between the 
sample and population are due to chance and not selection bias. This requires a 
list of everyone with TB, which is rarely available.
Systematic random sampling of those diagnosed with TB in health facilities is a 
more feasible sampling method if precautions are taken to ensure randomness. 
To use systematic random sampling, divide the number of PWTB on your 
sampling frame (e.g., total patients on all lab registers and treatment registers, 
de-dupli!ed) by the number of people needed for the study, and then include 
every nth person for your study sample. 
For example, if the state has 3,000 people diagnosed, and you need 500 people 
for the study, 3,000/500=6, therefore n = 6, and every sixth person in the lab 
register would be included in the study. 
Strati!ed random sampling is important if you want to compare two populations, 
such as the stigma among persons treated for MDR-TB compared to the stigma 
among those treated for DS-TB. In this case, you can choose to select the same 
number of clients from each group (disproportionate strati!ed random sampling) 
or different numbers based on the proportion of each group to the overall 
population (proportional strati!ed random sampling). 
Sample Size
The sample size is the number of people from which you will gather information. 
The sample is a representation of the study population, and does not need to 
be the whole study population. You need to identify the minimum number 
of people to include, ensuring that you have enough to fully represent the 
population or allow for meaningful comparisons between populations, while 
not wasting resources. However, once you have found the minimum number 
of people required to get a good representation, increasing this number will not 
signi!cantly increase the accuracy of the results. 
Calculation of the sample size and adjustment for clustering (in case of clustered 
sampling frames, see Chapter 5) are perhaps the most challenging aspects of 
measuring TB in clients for non-researchers. It may be useful to seek help from 
those with expertise. 
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n ≥ 
(N) (p) (1-p)
(N-1) (D) + (p) (1-p)
n ≥ 
(3,000) (0.5) (0.5)
(2,999) (0.00065) + (0.5) (0.5)
D =
(Con!dence Interval)2
Z2
D =
(0.5)2
(1.960)2
D = 0.00065
n = Crude sample size
N = Population size (the total number of PWTB from which the sample will be 
selected)
p = Prior assumptions about TB stigma level. For example, if you have a good 
reason to believe that 90% of people will answer yes to a question, then P= 0.9 
If you are unsure of how the study population will answer the questions, you can 
use P= 0.5 
 Z = Z score represents the area under the curve for the desired con!dence level 
Using the example of a PWTB population size of 3,000 and a desired 95% 
con!dence level with a con!dence interval of ±5%, the crude sample size would 
be calculated as follows:
Con!dence Level Z Value
90% 1.65
95% 1.96
99% 2.58
To !nd the crude sample size (i.e., sample size for a random sample) required, 
there are multiple online tools available. These can be found by searching for a 
“sample size calculator.” To !nd it manually, you can use this formula:
n ≥ 341 
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Example of a crude sample size calculation, on 
maximum sample size requirement
The sample size calculation is used to ensure that the people who you interview 
are an accurate representation of your study population, as it is not feasible 
to interview everyone with TB. It is best to use a conservative approach to the 
sample size calculation if you are unsure of the TB stigma assumptions in your 
area. This means that you should calculate the largest possible sample size 
required. This assumes that half of the population (50%, or p= 0.5) experiences 
stigma. In general, most studies use a 95% con!dence interval, therefore D will 
equal 0.00065. If we use the unknown prior assumption value of p= 0.5 (and 
thus (p) (1-p) = 0.5*0.5= 0.25), then the calculation will be: 
n ≥ 
(N) (0.25)
(N-1) (0.00065) + (0.25)
You only need to know the N value, which is the study population (number of 
TB clients in your area) to complete the calculation. This can sometimes be found 
on the Ministry of Health database, the NTP website, the WHO website, or the 
hospital or clinics registry. Once entered into the formula (ensure you place the 
population number in the capital N and not lower case n), that is the minimum 
number of people you need to survey to make your results a true representation 
of your study population. 
Another consideration for sample size (i.e., total persons with TB surveyed) is 
that the sample is also adequate for a factor analysis. Factor analysis is used to 
measure the internal consistency of a scale; that is, that your scale is measuring 
what you want it to measure. In order to conduct an adequate factor analysis, 
the minimum sample size needs be 5-10 times the number of items in the scale.29 
For example, if the scale contains 18 items, the minimum sample size should be 
7 x 18 = 126. 
In the examples above, we focus on sampling clearly de!ned, easily recruitable 
populations for quantitative research. Chapter 3 has guidance on sampling TB 
clients for qualitative research. Chapter 9 has guidance on sampling persons 
affected by TB within hard-to-reach populations.
Adjusting sample sizes for clustering of stigma
Recruiting PWTB from health facilities is convenient. As PWTB are grouped or 
clustered through the facilities where they are diagnosed and/or treated, this 
is called cluster sampling. Each facility represents a cluster of clients. Cluster 
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sampling is often used to simplify logistics and reduce study costs. However, 
the convenience of facility-based recruitment also comes with some risk of bias. 
Stigmatizing attitudes and behaviors are typically clustered.30–32
The discriminatory attitudes or behaviors of a single care provider or single 
treatment supporter can impact all of the TB clients under his/her care. A 
particular health facility may enact discriminatory policies that harm everyone at 
that site. Take efforts to reduce the ability of extreme cases to in"uence study 
estimates. 
Figure 3. How Stigma Exposures are Clustered by Care Giver and Facility
The disadvantage of cluster sampling is that there is population clustering around 
one facility, as they share the same geographical context and potentially the 
same TB treatment supporter. Therefore, several corrective steps need to be 
taken. 
How to minimize bias due to clustering
There are two ways to reduce bias associated with clustering: minimizing, and 
adjusting and documenting:
1. Make the clusters as small as possible. First, include as many different health 
care facilities, providers, and treatment supporters as possible when drawing 
a TB client sample. This will reduce the potential for ascertainment bias. 
2. Increase the number of clusters to reduce the potential for sameness among 
the sample.
While often necessary, cluster sampling creates uncertainty about the results 
(e.g., loss of precision). To maintain precision, the sample size needs to be 
increased. The extent of increase can be determined by analyzing the intra-
cluster correlation coef!cient (ICC) and adjusting the effective sample size 
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accordingly. To calculate the ICC, you !rst need to identify the between cluster 
variance (the amount by which the stigma score of each cluster differs) and the 
within cluster correlation (how much the stigma score of the individuals within 
the cluster differ). These numbers can then be added to the following formula to 
identify the ICC, which is also denoted by the Greek letter l33:
 
ICC or l
(Between cluster variability)
(within cluster variability + between cluster variability)
This will give a value ranged from 0-1, where 0 means that there is no 
correlation within a cluster and 1 meaning that there is a strong correlation 
within the cluster. As the ICC number increases, the sample size also needs to 
increase as the number needed to identify a difference or change is increased. It 
is best to conduct a pilot study !rst to identify the ICC, and then the sample size 
can be adjusted accordingly.
 
To adjust the sample size for clustering, you need to !rst identify the Design 
Effect (DE). To do this, you need to know the l value (from the pilot study) and 
n (the average cluster size):
This can then be used to identify the effective sample size needed (ESS) with the 
following formula:
m=the number of subjects in each cluster
k=number of clusters
For example: A study measuring stigma in people with TB recruits patients 
from !ve TB clinics (clusters). Each cluster has recruited 30 patients. There was 
a strong correlation within each cluster, as the PWTB are faced with the same 
exposure to stigmatization by interacting with the same set of health care 
policies and providers. The ICC is 0.05.
DEFF = 1 + (n - 1) l
DEFF = 4.9 =  =
ESS = ((m * k)) * DEFF
(30 * 5)
1 + 0.05 (30 - 1)
(150)
(30.45)
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Therefore, the number of PWTB required in this study increases from 150 to 739 
(4.9*150.) 
Sometimes clustering is unavoidable, such as when facilities have only one or 
two DOTs providers. In this case, you should be sure to gather information on 
the speci!c cluster (stigmatizing exposures) a TB patient belongs to. Always 
document the code (not name) of the main healthcare worker and the treatment 
supporter that a TB patient sees.
Special considerations for measuring DR-TB stigma
Persons with DR-TB may be uniquely exposed to and disadvantaged by stigma, 
and their experiences of stigma often differ markedly from patients with drug 
susceptible TB.34–38 There are four reasons for this difference.
1. DR-TB treatment takes longer than DS-TB treatment, and therefore the 
exposure to stigma may be longer as the identity “TB patient” is less 
transient.
2. DR-TB treatment is typically more toxic, with more side effects. People with 
DR-TB are more likely to experience neuropsychiatric or perception altering 
side effects as a consequence of their comprehensive treatment regimens 
and catastrophic costs due to the length of their treatment, both of which 
can heighten their vulnerability to stigma.39 Hearing loss, psychological side 
effects, and impoverishment can reinforce the social construction of DR-TB 
patients deviant, unpredictable, and dangerous.36
3. DR-TB is often assumed to be caused by misbehavior. Unlike in cases 
of drug-susceptible TB, in the case of DR-TB, there may be treatment 
adherence behaviors that may contribute to the development of acquired 
DR-TB. This may tempt health workers to blame individuals for their 
disease.39 DR-TB clients may be at higher risk of self-stigma if they harbor 
self-blame or guilt related to drug resistance caused by non-adherence. 
4. DR-TB has more potential to create fear. One of the main facets of all stigma 
constructs is the social construction of people with TB as being dangerous to 
the wider community. Perceptions of TB curability is associated with lower 
levels of TB stigma.40,41 When a person has DR-TB, doubts about curability 
may fuel the notion that DR-TB patients represent a mortal risk to others. 
Therefore, MDR-TB may have a greater ‘mark’ than drug-susceptible TB.39
These differences make it vital to stratify your stigma analyses by type of TB. 
There are currently no validated stigma scales available speci!cally for DR-TB 
stigma. There are currently two DR-TB stigma scales being validated, which 
should be available by late 2018. The Cataldo Lung Cancer scale has been 
adapted to DR-TB (See appendix.)
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Choosing an appropriate TB stigma scale
There are multiple choices when choosing a stigma scale. Table 3 provides 
an overview of the scales available, as well as studies that have re-used an 
existing validated study. If a scale has already been used in the country in which 
you wish to measure stigma, there is no need to conduct the pilot study with 
cognitive interviews. When choosing a study, it is important to validate it in 
your setting and that it be reliable. Cronbach alpha is a measure of reliability, 
as it assesses the internal consistence of the scale. A score greater than > 0.7 is 
deemed acceptable. Validity can be assessed based on how they developed the 
scale, whether in depth interviews were conducted, if a literature search was 
conducted, and if the scale was compared to a pre-existing like-scale.
Table 3. An Overview of Validated TB Stigma Scales for PWTB
First Author Country
Content 
Validity
Construct 
Validity
Reliability
No. of 
items
Sub-scales (if 
identi!ed)
Coreil 
(2010a)
United States Somma TB 
stigma scale
Local 
interviews
Item correlation 
(not reported)
_=0.87 25
Coreil 
(2012)
United States Somma TB 
stigma scale
Local 
interviews
_=0.93 
(HCW); 
_=0.83 (LTBI)
20
Meulemans 
(2002)
Pakistan None reported SEM; correlation 
with family 
support (r=-0.15)
_=0.64 2 Prejudice/
discrimination
Macq 
(2006)
Nicaragua Literature 
review
Stakeholders
Ritsher mental 
illness scale
Expert review
Rosenberg self-
esteem (not 
reported)
_=0.70 10 4 sub-scales: 
Alienation, 
Stereotypes, 
Discrimination, 
Social 
withdrawal
Somma 
(2008)
Bangladesh, 
India, 
Malawi, 
Colombia
Literature _ for each 
country was 
0.65 to 0.85
18 gendered 
questions on 
marriage, sex 
refusal
Van Rie 
(2008)42–44
Thailand Literature
Interviews
Focus groups
Expert review
EFA followed 
by CFA in larger 
sample
Correlation with 
O’Brien social 
support (r=-0.14 
and -0.25)
Correlation with 
HIV stigma (range 
0.39 to 0.63
_ for 
subscales was 
0.83 to 0.90
test/re-test 
correlation 
(r=0.46 and 
0.64)
24 2 sub-scales: 
Patient 
perspectives 
towards TB; 
Community 
perspectives 
towards TB
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Woith & 
Larson 
(2008)
Russia Fife and 
Wright HIV 
stigma scale
_ for 
subscales was 
0.50 to 0.84
24 4 Sub-scales: 
Social rejection, 
Financial 
insecurity, 
Internalized 
shame, Social 
isolation
Abdulelah 
(2015)
Iraq FACIT-G and 
FAHI
EFA _=0.81
Test/re-test 
correlation 
(r=0.70)
11 Emotional well-
being/stigma 
(contains non-
stigma items)
Westaway 
(1994)
South Africa Jenkins and 
Mata
EFA None 
reported
3 1 sub-scale 
is Perceived 
Social Stigma 
(stereotypes)
Moya 
201445
Mexico Van Rie EFA _=0.88 12 Disclosure items 
did not load
Crispin et 
al.2016, 
201746,47
Brazil Van Rie EFA _=0.71 12 Infection control 
item and HIV 
item did not 
load
Bond 
(2017)48
Zambia, 
South Africa
Literature 
review
Qualitative 
studies
Discussions 
with ICRAAS 
Not reported Not reported 12
Hayes-
Larson 
(2017)49
Lesotho Van Rie 
community 
perspectives of 
TB scale
EFA _=0.9 (from 
Van Rie)
11
Not reported EFA Not reported 3
ICRASS = International Consortium for Research and Action Against Health-related Stigma
EFA = Explanatory Factor Analysis 
CFA = Con!rmatory Factor Analysis
Self-stigma scales
An example of a validated scale for measuring self-stigma among people with TB 
is the Van Rie scale.42 It is one of a small number of scales that has been evaluated 
for content validity, construct validity, and reliability in multiple settings using 
rigorous methods.45,47,49,50 Content validity evaluates whether the items in the scale 
comprehensively cover the domains.29 To ensure that the content of the scale 
was culturally and linguistically appropriate, Van Rie (2008) conducted in-depth 
interviews and focus groups with people affected by TB, their family members, 
health care workers, and community members. The scale uses items phrased in the 
third person to ask questions in an indirect manner. Less direct phrasing was found 
to be more appropriate where it was originally designed (Thailand). Third person 
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also can be effective for use in newly diagnosed individuals, who may not have 
much personal experience with the disease.50 
Construct validity is used to measure a new scale to a pre-existing ‘gold 
standard’ scale or validated scale.29 Strong correlations were found when the 
new scale was compared to the O’Brien social support scale.22 To assess the 
reliability of the Van Rie stigma scale, the questionnaire was conducted twice 
within a 30-day period on 15 study participants, the scores were similar, which 
indicates good reliability and reproducibility. The results are limited due to the 
small sample size.22,29 The Van Rie scale consists of 12 questions assessing the 
patient’s perspectives towards TB.22 A strength of this scale is its re-validity in 
different populations, including the United States and Mexico.17,50
Enacted stigma scales
Enacted or experienced stigma is the mistreatment of an individual known to 
have TB.29 Enacted stigma can have serious internal and external harmful effects 
on the person with TB. People with TB, especially MDR-TB, can suffer from a 
variety of mental health issues due to stigma.39,51 Some types of enacted TB 
stigma constitute discrimination. There is no consensus on the de!nitions and 
boundaries between the two concepts.52,53 Human rights lawyers tend to see 
most mistreatment of PWTB as discriminatory whereas social and behavioral 
scientists tend to view behaviors as stigmatizing. In practice, measure the extent 
of the problem and attempt to stop it. Chapter 5 details the measurement of 
discriminatory behavior.
The EMIC (Explanatory Model Interview Catalogue) interview used by Somma 
et al. (2008) contains 18 indicators of stigma, seven of which are related to 
experienced stigma (see Table 3).54 This scale can also distinguish the areas of 
Stigmatization Discrimination
Figure 4. Overlap between stigma and discrimination
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experienced stigma (see Table 1). A family member, a friend, or a member of the 
community can direct enacted stigma towards the person with TB. It can also 
be directed at a family member or friend of the person with TB by a community 
member, which is known as courtesy or secondary stigma (See Figure 5. For 
more information on courtesy stigma, refer to Chapter 8.) The EMIC has two 
of the three criteria for scale validation. It used literature and local interviews 
to make it context-speci!c, and was reliable with fair-to-good levels of internal 
consistency. The Cronbach alpha ranged from 0.65-0.85 (depending on study 
site). The scale was not compared to other like scales, resulting in an unveri!ed 
criterion validity.55 One criticism of the EMIC scale is that a number of its items 
are gender-blind. In other words, they are insensitive to gendered power 
relations within relationships that in"uence getting married, refusing sex, or 
providing support. For this reason it may underestimate TB stigma among men, 
and should be used primarily for samples of women.
Table 4. Explanatory Model Interview Catalogue (EMIC) Interview – 18- items
1 Desire to keep others from knowing
2 Disclosure to con!dant
3 Think less of yourself
4 Shamed or embarrassed
5 Others would think less of you
6 Adverse effect on others
7 Others have avoided you*#
8 Others refuse to visit *#
9 Others think less of the patient’s family*^
10 Problems for your children*^
11 Problem getting married despite cure*#
12 Support from spouse expected
13 Partner refuses sex due to TB *#
14 Other problem in marriage (after cure)
15 Problem for relative to marry*^
16 Asked to stay away from work, groups *#
17 Decided to stay away from work, groups
18 Presumed other health problems
There are also very useful generic tools for measuring enacted stigma described 
in Chapter 14, including:
tEveryday discrimination scale; and
tExperiences of discrimination (EOD) index.
Generic measures are useful if you need to compare two stigmatizing conditions.
Notes: *Enacted stigma; #Primary stigma (person with TB is stigmatized); ^Courtesy stigma (PWTB family members are 
stigmatized).
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Figure 5. Enacted Stigma in Persons Living with TB and Friends and Family of Persons with TB
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Measuring TB disease disclosure: is it a proxy for 
stigma?
A desire to conceal a stigmatized disease is not a direct measure of stigma, but 
is often a consequence of stigma.32,45,56 In the case of TB, where rapid diagnosis 
and effective treatment leave no sequelae, there is no reason to promote 
disclosure.
“Disclosure concerns are highly related to stigma in general, and more 
speci!cally have been theorized to constitute the basis of felt and internalized 
stigma; thus, receiving support after disclosure plays a key role in the reduction 
of stigma. Another approach suggests that felt stigma is likely to internalize if 
there is a lack of social support, implying that a higher level of social support 
reduces social isolation, which in turn decreases disclosure concerns.”57 
Disclosure can be challenging to interpret as both af!rmative and negative 
responses could indicate stigma. In Somma et al.(2008), the disclosure item was 
dropped in two of the four study sites as it lowered the internal consistency.54 
Disclosure items should be minimized or avoided in TB stigma scales.
Subtle forms of TB Stigma: Microaggressions
A common form of enacted stigma is microaggression. Microaggression is a 
more subtle form of stigma, and involves prejudice, demeaning communication, 
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and discreet discrimination to certain individuals based on their marginalized 
social groups.5 There are three sub groups in measuring microaggression: 
microassault, such as name calling and avoiding the individual, microinsult, being 
rude and insensitive towards the individual, and microinvalidation, which is the 
exclusion of individuals and nulli!cation of their feelings, thoughts, and reality.5 
Gonzalez argues that microaggression has arisen due to the increase in social 
censure of crass mistreatment, political correctness, and norming of behaviors 
that restrict the acceptability of more overt forms of enacted stigma. 
There have been several scales developed to measure microaggression in several 
groups of marginalized people, such as the Racial and Ethnic Microaggression 
scale (REMS), the LGBT People of Color Microaggression scale (LGBT-PCMS), 
and the Mental Illness Microaggressions Scale-Perpetrator (MIMS-P).5 There 
is no validated discrimination scale available for use in TB stigma; however, 
the themes are highly pertinent, and the items could be adapted for the future 
development of TB stigma scales. They can ensure that the more subtle forms 
of enacted stigma are captured. Comprehensive TB stigma scales should query 
a broad range of issues related to TB clients’ rights, as these are particularly 
actionable.58 
Domains in the patient rights charter include:59
1. Care: There should be equitable access, without discrimination, to TB 
education, prevention, and care according to established standards. This 
includes the needs of PWTB with MDR-TB and HIV co-infection.
2. Dignity: TB services should be offered in a respectful environment, without 
stigma, and with moral support from the community.
3. Information: Information should be provided on all aspects of TB, including 
prognosis, costs, and side effects. Experiences should be shared with peers.
4. Choice: Patients have a right to a second opinion, access to medical records, 
and the right to accept or refuse medical interventions or to take part in 
research.
5. Con!dence: There should be personal dignity, privacy, and con!dentiality 
about the medical condition.
6. Justice: Patients have the right to complain, appeal, and to be heard 
promptly and fairly.
7. Organization: Patients have the right to participate as stakeholders in policies 
and programs and establish TB patient platforms.
8. Security: There should be job security and rehabilitation, nutrition security, or 
food supplements, if needed.
The reproductive health !eld has validated scales for respectful care that can be 
adapted for TB (Appendix 2), and the Cataldo scale (Appendix 1) has domains 
speci!c to respect. 
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Harms of enacted stigma
The effect of stigma on people with TB can be severe and may outlast the 
impact of the illness itself. Enacted stigma can be small, compounding factors, 
such as microaggression, or it can be overt drastic social exclusion. Some 
people with TB also experience divorce, being !red from their workplace, or 
banishment to another village.7 A comprehensive measure of enacted stigma 
(i.e., discrimination) should cover infringement of patient’s rights (See Chapter 6 
for more on Human Rights). 
Accounting for multiple forms of exclusion and sources 
of stigma
When studying TB stigma among patients, it is important to also measure 
the extent and severity of other forms and root causes of exclusion and 
discrimination, as it is possible to confuse mistreatment due to TB stigma with 
mistreatment re"ecting racism, xenophobia, homophobia, sexism, or other 
hostile attitudes. Ways to approach syndemic or intersecting stigmas are covered 
in Chapter 14.
Piloting the scale and cognitive interviews
Once you have completed your study design and chosen a previously validated 
scale to use, you need to test it to ensure that it is appropriate for the context. 
It is also important to include other scales, where appropriate, such as a social 
desirability scale and questions referring to other potential stigmas to account for 
confounders (see below). The pilot study can be conducted on a smaller number 
of participants (5-20), and the participants can be selected by convenience 
sampling, not random sampling. This method is easier than random sampling, as 
you can visit one or two TB clinics and ask PWTB to participate as they enter or 
leave the facility. 
Cognitive interviews are used to assess the study participants understanding of 
the scale and questionnaire. It includes question such as “what did this question 
mean to you?” or “what does (refer to certain question) mean to you?” You can 
then use these results to alter the scale and questionnaire if needed. 
Conduct the interview/data collection
Once you have revised the TB scale, you can conduct your interviews.
 How to measure TB stigma among people with TB: Who asks matters
The best people to conduct the interviews, if self-surveys are not being used, 
are researchers and TB survivors. With training, many community advocates can 
also be interviewers. As explained in Chapters 1 and 12, engaging TB survivors 
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in research roles has many advantages. Former TB patients and their families 
have indispensable insider knowledge, and their engagement often enhances the 
quality, acceptability, and social validity of the work. As with all researchers, TB 
survivors need research training to perform effectively. Being a TB survivor does 
not automatically imply that one does not harbor stigmatizing beliefs, so all data 
collectors need basic stigma training.66
It is best to avoid healthcare workers as interviewers or proxies. The use of the 
local health care workers or local community health volunteers might introduce 
bias.20 Examples from the study in Kenya show different prioritization of stigma 
by PWTB versus health workers (Table 5). TB patients ranked TB stigma as a 
greater challenge than healthcare workers in the same setting.
Table 5. Ranking Challenges, TB Patients versus Providers [adapted from Onyango-Ouma W., 
2005]
TB Patients Provider/Stakeholders
1. Delay/inef!cient services
2. Negative provider attitudes
3. Provider lateness/unavailability
4. Long treatment duration
5. Strict drug collection times
6. Suspicion that one has HIV
7. Many injections
8. Lack of privacy
9. Congestion
10. Discrimination
11. Open waiting area
12. Bad food
13. Being asked for a transfer letter
14. Weekly drug doses
15. Shortage of providers
1. Shortage of staff
2. Delay
3. Seminars that take providers away for a long time
4. Open waiting space
5. Lack of privacy
6. Isolation
7. Feeling unvalued/stigma
8. Lack of full-time services at chest clinic
9. Duration of treatment
10. Proximity of TB clinic to voluntary counseling and 
testing (VCT) 
Analyze the data and interpret the results
Most scales use the Likert system, where 0 is assigned to the negative stigma 
response and 5 is assigned to the af!rmative stigma response. Pay attention to 
any positively phrased questions to ensure you recode them correctly (e.g. if 
someone responds “strongly agree” to the statement “TB patients are just like 
me,” that would need to be reverse coded as a 0). The scores are then added 
and compared across multiple variables, such as gender, location, age, treatment 
duration, health care provider, etc. 
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Beyond TB stigma prevalence
In order to effectively address stigma, one needs to know more about it 
than its prevalence. Mixed-method studies are typically required to develop 
interventions. See Chapters 3, 10, and 17 for how to identify the mechanics of 
stigmatization.
Combining TB stigma questions with other surveys of 
people treated for TB 
Depending on the time and resources available, TB stigma can be measured 
in many different, valid ways. Measuring stigma can be made part of an array 
of routine TB projects, including catastrophic cost surveys,60,61 quality of care 
measurements, situation analyses, prevalence surveys,62–64 knowledge attitudes 
and practices (KAP) surveys, and national program reviews.
It is often assumed that TB stigma plays a primary role in the treatment 
experience. It is frequently assumed to be one of the most important challenges 
for patients. However, in some settings, stigma is less important to patients than 
treatment affordability, waiting time, and drug availability. A 2013 TB patient 
survey suggested that TB stigma ranked among the lowest priorities for Nigerian 
PWTB when contextualized among all of the challenges they faced.65 It is useful 
to be able to situate the severity of TB stigma in the wider context of patients’ 
perceptions of quality of care. 
Since 2009, the TB community has been measuring stigma, as part of a patient-
centered approach, using the QUOTE-TB tool.38,65 The QUOTE-TB tool is an 
innovative approach involving locally grounded and validated measurement. The 
methodology originated in the European patients’ rights community. QUOTE-TB 
can be assessed here:
http://pdf.usaid.gov/pdf_docs/Pnadp455.pdf
Conclusion
Studying the prevalence and severity of stigma from the perspective of PWTB 
and survivors is vitally important.37 It is crucial to engage TB survivors in the 
study process and to plan the research so it has a clear population and to 
mitigate the effects of biases. The three main biases are selection bias, social 
desirability bias, and ascertainment bias. The use of random sampling in the 
correct population will reduce the effect of selection bias. To reduce the possible 
impact of ascertainment bias, you will need to increase the sample size in cases 
of clustered sampling. This can be further reduced by the inclusion of patients 
who have been lost to follow-up or who have not yet commenced TB treatment. 
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Appendix 1
Cataldo et al. (2011) – Cataldo Lung Cancer Stigma scale - Self-
perceived lung cancer stigma (adjusted to DR-TB)67
Response Categories Strongly 
Disagree
Disagree Agree
Strongly 
Agree 
Stigma and Shame
I feel guilty because I have DR-TB. 
I work hard to keep my DR-TB a secret.
Having DR-TB makes me feel like I’m a bad person. 
I’m very careful whom I tell I have DR-TB. 
I feel I’m not as good as others because I have DR-TB.
I worry people who know I have DR-TB will tell others.
Having DR-TB makes me feel unclear.
In many areas of my life, no one knows I have DR-TB. 
I feel set apart, isolated from the rest of the world. 
I told people close to me to keep my DR-TB a secret. 
Telling someone I have DR-TB is risky. 
People’s attitudes make me feel worse about myself.
As a rule, telling others has been a mistake. 
My DR-TB diagnosis was delayed because I put off 
going to the doctor.
I regret having told some people that I have DR-TB.
Having DR-TB in my body is disgusting me. 
Some told me DR-TB is what I deserved. 
My DR-TB diagnosis was delayed because my 
healthcare provider did not take my” (smoker’s) cough” 
seriously.
Smokers could be refused treatment for DR-TB. 
Social Isolation
I have lost my friends by telling them I have DR-TB.
I stopped socializing with some because of their 
reactions.
People have physically backed away from me.
People I care about stopped calling after learning that I 
have DR-TB.
People seem afraid of me because I have DR-TB.
People who know tend to ignore my good points.
People avoid touching me if they know I have DR-TB.
Some people don’t want me around their children.
People avoid me because they associate DR-TB with 
death.
Some people have grown more distant.
Knowing, they look for "aws in your character.
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I was hurt by how people reacted to learning I have DR-
TB. 
I worry about people discriminating against me. 
Discrimination
People with DR-TB are treated like outcasts. 
Most people believe a person with DR-TB is dirty.
Most people think a person with DR-TB is disgusting.
Most are uncomfortable around someone with DR-TB. 
I worry that people may judge me when they learn I 
have DR-TB.
People with DR-TB lose jobs when employers learn 
about the disease.
DR-TB related to adherence (dependent on the context)
DR-TB is viewed as a self-in"icted disease.
Others assume that a patient’s DR-TB was caused 
by non-adherence, even if he or she never missed 
treatment.
Others assume that a patient’s DR-TB was caused by 
smoking, even if he or she had stopped smoking years 
ago.
Some people act as though it is my fault that I have DR-
TB.
Healthcare providers don’t take coughs seriously. 
Source: Cataldo, J. K., Slaughter, R., Jahan, T. M., Pongquan, V. L., & Hwang, W. J. (2011, January). 
Measuring stigma in people with lung cancer: pPychometric testing of the cataldo lung cancer stigma 
scale. In Oncology nursing forum (Vol. 38, No. 1, p. E46). NIH Public Access.
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Appendix 2: Illustrative Exit interview items for measuring respectful 
care adapted from Sheferaw et al.68
Below are some examples of items used in exit interviews:
Friendly care:
I felt that health workers cared for me with a kind approach.
The healthcare workers treated me in a friendly manner.
The healthcare workers talked positively about my recovery.
The healthcare worker showed his/her concern and empathy.
Abuse-free care:
The health provider threatened me with negative consequence if I did not obey. 
The healthcare workers shouted at me because I haven’t done what I was told to do.
I was assured that information about my health status would be protected.
Discrimination-free care:
Some of the healthcare workers did not treat me well because of some personal attributes.
Some healthcare workers insulted me or my companions due to my personal attributes. 
I was treated the same as any other client.
Once I was no longer infectious, I was not segregated from others.
Respectful care:
I was kept waiting for a long time before receiving services. 
Service provision was delayed due to internal problems in the health facilities. 
All healthcare workers treated me with respect as an individual.
The healthcare workers spoke to me in a language that I could understand.
The healthcare provider called me by my name.
The healthcare care workers discussed with me how best to engage my close contacts while 
preserving my privacy.
Empowering care:
I was encouraged to choose my treatment supporter.
I was given enough control over my own treatment decisions.
I was given enough information to understand TB disease. 
I received information and tools to help me to protect my family and friends.
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Chapter 8
Measuring secondary stigmas among 
TB-affected workers and families 
Julia van der Land, Ellen M.H. Mitchell, Sarah van de Berg and Ieva Leimane
Abstract
This chapter focuses on strategies for measuring secondary TB stigma among 
those who may not have TB themselves, but are associated with the disease 
through their work or relationships. This chapter aims to provide insight into 
secondary stigmas in TB-affected families and members of the TB-associated 
workforce by introducing courtesy and dirty work stigma. We discuss common 
drivers and domains of courtesy and dirty work stigma. We outline the 
advantages and disadvantages of available validated secondary stigma scales. 
Healthcare workers and family care givers who care for people with tuberculosis 
are scarce and serve as a vital resource for the elimination of TB. Understanding 
the community and workplace stigmatization affecting this group will help in 
designing effective programs and policies that support their life saving work.
Objectives
1. To introduce two secondary TB stigmas: dirty work and courtesy stigma. 
2. To familiarize readers with drivers, experiences, and consequences of 
secondary stigmas.
3. To describe the relative merits of available scales, and the need for innovative 
new scales.
Target Audience
This chapter is for people who plan to measure TB-stigma in families or workers 
affected by TB. This chapter was written for national TB program staff, labor 
unions, environmental and occupational health organizations, NGOs, CBOs, 
partners, and advocates. The content is also appropriate for social workers, 
palliative care workers, and organizations working on family welfare as this 
chapter teaches readers how to measure secondary TB stigma that extends to 
families and care givers affected by TB.
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Introduction to Secondary Stigmas
The problems caused by TB stigma extend beyond the denigration of people 
with TB. Although the bulk of stigma research has focused on TB patients, 
research has shown that stigma does not only devalue a person or a group with 
a disparaged trait (e.g., TB) but can likewise harm family members, friends, 
volunteer caregivers,1 HCWs, TB activists, and miners who are associated with 
said trait.2,3
The aim of this chapter is to provide an overview of existing ways of measuring 
secondary stigma, and ultimately to reduce secondary stigma.
Introduction to Dirty Work Stigma
Dirty work stigma is a form of occupational secondary stigma. Dirty work is 
de!ned as a sociological term for occupations that are stigmatized. According to 
Hughes (1951), “Work is said to be dirty if society perceives it to be physically, 
socially or morally tainted.”4 In other words, occupations that are widely 
perceived by society as disgusting, degrading, dangerous, or immoral are 
referred to as dirty work’(see Figure 1)5 In contrast to courtesy stigma, where 
stigma is attached to family members and those related to people with TB 
(PWTB), dirty work stigma entails devaluation due to a disparaged occupation. 
Health care workers specialized in infectious diseases, including TB, may face 
dirty work stigma. 
Dirty work stigma is correlated with low job satisfaction and depression.6 
Health care workers who specialize in drug and alcohol dependency, sexually 
transmitted disease, mental illness, or those who treat marginalized populations 
also face similar stigma.2,6–9 
Why dirty work stigma is important to measure
Dedicating oneself to the !ght against TB is noble, but it is not necessarily 
perceived as a prestigious specialization for many HCWs. In Europe, specializing 
in treating infectious diseases (and in particular TB) is low in the hierarchy of 
medical specialty prestige.10–13 
TB HCWs can experience stigmatization and discrimination due to being in close 
contact with TB patients.14,15 HCWs who offer TB services may be discredited or 
devalued in workplace hierarchies by other HCWs.16 Those who feel discredited 
by their jobs may begin to feel that they are performing dirty work instead of 
saving lives.17 Those who believe their TB work will evoke disdain from peers 
or family may be less able to champion the needs of TB patients when they are 
disparaged. Stigmatized health workers may lack empathy, concern, and respect 
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for their TB patients.18 HCWs discredited for their work can experience declines 
in self-ef!cacy, self-worth, and self-care.6,9,15,19–22 Dirty work stigma discourages 
healthcare providers from attending onsite TB screenings or from disclosing their 
TB disease should they become ill.15,23,24 
Drivers of dirty work stigma
The drivers of dirty work stigma include structural factors (e.g., government 
policies, lack of protection of con!dentiality),25 low levels of institutional support 
(e.g., lack of investment in safe working conditions for those in TB-affected 
industries, lack of training and clari!cation among the health care force),26 
and exaggerated (irrational) fear of infection,27 which may be a function of 
insuf!cient knowledge of the cause, transmission-mode, and curability of TB and 
DR-TB disease.28 In some settings, dirty work stigma is compounded by links to 
stigmatized groups and identities (e.g., homelessness, drug dependency).27 
Manifestations of dirty work stigma 
The manifestations of dirty work stigma for HCWs may include:
tDecreased, inconsistent, or no social support from family.7
tDenial of professional development opportunities. 
tSocial rejection, prejudice and discrimination by peers.
tFeeling of being treated poorly by peers.7
tGossip/fear of gossip.6
tInsulting, blaming, and shaming. 
tLabeling (e.g., labeling as infectious themselves).14
tPhysical and social avoidance and exclusion by co-workers. 
Scales to measure dirty work stigma 
In the following section we introduce validated scales to measure secondary 
stigma in TB and related !elds. There are a few scales available to measure 
components of dirty work stigma. Although there is only one validated three-
item TB secondary stigma scale, other scales can be adapted and used to 
measure additional dimensions of dirty work stigma in the context of TB. 
Choosing a scale or merging items from different scales into one scale is 
dependent on the study objectives (Table 1). 
There is no validated TB stigma scale for TB dirty work stigma that includes drug-
resistant TB (DR-TB), but experts believe that dirty work stigma associated with 
care services provided to DR-TB patients may be qualitatively and quantitatively 
different in terms of the domains and severity.29
To help chose the scale that will meet your needs, it is helpful to review the 
stigma domains each covers and how the items are designed. First is the scale 
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detailed in “External and Internal TB stigma among HCWs” by Wouters et al., 
2016.30 
In 2016, Wouters et al. validated a tool to measure different levels of TB and 
HIV stigma among the healthcare workforce in South Africa.30 The entire 
questionnaire for the pilot study included 87 questions that were directly related 
to stigma, as well as socio-demographic questions (e.g., age, sex, occupation, 
and education), HIV-TB related knowledge questions (e.g., symptoms, way of 
transmission) and questions on con!dentiality in the workplace (e.g., “Do you 
think con!dentiality is maintained in your occupational health unit?”)
Wouters et al developed and validated two TB secondary stigma scales:
1. Others’ External Stigma toward TB (EOS): How respondents perceive 
stigmatizing behavior and attitudes of health providers towards TB-
associated HCWs (EOS) – !ve items
2. Respondent’s external stigma toward TB (RES): How respondents behave 
and think about TB-associated HCWs – three items (See Chapter 5).
It is more common to ask participants about other health providers stigmatizing 
than to ask about their own discriminatory behaviors.31 This is to avert social 
desirability bias. Five items in Wouters Others’ External Stigma toward TB (EOS) 
measure perceived stigma toward healthcare workers. The domains that are 
covered in EOS focus on blame and avoidance norms: 
Others’ external stigma toward TB (EOS):14
1. HCWs who are suspected of having TB are stigmatized in this hospital.
2. HCWs in this hospital avoid contact with coworkers who they think may 
have TB.
3. Some HCWs in this hospital would not want to eat or drink with a coworker 
who they think has TB.
4. Some HCWs in this hospital are stigmatized when others !nd out that they 
have gone for TB screening.
5. I have noticed that some other HCWs in this hospital feel uncomfortable 
working near coworkers with TB. 
Another scale is the Mental Health Professionals Secondary Stigma Scale/
MHPSSS by Jesse, 2015.9
This stigma scale was originally developed and validated to measure secondary 
stigma among mental health professionals. The psychometric properties of this 
measure were developed based on Goffman, 1963.9 The items were adjusted to 
the TB-context for this guidance. Further, it assesses the consequences that are 
related to HCW’s worries about their own health and reputation. This version 
substitutes the word TB for HIV. It has yet to be validated, and is included for 
illustrative purposes. 
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Response categories: !ve-point Likert scale ranging from strongly disagree, 
disagree, neutral, agree, to strongly agree. Items 1 to 11 address reactions HCWs 
get to their occupation. 
Domain: Negative Affect
1. People sometimes seem disgusted when they !nd out that I work with TB-
patients.
2. People often become uneasy when they learn that I work for TB-patients.
3. Sometimes even my family and friends seem disgusted by the kind of 
patients that I work with.
4. People sometimes talk to me about how they !nd the type of clients that I 
work with to be disgusting.
Domain: Peril
5. At times, family and friends tell me that I am in danger because of the type 
of patients that I work with.
6. People tell me that TB-patients can be dangerous.
7. People think that the type of patients that I care for can never really change.
8. People have strong (positive or negative) reactions when they lean about 
that I work with TB-patients.
Domain: Labeling
9. At times, I feel stigmatized by others because of the type of patients I work 
with. 
10. People will always associate me with the type of patients I work with now. 
11. At times, people hold me responsible for the poor choices made by my 
patients.
Items 11 to 19 aim to address the consequences for their choice of occupation.
Domain: Fear of patients
12. I worry that I could get infected by my TB-patients.
13. At times, I am fearful of the type of patients that I work with.
14. I would rather work with different types of patients. 
Domain: Concealability 
15. I usually don’t talk about what I do for a living to people that I have just met.
16. I feel reluctant to mention that I care for TB-patients when asked about my 
job.
17. I try not to talk about what I do for a living unless I am asked directly.
18. I like to talk to people about the work that I do.
19. I feel that it is important to talk with my family and friends about the types 
of problems my patients face.
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Another means of measuring stigma was detailed in HIV/AIDS-related stigma as 
perpetrated and experienced by nurses by Uys et al., 2009.32 
This study was the !rst to measure stigma experienced by nurses for HIV/AIDS 
care in !ve African countries.32 The study resulted in a nine-item instrument, 
(_=0.90). Two factors encompassed whether nurses who were caring for HIV 
patients experienced stigmatization in their social milieu or by colleagues. The 
response categories are a !ve point Likert scale, ranging from never, once or 
twice, several times, to most of the time. The items were adjusted to TB for the 
purposes of this guidance.
Domain: Gossiping 
1. People said HCW who provide TB care also have TB.
2. People said HCW would only work with TB patients if they had TB 
themselves.
3. Someone said that HCW who care for TB patients spread the disease.
4. People made negative remarks about HCWs involved with TB care.
Domain: Fear of infection
5. The spouse of a HCW who cares for TB patients feared that the HCW would 
bring the mycobacteria home from work and give it to him/her.
6. People said that HCW get infected by taking care of people with TB.
Domain: Labeling
7. People said HCWs who work in home care have TB.
8. Someone called a HCW names because she takes care of TB patients.
9. A HCW was stigmatized because of the TB services she provides.
It could be interesting to add questions that are related to loss of social support 
due to a HCW working with TB patients. Likewise, you could raise questions 
about the impact of decreased or loss of social support. 
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Content 
Validity
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Validity
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Wouters 
(2016)14
South 
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HCWs Literature
Coreil/
Van Rie 
scales
Expert 
review
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SEM
Correlation 
with HIV 
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to 0.98)
Correlation 
with TB 
knowledge (?)
Correlation 
with 
con!dentiality 
(r=-0.22 and 
-0.23)
I for 
subscales 
was 0.65 
to 0.87
 
3 Colleagues’ 
external 
TB stigma, 
respondent’s 
external 
TB stigma, 
respondent’s 
internal TB 
stigma
Coreil 
(2012)33
United 
States
HCWs EMIC Local 
interviews
_=0.93 
(HCW); 
20
Jesse 
(2015)9
United 
States
Mental 
health 
professionals 
Literature PCA _=0.88 21 Concealability, 
course, 
disruptiveness, 
negative 
affect, peril
Uys et al. 
(2009)32
South 
Africa 
Swaziland, 
Lesotho, 
Tanzania, 
Malawi
HIV/AIDS 
stigma 
instrument 
- nurses 
(HASI_N)
FGD EFA _=0.901, 
_=0.69
9, 5 Labeling, 
gossip, fear of 
infection, peer 
stigmatization 
of nurses
FGD, focus group discussion, EFA exploratory factor analysis, PCA principal component analysis
Table 1. Secondary Stigma Scales for HCWs
Stigma of other TB-Affected Occupations: Mining 
Workers in TB-associated industries, such as deep pit gold or platinum mining, 
can also be harmed by TB stigma.34 
Miners’ vulnerability to TB can result in being perceived and treated by family 
as vectors of infection, even when they have no health problems or have a 
non-infectious illnesses, such as silicosis.34 They may have their rights violated 
by over-zealous or involuntary TB screening efforts. Miners are frequently the 
target of TB campaigns, although mining associations have noted that often ill-
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conceived interventions compound the TB stigma they face (Vama Jele personal 
communication).35
“When I was working at the mine, when I got ill, at home they were 
suspecting that maybe I don’t have TB, maybe other illness, maybe 
HIV, so people called me names.”34 
Teurling’s study of stigma among employees at South African gold mines showed 
that miners were strongly aware of the stigma surrounding their occupation as 
contaminating.36 The social production of TB stigma in South African mines is 
hard to disentangle from the history of colonialism, migration, apartheid, and 
the political economy of health and wealth in the region.34,37,38 In the case of 
migrant silica miners (whose work is widely known to place them at risk for TB), 
TB stigma can lead to social distancing and distrust upon return to their home 
communities, and as a result miners may be reluctant to seek care for symptoms 
in order to avoid reinforcing stereotypes.4,34,39
There are no validated stigma scales speci!cally for miners, but Hayes-Larson 
et al. have tested an expanded Van Rie scale among a group of TB patients in 
Lesotho (many of whom were miners).40 Hayes Larson added items querying 
internalized stigma and personal social exclusion, which were particularly 
resonant among the men.40 Any tool developed for miners should include items 
pertinent to fear of discrimination in the job market, fear of catastrophic costs, 
and economic insecurity.34,41–43
Confounders
When measuring the impact of secondary stigma, it is important to be able to 
distinguish TB stigma from other potential sources of workplace stress that can 
be confused with stigmatization. Helping professions and repetitive physical 
work can have high levels of burnout.9,14 The Maslach burnout inventory (MBI) 
scale measures the work-related distress that can be a confounder of dirty work 
stigmas.44 Maslach (1993) developed a scale that describes three dimensions 
to assess burnout: emotional exhaustion, depersonalization, and personal 
accomplishment.44 The !rst dimension is characterized by feeling emotionally 
drained and exhausted by one’s work and relationship with patients.
Another potential confounder of secondary stigma is poor working conditions to 
the perceived organizational support scale.9 The eight-item scale was developed 
to measure the perceived level of organizational support and job conditions.45 
The items of this scale were formulated in a very general manner. It would 
be bene!cial to adjust them to the healthcare setting, in particular to the TB-
context. 
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Sampling
Based on your research question you need to decide who is essential and should 
be included in your study. Examples are:
tHCWs who are caring for DS-TB patients.
tHCWs who are caring for DR-TB patients.
tHCWs who are caring for DS-TB and DR-TB patients.
tThe whole medical workforce of a setting. 
tOther health professionals who are working with DS/DR-TB patients. 
Challenges
Key takeaways:
t When planning a study on measuring secondary stigma, consider previously 
validated questionnaires.
t Phrase questions appropriately for the target audience and study objectives. 
Courtesy Stigma in Families affected by TB
Goffman (1963) de!ned courtesy stigma and associative stigma as stigma 
acquired as a result of being related to a person with a stigma. Courtesy stigma 
is the loss of social standing experienced by those who interact with stigmatized 
people (see Figure 1) It entails overt disapproval due to the association of being 
in contact, caring, or working for a stigmatized individual or group. It is also 
referred to as carry over stigma. 
Figure 1. Family Members and Social Network
People with TBFamily & Social
network
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Why courtesy stigma is important to measure
People that feel ashamed or discredited by their association with a stigmatized 
individual often hide their relationships or encourage the affected individual 
to hide their TB-status. Family members who fear the courtesy stigma of TB 
have been known to discriminate against relatives with TB, including limiting 
their access to care, denying them household resources, and in extreme cases, 
disowning them.46 Family members of a TB-infected person can experience 
loss of social status as a consequence of negative inferences made about the 
extended family.1,25,47–51 In settings were TB is believed to be hereditary, a 
diseased relative can impose a persistent social taint on the whole family, which 
persists even if the loved one dies of TB.46,49 
The level and repercussion of courtesy stigma can vary widely by context.25 
Damage to family reputation can impact employment, education, and marriage 
prospects.25,47,52 In communities where social capital functions as a safety net, 
loss of social status can imperil family survival.25,51 Courtesy stigma may manifest 
as a reluctance to expedite care for ill family members, due to fear of disease 
disclosure to the broader community.1,33,46
“Thinking that neighbors might hate [him] I had not told them about 
his disease... We went to the village after his diagnosis, but I didn’t 
say that he is suffering from such disease because it was village and 
once they know they start back-biting and may hate us.”49
In addition to weakening the social standing of allies, courtesy stigma damages 
the support networks and quality of services given to those who have a 
stigmatized condition.1 The quality of social support has a big in"uence on 
treatment outcomes. 
Family social support is a powerful source of resilience and can be undermined 
by courtesy stigma.1,53 Studies suggest that courtesy stigma can be mitigated and 
is in"uenced by knowledge of cause, curability, and mode of transmission.28,54 
A lack of constructive engagement of families in the TB treatment process may 
foster stigma in families, particularly when members are inadequately informed.34
The evidence of the extent to which the social network of a person with TB 
experiences courtesy stigma comes largely from ethnographic studies. It is 
important to create an enabling environment where individuals with TB and their 
families can seek treatment free of discrimination and prejudice.55 The shrinking 
of a patient’s social network during treatment can have negative consequences 
for recovery.48,56 Atre found that female TB patients in India were less con!dent 
of family support than their male peers (2011).57 The household dynamics in TB-
affected families appear to vary widely. 
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Drivers of courtesy stigma in families
Touso found that families of lower socioeconomic status experienced more 
secondary stigma.58 They also found low TB knowledge to be correlated with 
stigma in families. The relationship between TB knowledge and TB stigma in 
the general public or patients is highly variable.51,59–61 However, it makes sense 
that scienti!c uncertainties about duration of infectiousness among patients 
on treatment and the ef!cacy of home-based infection control measures could 
contribute to stigma.62,63 Fear of infection is a major driver of stigma in families 
affected by TB.51,64–67
Whereas Coreil found that secondary TB stigma in Florida was tied to national 
identity and concerns about xenophobia among Haitians.25
Scales for measuring TB Stigma in Families
Courtesy TB stigma remains under-researched. Valid and reliable instruments are 
needed for an ef!cient mapping of courtesy stigma. Most of the measurement 
scales for courtesy stigma in families were developed in Haiti, Brazil, and Mexico.
First 
Author
Country
Content 
Validity
Construct 
Validity
Reliability Items Domains
Coreil 
(2010b)25
U.S. and 
Haiti
EMIC stigma 
scale
Local 
interviews
EFA _=0.80 
for both
21 
(US) 
20 
(H)
U.S. (four sub-scales): internal 
shame, external problems, 
disclosure, 
Haiti (!ve sub-scales): internal 
shame, external problems, 
disclosure, family reputation, 
other illness communicability
Bond 
(2017)68
South 
Africa 
and 
Zambia
Ethnographic 
work
n/a n/a 4 Blame, transmission knowledge
Arcêncio 
(2014)1
Brazil Literature 
review, FGD
CFA EFA _=0.79 9 Shame, treatment carry over, 
disclosure carry over
Arcêncio 
(2014)1
Brazil Literature 
review, FGD
CFA EFA _=0.79 7 Self-ef!cacy of social support, 
interactions with HCW
Touso 
(2014)58
Brazil Arcêncio 
(2014)1
Arcêncio 
(2014)1
Arcêncio 
(2014)1
10 Danger of infection, shame, 
treatment carryover, disclosure 
carry over
Table 2. Scales available to measure secondary stigma in families
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Coreil et al scale was derived from the EMIC scale (Chapter 7) and uses a locally 
relevant vignette. It includes two items on secondary stigma: loss of respect 
for the family, and problems for children.25 The EMIC scales focus on speci!c 
gendered consequences (marriageability), and therefore may not perform 
equally well across all settings or all social groups. The Arcêncio scale measures 
anticipated stigma, and is well-validated, perhaps because most items focus on 
disease concealment. 
Arcêncio scale (+ Touso addition)
1. My family member asks me to keep the TB a secret. 
2. I feel ashamed because my family member has TB. 
3. I hide the fact that my family member has TB from the community. 
4. My family member hides his/her diagnosis from the community. 
5. I avoid talking about TB in the presence of other family members or 
neighbors. 
6. I’m afraid that someone will see me at the health care clinic where my 
relative is being treated. 
7. I substitute another word for TB in my conversations with my family 
member. 
8. I substitute another word for TB in the conversations with my friends. 
9. I’ve noticed changes in my family member since the TB diagnosis.
10. (I am worried about becoming infected).
Touso’s added fear of infection (#10) to the Arcêncio scale to expand the stigma 
construct.58 Given the importance of danger/peril of transmission, a scale of 
courtesy stigma should include several items on fear of infection.
Arcêncio also developed a scale to measure family members’ attitudes toward 
engagement in TB treatment.1 This is a measure of the family members’ 
perceived self-ef!cacy in providing support as well as the effectiveness of the 
health system in empowering support systems. This scale is:
1. I was guided by the health care team regarding the TB medication.
2. The health care team includes me in the care. 
3. My family member trusts me and my advice. 
4. We talk about TB.
5. I have been examined at the clinic where my relative is receiving anti-TB 
treatment.
6. I follow the medication intake of my family member. 
7. I am prepared to follow the medication regimen. 
Use of the validated Arcênio scales (with the addition of fear of infection items) 
is recommended because the scales are validated, brief, self-weighting, and 
capture subtle forms of stigma. Combination with the Coreil (2010) and Bond 
176
(2017) items speci!c to family (problem with children, gossip, and respect for the 
family) are also likely to be very pertinent in high-burden settings. 
Conclusion
Secondary stigma among HCW should be measured and reduced to ensure 
a voluntary TB workforce.15,29,30,69 Secondary stigma among TB caregivers is 
counterproductive to global TB elimination efforts, since it deprives them of 
the right to contribute to TB treatment and prevention, dissuades talented 
people from joining the !ght against TB, and negatively impacts health care 
delivery, TB treatment adherence, and recovery. Perceptions and experiences 
of secondary stigmas can be detrimental to the well-being of those who lose 
status via care giving. More research is urgently needed to develop and validate 
measures to assess courtesy and dirty work stigma. Instruments to measure 
courtesy and dirty work stigma need to be re!ned to better understand the 
drivers and consequences of secondary stigma. Existing scales can be applied and 
expanded into a range of settings, or can provide a basis for local adaptation. 
Understanding the community and workplace stigmatization affecting caregivers 
will help to design effective programs and policies to support their work.
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Appendix 1 : The Maslach Burnout Inventory (MBI)44
The following statements deal with how you may or may not feel about your work as a TB health 
provider. Response categories: seven-point Likert scale ranging from one (very mild) to seven (very 
strong). 
Emotional exhaustion/regret of professional choice (Consequences)
1. I feel emotionally drained from my work.
2. I feel used up at the end of the workday.
3. I feel fatigue when I get up in the morning and have to face another day on the job.
4. Working with people all day is really a strain for me.
5. I feel burned out from my work.
6. I feel frustrated by my job.
7. I feel I’m working too hard on my job.
8. Working with people directly puts too much stress on me. 
9. I feel like I’m at the end of my rope.
Depersonalization (Consequences) 
1. I feel I treat some patients as if they were impersonal ‘objects’.
2. I’ve become more callous toward people since I took this job.
3. I worry that this job is hardening me emotionally.
4. I don’t really care what happens to some patients. 
5. I feel patients blame me for some of their problems. 
Personal accomplishment (Consequences) 
1. I can easily understand my how my patients feel about things.
2. I deal very effectively with the problems of my recipients patients.
3. I feel I’m positively in"uencing other people’s lives through my work.
4. I feel very energetic.
5. I can easily create a relaxed atmosphere with my patients.
6. I feel exhilarated after working closely with my recipients.
7. I have accomplished many worthwhile things in this job.
8. In my work, I deal with emotional problems very calmly.
Appendix 2: Perceived organizational support scale by Eisenberger 
(1997)45
Response categories: seven-point Likert scale ranging from one (strongly disagree) to seven (strongly 
agree) (Drivers). When thinking about my place of employment, I feel: 
1. My organization cares about my opinion.
2. My organization really cares about my well-being.
3. My organization strongly considers my goals and values.
4. Help is available from my organization when I have a problem.
5. My organization would forgive an honest mistake on my part.
6. If given the opportunity, my organization would take advantage of me.
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7. My organization shows very little concern for me.
8. My organization is willing to help me if I need a special favor. 
Appendix 3: Arcêncio scale1
1. My family member asks me to keep the TB a secret. 
2. I feel ashamed because my family member has TB. 
3. I hide the fact that my family member has TB from the community. 
4. My family member hides his/her diagnosis from the community. 
5. I avoid talking about TB in the presence of other family members or neighbors. 
6. I’m afraid that someone will see me at the health care clinic where my relative is being treated. 
7. I substitute another word for TB in my conversations with my family member. 
8. I substitute another word for TB in the conversations with my friends. 
9. I’ve noticed changes in my family member since the TB diagnosis.
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Chapter 9
Sampling methods for measuring TB 
stigma in hard-to-reach populations 
without sampling frames
Lisa G. Johnston
Abstract
Levels of TB stigma vary among different groups. Social exclusions can be 
compounded and may create measurement challenges. Measuring TB stigma 
among people who use drugs and/or alcohol, migrants, and those with a history of 
incarceration requires expertise and sophisticated methodology. Using a probability-
based sampling method to measure TB stigma among hard-to-reach populations will 
yield more representative and actionable estimates. 
This chapter presents two probability-based sampling methods, time location and 
respondent-driven sampling, for hard-to-reach populations (those with no sampling 
frame). Time location sampling involves mapping the times and places where the 
population congregates, and then randomly selecting and sampling mapped times 
and places. Respondent-driven sampling samples the network of the population 
and uses a chain referral peer-to-peer recruitment methodology. This chapter will 
also present the speci!c bene!ts and challenges of each methodology, and detail 
calculating a sample size. 
  
Objectives
In this chapter, you will learn:
1. The difference and importance of a probability versus a non-probability based 
sampling method.
2. The steps in conducting a survey using time location sampling, and information 
about additional resources.
3. The steps in conducting a survey using respondent driven sampling, and 
information about additional resources.
4. Parameters for deciding whether to use time location sampling or respondent 
driven sampling for a particular population.
5. To calculate a sample size for studies using time location or respondent driving 
sampling.
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Target Audience
This chapter is for social scientists, epidemiologists, researchers, and program 
planners who require TB stigma estimates in hard-to-reach populations. Due to 
the complexity of the sampling and analytic procedures, we recommend that 
these studies be undertaken in conjunction with a strong research partner.
Introduction
Accurately measuring TB stigma among populations that are hard to reach is 
essential for building comprehensive intervention programs. These groups are 
often socially excluded and stigmatized. 
By de!nition, it is challenging to conduct probability-based sampling on hard-
to-reach populations, as these populations may lack the sampling frames 
(i.e., a list of all persons you want to sample) needed to accurately determine 
the probability that each person has an equal chance of being selected into 
a sample.1,2 In addition, these populations, which comprise people who use 
drugs, people dependent on alcohol, the homeless, ex-offenders, ex-miners, the 
mentally ill, and undocumented migrants, are often marginalized, may practice 
illegal behaviors, have unstable living situations and irregular working hours, do 
not trust authorities, and are subject to high levels of stigma and discrimination.3 
It is widely understood that TB stigma can be enmeshed and con"ated with 
other kinds of social exclusions and marginalities. When measuring TB stigma in 
marginalized groups, it is important to measure other stigmas that can combine 
with TB stigma to have synergistic and reciprocal negative impacts on health-
seeking or adherence behavior. (See Chapter 14)
Actionable TB stigma estimates rely on sampling methods that are probability 
based, meaning that each member of the population has a known probability 
of being selected. Probability-based sampling is any sampling method that 
uses simple random sampling, systematic random sampling, strati!ed random 
sampling, and cluster or area random sampling. Probability sampling of a hard-
to-reach population allows researchers, program managers, and policymakers 
to make decisions with TB stigma estimates that better represent the population 
sampled. 
Convenience is not enough
Non-probability sampling, which includes purposeful and convenience sampling, 
samples populations with no known probability of selection, resulting in outputs 
that are biased and provide information that only represent the sample and 
not the population sampled. Although non-probability sampling methods are 
often less expensive and easier to implement than probability-based sampling 
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methods, they tend to give biased results that tend to be invalid. 
Doing it right
It is worth the extra cost and effort to have TB stigma estimates that represent 
the sampled population. Probability-based methods more closely resemble the 
truth.
Currently, two methods, time location sampling (TLS) and respondent-driven 
sampling (RDS), have been developed to approximate probability for sampling 
hard-to-reach populations without sampling frames. These methods have 
been used to measure behavior and disease burden in numerous hard-to-reach 
populations throughout the world for well over a decade.4,5,3,6,7 This chapter will 
describe the pre-survey research, implementation, and data analysis needed to 
conduct a TB stigma survey using TLS or RDS. 
It will also guide how to decide which method to use and the challenges and 
comparative advantages of each method. Finally, this chapter will discuss 
sample size calculation considerations, and provide information about the 
estimated costs and staf!ng needs. 
Overview: time location sampling (TLS) 
TLS, venue-day-time sampling or time-space sampling, is adapted from 
targeted and cluster sampling techniques.8–11 This method relies on mapping 
and listing venues where the population congregates and is therefore 
accessible.8,12 Brie"y, TLS entails identifying and listing the days and times when 
the population congregates at speci!c venues in a sampling area (e.g., a city). 
Deciding which venues to sample is important. Venues should not be locations 
that could over-represent people. For instance, if an important study outcome 
is discrimination at health care centers, you might want to avoid health care 
venues that are known to overly discriminate against the target population. In 
addition, you also want to avoid venues where your population would not be. 
That is, do not try to capture persons who use drugs at a drug treatment center. 
Table 1 lists some examples of appropriate and inappropriate venues for speci!c 
populations. 
Pre-survey
formative
research
Implementation Data-analysis
Figure 1. Process of conducting a TB stigma survey
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Table 1. Examples of more appropriate and less appropriate venues for speci!c hard-to-reach 
Hard-to-Reach Population More Appropriate Venues Less appropriate Venues
Undocumented migrants Day labor pick-up points, migrant 
neighborhoods, bars, restaurants 
and other venues where migrants 
socialize, migrant health clinics.
Immigration of!ces or ex-
patriot associations.
People who inject drugs Shooting galleries or other areas 
where people inject drugs, 
areas where people buy drugs, 
emergency rooms, and needle 
exchange programs.
Drug treatment centers, 
outpatient departments, opioid 
substitution clinics.
People dependent on alcohol Bars or shabeens (taverns). Alcohol treatment centers. 
The homeless Soup kitchens, homeless shelters, 
streets, transitional housing.
Jobs programs.
Former-offenders Day labor pick up points and 
places where former offenders 
socialize.
Parole of!ces.
Former-miners Transport hubs, Mining 
communities.
Mining employment of!ces.
Men who have sex with men Nightclubs, cruising sites or places 
where sex partners can be found, 
city blocks, parks, bath houses 
and other areas where men who 
have sex with men work, socialize 
and live, gay pride parades.
LGBT community centers or 
government-run HIV clinics.
Less appropriate venues are those where people may be non-representative 
of the group with regard to stigmatization. Places which oblige disclosure of 
stigmatized identities can be assumed to attract those who are more resilient to 
stigmatization.
The number of group members at each location provides a sampling weight 
that can be used a priori, to draw a self-weighting sample, or post priori, in 
analysis. The speci!c steps to completing a sampling frame of mapped time and 
location units, randomly selecting and then visiting time and location units, and 
systematically collecting information from consenting members of the population 
are described below.
Two questions to ask yourself before considering the use of TLS are:
 
1. Can the population be found at accessible venues? 
2. Can these venues be accurately mapped? 
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Mapping the venues-sampling frame construction
A complete mapping of venues is essential to conducting TLS and is the foundation 
of two sampling frames.11,13,14 The !rst sampling frame is a list of venues where 
the population can be found (public or private location attended by the target 
population), and the second sampling frame is a list of venue-speci!c sampling 
periods (usually four hours periods). Accurately identifying all possible venues 
will involve meeting with a diverse selection of the population, local research 
entities and community-based organizations, community leaders, venue owners, 
managers, workers, and patrons. Venues can be low frequency, such as a meeting 
or party that occurs once a month, or high frequency, such as a high traf!c street 
that is used 17:00 to midnight Monday through Friday. 
Enumeration
Two enumeration methods are used to set up the inclusion of a venue and the 
associated days and times in the complete list of venues.13,14 In order to discern 
venue-speci!c sampling periods, standardized enumerations of the population 
during possible high attendance day-time periods are conducted. Venues, days, 
and times are known as VDTs, and the time periods are usually four hours, but 
they can be other consistent periods of time. 
Type 1 Enumeration is performed at all venues and assures that the population of 
interest actually attends the venue at the days and time slots are high attendance. 
To do this enumeration, staff members go to the venue to observe activity and 
count patron attendance. Non-duplicate counts of patrons, often using a counter 
clicker, can be conducted for 30 minutes and then multiplied by eight to estimate 
the total number of patrons that might attend during a four-hour sampling event. 
Those VDT periods that produce suf!cient numbers will be thoroughly evaluated 
with Type 2 enumerations. This should be recorded onto a form that lists the 
venue name and location, the time frame and day of the week during which the 
enumeration was conducted, and the type of venue. 
Factors that could impede venue attendance should be recorded (holiday, security, 
natural hazards, etc.) Type 1 enumeration does not require interaction with the 
population. 
Type 2 Enumeration is conducted at venues that have suf!cient population 
numbers but where it is unclear if enough of the patrons are population members. 
The purpose of a Type 2 enumeration is to determine the number of eligible 
persons who attend a venue at a particular day and time period. 
Venues, days and times 
are known as ‘VDTs’.
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Keys components of Type 2 enumeration are:
 
1. Include venues that had suf!cient numbers of population members;
2. Count patrons (can use a clicker to record the counts); 
3. Approach patrons to establish that they are part of the population of interest 
and are potentially eligible for the study; and 
4. A general sense of where and what kind of enumeration area is best for the 
venue (e.g., if the venue is a street, identify which part of the street is the 
best place for the enumeration). 
Type 2 enumeration does require interaction with the population. Only those 
VDTs where more than 75% of the population of interest is present should be 
included in the !nal ‘complete list of venues’.
Both Type 1 and Type 2 enumerations are the basis for building the overall 
‘complete list of venues.’ Information about each venue is entered into a 
database that includes venue identi!cation number, venue type, name and 
location, and the year, day, and time (Table 2).
ID
Venue Information Venue Day Time Information
Name Type Location M T W TH F S
BR001 Mama’s 
lodge
Brothel T Street 20:00-
00:00
20:00-
00:00
BR002 No name Brothel X Lane 19:00-
2300
19:00-
23:00
19:00-
23:00
S001 No name Street V Street 17:00-
21:00
17:00-
2100
17:00-
21:00
B001 Sam’s place Bar Y 
Shopping
16:00-
20:00
16:00-
20:00
D001 Xtreme Disco Center
Corner, 
X and Y 
Streets
22:00-
02:00
 
Table 2. Example of a Universe of VDTs
Once the VDTs are listed, develop a calendar to schedule sampling events based 
on the number of VDTs available to sample on each day, staf!ng needs, and 
infrequent or one-time events, such as a meeting that is held once a month. The 
sampling calendar will be organized by hours, days, and weeks during a one 
month period or until the sample size is reached. 
Selecting VDTs to sample
Once all of the VDTs are selected and listed in the calendar, randomly select the 
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Figure 2. Example of 5 Randomly Selected VDTs
required number of venues (sometimes referred to as n by researchers.) The 
number of VDTs will be randomly selected based on the sample size for the 
study. 
If 150 patrons must be interviewed for a certain study, and you know that 
selecting !ve VDTs will give you a hypothetical sample size (based on the 
enumeration described above) of 150, then run a random selection of !ve VDTs. 
You can use an online program such as Stat Trek (http://stattrek.com/statistics/
random-number-generator.aspx) to randomly select venues. Once the random 
list of VDTs is determined, they can be arranged in order of smallest number 
of VDTs to largest.13 For instance, since ID D001 in Figure 2 has the smallest 
number of VDTs (n=1) compared to the others venues, it would be !rst on the 
list. Schedule the venue with the smallest number VDTs !rst, as these should be 
the easiest to sample. 
When venues have more than one date and time, randomly select one of the 
dates and times, and then schedule the randomly chosen dates and times on 
the !rst available day of the week.13 Continue until all sampling events are 
scheduled. 
VDTs should be selected without replacement, meaning that the same site 
cannot be sampled twice.
Sampling at VDTs
Data collection may take place at the venue, if space permits, in a mobile site 
near the location, such as a van, or by making appointments for potential 
participants to come to a designated study site.
Venue 1 Venue 2 Venue 3
TB
Stigma
Sampling
Venue 4 Venue 5
30-40
ex-miners
10-20
ex-miners
40-60
ex-miners
20-30
ex-miners
(mostly
migrants)
5-10
ex-miners
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Sampling usually takes place during four hour time frames. Sampling boundaries 
should be established at each selected venue by creating an imaginary line, such 
as on a street corner or in a park, or based on the area, like the interior of a bar.13 
When a selected venue is visited by staff for sampling, enumeration Type 2 is 
used to count the population members that cross the imaginary line or that enter 
a boundary area during the sampling period and event (usually four hours). 
Type 2 enumeration is important for counting population members and 
intercepting and determining if population members are eligible for the study. 
During the sampling event, if someone is eligible for the study, they may 
complete a consent process and proceed with the interview. This process 
continues until the x hour sampling event is !nished (e.g., for D001 in Figure 2, 
this would be at 2 a.m.). Record when someone refuses to participate. 
All participation is voluntary and refusals are normal and expected. Permission 
should be obtained from venue owners or managers before sampling. Incentives 
are usually offered to those who enroll and complete a survey.13,14
TLS Staf!ng
The sampling staff for TLS usually consists of a team leader and interviewers. The 
role of the team leader is to enumerate, oversee interviews, and manage staff 
safety. The interviewers approach potential interviewees and assesses them for 
eligibility. If eligible, the interviewers enroll them into the study by conducting 
consent and completing the interview. 
Analysis of TLS Data
Differences in venue size and attendance patterns require that weights be 
applied to TB stigma estimates collected through TLS. Commonly used weights 
are produced using the enumeration count (Type 3) of each event as the basis 
for the weight.13 
The weighting is based on enumeration counts of each sampling event which 
can be used as probability weights (p weights). This adjustment should produce 
estimates that re"ect the ratio of the number of persons enrolled to the number 
of eligible persons at each recruitment event. If the same ratio is seen across 
all recruitment events, then the sample is self-weighted and no adjustment 
is needed. To do this, simply take the total number of potential subjects 
enumerated at each event over the total number of subjects enumerated for all 
events (for instance, if 102 people were enumerated (eligible) for event X and 
the total number enumerated for all events was 6300, that would be 102/6300 
= 0. 0162). In addition, take the total number of interviews completed at each 
event over the total number of completed interviews for all events (for instance, 
if 7 people were interviewed at event X and the total number of interviews 
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for all events was 435, that would be 7/435 = 0.0161). To calculate the p 
weight for each event simply divide the enumeration weight over the sample 
weight: 0.0162/0.0161 = 1.006. This p weight can be applied to each interview 
completed during that event. 
An additional weight of frequency of attendance is also recommended to 
account for some people having a higher probability of being in the sample 
because they frequent a venue more often than others.15 This is a weight 
that is generated based on a survey question about the number of times each 
respondent has attended that venue in a given week and is the proportion of 
frequency by each person in each event over the sum of frequencies. 
Limitations of TLS
When the full sample size is !nally reached and analyzed, it should be 
representative of the population that attends the venues. Keep in mind that 
these are more visible members of hard-to-reach populations and that there 
may be differences with those who do not attend venues. The actual data 
collection from population members may be fast (no longer than one month), 
but the complete mapping of venues and enumeration can be time-consuming, 
depending on the size of the geographic area being sampled. 
Because population members may be asked to participate as they are walking 
down the street, at home, at a meeting, or while they are socializing with friends 
at a bar or dance club, refusal rates may be high.11,15,16 To improve acceptability:
1. Ensure visual and auditory privacy;
2. Keep your questionnaire short; and
3. Offer incentives during the interview. 
Overview: Respondent-driven Sampling
Respondent-driven sampling (RDS) was introduced in 1997 as a novel method 
to recruit and provide generalizable estimates of socially networked hard-to-
reach populations.17 RDS is considered both a sampling and an analysis method, 
and every survey requires both in order to be termed RDS.18 RDS is adapted 
from chain referral sampling methods, which rely on referrals from initial 
survey participants, referred to as a seed in RDS, to recruit additional survey 
participants. Chain referral sampling alone produces biased samples because 
the recruited respondents most likely have characteristics similar to that initial 
respondent.19 
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Figure 3. Problems with Chain Referral Sampling
This results in a !nal sample that is over-representative of the characteristics 
of respondents with more social connections and under-representative of the 
characteristics of those respondents with fewer social connections. 
RDS uses several theory-driven statistical adjustments to sampling and analysis 
to mitigate the biases of convenience chain referral sampling.3,20,21 RDS relies on 
people to recruit their peers through coupons with unique code numbers.17,22 The 
recruitment process includes small incentives for survey participation and peer 
recruitment. Incentives, and peer norming from recruits, (i.e., “I know you and 
you know me and I want to enroll in the survey since you have already enrolled 
and you are asking me to enroll”), encourage people to enroll in the survey and 
to in"uence their peers to enroll as well.23 
Two questions to ask yourself before considering the use of RDS are:
 
1. Do members of the population recognize each other as a member of that population? 
2. Can a handful of these population members be identi!ed to participate in a survey?
Pre-survey Assessment
Formative qualitative research is needed to inform the design of any study in 
hard-to-reach populations. Chapter 3 provides guidance on how to conduct 
formative work. A pre-survey assessment will contribute to RDS planning 
by describing the target populations’ social network properties (i.e., how 
populations are socially networked and the types of activities they do together), 
These respondents all view TB stigma the same way
because they share experiences.
This group has a different
experience of stigma, but they
are not as socially connected and
so their view seems less common.
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Table 3. Questions to Measure Networks during Pre-Survey Assessments for RDS21
 Social Networks Questions
Do population members 
form a social network?
Do you know or spend time with other population members?
Are population members easily recognizable to one another?
How are they recognizable? 
What types of activities or behaviors bring them together?
Do the target population 
members have large 
social network sizes? (This 
question is tied to the 
survey eligibility criteria.)
In a survey of males who currently inject drugs, ≥18 years, living 
in city A, ask: How many males do you know who also know you, 
currently inject drugs, are ≥18 years and live in city A? How many of 
them have you seen in the past month?
Do the target population 
members form diverse 
social network ties?
Please tell me about how your population members, friends and 
acquaintances interact with each other (What activities do they do 
together?)
What is the structure of 
the social network? Are 
there cliques and if so, can 
you !nd bridges to include 
them?
If you suspect that population members form distinct geographic 
social networks, ask: Do you know population members who 
socialize/work in or are from other parts of the city? 
If you suspect that population members form distinct social network 
types, ask: Do you know population members who are different than 
you (e.g., older vs. younger miners; street vs. home-based persons 
who inject drugs, etc.)?
identifying useful seeds, measuring the acceptability of RDS recruitment, and 
informing RDS survey logistics.3,21,24
The most important evaluation is whether the population is socially networked 
to the extent that they can recognize and recruit each other as part of that 
population. Ideally, social network sizes should be large enough (≥ three) to 
sustain recruitment and develop the long recruitment chains needed for RDS 
analysis. In addition, population members should be able to recruit at least three 
of their peers into a survey. If they do not know or would be unable to do this, 
then RDS will probably not work. 
It is also important to understand how strong connections are between peers 
within social networks (i.e., are their peers just acquaintances that they see 
once a month, co-workers that they only see while at work, are they casual 
friends that they meet for coffee or close friends that they spend time with each 
day?) Having both weak and strong ties can assist in RDS recruitment, whereas 
just having strong ties may indicate that recruitment is not suf!ciently spread 
throughout the entire network. 
A pre-survey assessment should help ensure that networks comprise multiple 
types of relationships (e.g., friendships, acquaintances, co-workers, room-
mates, sex partners, etc.) and activities. Table 3 lists the questions that should be 
included during the pre-survey assessment.
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A pre-survey assessment, often the !rst contact by researchers with the 
community, can demonstrate that the survey staff are willing to listen and 
to make survey changes based on feedback. Most importantly, a pre-survey 
assessment can help inform whether RDS is an appropriate method for a 
particular population and socio-cultural context.
Data Collection
Recruitment begins with a small, diverse and in"uential group of people referred 
to as “seeds” or eligible respondents pre-selected by the researchers.17
Figure 4. Preselected respondents (Seeds) who will recruit respondents with unique coupons
Each seed receives a set number, usually no more than three, of coupons to 
recruit their peers. These peers present the coupons, usually at a !xed site or 
web address, to survey staff to enroll in the survey.21 Eligible recruits who !nish 
the survey process are also given a set number of coupons (no more than three) 
to recruit their peers. The recruited peers of seeds who enroll in the survey 
become wave one respondents, and the recruits of wave one respondents 
become wave two respondents (Figure 5).21
This recruitment process continues through successive waves until the calculated 
sample size is reached. The waves produced by effective seeds make up 
recruitment chains of varying lengths (Figure 5). The goal is to acquire long 
recruitment chains made up of multiple waves, an indication that the !nal 
sample is not biased by the non-randomly selected seeds. In Figure 5, there are 
!ve recruitment chains, with the longest recruitment chain reaching 14 waves. 
The seeds are the larger nodes with arrows pointing away from them. The grey 
nodes are females and the blue nodes are males. 
Seed
Coupon
Coupon
Coupon
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Figure 5. Recruitment Graph of Males and Females in the sub-Saharan African Anglophone Migrant 
Sample (n=277), with Five Recruitment Chains, Rabat, Morocco, 2013.25
Essential data to collect during data collection
During data collection, it is vital to gather information on who recruited whom 
and each participant’s social network size for analysis purposes.20,26 Recruitment 
information is monitored through unique numbers on recruitment coupons, 
and should be carefully recorded as each participant enrolls. Each respondent’s 
social network size is measured through questions about the number of 
people each participant knows who ful!lls the eligibility criteria and whom 
they have seen during a set time period, usually one week to one month. 
These are usually a cascade of questions resulting in a !nal, non-zero, number 
representing a participant’s network size (Figure 6).
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Figure 6. Description of the Social Network Size Question Topics and an Example of the Questions 
among Sub-Saharan Migrants in Rabat, Morocco25
Figure 7. Example of a Coupon used in an RDS Survey of Migrants
Clear de!nition of 
the target population
The meaning of 
what it is to know
someone
Geographic
Parameter
Time frame during
which the respondent
has seen their peers
How many people do you know who are sub-Saharan
migrants native to Ghana, Liberia, Nigeria, 
Sierra Leone, or Uganda who speak English?
By “know”, we mean you know each other personally?
Among these persons, how many of them 
lived and worked in Rabat for three months or more?
Among these persons, how 
many have you seen in the last 30 days?
RDS Coupons
Coupons must contain a unique RDS identi!cation code to link recruiters with 
recruits.21 Coupons should be carefully developed, easy to read, and have a 
pleasant appearance so that study participants realize that the coupons have 
value. Coupons should include unique RDS identi!cation codes, interview site 
location, mobile phone number to make appointments, days and hours of 
enrollment, and expiration dates. Below is an example of a coupon used for 
a survey of undocumented women from Central America who are living in 
Houston.3,27 
0702
INVITATION COUPON TO PARTICIPATE
Project Linkages
Health Survey of Central American Women in Houston
The University of Texas School of Public Health
Disbursement date Expiration date
Compensation for your time ($35)
We take appointments and walk-ins Monday-Friday; by
appointment only on Saturdays
“Cornwall Square” Apartments
123 Noname St.
Apartment # 100A
Hours:
Please call for a special appointment
“Preston Point” Apartments
Corner of Nowhere and Somewhere
Apartment # 100A
Hours:
Monday & Wednesday: 9:30 - 15:30
Tuesday & Thursday: 9:30 - 16:30
Questions? Or to make an appointment please call
713-XXX-XXXX or 713-XXX-XXXX
In
te
rv
ie
w
Si
te
s
You must
present this coupon
to participate in 
the survey!
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Table 4. Example of a coupon ledger using random or serial numbers
Coupon numbering
There are many different ways to track who recruited who during RDS data 
collection, including a random or serial numbering system or a systematic 
numbering system. The key to either system is to correctly manage who 
recruited whom. For the purposes of analyzing RDS data, either numbering 
system described below is acceptable.
Random or serial numbering
Random or serial numbers are merely numbers that identify each participant. For 
instance, some surveys use a four-digit number. The !rst number can represent 
the city or the population being studied. For instance, 1 means the study is being 
conducted in Bangkok, Thailand. The remaining three digits can be numbers that 
start from 001 up to the sample size, for instance, 450. These numbers could 
also be alphabet characters. For instance, at the beginning of the identi!cation, 
you could have F for female sex worker and 1 for Bangkok. See Table 4 for a 
sample coupon monitoring system.
In the example above, the participant coupon numbers are in column 2 and 
the coupons given to each participant are in the columns 3, 4, and 5. You will 
see that in the sixth column under notes, that one person (coupon number 
F1214) who tried to enroll was found to be ineligible, so this person was not 
given recruitment coupons. There are bene!ts and challenges with this coupon 
numbering system. 
A bene!t is that the coupon numbers can be preprinted as barcodes on labels 
and easily af!xed to coupons and in the coupon ledger. The numbers are only a 
few digits and easy to record. A challenge to this method is that if any mistakes 
occur, it is hard to know who is linked to whom. Any errors in the numbering 
system may result in data analysis problems. If collecting data with monitors, this 
method is practical. 
Date Participant Coupon 1 Coupon 2 Coupon 3 Notes
June 1, 2017 F1001 F1007 F1008 F1009
June 1, 2017 F1008 F1111 F1112 F1113
June 2, 2017 F1111 F1213 F1214 F1215
June 2, 2017 F1214 -- -- -- Ineligible
June 3, 2017 F1009 F1223 F1224 F1225
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Systematic Coupon Numbering
Some researchers, especially those who rely on paper management, may prefer 
to use a systematic numbering method that identi!es seeds and the completion 
of each seed’s waves. Depending on the number of seeds, this coupon 
numbering system will start with a unique number provided to the seed. For 
instance, in a study with ten seeds, the !rst two-digits on each coupon will be 1 
through 10.
For example, Seed 1 has the number 1, and then Seed 2 has 2, etc. 
Seed 2 2
Seed 3 3
... to Seed 10 10
Since most RDS studies allow for the recruitment of three peers, the numbers 
following the seed numbers are 1, 2, or 3 as shown in Table 4. For instance, if 
seed number 5 is interviewed and given three recruitment coupons, then the 
recruits for seed number 5 would receive the following coupon identi!cation 
numbers: 51, 52 and 53. If a recruit with coupon 53 is interviewed, then he or 
she will receive coupons with the identi!cation numbers of 531, 532 or 533. This 
process occurs according to the number of waves produced by each seed. So 
coupon 533 represents the second wave produced by seed 5. You can also put 
letter of the alphabet at the beginning to denote the population or the city being 
sampled.
Table 5. Example of a Coupon Ledger using Random or Serial Numbers
Date Participant Coupon 1 Coupon 2 Coupon 3 Notes
June 1, 2017 1 11 12 13
June 1, 2017 12 121 122 123
June 2, 2017 123 1231 1232 1233
June 2, 2017 121 -- -- -- Ineligible
June 3, 2017 13 131 132 133
June 3, 2017 1233 12331 12332 12333
June 4, 2017 12333 123331 123332 123333
In the example above, the participant coupon numbers are in column 2 and the 
coupons given to each participant are in the columns 3, 4, and 5. You will see that 
in the sixth column under notes one person (coupon number 121) who tried to 
enroll was ineligible, so this person was not given recruitment coupons. 
This method makes it easier to manage the progress of the seeds. For instance, 
you can track which seeds are ef!cient recruiters, which seeds did not recruit 
anyone and the number of waves completed by each seed. In the last row, you 
can see that the participant enrolled on June 4, 2017, with coupon number 
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Figure 8. Example of the Systematic Numbering System Increasing by Wave
12333. This person was recruited by 1233 and was given three recruitment 
coupons (123331, 123332, and 123333.) The number of waves for the 
participant enrolling on June 4, 2017, is 4. That is, the !rst digit is the seed 
(number 1) and the remaining digits tell us the number of waves (2333). Figure 
8 depicts the growth of the waves in a chain, starting with seed 3.
The three recruitment coupons given to this person will produce participants 
for seed 1 and have 5 waves. So during data collection, it is easy to see which 
seeds are recruiting and how many waves there are. Knowing which chains are 
producing (by looking at the seed number) is important for knowing if a new 
seed needs to be added (in case one seed has not recruited anyone). Knowing 
the number of waves is important for decisions about coupon reduction (if 
recruitment is fast and/or chains are too short or there are too few waves) and 
ending the survey so that no valid coupons remain in the community once the 
survey is !nished. These numbers also make it easy to visually see who recruited 
whom. One of the challenges to using this number is that they can get very 
long, so extra care is needed during monitoring. For instance, coupon number 
411111222222111, initiated from seed 4 and makes up 14, waves is not 
unusual in an RDS survey. 
RDS Staf!ng 
The data collection staff in RDS usually consists of a site manager to manage 
the "ow of participants, a screener who oversees someone arriving at the 
interview site with a valid coupon (the screener may also explain the study to 
the participant, conduct the consent process, and ask questions about social 
networks). There also may be someone to explain how to use the computerized 
system, and a coupon manager who explains the recruitment process and gives 
out properly numbered coupons.21 The coupon manager may also pay out the 
incentive, since they are the last person a participant usually sees.
Web based RDS
Given the large percentages of people using the internet and who have cellular 
phones, the increasing cost involved in conducting these types of surveys, 
researchers are modifying RDS for use in a web or mobile phone-based 
format.28–31 This involves the strict control of coupons being passed through 
online networks. Once someone receives a coupon, they can respond to 
questions online. Incentives (i.e., a gift card or phone card) can be sent online 
3 32 321 3211 32112 321123
Seed Wave 1 Wave 2 Wave 3 Wave 4 Wave 5
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once a survey is completed. This methodology requires fewer staff and does not 
involve the cost of a !xed site. 
RDS Data Analysis
Once TB stigma estimates are collected with RDS methods, they must be 
analyzed to reduce biases by applying computational weights. RDS uses a 
weighting system whereby those with larger network sizes are given less weight 
and those with smaller social network sizes are given more weight.20,26,32 The 
unit of analysis in RDS is a network structure rather than an individual, and 
the analysis generalizes to the networks of the sampled population.26,33 This 
in"uences the kind of estimators we use, the way we understand the variance 
around the estimates, and how we interpret the !ndings. 
Because the weighting techniques are complicated, there are free software 
packages available for adjusting TB stigma estimates collected with RDS. There 
are currently two widely used open source software programs: the RDS Analysis 
Tool (RDSAT) (www.respondentdrivensampling.org) and RDS Analyst (www.
hpmrg.org). The latter program is based in R Project for Statistical Computing 
(a free software programming language) and has graphical user interfaces with 
drop down boxes to make analysis easier. It includes all the current estimators 
(available up to 2013) and allows direct downloading of all !le types (SPSS, 
STATA, SAS, R, Excel, txt, etc.). In addition, it allows you to build graphics and 
plots to use in diagnoses if the population is made of subgroups that are distinct 
to individual chains or “bottlenecks”, whether the estimates are still biased by 
the non-randomly selected seeds, convergence, or other biases (i.e. you want 
to avoid bottlenecks and you want convergence) in the data. It can also display 
results.18 
Key variables should be assessed for convergence to know whether or not the 
recruitment chains are long enough to have minimized the bias from the selected 
seeds. For instance, in Figure 9, the vertical axis shows the adjusted estimate 
in RDS Analyst for four age groups, and the horizontal axis shows the number 
of subjects (n=250) enrolled in the survey. The solid lines indicate variation, 
beginning from the seeds, as the participants enroll in the survey. When the solid 
lines rest upon the dotted lines that represent the !nal weighted estimate for 
each of the categories, convergence has been reached. 
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Figure 9. Plot showing Convergence for Age Groups
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Choosing between TLS and RDS
If the majority of the population you want to study are found at visible 
venues, then TLS may be the best sampling option. If the population is 
socially networked and can be motivated to recruit, then RDS may be the best 
sampling option. RDS may include more hidden persons and/or subgroups that 
are not well connected to the larger network. Neither method may provide 
representative TB stigma estimates on all parts of the population sampled. 
As an example, RDS surveys of males and females who inject drugs often 
struggle to enroll females. This may be because the networks of males and 
females who inject drugs are substantially different. In an RDS survey conducted 
in Myanmar, males who inject drugs were found to be more connected to other 
males who inject drugs and to some females who inject drugs, but females who 
inject drugs were not connected to any other females who inject drugs. When 
the samples were !nally gathered, there were so few females in the sample that 
the estimates ended up representing the network of males who inject drugs only. 
Costs of the surveys 
The overall costs of conducting these surveys will vary based on sample size, 
country, population, number of staff members, costs for a !xed site (RDS), and 
numerous other factors. There are few cost comparisons conducted between 
TLS and RDS. One survey conducted among people who inject drugs in Vietnam 
found the costs to be slightly lower for RDS (Table 6).34 
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Table 6. Field Implementation and Logistics Expenditures in USD for RDS and TLS Among People 
who Inject Drugs, Hai Phong, Vietnam, 2011-2012
RDS (n = 415) TLS (n = 432)
($) Total
($) Cost/
participant
($) Total
($) Cost/
participant
Recruitment* 1,000 2.4 4,800 11
Incentives 2,050 5 2,100 5
Staf!ng and other costs^ 9,200 22 10,300 24
Total 12,250 29.4 17,200 40
*For RDS, this includes payment for referrals. For TLS, this includes cost of peer-educators, mapping staff, and coupon distribution. 
^For both RDS and TLS, this includes survey team management and data collection staff, including interviewers, lab technicians, and 
data entry specialists. All surveys were conducted in existing health clinics, for which there were no charges. 
Planning and data collection time
Both methods require the submittal and approval of a protocol, which can 
take between one to six months. Planning times will vary between survey 
methodologies. Remember that TLS will require more up-front time, as it is 
necessary to map venues and create and select VDTs. In many surveys, with all 
else being equal, RDS data collection may take more time than TLS. 
In the example above of RDS and TLS among people who inject drugs, the RDS 
survey took six weeks, and the TLS survey took 10 weeks, including mapping. 
In another example of RDS and TLS among men who have sex with men in 
Guatemala, a sample size of 507 was reached in 11 weeks using RDS, while for 
TLS a sample size of 609 was obtained in 7.5 weeks.35 Both surveys included a 
formative research phase, which for RDS includes assessing networks and survey 
logistics24, and for TLS it includes mapping and enumeration. RDS formative 
research took four weeks, while for TLS it took 8 weeks.35 In a 2008 review 
of 123 RDS surveys (published and unpublished) conducted worldwide, the 
median number of weeks it took for data collection was eight, with a range of 
2 to 52 weeks.4 In a 2016 review of 222 publications reporting on RDS surveys 
conducted worldwide, the median number of weeks for data collection was 12, 
with a range of 2 to 124 weeks.36 
Sample size calculations
Any standard sample size calculation formula can be used to sample populations 
using TLS or RDS, however a minimum design effect of two is needed for 
RDS.37,38 The sample size needed to conduct a survey can be based on the 
number of participants needed to accurately measure a stigma indicator in a 
population. For the formula detailed below, the expected proportion is needed. 
For instance, past surveys of migrants may have found that 20% of migrants 
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have experienced discrimination at a healthcare facility. This would be the 
expected proportion. However, when nothing is known about the population, 
an expected proportion of .50 is most often used to calculate the sample size.11 
Below is an example of a general formula to calculate a sample size (n) in order 
to measure a stigma indicator: 
Using the formula above and assuming a design effect of 2, a 95% con!dence 
interval and an expected proportion of .5 (50%), the sample size will need to be 
769. The following website allows you to plug in the parameters and calculates 
the sample size using the above formula: 
http://epitools.ausvet.com.au/content.php?page=1Proportion 
http://www.sample-size.net/sample-size-conf-interval-proportion/
If a design effect is not included in the calculator, then double the calculation. 
Conclusion
This chapter presented two probability-based sampling methods, time location 
and respondent-driven sampling, for measuring TB stigma in hard-to-reach 
populations (those with no sampling frame). Conducting a survey using TLS 
or RDS can be challenging and requires that numerous assumptions be met. 
The extra efforts are necessary to ensure that the breadth and extent of 
stigmatization of vulnerable groups are fully captured so that actions can be 
taken to address it.
Resources for conducting TLS or RDS surveys
In order to ensure the proper implementation and analysis of TLS and RDS, it 
is best to use the following resource guides, all of which provide step-by-step 
information for conducting these surveys. 
 n  =  Sample size required 
 D = Design effect 
 Z = The z score for power (.95 is often used)
 P = Expected proportion
 SE = Precision or standard error (usually set at .01)
1-_2
n = D*
SE2
P(1-P)Z1-_2
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References for Time-location sampling
Family Health International. Behavioral Surveillance Surveys (BSS). Guidelines 
for Repeated Behavioral Surveys in Populations at Risk of HIV. Family Health 
International; 2000.
Lipovsek V, Long!eld K. Sampling hard-to-reach populations: Learning 
objectives. Population Services International, Washington, DC. 2007. https://
www.k4health.org/sites/default/!les/Sampling-Hard-To-Reach-Populations-
Toolkit.pdf
San Francisco Department of Public Health. Resource Guide: Time Location 
Sampling. 2010. Accessed at: https://globalhealthsciences.ucsf.edu/sites/
globalhealthsciences.ucsf.edu/!les/tls-res-guide-2nd-edition.pdf
References for Respondent-driven sampling
Johnston LG. Introduction to Respondent-Driven Sampling. Geneva, Switzerland: 
World Health Organization; 2013. Accessed at: http://applications.emro.who.
int/dsaf/EMRPUB_2013_EN_1539.pdf
Johnston, LG and Malekinejad M. 2015. Respondent-Driven Sampling for 
Migrant Populations. In Migration and Health: A Research Methods Handbook. 
Eds. Castaneda VMB, Rodriguez-Lai Schenker X.
Johnston LG. A Guide to Using RDS Analyst and NetDraw. Geneva, Switzerlands. 
Accessed at: http://applications.emro.who.int/dsaf/EMRPUB_2014_EN_1686.
pdf?ua=1&ua=1
Tyldum G, Johnston L. Applying Respondent Driven Sampling to Migrant 
Populations: Lessons from the Field. Palgrave Macmillan; 2014. 146 p.
Important websites
For information on downloading RDS analyst software and analyzing RDS data:
www.hpmrg.org
For information on downloading RDSA software and resources: 
www.respondentdrivensampling.org
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Chapter 10
Measuring self-stigma, well-being, 
resilience and self-agency among 
people with TB
Nadine Ferris France, Stephen H-F Macdonald, Ronan R. Conroy, Deirdre Ni 
Cheallaigh, and Elaine Byrne
Abstract
The chapter covers key features of self-stigma and methods to measure it. We 
!rst present several challenges in de!ning self-stigma, notably the need to 
consider its complex nature. We then highlight common drivers and domains of 
self-stigma, and their relevance to people being treated for TB or having survived 
it. We then focus on the assessment of TB self-stigma, reviewing evidence from 
TB studies and other conditions for which self-stigma is a challenge, such as 
mental health and HIV. We describe methods to assess not only how much, but 
also why self-stigma is being experienced. We recommend a new measure, the 
Ryff Scales of Psychological Wellbeing, to help shift the scope of measurement 
away from purely assessing negative personal experiences toward a more holistic 
and supportive approach.
Objectives
1. Provide an overview of self-stigma and the ways in which it affects people 
living with TB.
2. Review the common drivers and major domains of TB self-stigma.
3. Present methods of assessing TB self-stigma and why it is important not to 
focus solely on the negative experiences of PWTB.
4. Provide guidance on understanding and measuring coping and support 
strategies against TB self-stigma.
Target Audience
The intended audience includes researchers, national TB program managers 
healthcare workers, NGO and CBO staff and volunteers, outreach workers, and 
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survivors of TB. Readers are likely working with people who are in treatment 
for TB who may be experiencing self-stigma. This chapter may also be useful to 
those involved in developing interventions to address self-stigma. Other users 
may bene!t from applying the recommended measurement tools to improve 
their understanding of how self-stigma may affect their programs. 
Introduction
One of the major challenges in measuring self-stigma is the approach and the 
terminology used. The term “self-stigma” or “internal stigma” can encompass 
a number of different manifestations such as shame, guilt, and withdrawal.1–3 
However, these are individual manifestations of self-stigma and do not 
necessarily describe the concept in full. 
While measurement of self-stigma is a useful exercise, it is important to note that 
self-stigma is multifaceted. Valuable insights can therefore be lost if self-stigma is 
treated as one simple measure. For example, guilt and social withdrawal are both 
domains of self-stigma.2,4,5 However, a person with high levels of guilt but low 
levels of social withdrawal is different from a person with low levels of guilt but 
high levels of social withdrawal. It is important that self-stigma, and its drivers 
and its manifestations are viewed as complex, interacting factors, rather than as 
isolated items on a scale. 
There are two ways of assessing self-stigma. In epidemiological studies, it can 
be useful to get an overall measure of self-stigma for each individual. However, 
when we are implementing programs to bring about change in an individual, 
self-stigma must be measured in such a way that a person’s individual experience 
is shown. This approach can be used to set goals for change and to monitor 
progress and achievements. The same scale may be used for epidemiological 
research and case formulation; however, the goals are different.
In addition, when a case-formulation instrument is needed, there is a lack of 
tools for measuring stigma and self-stigma outside a high-income country 
context. As such, existing tools may not suit the cultural and social contexts of 
other regions. There is also a lack of research on the interface between stigma 
scales and the experience of self-stigma in other cultures. 
Overview of self-stigma
De!ning self-stigma
Stigma occurs at various, interrelated levels, as described in previous chapters. 
Enacted stigma (discrimination) refers to actions or omissions because of stigma 
(e.g., microaggressions). They can lead to an individual anticipating or perceiving 
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him or herself as stigmatized. External stigmas can manifest themselves as 
prejudices and negative stereotypes. They can lead to targeted individuals being 
perceived negatively, harmed, or socially ostracized.1 On the other hand, self-
stigma or internal stigma*1exists within the individuals with HIV, TB, hepatitis, 
diabetes, mental health or addiction issues.6 It can occur or exist independently 
of experiences and perceptions of social stigma, and in anticipation of negative 
social reactions. For example, an individual who develops a stigmatized condition 
such as TB may also hold the same negative and prejudicial beliefs held by 
wider society. This can result in harmful effects, such as shame, guilt, self-blame, 
feelings of worthlessness, and disempowerment.1,2,7–9 A useful de!nition, which 
accurately re"ects the complexity of HIV self-stigma, has been proposed by 
Justice Edwin Cameron. His de!nition is highly transferable to TB: “Self-stigma 
is self-disabling inner feelings of contamination, shame, self-rejection, and 
self-loathing experienced by people with HIV, and those who fear they have 
HIV, even when there is no objective reason to fear rejection or discrimination, 
and even when there is good objective reason to believe that they will receive 
external support, protection, treatment, and acceptance.”10 Self-stigma has a 
detrimental impact on the lives of people affected by diseases like addiction, HIV, 
and TB. For example, it can lead to depression, social withdrawal, and fear. Self-
stigma can reduce access to health services, and negatively in"uences treatment 
compliance, mental health status, and general wellbeing.11–14 The phenomena of 
external stigmas and self-stigma are highly complex and inter-related.15,16
Self-stigma has added potential for harm in the context of people coping 
with TB, other infectious diseases, or other chronic conditions. This is because 
they require consistent engagement with health services and social support 
to maintain good health and wellbeing. Self-stigma is growing as an area of 
concern and has been documented across a broad range of domains, including 
mental illness, HIV, diabetes, leprosy, weight disorders, and tobacco use.2,5,17–21,2,5 
Research in the !elds of HIV, TB, and epilepsy has found that people affected by 
these conditions stigmatize themselves much more than other people actually 
stigmatize them.22,23
Self-stigma can lead to social withdrawal, disengagement from health services, 
reduced treatment compliance, and more. While the impact of TB on physical 
health can be plainly seen, its immediate effects on other areas of a person’s life 
and well-being should also be considered when formulating strategies for coping 
and resilience.2,24–27 This chapter, therefore, focuses not only on methods and 
strategies for measurement of self-stigma, it also suggests methods to better 
understand and characterize self-stigma so that tailored plans to limit its negative 
effects can be developed.
* Self-stigma or internal stigma is often called “internalized stigma” in the literature, which we feel 
does not fully explain the complexity of the issue. “Internalized” suggests that stigma is something that 
only exists outside and is then internalized. This misses the important point that stigma can already exist 
inside a person because he or she is part of the same society as those who stigmatize.
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Common drivers of self-stigma
The challenge in identifying the drivers of self-stigma is that the outcome is 
driven by several interacting factors. First, there are social factors, such as 
cultural background and context, access to services, and sources of information. 
There are also self-factors, including the individual’s own belief system, life 
experiences, and coping mechanisms. Third, the contextual factors, such as 
the conditions of the individual’s life, their power relationships with others, 
and their living conditions. These factors are illustrated in Figure 1, which is 
a conceptual framework of the drivers of self-stigma in relation to HIV. This 
framework was published in 2015 in Ferris France et al. as a distillation of 
concepts from Morrison.2,8 Although it originally focused on HIV, the framework 
can be applied to other conditions where self-stigma is a concern, such as TB. 
We should also note that stigma can exist in a person’s immediate surroundings, 
despite not being obvious in the population as a whole. For example, stigma 
and discrimination in the overall population may be low, however, an individual 
may be stigmatized by healthcare workers or family members. The factors in 
this framework may therefore operate at both the population and the individual 
levels.
PEOPLE WITH TB SELF-STIGMA DOMAINS
BELIEFS
FEELINGS
ACTIONS
PROTECTIVE
CHARACTERISTICS
Gender
Age
Class 
Ethnicity/caste/race
Other disparaged identities
Life experience
Self-esteem 
Belief systems
STRUCTURAL AND
ENVIRONMENTAL STIGMA
Stigmatization in the legal, educational,
healthcare, and employment arenas
INTER-PERSONAL STIGMA
Frequency and severity of exposures
to stigmatization by friends, family
coworkers, neighbors, and care givers
STRUCTURAL STIGMA
Treatment side effects - mental and
physical sequelea
Other prevalent forms of stigmatization,
discrimination
Access and Quality of healthcare -
response to needs
Access to valid information
STEREOTYPE ENDORSEMENT
SELF-BLAME
SHAME
GUILT
SELF-ISOLATION
LACK OF SELF-AGENCY
Resilience
Self-agency
Strength of supportive social network
Social protections (laws, safety net) 
to buffer consequences of stigmatization
HEALTH STATUS
Type of TB (drug susceptible,
resistant)
Understanding of TB
Co-morbidities 
(e.g., depression, addiction)
Figure 1. Conceptual Framework
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Process (self and public stigma)
due to health condition
Consequence
Manifestations
Experiences of negative
social reactions
Self/internal and internalized stigma
(including negative stereotype endorsement)
Feelings of guilt, shame, embarrassment, exclusion, isolation, secrecy, concealment, feeling different
from others, worthlessness, lack of self-agency etc.
Negative feelings about the self
Perceptions of negative
social reactions
Identity transformation
Anticipation of negative
social reactions
Pre-existing prejudice and
negative beliefs within the
affected individual
Maladaptive behaviour
Common domains of self-stigma
The framework in Figure 2 has been adapted from Stevelink et al.’s 2014 paper 
reviewing internalized stigma instruments4 (originally adapted from Livingston and 
Boyd28). The framework was developed from evidence published on many different 
illnesses and conditions, including HIV, TB, mental illness, cancer, etc. It outlines the 
processes and conditions that drive self-stigma and its consequences. The common 
domains of self-stigma are not solely applicable to any one condition; they are likely to 
be observed to some degree irrespective of the disease context. Building on Stevelink 
et al.’s work, we have added concepts that recognize self-stigma as existing in the 
individual, often independently from social stigma and in anticipation of negative 
social reactions.
Figure 2. Framework of the processes, consequences, and manifestations of self (internal) stigma 
(adapted from Stevelink et al. 2012). 
Self-stigma and TB
Addressing self-stigma among people treated for TB is part of the evolving 
landscape of TB care, where an increased focus on social and behavioral factors 
acts as a necessary complement to speci!c health system improvements, such 
as access to medications, health facilities, and the provision of services.29 The 
outward behavioral manifestations of TB self-stigma may vary, depending on 
illness severity. For example, people without outwardly visible symptoms may 
avoid accessing services that are known to be frequented by other people with 
the same condition, or may take medications only when others cannot see 
them, if they take medications at all.30 Conversely, TB self-stigma may have 
parallels with self-stigma experienced in conditions such as leprosy, which have 
more obvious physical signs. If a patient with TB experiences chronic coughing 
or wears a mask to prevent its spread, this may identify the patient as a target 
for stigmatization, potentially worsening the dimensions of self-stigma, such 
as fear or poor self-image. The potential for compounding stigma’s effect due 
to multiple stigmatized identities or conditions must also be recognized (See 
Chapter 4).31
How does stigma change 
during TB diagnosis, 
treatment and cure?
What are the temporal 
or lasting effects of TB 
stigma (e.g. once TB is 
treated)?
217
Figure 3. TB and self-stigma across the person’s treatment itinerary 
Figure 4. Measurement of domains of TB self-stigma
Sickness
Body image
Shame
Guilt
Dependency on
treatment
Fear
Self-doubt
Shame
Identity
Fear of
re-occurrence
Shame
Guilt
Identity
Self-agency
Secrecy
Hopelessness
Intensive
Surveillance
Infectiousness
Financial burden
Isolation
Illness, weakness,
fatigue
Turmoil
Dealing with
Sequelae
Moving on
Not infectious
Strength returns
Reintegration to 
work
SELF-STIGMA
ISSUES TO DEAL WITH
STAGES OF TB Diagnosis Intensive Phase Continuation Treatment Ending Cured
Methods for assessing TB self-stigma
Overview
Quantitative measures can clearly show the ‘how much’ of TB self-stigma, that 
is, the net burden. However, it is also critical to investigate the what and the 
why, meaning, the characterization of self-stigma at the level of an individual. 
Attention should also be paid to the processes that create and maintain stigma. 
This ensures that prevention and management strategies can be formulated to 
mitigate self-stigma’s harmful effects. To assess self-stigma, mixed methods can 
be used to build an understanding of the quantitative data, which may otherwise 
lack meaning and context. (See the TB Stigma Measurement Companion 
Curriculum for more detailed information). Most research to date measuring 
stigma has been quantitative psychometric studies. (See Chapter 7 for a 
discussion of the methodological issues for such studies, such as sample size and 
statistical analysis.) What is largely missing is phenomenological research to help 
understand the experience of self-stigma and its associated meaning and beliefs, 
at both the level of an individual and their culture. 
STEREOTYPE ENDORSEMENT: 
believing negative stereotypes about 
myself 
SELF-BLAME: believing I am 
personally responsible/ to blame
for my TB
LACK OF SELF-AGENCY: believing 
that I cannot change or improve my 
situation
SHAME: Feeling ashamed of who I 
am or who I am not
GUILT: feeling guilty for what I have
done or not done
PERCEPTION OF WHAT OTHERS
THINK: feeling afraid of judgement,
what others think, do, not do, 
anticipated stigma
SOCIAL WITHDRAWAL: letting my
support system unravel by turning
inwards
 
LACK OF SELF-AGENCY: shrinking
my ambitions, plans, hope
NEGATIVE COPING: limiting self-care
BELIEFS FEELINGS ACTIONS
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Sample quantitative measure: Van Rie Tuberculosis-
Related Stigma Scale
An example of a well-validated scale to assess TB stigma and self-stigma is 
the one created by Van Rie et al. in 2008.32 The Van Rie Tuberculosis-Related 
Stigma Scale examines stigma across key domains, such as: fear surrounding 
transmission and disease; values and attitudes relating to shame, blame, and 
judgment; and disclosure. The scale was positively evaluated in Stevelink et 
al.’s 2012 psychometric assessment of internalized stigma instruments.4 For 
more information on the Van Rie scale, see Chapter 7. For guidance on the 
use of quantitative measures to assess TB self-stigma, please refer to section 
B, “Measurement,” in the companion curriculum. For general notes on 
methodology, see Section E, “Methodological Considerations for Self-Stigma 
Measurements.” 
Qualitative measures to assess TB self-stigma
Self-stigma has been investigated in a wide range of qualitative studies across 
different !elds. The application of qualitative methods, such as key informant 
interviews and focus group discussions, has yielded in-depth information on the 
types and conditions of self-stigma that are experienced. However, research on 
the core self-stigmatizing beliefs of people living with a speci!c disease is still 
missing. No “best” instrument exists because many of the underlying drivers of 
self-stigma are fundamental in human social interactions. Self-stigma impacts 
on common and often predictable aspects of life, such as personal interactions, 
education, social participation, and access to health care. Van Brakel et al. 
acknowledged this fact in their 2006 review on the measurement of health-
related stigmas,33 noting that: “… the similarity in the consequences of stigma 
in many different cultural settings and public health !elds suggests that it would 
be possible to develop a generic set of stigma assessment instruments.”33 The 
challenge lies in con!guring a qualitative instrument to produce the best data to 
!t the research question at hand. The Companion Curriculum contains examples 
of qualitative tools that can be used without modi!cation, or as a framework 
for developing instruments that work in a speci!c context. See section C, 
“Assessment and Understanding,” in the Companion Curriculum for practical 
guidance on using qualitative measures to analyze self-stigma. Please also see 
Section E, “Methodological Considerations for Self-Stigma Measurements,” for 
general notes on methodology.
Adapting other scales to measure TB self-stigma
Practitioners may also wish to look at other self-stigma scales to !nd scale 
items that may be useful to adapt for application in their speci!c work. We can 
recommend several scales: the Internalized AIDS Stigma Scale (IASS34 developed 
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by Kalichman et al. in 2009, and the early work of Holzemer et al. in 2007).35 
Both provide useful frameworks to understand and assess self-stigma, which 
would have to be adapted to the TB context. The Self Stigma Scale by Kato et al 
designed for diabetes is also well validated and predictive of self-care.19,36,37
There are also scales that can be used to measure dimensions of well-being 
affected by the presence of self-stigma, such as depression, engagement in 
life, and quality of life. Examples include the Center for Epidemiologic Studies 
Depression Scale, (CES-D)38 and the Quality of Life Scale, (HAT-QoL)39 to 
measure mood and perceived stress. The People Living with HIV Stigma Index40 
contains quantitative and qualitative measures; it is considered by some to 
have unique social validity because it is implemented by and for PLHIV. Other 
scales assessing internal stigma can be found in the 2012 Systematic Review by 
Stevelink et al.4 
Innovation and expanding measurement of self-stigma 
intervention outcomes: The Ryff Scales of Psychological 
Wellbeing
When measuring self-stigma in interventions and programs, one signi!cant 
drawback is that many of the existing measures capture only negative personal 
experiences. They do not capture a person’s aspirations for change or the vision 
of the life that they would like to lead. Our analysis of qualitative data from 
intervention groups in Zimbabwe pointed to the real need to assess aspirations 
and goals. This led us to adopt the Ryff Scales of Psychological Wellbeing41,42 
approach. 
In our earlier work,2 we observed that the core beliefs and drivers of self-stigma 
in"uenced many areas of participants’ lives. The core beliefs and drivers were 
much broader than can easily be described by scales that examine self-stigma’s 
manifestations, such as guilt, shame, or social withdrawal. We also identi!ed 
the need for a framework to guide the analysis of qualitative data, to help 
with the characterization of self-stigma, and thus the development of future 
interventions. The Ryff Scales are adaptable for both purposes, and have been 
applied in a wide variety of settings.41–43 
The Ryff Scales were designed to look at psychological wellbeing in a holistic 
manner. They examine six dimensions: purpose in life; environmental mastery; 
positive relationships; personal growth; autonomy; and self-acceptance. The 
scales can help measure how well a person has mastered these areas of his/
her life, with a high degree of reliability and validity.43–45 Many of the common 
manifestations of self-stigma, such as shame, isolation, and worthlessness, map 
strongly to the Ryff dimensions. This makes the Ryff Scales a useful positive 
measure to use, together with existing negative self-stigma scales. 
The Ryff Scales are useful for both quantitative and qualitative methodologies. 
For example, during our work on self-stigma among PLHIV in Zimbabwe,46 
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we included the Ryff Scales in a quantitative questionnaire pre- and post-
intervention. This allowed us to compare wellbeing between baseline and follow-
up time points. At the same time, we conducted focus group discussions and 
interviews with respondents, using the Ryff Scales as a framework for analysis. 
This yielded insights into the drivers and coping mechanisms of individuals 
experiencing self-stigma, and how these mapped to the six dimensions of 
psychological wellbeing. See Section D, “Merging Qualitative and Quantitative – 
One Tool,” in the companion curriculum for guidance on how to apply the Ryff 
Scales in a practical setting. See Section E, “Methodological Considerations for 
Self-Stigma Measurements,” for general notes on methodology.
Measuring resilience 
The personal impact of having TB varies widely. Understanding resilience may be 
a useful lens through which to know the differential impact of stigma upon TB 
patients. Resilience is the process of adjusting to, and managing and de"ecting 
stress or trauma. There are many domains of resilience that can be measured, 
including: personal competence; coping ability; tolerance; strengthening effects 
of stress; acceptance of change; secure relationships; control; and spiritual 
in"uences. Other authors have identi!ed key resiliency attitudes, including: 
insights, independence, creativity, humor, initiative, relationships, and values 
orientation. While there is no gold standard tool, Windle et al.’s review of the 
quality of resiliency scales advocates for the use of three scales, based on their 
psychometric properties:47
1. The Resilience Scale for Adults (RSA) has 37 items48 and has been validated. 
It is available in English and Spanish.
2. The Brief Resilience Scale has !ve self-weighting items on a Likert scale.49 
3. The Connor-Davidson Resilience Scale (CD-RISC) has 25 items. It is available 
at: http://www.connordavidson-resiliencescale.com/
Please respond to each item 
by marking one box per row
Strongly
Disagree
Disagree Neutral Agree
Strongly
Agree
BRS 1
I tend to bounce back quickly after 
hard times 1 2 3 4 5
BRS 2
I have a hard time making it through 
stressful events 5 4 3 2 1
BRS 3
It does not take me long to recover 
from a stressful event 1 2 3 4 5
BRS 4
It is hard for me to snap back when 
something bad happens 5 4 3 2 1
BRS 5
I usually come through dif!cult times 
with little trouble 1 2 3 4 5
BRS 6
I tend to take a long time to get over 
set-backs in my life 5 4 3 2 1
Table 3: The Brief Resilience Scale
221
Approved translations of the CD-RISC currently exist in the multiple languages. 
The choice of resilience scale depends on whether you plan to intervene to 
improve resilience. If you plan to measure resilience as part of a baseline, then it 
is wise to use a more comprehensive tool to help inform your interventions.
Measuring TB treatment self-ef!cacy
Self-stigma is thought to be a determent to self-care. A closely related concept is 
self-ef!cacy.
A scale to measure coping self-ef!cacy for TB treatment was developed and 
validated by Mason et al. in Vietnam.50 The scale was derived from ethnographic 
research and draws from social cognitive theory. It measures four domains:
t Self-ef!cacy for communication with the doctor (5 items)
t Self-ef!cacy for support seeking (4 items)
t Self-ef!cacy for disclosure of diagnosis (7 items)
t Self-ef!cacy for medication adherence (10 items)
Patients rate their level of con!dence for the series of questions on a 
temperature scale, from zero to ten, with zero being the lowest and ten 
representing maximum con!dence.
Conclusion
There are few well-validated measures to assess self-stigma among people 
treated for TB. However, those that do exist, such as the Van Rie Tuberculosis-
Related Stigma Scales, are being used in an increasing range of settings. Many 
of self-stigma’s outward manifestations are fundamentally human in nature, and 
may transcend culture and language. This means that quantitative measures may 
be adapted to different contexts and patient groups. It also means that tools that 
have already been well-tested in measuring self-stigma for conditions such as 
HIV or mental illness also have the potential to be adapted. Several factors help 
with successful measurement. They include the careful choice of instruments, 
combining quantitative and qualitative approaches, appropriate selection of 
individual items, rigorous piloting, and use of information derived from the pilot.
Qualitative approaches are needed to examine and understand the underlying 
beliefs and drivers of TB patients and to further identify coping strategies. 
The Ryff Scales provide an opportunity to bring together the quantitative and 
qualitative methods. This may help to enhance the ways in which we approach 
the management of self-stigma, and shift the focus toward the promotion of 
patient well-being, rather than simply aiming for the simple absence of negative 
symptoms. Finally, there is also the need to develop new interventions to address 
TB self-stigma.
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Appendix 1: Self-stigma domains and illustrative items
IDEAS: COGNITIVE DOMAINS OF SELF-STIGMA
Stereotype Endorsement 
Stereotype Endorsement
I think that I am less careful than others because I developed TB disease. 
I am not clean because I developed TB disease. 
My body is inferior to others because I developed TB disease.
I cannot measure up to ordinary people because I developed TB disease.
TB disease is a sign of weakness.
TB disease is something that happens to careless people.
It is quite natural to be rejected because of TB disease. 
Self-Blame
If I had taken better care of myself, I would not have developed TB disease.
If I had taken my TB treatment as instructed, I wouldn’t have developed drug-resistant TB.
If I had taken my ART and IPT as instructed, I would not have developed TB disease.
If I had not smoked, I would not have got TB.
If I had not been drinking or drugging I would not have got TB.
If I had not been detained, I would not have got TB.
If I had worn my respirator at work, I would not have got TB.
If I had not spent time in certain places, I would not have got TB
If I had avoided certain people, I would not have TB.
Seeing the light at the end of the tunnel
Things will go back to normal once TB treatment is done.
I have plans for my life after TB treatment is over.
I will feel relief once my strength returns.
When I get over TB disease, there is a lot ahead of me.
FEELINGS: AFFECTIVE DOMAINS OF SELF STIGMA
Shame 
I cannot feel con!dent about who I am because of myself with TB. 
I have negative feelings about myself with TB.
I am unhappy because I developed TB disease . 
I hate my body because TB disease made me physically weak. 
I get embarrassed because of having TB.
I feel angry because I developed TB disease.
I feel uncomfortable that my TB infection progressed to disease.
I am ashamed of having TB.
224
Guilt 
I cannot forgive myself for exposing my loved ones to TB.
I feel upset that TB disease makes it hard for me to care for my family. 
Caring for me is a !nancial burden on my family that is hard for me to accept.
Perceived Self-Ef!cacy
I give up on myself because I developed TB disease.
There is nothing I can do to get rid of TB.
I cannot change my situation now that I have TB.
I feel helpless because I developed TB disease.
I am discouraged because I developed TB disease.
I need assistance from others because I developed TB disease.
Even if my TB is cured, the treatment side-effects may be permanent.
Completing my TB treatment makes little difference, because it could come back.
Anticipated Stigma
Others would mistreat me if they !nd out that I developed TB disease. 
TB will create obstacles for me in the future. 
I worry that my family will be discredited by my having TB disease.
I will be denied work because I developed TB disease.
ACTIONS: BEHAVIORAL DOMAINS OF SELF-STIGMA
Self-isolation, social withdrawal
I avoid interacting with others because I developed TB disease.
I keep my distance from others because I developed TB disease. 
I hide myself to protect other people’s health. 
I dare not make new friends because they might !nd out that I developed TB disease.
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Chapter 11
Measuring Discursive and Rhetorical 
Stigma
Nora Engel, Gill Craig, and Agnes Meershoek,
Abstract
This chapter provides an introduction to critical discourse analysis to detect TB 
stigma in language and text. The chapter introduces several frameworks useful 
to identify discursive TB stigma, and provides guidance for developing research 
questions and collecting and analyzing data.
Objectives
1. To introduce basic concepts of discourse and textual analysis and its 
importance for healthcare policy-making.
2. To sensitize readers to how TB stigma can be hidden in rhetorical framing and 
use of language.
3. To provide examples of earlier studies of discursive (TB) stigma.
4. To teach methods to trace/unveil a discourse in TB text.
5. To provide practical suggestions for how to identify, analyze, and interpret 
discourse for TB stigma.
Target audience
This chapter meets the needs of activists, national TB program staff, 
implementing agencies, non-governmental organizations, donors, partners, 
and advocates who seek to scrutinize written materials, speeches, policies or 
visual communication to detect stigmatization. The techniques described are 
readily accessible for those with a background in social sciences, humanities, or 
communication sciences. No detailed knowledge of statistics or legal concepts is 
necessary. 
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Introduction
There are different approaches to the analysis of textual data, such as interviews 
or policy documents, in order to understand how stigma is produced and its 
effects, including content, discourse, discursive, and textual analyses. These 
approaches are rooted in different philosophical traditions, ranging from more 
positivist approaches (content analysis), post-positivist (certain forms of discourse 
and discursive analysis), and constructivist and critical discourse analysis. The 
reader is referred to Flick1 for more information. This chapter explores critical 
discourse analysis of TB texts to identify how language and discourses construct 
stigma.
Discourses and stigma
Stigma entails a normative judgment based on speci!c values. It is present in text 
and how we speak about other people or an illness. Practices might be re"ected 
in these words, and words in"uence the practices and how patients and illnesses 
are handled. As shown in Chapter 1, the process of building enduring and 
harmful stigmas often starts with subtle terminology and framing. 
Figure 1 summarizes the key concepts of measuring discursive stigma. All stigmas 
are built upon a common backbone. With practice, it becomes easy to pick out 
these building blocks of stigmatization in dialogue and text. 
Figure 1. Discursive Steps toward Stigmatization
Imply negative
traits
Link to other
stigmas
Locate
Fault
Emphasize
Peril
Emphasize
Differences
STIGMA
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Many approaches to the study of text dispute that language is a neutral medium 
that re"ects reality.2 Rather, the language we use actively constructs, shapes and 
(re)produces practices, identities, roles, and experiences. 
Box 1: De!ning Discourse
A discourse is a set of ideas or patterns of thinking that can be identi!ed within text, messages, 
dialogues, conversations, and art.3 A discourse includes producing, disseminating, and receiving 
the text4 A discourse brings meaning into social relations. It characterizes relations between 
people who communicate with each other. It entails speci!c communication events (newspapers, 
articles, or reports) and links with other discourses.2
Discourses de!ne obligations and distribute responsibilities.5 A text is not meaningful by itself, but 
only through the interconnection with other texts, the different discourses it draws upon, and the 
social context of its production, dissemination, and consumption.
Using a certain discourse has consequences. It can “..reinforce, reproduce, or support a given 
discourse and at the same time deny, disqualify or silence that which does not !t with that 
discourse.” (p.119)6
Discourses may be explicit or obvious, or hidden within a text.
Discourses that dwell on differences
To stigmatize, one !rst needs to create categories. This requires marking 
differences and over-emphasizing the differences between groups. The 
invention and over-use of clinical classi!cations and labels can contribute to 
stigmatization, even if the labels themselves seem neutral. Advocates have 
recently called for ending the use of stigmatizing and discriminatory language 
in TB research and practice (see Box 2 for examples).7 Many of the labels used 
to describe TB patients are disempowering, assign blame or punishment, and 
contain moral judgments (such as ‘treatment defaulter’ instead of ‘loss to follow-
up’, ‘TB suspect’ instead of ‘person to be evaluated for TB’, ‘non-compliance’ 
instead of ‘non-adherence’). This terminology also serves to mask other actors’ 
responsibilities for providing care, and the structural reasons for why patients 
might not be able to access or adhere to treatment (such as health system failure, 
drug stock-outs, lengthy and toxic treatment regimen, the cost of treatment and 
poverty, etc.).7,8
For example, the term TB care (rather than control) suggests a more egalitarian 
and collaborative approach, which supports the adoption of alternative ways to 
support PWTB, such as peer support and buddying systems. Some of these labels 
have been changed in of!cial WHO guidance documents.
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Box 2: Non-Stigmatizing Terminology in TB7
Box 3: The Implications of Naming People Affected by an Illness Differently
Moving to non-stigmatizing terminology in TB
Treatment default - loss to follow-up
Tuberculosis suspect - Person to be evaluated for presumptive tuberculosis
Tuberculosis control - Tuberculosis prevention and care
Compliance - Adherence
Research subjects - Research participants
Additional suggestions can be found in the Stop TB Partnership’s Tuberculosis Terminology Guide:
http://www.stoptb.org/webadmin/cms/docs/Every%20Word%20Counts%20TB%20
Language%20Guide.pdf
‘TB Patients’ refers to people that have an illness. This term is associated with services of the 
welfare state. Patients are entitled to visit health care services. Traditionally, the role of the patient 
is considered to be passive: they undergo treatment. 
Consumptive implies a person who is gradually being depleted, who is dissipating, and becoming 
less of her/himself.
Person living with TB (PLTB) suggests a person who is coping with a situation, and the emphasis 
is placed on the humanity of the individual and their vitality.
Depending on how we name people with a disease, different roles and options are implicitly 
assigned to them.9
Discourses that link TB to negative traits, stereotypes, 
and labels
The way we talk about people suffering from and coping with a disease is not 
neutral (Box 3). Susan Sontag, in her book on Illness as Metaphor, uses TB and 
cancer to show how the language used to describe patients and diseases can 
associate conditions with certain character traits. For example, when militaristic 
metaphors are used, patients are often encouraged to “!ght against” their illness. 
Winning or losing a battle is not only a matter of strength but also of character 
and will. The war metaphor suggests that recovery therefore, is largely a matter of 
willpower, and holds people individually responsible for getting better. Those who 
appear to passively accept their illness, rather than !ght it, are rendered culpable 
and shamed, leading to victim blaming. The metaphor could, therefore, have 
stigmatizing effects.9
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Discourses that emphasize peril and danger to generate 
fear 
TB is transmitted through the air via droplets produced by coughing and singing. 
However, this ‘fact’ can be described in many different ways. It is also ‘a fact’ that 
approximately 90% of those infected never develop the disease. Which facts are 
highlighted in"uences how afraid we become. 
The political uses of language are well known. Several frameworks can be 
employed to analyze discourses on TB. 
Politicians and policymakers tend to depict the problems they would like to address 
in a way that will convince others that the situation needs change. According to 
Stone11, several symbolic devices are crucial in representing problems in policy 
text. Metaphors frame issues in a certain way and often imply things not explicitly 
stated (such as the war metaphor discussed above). Storylines are important 
symbolic devices. Policy texts quite often make use of a story of decline by 
depicting a situation as becoming worse and predicting that it will end in a disaster 
if we do not intervene immediately. Such a narrative makes the reader fearful, and 
thus more receptive to the proposed action to avoid the disaster. 
Numbers are also symbolic devices that can be used to substantiate storylines. 
Although numbers are considered objective, the choice to mention certain numbers 
and not others can change the message dramatically11 and the way they are 
categorized and represented may marginalize some patients (Box 4). An example is 
if the storylines depict a population as high prevalence and a transmission threat to 
others due to their assumed inherent characteristics or practices.
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Box 4: How Numbers and Counting can foster Stigma
Several scholars indicate that the way TB treatment and patient categories are de!ned marginalize 
some patients from treatment and have stigmatizing effects. For instance, the DOTS strategy 
focuses on patients who are infectious and counts those in treatment as category 1. Patients who 
are non-infectious to others receive less attention, and their diagnosis and treatment is of lower 
priority (such as sputum negative or extra-pulmonary TB).12 Patients need to have a residential 
address to be eligible for treatment.13 The biomedical categories of newly diagnosed, retreatment, 
relapse, and failure cases do not always match the treatment and pharmaceutical history of 
patients in Nepal. For instance, the de!nition of a new smear-positive patient, presenting for the 
!rst time to the health center and having received less than a month of treatment, meant that 
those patients who had received more than a month treatment in the private sector were not 
allowed into the national TB program. They were not in the newly diagnosed, retreatment, or 
relapse categories. By generating non-eligible TB patients and turning them away, the TB program 
might be creating MDR-TB if patients are forced to continue unregulated or interrupted treatment 
in the private sector. Those patients that are not allowed into the program are not being counted 
as having MDR-TB. They will ultimately not show up in national databases.14
Discourses that link TB to other disparaged behaviors 
or identities
Bacchi15 argues that not only do politicians represent a problem in a certain 
way, they also shape and create problems by de!ning a phenomena or 
situation as a problem in the !rst place. For instance, if TB is de!ned as a 
problem of a particular group, it becomes a disease of others and a non-native 
threat. This is inaccurate and counterproductive because immigrants who are 
then unsure of their immigration status and legal rights to health care are less 
likely to access health care.
Similarly, Gus!eld16 shows that solutions depend on how public problems 
are de!ned. According to him, public problems have moral and cognitive 
dimensions. The cognitive side consists of beliefs about the facts and events 
which compromise the problem (these can be theories, empirical beliefs about 
poverty, mental disorder, alcoholism, or MDR-TB, etc.) The moral side allows 
the situation to be viewed as painful, immoral, or unjust, and it allows moral 
judgments and makes alteration desirable. Not all groups have the same ability 
and power to de!ne and shape public problems such as TB control or MDR-
TB.17 Those who own the problem (e.g. the government or WHO) publicly 
de!ne the problem. Owners have credibility, can capture public attention, 
possess authority, and can make claims. Public problems are characterized by 
con"icts over such ownership.
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In order to analyze discursive TB stigma in policy and politics, the researcher 
needs to:
1. Identify the particular storyline that is used; and 
2. Analyze the different symbolic devices used and identify how problems are 
de!ned.
Overall, these metaphors, ideologies, de!nitions, and discourses have 
implications for the explanations chosen and the solutions sought (Box 5). 
Box 5. The ‘Risk Of Contagion’ Discourse in UK TB Policy through the Construction of Risk 
Categories
Craig analyses the public health policy on TB in the UK, and reveals how TB is constructed within 
a public health discourse of ‘risk of contagion’. She shows how different categories of risk for TB 
are constructed through discourses of immigration, creating insiders and outsiders and producing 
racialized risk categories. The implications of this risk discourse are that the different risk 
categories provide justi!cation for enhanced surveillance of those who cannot manage their risks. 
The risk of TB is thereby attached to particular social categories (e.g. the ‘foreign-born’), and not 
to the structural inequalities that place people at risk and help maintain such racialized positions. 
The consequence of such a stigmatizing discourse is that the response to TB is mainly focused on 
local risk management, and those individuals who are seen as unable to manage their risk.18
How to analyze TB stigma using discourse analysis
Discourse analysts examine how individuals and problems are constructed in text 
and language and the implications for assigning responsibilities and solutions. 
A discourse analysis of TB stigma would, for instance, examine explanations of 
the problem of TB, who is being blamed for it, how solutions are justi!ed and 
legitimized, and what the underlying value claims are in these explanations, 
justi!cations, and legitimizations.2
When conducting critical discourse analysis, the researcher is interested in 
understanding the relations between a discourse and its social and historical 
context. Examples include the relationship between discourse and state 
power and how state power is manifest in discourses (legislation, policies, and 
communication). A critical discourse analysis adds a normative element, as the 
analysis also focuses on how a discourse departs or overlaps with certain value 
standpoints.2 Discourse analysis includes a set of methods or tools and a lens for 
framing the problem.4
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Box 6. Possible Research Questions to Identify Discursive Stigma
tHow are TB and TB patients constructed? What are the implications for assigning responsibilities 
and solutions?2,4,19
tWhat are the explanations for the causes of TB (or MDR-TB, diagnostic delay, screening, 
treatment adherence, quality control, etc.)? Who is being blamed for it, how are solutions 
justi!ed and legitimized, and what are the underlying value claims in these explanations, 
justi!cations, and legitimizations?2,16
tHow are policy problems (such as TB, MDR-TB, diagnostic delay, screening, treatment 
adherence, quality control, etc.) represented and shaped through symbolic devices (metaphors, 
story lines) and numbers?11
tHow are policy problem represented and constructed? How has this discourse come about?15
Identifying a research question to analyze discursive 
stigma
There are different frameworks to analyze discursive TB stigma. These will lead 
to slightly different research questions. In order to determine how discourses are 
stigmatizing, the following questions are helpful (Box 6).
Collecting, selecting and identifying texts 
TB control efforts entail many different words and texts that can contain 
stigmatizing notions and thus are useful for an analysis of discursive stigma. 
These include not only those words spoken between patients and caretakers, but 
also between healthcare workers, program of!cers, policymakers, written text in 
TB policy documents, guidelines, education material, lea"ets, posters, records, 
registers, treatment cards, package inserts of diagnostics and drugs, articles in 
the media, and government reports. 
Primary and secondary data sources 
The data for a discourse analysis can be from secondary sources collected from 
existing text, such as documents, publications, databases, and records. They can 
also draw on primary data sources, such as interview transcripts, observation 
notes, or conversation recordings. An analysis of policy and media discourses 
would generally rely on secondary data sources, such as newspaper articles, 
policy guidelines, and meeting notes. In addition, it could be accompanied by 
interview material to further explore the underlying reasons for the use of certain 
language. An analysis of conversation pattern between providers and patients, 
for instance, would rely primarily on recordings and observations (primary data 
sources), but could also be accompanied by medical reports, referral slips, and 
letters (secondary sources). 
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The advantages of primary data sources are that the analyst is involved with 
the collection and can steer data collection and adapt it to research needs (by 
choosing participants and sites, framing questions in interviews differently, etc.) 
However, collecting primary data sources is not always feasible. Some of the 
databases that might be helpful in identifying secondary data sources include 
PubMed, Social Science Citation Index, Communication Source, Arts and 
Humanities Citation Index, ProQuest, and Web of Science. National newspaper 
and hospital archives, government archives, and global media databases (Factiva, 
LexisNexis, PressReader) may also be useful. 
Sample size
In order to limit the secondary data sources to be studied, it helps to choose the 
most important and widely distributed texts or those that compare settings/
topics or limit the analysis to a certain time period.4 Consult Chapter 6 on 
sampling techniques for texts and Chapter 2 for collecting primary data sources.
Box 7. Examples Data Collection Techniques
Reitmanova and Gustaffson aimed to uncover press constructions of the presumed or imagined 
health risk to Canadians posed by immigrants exposed to TB or other infections. The authors 
sampled newspaper articles in ten major Canadian newspapers (from those cities with high rates 
of TB or immigrants) over a ten year period through keyword search in Factiva, LexisNexis, and 
newscan.com. They chose only English-speaking newspapers (a bias), and those with the widest 
circulation and reach. This resulted in 273 pieces of text for analysis. They identi!ed racializing 
and medicalizing discourses stigmatizing the immigrant body as a health threat.20
Andrade and colleagues analyzed the discourses of nurses around the challenges of adherence to 
MDR-TB treatment. They interviewed 13 nurses working with TB patients in Brazil. The interviews 
revealed the prejudices in nurses’ speech that is linked to TB which is marked by stigma, 
segregation, and exclusion.21
Making data manageable
Audio !les are converted into written form once data collection is complete. 
The text is coded, or organized into chunks that are tagged with keywords. 
Usually, one would code for research question, different discursive elements 
(symbolic devices, use of numbers, problem de!nitions), and discourses 
emerging from the data.
The coding can be done by hand or by using a qualitative data analysis software 
package such as (Atlas.ti, Nvivo, or MAXQDA). See Chapter 17 on qualitative 
analysis methods for more information on coding and software.
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Data analysis
Below are a set of stages and prompts that can guide a critical analysis of 
discursive TB stigma. These were adapted and collated from different authors 
and frameworks using discourse analysis or critical policy analysis.2, 11, 16, 19, 22-
26 The analysis identi!es the constructs of individuals and problems and the 
rhetorical devices used and examines assigned solutions and the implications of 
these discourses.
0. Pre-analysis:
t Free association: what is the !rst thing that comes to mind when reading the 
text?
t Itemize objects and subjects that appear: identify these nouns in the text, list 
them, and write a short description of each. These can now be considered the 
objects of your study and they represent discourses.
t Itemize the subjects: who are the people that appear in your text? List them. 
The author and the audience are two subjects that are always present, even if 
not mentioned explicitly. This list will help you to answer some of the following 
questions.
1. What constructs of TB, a TB patient, a TB health worker, work with TB  
 patients, and work with TB are being produced, and by whom?
 
tHow is the individual de!ned? (e.g., patient, citizen, client, threat, someone 
coming from outside the area or country, etc.) How are people in the text 
represented or characterized? (e.g., deserving or undeserving of sympathy, not 
to be trusted, unreliable.)
tConsider the assumptions that the author makes (in case of secondary source 
materials only) about the individuals and how the de!nition of the individual 
would change if these assumptions were different.
t If accompanying visual material is used: what does the image represent? Who 
is the producer? In what context is the image used? How does it interact 
with other pieces of the text? What symbols, cultural references, or signs are 
depicted? Why was this image chosen? How is the image given meaning? 
What is made visible or invisible by the image?
tHow is the problem de!ned? (e.g., the disease, the work, the control efforts, 
etc.)
tWhat are different theories about the causes for the problem? What are 
explanations of the problem? What are underlying assumptions? Is there an 
assumption of blame?
tWho can speak, and who is given voice in the text?
tWho cannot speak?
tWho is being referred to?
tWho is the intended audience?
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tWhat is silenced? (that is, not mentioned or left out of the account.)
tWhat message(s) are intended by the author (explicit and implicit)?
tCould this event have been reported in a different way? Identify all words with 
a negative meaning and substitute them with a positive meaning.
tWho is the owner of a discourse/problem de!nition? Who has credibility, can 
capture public attention, possess authority in the !eld, can make claims, and is 
being reported by others looking for de!nitions and solutions?
tWhere and when were these discourses developed?
tWho would bene!t or be threatened from alternative discourses?
2. What rhetorical devices are being used (to construct TB stigma?) 
tHow are problems presented? What are the rhetorical instruments? What 
story lines, metaphors, and numbers are used to convince others?
tWhat underlying norms are included?
tWhat are the historic roots of these norms/ideologies? What is the socio-
cultural and political context of these norms/ideologies? 
t To what extent are these rhetorical instruments stigmatizing? Is there 
medicalizing, creating difference as untrustworthy or dangerous, locating 
responsibility for difference, evoking peril and threat to those considered 
normal, blaming?
tHow far are stigmatizing attitudes and approaches identi!ed in discourses (in 
reports, categories, or text) in"uenced by history and historical discourses, or 
by a country’s or institution’s past?
t To what extent and in what ways do research, science, and knowledge in 
the TB community (evidence based medicine, evaluation of interventions, 
monitoring requirements) in"uence the identi!ed discourses?
3. What are the action outcomes of these descriptions? 
tWhat solutions are assigned?
tHow are solutions justi!ed and legitimized? What are the underlying value 
claims in these explanation, justi!cations, and legitimizations? 
tHow are these actions stigmatizing, if applicable? Is mistreatment justi!ed, is 
there exclusion and discrimination?
4. What are the implications?
tHow do these actions challenge, sustain, or foster stigma in relation to TB?
tHow does an identi!ed discourse make visible/invisible actor positions?
tWhat can and cannot be said?
tWho can speak and who must listen?
tWhat is the individual expected to know in response to the discourse?
tWhat is the individual expected to do in response to the discourse?
tWhose social constructions are valid and which are unimportant?
239
Results of such an analysis can involve identifying several potentially competing 
discourses or mutually reinforcing discourses. It may demonstrate how discourses 
construct, maintain, and reproduce stigma, and also reveal that individuals may 
be unaware that their discourses have stigmatizing effects (Box 8). Such a critical 
analysis helps to understand how a certain discourse legitimizes particular ways 
of seeing and understanding TB, and how this becomes accepted as normal 
practice. It also explains how individuals and alternative discourses are able to 
challenge the existing discourse.22 It can also reveal how discourses are linked 
with the ways in which epidemiological knowledge about TB is produced, such 
as through a particular categorization of ethnicity or migration-related status in 
medical records.25
Box 8. Example of Data Analysis Steps
Ranjbar and colleagues conducted a discourse analysis of text passages from 63 interview 
transcripts of HIV caregivers who discuss their work with HIV-positive individuals. They chose text 
passages and analyzed them for the different versions of reality that caregivers constructed, and 
what actions followed. They identi!ed the caregivers’ descriptions and constructions of HIV/AIDS, 
their clients, themselves, and of their work. They examined the rhetorical devices that they used 
in their constructions, and then they looked at what actions resulted from these constructs and 
if these actions fostered or challenged stigma. Thanks to this analysis, the authors were able to 
show that the healthcare workers own discourses of how they followed rules and minimized their 
own risk of HIV infection inadvertently contributed to broader discourses of HIV as controllable 
and manageable. These discourses are stigmatizing and blame HIV-positive individuals for their 
own illness. This also shows that individuals are not always aware when their discourses have 
stigmatizing effects.23
Below are two examples of the analysis of the discourses reported. These are 
discourses that one can identify when using some of the questions listed above. 
Ogden examined the discourse of power and control in the language of public 
health and its effect on interventions such as DOTS. Craig highlighted discourses 
in the popular press, policy, and practice, and demonstrated how stigma is 
reinforced or reproduced through different texts and practices.
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Discourse 1: Discourse of 
control 
Discourse 2: Risk of contagion 
from a new pandemic in the 
UK18
How is the individual de!ned? Poor patient, infectious, 
uneducated, passive recipient of 
care.
People born outside the UK 
constructed as sources of 
contagion and polluters in 
the popular press who bring a 
disease into the country. The 
groups are identi!ed as coming 
from different ethnic minority 
backgrounds who engage in 
practices (such as spitting) that 
are implicated in the spread 
of disease. Communities are 
stigmatized. Other groups that 
may be stigmatized through risk 
discourses include drug users, 
homeless people, and prisoners.
How is the problem de!ned? Non-adherence to TB treatment The public health problem 
of the new pandemic, risk of 
contagion.
What are the rhetorical 
instruments? What storylines, 
metaphors, and numbers are 
used to convince others?
Metaphor of control, TB 
patients cannot be trusted, need 
to be controlled.
Masks old causes (poverty, 
poor housing/sanitation) by 
presenting new attributes (MDR 
& HIV).
Metaphor of pollution, insider/
outsider. Categorizing people 
with TB as coming from outside 
and posing a risk to the country. 
What are the underlying norms? Control is better than trust. Individuals are held responsible 
for their plight and a neo-liberal 
discourse of ‘no rights without 
responsibilities’ underpins social 
policy, further implicating the 
individuals as being responsible 
for their own health and illness.
What solutions are assigned? Supervision of treatment intake. Micro risk management, 
surveillance, infection control 
and screening at ports, 
sanatoria, detaining, and 
removing the ’polluters’.
Box 9. Two Example Discourses on TB
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How do these actions impact 
stigma?
Victim/patient blaming. Risk of TB is attached to social 
categories, such as ‘foreign 
born’, which reproduces 
categories of racialized risk.
What cannot be said? What is 
silenced?
Patients might not be able to 
adhere because of structural 
reasons, inaccessibility of health 
centers.
Structural inequality and 
processes that place people 
at risk and maintain racialized 
positions are ignored.
What must the individual do? Access health center Manage their own risk.
What must the individual 
know?
When to access health center 
for screening, adherence to 
treatment, and monitoring.
How to manage their own risk.
 
Overcoming challenges to discourse analysis
One of the major challenges in analyzing discourses is that people are so used 
to certain discourses that we take them for granted and are not able to distance 
ourselves from them. One way to overcome this is to replace words with synonyms 
or replace negative words with positive ones. In what way does the outcome, 
connotation, or meaning of the message change? This exercise will make you aware 
of how words matter and how they might represent a certain discourse of control or 
risk of infection. Another way to overcome this challenge is to include those affected 
by TB into the research team. Lastly, thinking through alternative problem de!nitions, 
representations, or metaphors and their implications may aid in analyzing discourse. 
If a problem is de!ned in economic terms, what consequences would de!nitions in 
social and political terms have?
Discourse analysis is a three-dimensional analysis of text, context, and discourse, 
and how they interrelate. Texts belong to discourses on which they draw, that they 
might constitute, and which are in"uenced by social reality.4 Researchers studying 
discourses need to go beyond pointing out the relationship between text and context, 
but instead analyze the role of discourse, which requires an understanding of how 
structured sets of text and their production, dissemination, and reception constitute 
the social practices.4 Such an analysis is challenging but necessary to show how 
language matters, especially in the context of stigmatization.
Suggested Reading for Further learning
Craig, G.M. (2007). Nation, Migration and Tuberculosis. Social Theory and Health, 5, 
pp. 267–284.
Engel, N.C. (2012). The making of a public health problem: multi-drug resistant 
242
tuberculosis in India, Health Policy and Planning, doi: 10.1093/heapol/czs069. 
Ogden, J. (1999). Compliance versus adherence: Just a matter of language? 
The politics and poetics of public health. In J. M. Grange & J. Porter (Eds.), 
Tuberculosis: An interdisciplinary perspective (pp. 213-234). London: Imperial 
College Press.
Philips, N., & Hardy, C. (2002). Discourse Analysis. Investigating Processes 
of Social Construction (Vol. 50). Thousand Oaks, London, New Delhi: Sage 
Publications.
Sontag, S. (1978). Illness as Metaphor. New York: Farrar, Straus and Giroux.
Acknowledgements
We wish to acknowledge the valuable technical critiques from Julia van der Land, 
Silke Heumann, and Susan van den Hof.
243
References
1. Flick U, editor. The SAGE Handbook of Qualitative Data Analysis. London: SAGE Publications Ltd; 
2014.
2. Fairclough N. Critical discourse analysis: The critical study of language. 2nd edition ed. New York: 
Routledge; 2010.
3. Lupton D. Discourse analysis: a new methodology for understanding the ideologies of health and 
illness. Australian Journal of Public Health. 1992;16(2):145-50.
4. Philips N, Hardy C. Discourse Analysis. Investigating Processes of Social Construction. Thousand 
Oaks, London, New Delhi: Sage Publications; 2002.
5. Parton N, Marshall W. Postmodernism and discourse approaches to social work. In: Adams 
R, Doninelli L, Payne M, editors. Social work Themes, Issues and critical debates. Hampshire: 
MacMillan Press Ltd.; 1998.
6. Law I. A Discursive approach to therapy with men. In: Parker I, editor. Deconstructing 
Psychotherapy. London: Sage; 1999. p. 115-31.
7. Frick M, Delft Dv, Kumar B. End stigmatizing language in tuberculosis research and practice. The 
BMJ. 2015;350:h1479.
8. Zachariah R, Harries AD, Srinath S, Ram S, Viney K, Singogo E, et al. Language in tuberculosis 
services: can we change to patient-centred terminology and stop the paradigm of blaming the 
patients? Int J Tuberc Lung Dis. 2012;16(6):714-7.
9. Sontag S. Illness as Metaphor. New York: Farrar, Straus and Giroux; 1978.
10. Mol A. Klant, burger, zieke. Het goede in drie talen. [Customer, Citizen, Patient; The good in 
three languages]. In: Verkerk M, editor. Denken over zorg; concepten en praktijken [Thinking 
about care; concepts and practices] Utrecht: Elsevier/De Tijdstroom; 1997.
11. Stone D. Policy Paradox. The art of political decision making. New York: W.W. Norton & 
Company; 2012.
12. Narayan T. A violation of citizens’ rights : The health sector and tuberculosis. One’s 
understanding of the problem of tuberculosis affects the choice of intervention strategies. Indian 
Journal of Medical Ethics. 1999;7(3):75-8.
13. Engel N, Zeiss R. Situating Standards in Practices: Multi drug-resistant Tuberculosis Treatment in 
India. Science as Culture. 2014;23(2):201-25.
14. Harper I. ANTHROPOLOGY, DOTS AND UNDERSTANDING TUBERCULOSIS CONTROL IN 
NEPAL. Journal of Biosocial Science. 2005;38(1):57-67.
15. Bacchi CL. Analysing Policy: What is the problem represented to be? French Forests NSW: 
Pearson Australia; 2009.
16. Gus!eld JR. The Culture of Public Problems: Drinking-Driving and the Symbolic Order. London: 
University of Chicago Press; 1981.
17. Engel N. The making of a public health problem: multi-drug resistant tuberculosis in India. Health 
Policy and Planning. 2013;28(4):375-85.
18. Craig GM. ‘Nation’, ‘Migration’ and Tuberculosis. Social Theory & Health. 2007;5:267-84.
19. Parker I. Discourse Dynamics: Critical Analysis for Social and Individual Psychology. London: 
Routledge; 1992.
20. Reitmanova S, Gustafson DL. Coloring the white plague: a syndemic approach to immigrant 
tuberculosis in Canada. Ethnicity & health. 2012;17(4):403-18.
21. Ballestero JGdA, Moncaio ACS, Silva LMCd, Surniche CdA, Lima MCRAdAd, Palha PF. 
244
Tuberculose multirresistente: integralidade da atenção à saúde na perspectiva discursiva. Escola 
Anna Nery. 2014;18:515-21.
22. Allender S, Colquhoun D, Kelly P. Competing discourses of workplace health. Health:An 
Interdisciplinary Journal for the Social Study of Health, Illness and Medicine. 2006;10(1):75-93.
23. Ranjbar V, McKinlay A, McVittie C. The micro and the macro: How discourse of control maintains 
HIV-related stigma. Journal of Health Psychology. 2016;21(2):206-16.
24. Reitmanova S, Gustafson DL. Exploring the Mutual Constitution of Racializing and Medicalizing 
Discourses of Immigrant Tuberculosis in the Canadian Press. Qualitative Health Research. 
2012;22(7):911-20.
25. Scott P, Odukoya D, von Unger H. The classi!cation of “migrants” as a discursive practice in 
public health: A sociology of knowledge approach. Discussion Papers, Research Group Science 
Policy Studies [Internet]. 2014 14. February, 2017; SP III 2014-601. Available from: http://
EconPapers.repec.org/RePEc:zbw:wzbsps:spiii2014601
26. Hill R. A guideline to discourse analysis: With personal construct psychology undertones. 
ReConstrue Publications2012.
245
Chapter 12
Community Advocacy in TB Stigma 
Research
Caoimhe Smyth, James Malar, Timur Abdullaev, Olive Mumba, and Tushar Nair. 
Abstract
The focus of this chapter is community advocacy in TB and the role community 
advocates play in measuring, reducing, and eliminating TB stigma. 
TB community advocacy momentum is building. Advocacy has become a 
mechanism to increase investment in scienti!c research, access to new drugs and 
diagnostics, particularly for the vulnerable and underserved, and to enhance the 
realization of human rights in the context of TB policy and programming. Stigma 
is one of the many factors hindering TB control. Measuring and responding to it is 
now a priority for the global TB community. As efforts to !nd, treat, and care for 
people with TB intensify, TB community advocates must join forces and engage 
in advocacy that contests policy and programmatic norms and shifts societal 
perceptions of TB. This chapter echoes the critical need to measure stigma in 
order to reduce and eliminate it. This chapter also emphasizes the role community 
advocates must play in leveraging measurement results for advocacy and 
throughout the entire measurement process and thereafter. 
The topics covered in this chapter include:
1. The role of advocacy in reaching the global TB elimination targets. 
2. The TB advocacy community. 
3. Engaging TB community advocates in stigma measurement processes: 
a. Before the research begins;
b. During the research process; and
c. After the research is concluded.
4. Top tips for community advocates and recommended advocacy priorities to 
modify practices that stigmatize people with TB. 
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Objectives
1. To emphasize the importance of community advocacy in reaching the global 
TB elimination targets. 
2. To highlight the value of community advocates in research, and the 
connection between the two. 
3. To explore who TB community advocates are. 
4. To engage TB advocates throughout the research processes.
5. To outline top tips for community advocates and provide recommendations 
on advocacy priorities to modify practices that stigmatize people with TB. 
Target audience
This chapter is for people affected by TB, community and civil society advocates, 
researchers, and policymakers.
 
The Role of Advocacy in reaching the global TB 
elimination targets
 
Stigma towards people with or vulnerable to TB drives discriminatory behaviors 
in the workplace, health facilities, schools, and communities. In many countries, 
discriminatory laws and policies reinforce this environment of social exclusion 
and marginalization. When society discriminates against people with TB, this 
discourages people from accessing health-care services, getting a diagnosis, and 
enrolling and adhering to treatment. This in turn hampers efforts to reach the 
people centered at the 90-(90)-90 Global Plan targets to end TB. 
Figure 1. The Targets of the Global Plan to End TB
Reach at least
As a part of this approach,
reach at least Achieve at least
and place all of them
on appropriate therapy - 
!rst-line, second-line and
preventive therapy as
required
the most vulnerable, 
underserved, at-risk
populations
for all people diagnosed
with TB through
affordable treatment
services, adherence to
complete and correct
treatment, and social
support
90%
OF ALL PEOPLE
WITH TB
OF THE KEY
POPULATIONS
TREATMENT
SUCCESS
(90)% 90%
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Global Plan to End TB 2016-2020
To reach the End TB milestones, the Global Plan advocates for safe environments 
that are free from stigma and discrimination and supports community centered, 
human rights-based, and gender-sensitive advocacy efforts to eradicate stigma. 
Health advocacy started gaining momentum in the early 1980s in reaction to 
public health’s over-emphasis on curative medicine, which was pigeonholing 
policy development.1 The Ottawa Charter on Health Promotion2 identi!ed 
advocacy as a strategy for health promotion in 1986,3 and the World Health 
Organization de!ned health advocacy in a Health Promotion Glossary in 1998, 
recognizing the role advocacy plays in policy engagement as well as the need 
to foster collaboration and innovation across disciplines. Today health advocacy 
is often described as one of the foremost strategies for the achievement of 
health promotion aims, which embrace democratic participation, community 
development, and empowerment.4 Health advocacy has two main goals: 
the protection of vulnerable people (representational advocacy), and the 
empowerment of people who require support by enabling them to express their 
needs and make decisions (facilitation advocacy).5 In the !eld of international 
development, there is an increasing emphasis on evidence-based policy making,6 
evidence as a means to bolster advocacy7 and the need for collaboration to 
enhance research. 
Community advocates play a critical role in research, and their increased 
engagement stems from community and advocate demands for self-
determination and meaningful participation in interventions.8 Communities are 
also uniquely placed to document and analyze the intersectionality between 
stigma and poverty, stigma and social exclusion, stigma and gender, and HIV 
and TB, which is required to understand the subtleties of TB communities and 
effective TB responses. 
One model for community advocates engagement in research is community-
based participatory research (CBPR). It is grounded in principles of collaborative 
and equitable community engagement in research and shared ownership 
of research issues, processes, and products. It is based on two principles, 
perspective and politic. The variety of perspectives inherent in CBPR infuse 
diversity into research design, and many advocates leverage their political 
in"uence by owning research !ndings, incorporating them into policy, and using 
their authority and networks to realize change.10 According to the Institute of 
Medicine, CBPR increases community understanding of the issues and enhances 
researchers’ ability to understand community priorities, the importance of 
addressing community priorities, and the need for culturally sensitive advocacy, 
communications, and research approaches.11
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Why researchers are increasingly turning to 
Community-based Participatory Research
t There is a growing recognition that traditional research approaches have failed 
to solve complex health disparities.
tCommunity members are increasingly demanding that research address their 
locally identi!ed and de!ned needs.
t Signi!cant community involvement can lead to scienti!cally sound research.
tResearch !ndings can be applied directly to develop interventions speci!c for 
communities.
t This approach to research has the potential to build greater trust and respect 
between researchers and communities. 
When this approach is not pursued, a number of negative outcomes can occur. 
Communities can become disengaged and disempowered. The breakdown in 
relationships can mean that research may be incomplete or inaccurate, not have 
options for follow-up, or lose key partners. 
In the case of TB, marginalized and vulnerable communities must be engaged 
and empowered if we are to treat all people with TB.12 A guiding principle in TB 
research, particularly that focused on the experiences of those living with TB, 
should be ensuring that communities and people affected by TB are included 
as equal partners during research and that capacity is built to ensure this 
engagement is effective.
 
One reported barrier to the uptake of research !ndings is the lack of contact and 
collaboration between researchers, policymakers, and community advocates,13 
as well as the capacity (!nancial and skills) of community organizations to 
promote research uptake and in"uence policy.14 Researchers collect data and 
advance science by reporting and summarizing their !ndings. They are usually 
less familiar, however, with engaging policy makers and communities in the 
research process, which drives advocacy efforts. Successful advocacy that effects 
change requires close partnerships and communication and interaction across 
various disciplines. Research that informs advocacy can push infrastructural (e.g., 
community infrastructure), public policy (e.g., changes to laws) and societal 
change (e.g., attitudes to the construct), as conveyed in Figure 2. 
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Figure 2. Key Partnerships and Processes of Communities across various Disciplines of the TB 
Stigma Measurement Process.
Public Policy
Change
Organizational
Infrastructure
Change
Community
Societal
Change
Advocacy
TB STIGMA RESEARCH MANAGEMENT
Examples of Community Advocates in HIV and TB 
Research 
Community Advisory Boards - HIV
An example of CBPR can be seen in the context of HIV/AIDS research when the 
U.S. National Institutes of Health (NIH) !rst mandated the use of Community 
Advisory Boards (CABs) in clinical trials in 1987.15 This was in response to AIDS 
activism of that time. CABs can be used as a liaison between the community 
and researchers, informing the community about the research, including their 
rights to consent, strengthening the consent process, ensuring subjects are 
protected during the process, disseminating results, and advocacy.16 Today CAB 
involvement is a requirement for all National Institute of Allergy and Infectious 
Diseases (NIAID) sponsored programs.17
While research can help community-driven advocacy, community-driven 
advocacy can help research. The potential value of the skills and reach of 
community advocacy networks have persuaded many researchers to partner and 
collaborate with civil society.18 Evidence-based advocacy integrates the otherwise 
independent but overlapping work of communities, researchers, clinicians, public 
health of!cials, and policymakers to apply scienti!c principles to widespread 
health promotion efforts.19
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People Living with HIV Stigma Index
One extraordinary initiative that merges research, health promotion, and 
advocacy is the People Living with HIV Stigma Index. People living with HIV and 
HIV Policy and program managers understand that to achieve universal access to 
treatment, prevention, and services, you must address stigma and discrimination. 
The HIV Stigma Index is a tool that measures and detects changing trends in the 
stigma and discrimination experienced by people living with HIV. Over 100,000 
people living with HIV have been trained and engaged with this tool, which 
helps the community own the process and enhances their capacity to engage 
in research. The HIV Stigma Index is the world’s largest social research project 
implemented by people living with HIV. According to GNP+ (Global Network 
of People Living with HIV), the process was as important as the output, as it 
operationalized the Greater Involvement of People Living with HIV and AIDS 
(GIPA) principle, while building an evidence base to inform advocacy.
Community Advisory Boards & Community Research 
Advisory Group – TB
The Global TB Community Advisory Board (TB CAB) and the Community 
Research Advisory Group (CRAG) to the U.S. Centers for Disease Control and 
Prevention’s Tuberculosis Trials Consortium are two groups of research-literate 
community activists who advise on community needs and scienti!c priorities 
for the TB response. Working closely with Treatment Action Group (TAG), both 
groups advise institutions conducting TB clinical trials. TB CAB advises institutions 
conducting clinical trials on new TB drugs, treatment regimens, diagnostics, and 
vaccines, and provides input on study design, early access, regulatory approval, 
post-marketing, and implementation strategies.
 
Who are the TB advocates? 
In the past, TB advocacy efforts contrasted starkly with those for HIV/AIDS. 
While communities of people living with HIV joined forces, the TB response 
remained passive. This reaction can be explained by the top-down bio-medical 
approach to TB, the lack of commitment to engage with communities, and the 
absence of funding for community support groups and community advocacy 
platforms. Today, however, the TB advocacy community is expanding, as more 
advocates engage strategically and collectively within complex social, scienti!c, 
and political environments.20 Stigma must now become a focus of these TB 
community advocacy and peer support structures. Given the very nature of 
stigma, people affected by TB can become disconnected from their social support 
networks, their family members, and partners. Community networks already 
address the social exclusion stigma has in"icted on their peers. Stigma advocacy 
is a critical next step. 
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There are different community and civil society advocacy platforms at the global, 
regional, and national levels who must be engaged in all aspects of the TB 
response. These include:
Global advocates
t Treatment Action Group. 
t The Global TB Caucus.
tRESULTS. 
tGlobal Coalition of TB Activists. 
Regional advocates
1. Europe and Central Asia 
t TB People. 
t TB Europe Coalition (TBEC).
2. Africa 
t African Coalition on TB (ACT). 
3. Asia and the Paci!c
t Activists Coalition on Tuberculosis Asia Paci!c (ACT Asia-Paci!c). 
4. Latin America and the Caribbean
t Americas TB Coalition.
t Red de Personas Afectadas por Tuberculosis en Latino América y El Caribe 
(REDTBLAC). 
National Community Advocates
At a national level, there are a plethora of organizations engaged in TB advocacy 
that connect TB experiences to the broader political, social, scienti!c, and 
advocacy realms. Throughout 2016-2017, Stop TB Partnership supported these 
networks to engage in collective, informed, and community-driven advocacy at 
the national, regional, and global levels. These include:
t Tajikistan: STOP TB Partnership Tajikistan.
t India: Touched by TB.
tCameroon: National TB Community Coalition Cameroon. 
tDemocratic Republic of Congo: Stop TB RDC. 
tCambodia: National Network of People Living With or Experiencing TB. 
tGhana: Ghana Unites Against TB. 
tGeorgia: TB Georgian Coalition. 
t Tanzania: Tanzania TB Community Forum.
t Ethiopia: Ethiopian national TB Community Coalition. 
t Sierra Leone: Civil Society Movement Against Tuberculosis in Sierra Leone 
(CISNAT-SL). 
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Engaging TB community advocates in the stigma 
measurement process
Like other research processes, measuring stigma should not be imposed on 
communities, but rather it should embrace a participatory approach that calls for 
grassroots engagement.21 Figure 3 depicts the role community advocates can 
play throughout the research cycle.
Figure 3. Community engagement in TB stigma measurement. Adapted from A. DeLuca, et al.22
Before research begins
Communities must !rst mobilize before research begins (De Luca et al.) 
Community engagement can be in the form of a community advisory board, 
which can manifest the social value of TB stigma research for communities and 
can help communities accept the research as a partnership.23 The community 
advisory board can also help formulate research questions. A key sub-population 
to engage in stigma measurement are those who were lost to follow-up. A 
better understanding of the link between lost to follow-up during treatment, 
timing, and their assessment of stigma factor could be key to designing timely 
intervention strategies.24
When soliciting community engagement in research, researchers will have to be 
mindful of label avoidance, and how community members may opt out if they 
perceive that their participation is to be accompanied by a label. In the context 
of mental health and service provision, many people choose not to access health 
services for fear of the “mental patient” label, and the potential discrimination 
Before Research Begins
When Research Ends
Program
Implementation
& Policy Change
During Research
Formation of formal Community Advisory Boards
(Framing of measurement questions
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Community capacity building, empowerment and funding
Implementers 
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associated with this label. Researchers and community members should 
work together to address ways to avoid labeling in the context of TB stigma 
measurement. 
For example, the mental health community is changing the terminology to 
be more sensitive to those with the condition; e.g., dementia is now called 
Alzheimer’s disease, and manic-depressive illness is now called bipolar disorder. 
TB suspect is an example of terminology related to TB that could be more 
sensitive and empowering for those with the disease. In order to be empowering 
and inclusive, there must be thoughtful discussion between community members 
and researchers regarding how research is framed and presented to communities 
as well as the process and language used to recruit community members.
Ethical research
Other ethical considerations that should be taken into account are informed 
consent and con!dentiality, as well as cultural and linguistic sensitivities. Like all 
studies that involve human subjects, the TB stigma measurement process will 
have to observe standards pertaining to ethical issues and data protection. Those 
implementing the research should make sure that it conforms to that country’s 
ethical and data protection requirements. Each interviewee must be asked to 
consent to the collection and processing of their personal data after being fully 
informed about the nature of the TB stigma measurement research, who is 
involved, how the data will be managed and kept, and what the data will be 
used for. 
Similarly, every effort must be made to ensure that the data collected from 
the community is kept con!dential. Any breaches of con!dentiality could lead 
to supplementary stigmatization, loss of employment, or more serious legal 
consequences for individuals who identify with a criminalized community, 
including people who use drugs. Measures to avoid this must be developed 
in collaboration with community members. This should be part of a broader 
community engagement strategy in support of research. A barrier to community 
engagement is lack of funding.
Other ethical considerations that should be explored include the cultural, social, 
and linguistic sensitivities of communities. Engagement should be appropriate to 
the groups being engaged. The appropriateness of imagery or terminology may 
vary across cultures, genders, and languages. 
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When research ends 
Community advocates can play a critical role in leveraging the results of stigma 
measurement research. The community can push for change at the public policy, 
community, and organizational/infrastructural levels. Research results can be 
the solid foundation for in"uential and effective advocacy. This is particularly 
signi!cant in the case of operational research focusing on community-based 
models of prevention, treatment, care, and support. Communities have a vested 
interest in these approaches, and are therefore an important ally in driving 
change.
Affected communities can also play an important role in monitoring and shadow 
reporting. This potential increases as the potential to access and engage new 
technologies increases. Communities can connect with the National TB Program, 
advising them of issues with implementing new policies, laws, or systems in 
an appropriate manner that is people-centered, gender sensitive, and based 
on human rights. Communities can therefore gather evidence and educate. 
They can also connect with other stakeholders, or the Country Coordinating 
Mechanism for eligible Global Fund Countries, to report implementation 
challenges. This form of shadow reporting, especially in partnership with the 
National TB Program, can actively result in stronger TB programs. 
Finally, the community can work with other actors to effectively address research 
!ndings and policy changes. When education, monitoring, and reporting 
prove ineffective, communities can connect with the media, court system, and 
independent human rights commissions to access legal aid. 
Using the courts for advocacy 
The court system can provide an avenue for advocacy. KELIN is an organization 
in Kenya established to protect and promote health-related human rights. This 
organization !led a petition against a TB patient being sentenced to prison. 
On March 24, 2016 (World TB Day) the High Court declared that the practice 
of incarcerating TB patients is illegal and unconstitutional.25 Another example 
is Lawyers Collective, an organization in India that successfully fought to get 
one woman access to the medication Bedaquiline.26 A legal route also sets a 
precedent for subsequent court cases. 
Legislative and regulatory advocacy 
Regulatory and legislative advocacy are often used by organizations seeking 
to have their voices heard. Although the speci!c procedures vary depending 
on the legal jurisdiction, the strategies are common across countries. Led by its 
members, the Global TB Caucus is a unique international network of political 
representatives who work together at the local, regional, and global levels to 
advocate for TB prevention and control. 
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Members of the Caucus in particular commit to:
tWorking across geographical and political divides in a non-partisan and 
inclusive fashion; 
t Engaging with civil society and all other stakeholders involved in the !ght 
against the TB epidemic; and
tConfronting the stigma and social isolation associated with the disease.
In the Philippines one of the most comprehensive global laws on Tuberculosis 
that has been signed into law was sponsored by the Asia Paci!c TB Caucus Co-
Chair, Congresswomen Dr Helen Tan MP. It seeks to increase state investments 
for the prevention, treatment, and control of TB. The Philippines and Japan are 
among a few countries in the world that have existing legislation against TB. 
Advocating through the media
The media is one of the most common mediums leveraged for health advocacy. 
It is challenging for advocates to generate enough interest for the media to 
address their issues over an extended period of time. New media platforms, 
including social media, offers opportunities for affected communities to capture 
and maintain the mainstream media’s attention. Public health communication 
and advocacy campaigns are credited with raising awareness and encouraging 
people to access treatment and care. Communication and engagement strategies 
that engage different media industries and audiences are critical to bringing 
about meaningful change. 
Mass media interventions have proven effective in changing individual behavior, 
reducing stigma and raising awareness.27,28,29 The media has the potential to 
generate knowledge about TB, promoting awareness of TB services, and reduce 
stigma.30 Unmask Stigma is an international TB stigma awareness and education 
campaign motivated by the personal experiences of health care workers and 
patients with TB.
The challenge for the media and advocates is to not reinforce biased beliefs 
and stigmatizing attitudes. According to research conducted by the European 
Commission and the London School of Economics and Political Science, the 
media has contributed to the negative attitudes towards people with mental 
health problems in the European Union by sensationalist and inaccurate 
portrayals of mental health.31 Unmask Stigma mitigated this potential problem by 
designing and promoting the campaign under the leadership of those who were 
directly impacted by TB and TB stigma. 
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Tips for community advocates
1. Understand your epidemic. Be knowledgeable, informed, and prepared. 
2. Understand your environment. Develop an in-depth understanding of the 
political and social context you wish to in"uence. 
3. Understand the strengths and weaknesses of your position. Scrutinize the 
issue from all perspectives, including opposing views. 
4. De!ne your desired outcome. De!ne what you want to achieve (inform and 
educate, build awareness, or change laws, policies, or behaviors.)
5. Identify key people and partnerships. Understand who the strategic partners 
that you need to in"uence are. 
6. Develop a strategy. Plan how you are going to achieve your desired 
outcome. 
7. Be certain of the facts. Inaccurate or misinterpreted information will diminish 
the advocacy efforts and the issue itself. 
8. Be constructive. Build partnerships and allies and propose solutions rather 
than problems. 
9. Be regular and consistent. Be present in order to be effective. 
Table 1. Recommendations for advocacy priorities to modify practices that stigmatize people with 
TB32
TB Policy or 
Practice
Strategies to Mitigate Stigma
TB screening 
and testing
t Inform and counsel patients about TB and/or differential diagnoses pre- and post-
screening
t Protect patient con!dentiality (e.g., share test results in private)
t Advise patients of their right to access treatment
TB noti!cation t Protect con!dentiality of TB test results and patient anonymity (e.g., use unique patient 
IDs, or draw on local HIV reporting methods)
t Institute safeguards to ensure that TB test status does not affect a person’s employment 
status, immigration status, or quali!cation for other government bene!ts or services (e.g., 
implement !rewall policies between public health services and other state functions, such 
as immigration and border control)
Contact 
tracing
t Integrate TB-related health literacy and counseling into contact investigations (e.g., family 
counseling and support patients in disclosing their illness)
t Protect patient con!dentiality (e.g., avoid naming or labeling the index patient wherever 
possible)
t Provide preventive therapy where warranted (i.e., ensure that a TB diagnosis is followed 
by the option to initiate therapy under free and informed consent)
Control 
infection risk
t Inform and counsel patients about TB transmission risks and how to reduce these 
t Normalize face mask use and emphasize its capacity to protect patients 
t Identify safe peer and social support networks to mitigate social isolation
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TB Treatment t Inform and counsel patients about TB treatment, including duration, potential side 
effects, expected initiation bene!ts, availability of free treatment, and the importance of 
adherence
t Promote equitable access to newer, safer, shorter, treatment regimens
t Engage patients in decisions regarding auxiliary therapy, where possible (e.g., 
management of side effects, mental health, and nutritional supplementation)
t Refer patients to services and resources to facilitate adequate support for adherence, 
including referral to champion patients and TB survivors
t Advise patients of their right to access treatment as opposed to just their mandate to 
initiate and adhere to therapy
t Establish systems that respect patient decisions to access TB services from their preferred 
provider and maintain continuity of care (e.g., public–private health partnerships, 
integration of TB and HIV services)
TB treatment 
monitoring
t Build TB treatment literacy to support self-administration
t Implement adherence promotion strategies that are feasible and acceptable to patients 
(e.g., phone reminders, smart pill boxes, and peer networks)
t Promote mechanisms to protect patients’ employment and enable access to social security 
during TB treatment
t Facilitate safe reintegration of patients into social and work settings to foster social well-
being and !nancial independence (e.g., by sensitizing employers and families to TB)
t Assess palliative care needs and resources for patients who may be incurable, and their 
caregivers
TB research 
activities
t Involve research participants and other community members and stakeholders in the 
research development and dissemination process (e.g., following the recommendations of 
the Good Participatory Practices for TB Drug Trials)
t Create a community advisory group to inform the research process and ensure that 
research practices and procedures do not inadvertently result in stigmatization of patients 
with TB
TB 
consciousness 
and 
awareness 
raising 
activities
t Raise global consciousness by connecting TB-affected communities through media and 
other forms of public representation (e.g., via stories and images of healthy TB survivors 
rather than those that reinforce negative stereotypes against groups most affected by TB)
t Disrupt the current narrative underlying practices that may be stigmatizing (e.g., reframe 
TB screening contact tracing practices as empowering so that an index patient gains 
control of his/her illness and uses this knowledge to protect others)
t Use TB science to af!rm rather than neglect the rights of patients with TB (e.g., emphasize 
when a patient becomes non-infectious just as vigorously as his/her infectious state was 
emphasized)
t Sensitize employers to support employees with TB and promote employment of TB 
survivors
t Build spaces for consciousness raising by bringing together people affected by TB to share 
their experiences and identify common challenges to change practices that stigmatize or 
impede patient-centered care (e.g., through peer networks and advocacy forums)
t Routinely invite TB survivors to speak at TB conferences and meetings to acknowledge 
their suffering and to give them a voice in the mainstream TB community
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Other effective principles and interventions for stigma-related advocacy priorities 
are informed by the Global Plan to End TB and adapted from Confronting 
discrimination – Overcoming HIV-related stigma and discrimination in health 
care settings and beyond.33
At the community level, priorities include empowering individuals and 
communities to address and respond to discrimination, leveraging community 
healthcare workers who can mitigate discrimination and stigma, and leveraging 
community-based organizations who can document rights violations. One 
example of this is Stop TB Partnership’s OneImpact, a digital platform that 
enhances community empowerment and social accountability. 
In the healthcare setting, priorities include training and supporting health 
workers to overcome personal and institutional discriminatory attitudes and 
actions, and strengthening accountability for discrimination-free health care. 
The fundamental ethical principles at the heart of clinical care are those of non-
male!cence (do no harm), bene!cence (do good), and trust. Other priorities 
include enforcing the right to health, which includes judicial accountability, and 
providing people-centered services, rather than those that put diseases at the 
center of health systems. Examples of this include: 
tAdapting service opening hours to suit service users;
t Integrating HIV and sexual and reproductive health services to avoid the 
disclosure of con!dential information;
tAddressing discrimination and building trust between stakeholders; and 
tConsultation with bene!ciaries to ensure that their needs are understood and 
actually met, and to improve their overall engagement with health services. 
At the policy level, priorities include eliminating discriminatory laws and policies, 
introducing protective legislation, strengthening the legal and policy frameworks 
to address discrimination, and ensuring that all actors take responsibility for the 
elimination of discrimination.
Conclusion
Stigma must be eliminated in order to reach the people centered at the 90-(90)-
90 targets. It must !rst be measured, however, before it can be addressed. The 
TB community advocacy movement is expanding, and community advocates 
have a critical role in measuring and eliminating stigma. Community advocates 
need to be involved in the research processes and implementation from 
beginning to end. Drawing from the contexts of TB and HIV, protective laws 
and policies must replace those that discriminate. Health-care workers must 
provide people-centered care and be aware of personal rights. Individuals and 
governments must be held accountable by empowered communities who 
can monitor health services, help address grievances related to stigma and 
discrimination, and improve health services. When governments, health service 
259
providers, and communities put these measures into place, the global commitment to end stigma and 
TB can be realized. 
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Chapter 13
Costing Stigmatization: Justice 
enhanced cost-effectiveness methods
Alice Zwerling
Abstract
This chapter lays out the methodological foundations for incorporating social 
justice into a cost-effectiveness analysis. Many core strategies in TB have 
unintended consequences that are not yet quanti!ed in policy debates. For 
example, contact investigation can result in legally sanctioned violation of patient 
privacy – disclosing disease status to social networks.1 Even direct observation of 
treatment (DOT), has a stigmatizing dimension due to its underlying assumption 
on untrustworthiness. Methods for discerning these trade-offs are explained in 
this chapter in easy to follow step-by-step approaches.
Objectives
1. To understand the fundamentals of economic evaluation and its application 
to understanding impacts of TB stigma.
2. To introduce the concept of a novel methodology: Justice-enhanced cost-
effectiveness analysis, designed to incorporate social justice concerns, such as 
stigma, into traditional cost-effectiveness analyses.
Target audience
The chapter is for National TB program staff, implementing agencies, non-
governmental organizations, donors, policymakers, activists and technical 
partners. Health economists in university settings, organizations with research 
staff, and teams with economics backgrounds can also gain from applying the 
principles described in this chapter.
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Introduction to economic evaluation and its role in TB 
control
In the words of Drummond et al., “economic evaluation is the comparative 
analysis of alternative courses of action in terms of both their costs and their 
consequences.”1 It provides a systematic and transparent framework for 
assessing and comparing costs – both explicit and implicit - and ef!ciency. 
Economic evaluation can provide evidence to support of!cials making dif!cult 
choices around what and how to fund key interventions and programs. It can 
provide the framework to systematically approach key decisions, increasing the 
explicitness and accountability in decision-making.
For example, when the novel diagnostic TB test GeneXpert (Xpert) was 
introduced, several economic evaluations were conducted to assess the 
additional yield from Xpert (additional cases diagnosed, unnecessary treatment 
avoided, reduction in time to treatment initiation) and the costs of the Xpert 
system compared with the standard of care at the time, sputum smear 
microscopy (SSM). Economic studies showed the additional sensitivity and 
speci!city of Xpert could be highly cost-effective compared with SSM in certain 
settings.2-4 In the absence of evidence, decision-makers often rely on educated 
guesses or gut-feelings, or they simply continue supporting the status-quo. 
Economic evaluations help ensure limited resources are used to achieve the most 
health bene!t for the least cost, leading to more ef!cient programs, less waste, 
and larger health gains.5
If resources, such as drugs, healthcare workforce, time, and money were at 
in!nite supply, there would not be a need for economic evaluation. However, 
NTPs, NGOs, and large funding agencies all operate with !nite and scarce 
resources. Decision-makers in the TB community want and need to use scarce 
resources ef!ciently to ensure that the most health bene!t is attained for the 
smallest cost. Costs and cost-effectiveness are therefore important considerations 
when implementing and scaling-up TB programs. Economic evaluation is a key 
tool to ensuring this, and it provides a framework to support critical choices. 
Introduction to economic evaluation
Economic evaluation has become a critical element in the decision-making 
process of resource allocation. Many organizations, governments, and funding 
agencies now require it as part of the decision-making process, along with 
traditional clinical trial and epidemiological data. Economic evaluation is used to 
compare alternative programs or may assess the consequences of introducing 
a novel program or expanding an existing approach.1,6-8 Economic evaluations 
are concerned not just with how effective a program or test is (e.g., how many 
additional cases diagnosed with Xpert versus SSM), but also with program cost 
(Figure 1). 
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There are several types of economic evaluation. Cost-minimization analysis 
compared programs or interventions with the same outcome or assumed equal 
effectiveness (same number of persons diagnosed in standard of care approach 
and novel intervention) and seeks to compare only the costs, with the aim to 
identify the least costly approach. Cost-effectiveness analysis (CEA) compares 
both health and cost outcomes, with health units measured in natural units, 
such as the number of persons with TB diagnosed or cured, or number of deaths 
averted. Cost-utility analysis (CUA) is a form of cost-effectiveness analysis where 
health outcomes are measured as health bene!ts, commonly referred to in health 
economic literature as health utilities9: disability-adjusted life years (DALYs)10,11 or 
quality-adjusted life years (QALYs)12 as opposed to natural units. The outcomes 
in a CUA would be $ per DALY averted or $ per QALY gained. 
Figure 1. Economic Evaluation Always Involves a Comparative Analysis of Alternative Courses of 
Action
Choice? Decision
Option A
Option B
Costs A
Consequences A
Costs B
Consequences B
The incremental cost-effectiveness Ratio or ICER is a common primary outcome 
for most CEAs. It represents the incremental cost of a particular intervention or 
approach compared with another intervention (typically the standard of care) 
divided by the incremental effectiveness of that approach.
Taking the example of a CEA assessing Xpert versus SSM, the ICER could be $/
additional case diagnosed. In this case, it would represent the incremental cost 
of diagnosing one additional case of TB using Xpert compared with SSM. If 
the ICER is $200/additional TB case diagnosed, we conclude it would cost an 
additional $200 to diagnose each additional TB case using Xpert compared with 
ICER =
(Cost of Approach A – Cost of Approach B)
(Effectiveness of Approach A – Effectiveness of Approach B)
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SSM. When calculating an ICER, there will always be a comparison between two 
approaches, often a novel intervention under question and the current standard 
of care. 
Many analyses employ ICER thresholds to interpret whether a particular ICER 
value should be considered cost-effective or not. WHO recommends that an 
ICER value smaller than the gross domestic pro!t (GDP) per capita for a given 
country be considered highly cost-effective, and an ICER less than three-fold 
the GDP per capita be considered cost-effective. However, these thresholds 
can be very controversial when used to make resource allocation decisions 
in the absence of other important considerations, as they do not account for 
equity or social justice concerns. Finally, it is critical to note that cost-effective 
does not equal affordable. Many interventions which are found to be cost-
effective are still costly programs to implement, and affordability of scale-up and 
implementation of novel interventions requires careful consideration beyond 
simple cost-effectiveness estimates. 
The Cost-effectiveness plane
The cost-effectiveness plane (Figure 2) is a graphical expression of ICER and 
provides a useful way to think about cost-effectiveness outcomes.13 Along the 
horizontal axis is the difference in effectiveness between two approaches (e.g., 
the difference in effectiveness between Xpert cases diagnosed and SSM cases 
diagnosed). Along the vertical axis is the difference in cost between the two 
approaches (difference in cost between Xpert and SSM). If the ICER lies in the 
upper left quadrant, the novel approach or Xpert in our example is less effective 
(diagnoses fewer TB patients) and is also more costly. In this scenario, we would 
reject the novel test in favor of the more effective and cheaper standard of care 
or SSM. 
If the ICER lies in the lower left quadrant, the novel approach is less effective but 
also less costly. If the ICER lies in the lower right quadrant, the novel approach is 
more effective and less costly than the standard of care. This is the ideal situation 
(albeit rare), where a novel approach is both more effective and cheaper. Finally, 
if the ICER lies in the upper right hand, the novel approach is more effective and 
more costly. In such a case, which is common with new interventions, further 
resource allocation decisions will require consideration of available resources, 
health priorities and other demands, and affordability.
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Economic evaluation: study design
Designing a cost-effectiveness study follows many of the same principles as any 
research study, but instead of trying to prove that a hypothesis is true or false, its 
purpose is to aid in decision-making concerning a speci!c problem (i.e., should 
we invest in intervention A or B.) Table 1 outlines the key elements in designing 
a cost-effectiveness analysis. We will discuss each step in more detail, and 
additional resources on economic evaluation study design can be found at the 
end of this chapter.
Table 1. Key Steps in Designing a Cost-Effectiveness Analysis
1. De!ne the research problem
t  What decision needs to be made?
2. What interventions will be compared?
t What is the standard of care or the base case scenario?
t What is the alternative scenario that you want to evaluate?
3. De!ne the target population
t To what population should the results be generalizable?
4. Choose the costing perspective to model
t Who will be making the decision (health care system or societal perspective)?
5. Choose the time frame and analytic horizon under study
6. Decide on outcome measures for effectiveness data.
t Cases diagnosed, cases averted, DALYs/QALYs?
7. De!ne what costs are to be included
8. De!ne what functions and level of the health system to model. How detailed will the    
decision analysis or other model approach be?
Figure 2. The Cost Effectiveness Plane (modi!ed from Black 1990 Medical Decision Making13)
Intervention A less effective
& more costly than B
Intervention A more effective
& more costly than B
Intervention A more effective
& less costly than B
Effect Difference
Cost Difference
Intervention A less effective
& less costly than B
+
+
-
-
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De!ning the research question is a critical element, as this will guide the rest 
of the methodological design. You must know what question you are trying 
to answer or what decision you are trying to make before setting out a cost-
effectiveness study. Ensure your question is speci!c, with a clearly de!ned 
population, intervention/program of interest, comparison, and primary outcome. 
For example, in the case of the cost-effectiveness of Xpert compared to smear, 
a speci!c question should include the population and setting (e.g. persons with 
symptoms of active TB in Malawi). 
Choosing the alternatives to be compared is an important element of selecting 
the study question and objectives. Choice of comparison can be critical. 
Comparison with one approach can make your intervention look highly cost-
effective while another comparison could have it showing poorly. Some cost-
effectiveness analyses have looked at comparing SSM alone versus Xpert in 
addition to SSM, while others compare Xpert as a replacement for SSM. A novel 
intervention is often compared with the standard of care or status quo. This is a 
helpful comparison for policymakers and budget holders to know what a new 
approach would cost relative to what they are currently paying. Standard of care 
may be SSM or, in other settings, it may include LED microscopy. 
Cost-effectiveness analyses are not always generalizable, as they are highly 
dependent on the setting, population, and context modeled.14-16 Results from a 
CEA looking at Xpert in HIV + persons may not be generalizable to a setting with 
low HIV prevalence, as diagnostic accuracy varies across these groups. When 
choosing the target population, take great care to ensure the results will be 
generalizable to your population(s) of interest. 
Costing perspective
The costing perspective deals with the viewpoint used to assess the research 
question and affects which costs and outcomes will be included in the analysis. 
Typically, economic evaluations employ either a health system or societal 
perspective.1,17 The health system perspective, sometimes referred to as the 
decision-maker perspective, is concerned only with costs and outcomes relevant 
to the health system or decision-maker. In the case of government funded 
TB programs, only costs incurred by the health system would be included in 
the analysis. In the societal perspective approach, a wider range of costs and 
outcomes may be included, such as costs borne by the TB patient and their 
families, and costs borne by society in terms of lost time and wages through 
employment. 
Timeframe & analytic horizon under study
The time frame in an economic evaluation refers to the duration or time when 
the intervention is in effect, while the analytic horizon is the duration over which 
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Choosing outcome measures for effectiveness data
The effectiveness outcome measure should be chosen to have relevance to 
patients, providers, and decision-makers. They should re"ect the question under 
study. The TB patient diagnosed may be a natural outcome in an Xpert analysis, 
but would be unhelpful if the intervention looked at novel MDR-TB treatment 
regimen, for example. Natural units or intermediate outcomes generally are more 
speci!c to your research problem (i.e., cases or death averted, cases diagnosed, 
increased physical activity, or reduction in symptoms). But these units can be 
dif!cult to compare across different disease areas. How can one compare one 
additional TB case diagnosed versus one case of malaria treated? 
Final outcomes typically consider full expected lifespan, and can be compared 
across different diseases. They include the health utilities we discussed earlier 
(disability-adjusted life years (DALYs) - measure of years in perfect health lost, 
quality-adjusted life years (QALYs) - measure of years lived in perfect health 
gained). In our Xpert example, using health utilities as an effectiveness outcome 
measure, we can compare an ICER of $100/DALY averted (from Xpert CEA) with 
an ICER for prostate cancer screening of $300/DALY averted.
outcomes and costs are observable or measured (Figure 3).1,7 In some instances 
they may be the same duration. However, in TB we are often concerned with 
outcomes (death, treatment cure, etc.) that occur after the intervention period 
or time frame, therefore the analytic horizon is frequently much longer than the 
time frame. The analytic horizon must include all main costs and health bene!ts 
during this period. It should be chosen to allow for seasonal variation (if these 
are thought to be likely) and must include the intervention implementation and 
running time.
Figure 3. Schematic of Time Frame and the Analytic Horizon
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Figure 4. Options for Effectiveness
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Deciding what costs should be included?
Costing is a vast topic, and there are many good resources for methods on 
measuring and valuing cost inputs for economic evaluations.1,18-20 First, relevant 
activities for costing must be identi!ed. For example, in costing a novel test such 
as Xpert, we might identify activities to be costed to include symptom screening 
for TB, referral for sputum, sputum collection, performing the smear, performing 
the Xpert test, feedback of test results, initiating treatment, etc. All activities 
directly involved with the provision of the novel program and its comparator 
(standard of care, SSM in this example) should be included and costed. Once 
relevant activities have been identi!ed, unit costs will need to be calculated for 
each activity. Unit costs typically consist of overhead and capital costs, salaries, 
consumables and drugs, and equipment.
The key costs to include:
tOverhead costs including utilities.
t Buildings and furniture.
t Salary costs, including training and supervisory costs.
t Equipment.
tMaintenance.
t Transport.
tAdministrative costs, including internet, phone, stationary, postage, etc.
tConsumables.
tDiagnostics.
tDrug costs and ancillary drug costs.
t Program speci!c/novel intervention related costs (implementation costs may 
also be included if relevant to the study question).
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For economists, costs are not simply how much we pay for something (market 
price), but they are thought of in terms of opportunity costs as well. Opportunity 
costs refer to the value that could have been gained from the next best 
alternative when one course of action is chosen. For example, a nurse who 
decides to volunteer her time to do TB screening may have a !nancial or explicit 
cost of $0. However, if she does voluntary TB screening, society loses the ability 
to employ her skills in the emergency room of a public hospital, for example. The 
value of the donated time (or the implicit cost of working at a public hospital) 
should therefore be accounted for in a CEA analysis. More details on other 
costing approaches and methodologies can be found in the resources listed at 
the end of this chapter.
Unit cost estimation can be done using two different approaches: bottom-
up and top-down estimation. In the bottom up approach, one identi!es all 
resources used for each service and assigns a cost value to each resource. All 
resources used in a particular service or activity are then summed for that activity 
to build a total unit cost. This is often referred to as an ‘ingredients’ approach. 
For example, a unit cost for an Xpert may include overhead, consumables, 
including the cartridge, equipment, and labor costs. Bottom-up costing can be 
advantageous as it provides transparency, granularity, and versatility, but it tends 
to underestimate the true costs. 
Top-down costing involves using total expenditures for an activity or service and 
dividing the total cost by the number of units of activity. In the Xpert example, 
one can use the total program budget/number of patients tested to calculate 
a unit cost per person tested. Advantages of the top-down approach include 
its reliance on more easily available costing data. It is a simpler approach and 
typically requires fewer resources in terms of money and time compared with 
the bottom-up approach. However, it tends to overestimate true costs and 
cannot identify key drivers of cost. When adequate manpower and resources 
are available, performing both bottom-up and top-down costing for unit costs is 
strongly advised. Unit costs from the two approaches can then be averaged to 
de!ne summary unit costs.
How precise should cost estimates be?
Empirical costing is a resource-intensive process that takes time and effort. There 
may be limitations to the costing effort due to constraints on data availability 
or time. Some judgment calls are needed to decide how accurate or precise 
cost estimates should be within a given study. The degree of precision required 
will depend on the likely quantitative importance of each cost category in the 
evaluation.
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Figure 5. Precision in Costing
Micro-costing: each component 
of resource used is estimated 
and a unit cost derived for each 
(bottom-up approach).
Disease-speci!c daily cost: Daily 
average cost for treatments in 
each category. 
Case mix group: Cost for each 
category of case or hospital 
patient.
Average daily cost: Averages 
over all categories of patients 
(top-down approach).
More Precise
Less Precise
How can measured stigma be incorporated into 
traditional cost-effectiveness analyses
Some elements of measured stigma may be incorporated directly into either 
the cost or effectiveness measure in a traditional cost-effectiveness analysis. 
For example, stigma may result in !nancial costs when an individual with a TB 
diagnosis loses their job. As explained above, costing and cost-effectiveness 
analyses can take a health system or societal perspective. The societal 
perspective takes a broader approach and may include both direct and indirect 
costs to the patient, including costs associated with lost wages, travel costs, costs 
for additional medication not supplied by the health system, or additional child 
care or support for family members. 
While not all impacts and effects of stigmatization may be included in the costing 
component, some, such as lost wages, can be. Unfortunately, these costs are 
rarely incorporated in traditional CEA, as societal perspective is rarely employed 
in TB CEA due to the additional time and resources required. Traditional 
approaches capture only one small part (the !nancial aspect) of the stigma 
impact on a TB patient, neglecting other important social impacts.
While not typical in most cost-effectiveness analyses, some elements of stigma 
could conceivably be included in the effectiveness component. For example, 
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the health utility, speci!cally the quality-adjusted life year (QALY), is intended 
to capture both the morbidity and mortality experienced by a patient given a 
particular health state. Accounting for time spent not in full health, this can 
include adverse events from treatment, or mental health effects from having 
been diagnosed. Elements of stigma impacting an individual’s mental health 
and well-being could conceivably be included in this measure. However, this is 
rarely done, as it requires an involved and potentially lengthy undertaking to 
assign appropriate QALY weights to a variety of health states (including stigmas 
impacts) in a setting-speci!c manner. 
What does traditional cost-effectiveness analysis leave 
out in relation to stigma?
Traditional cost-effectiveness analyses have some important limitations which 
consumers should be aware of. From a policy perspective, it is important to 
consider that cost-effectiveness analyses assess average costs and effects, and 
do not necessarily account for the differences in costs and consequences of 
interventions among different patient or population groups. The identities of 
these groups (poor, migrants, vulnerable populations, geographically hard to 
reach populations, etc.) and the a priori distribution of costs and health status 
across these groups may have an important role in assessing social desirability or 
equity of certain interventions or programs under study. Therefore, the equitable 
distribution of costs and health effects across different groups should be an 
important factor in the decision-making process.
At the same time, more novel TB drugs and diagnostics are being introduced, 
and more are in development. Cost-effectiveness analyses continue to play an 
important role in the uptake and implementation of these new interventions 
and technologies. However, in many cases, the cost of new interventions can 
be prohibitively expensive while only conferring a small improvement in health 
bene!t for the general population. As a result, such interventions would likely 
not be cost-effective in a traditional CEA. 
For example, novel MDR-TB treatment regimens may reduce stigma impacts 
for patients with drug resistant-TB, but they come at a high cost and may not 
necessarily improve treatment outcomes when compared with standard therapy. 
In such instances, traditional cost-effectiveness analyses may !nd such novel 
regimens to be not cost-effective. In the absence of an explicit discussion of 
stigma, a CEA may lead to a policy decision that not only does not reduce stigma 
and other social injustices, but may in fact, promote interventions that increase 
stigma. In the case of novel MDR-TB drugs, which are very expensive and may 
offer only a small increase in effectiveness, a CEA in certain resource-constrained 
countries may deem these to not be cost-effective. Therefore, such countries 
may choose to continue using existing MDR-TB regimens, despite the potential 
for novel regimens to reduce stigma.21
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The vast majority of current cost-effectiveness analyses addressing decisions 
around implementation and scale-up of novel TB treatment regimens do not 
speci!cally address and include issues around stigma (beyond stigma-associated 
costs as outlined above). As more stigma measurement tools are now being 
designed and validated, there is an opportunity to adapt our traditional cost-
effectiveness approach to incorporate these elements and promote a more 
socially just decision-making process in which stigma is explicitly considered.
There are several methodological approaches now used in health economics 
developed with the aim of incorporating elements outside of traditional cost-
effectiveness analysis. These include direct integration through quantitative 
equity weighting (extended CEA or ECEA)22, mathematical programming to 
assess equity-related opportunity costs, and multi-criteria decision analysis 
(MCDA)23,24, in which small groups of stakeholders are asked to weigh equity 
in comparison with ef!ciency and other priority-setting concerns.25 While these 
approaches may offer some ability to incorporate equity elements beyond those 
typically accounted for in CEA, none were developed speci!cally to incorporate 
social justice concerns, such as stigma.
An innovative methodology to explicitly consider 
stigma in CEA: Justice Enhanced CEA
Justice-enhanced CEA or JE-CEA is a novel conceptual methodology developed 
to explicitly consider elements of social justice (such as stigma) alongside 
traditional CEA. JE-CEA is a systematic, data-informed approach to enable 
decision-makers to explicitly consider the expected impacts on social justice 
elements, including stigma, alongside a traditional CEA. It involves three steps: 
the systematic collection of data about the stigma people experienced, the 
empirical !ndings from step 1 to inform social justice assessments (this can also 
be limited solely to measured stigma), and incorporation of stigma assessments 
into a decision analytic framework, including traditional CEA assessments. Please 
note that JE-CEA is a novel methodology under development.26
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Figure 6. Impact on Social Justice to be Overlaid over a Traditional CEA Decision Tree
Expected not to worsen
Expected to worsen
May worsen
SOCIAL JUSTICE ASSESSMENT
Impacts on social justice will be represented in the 
decision tree by the color of each bar, as shown here 
and in Figure 7.
Box 1. Current Limitations in Traditional CEA and Examples of Ways Justice-Enhanced CEA May 
Bolster Traditional CEA
Current gaps in traditional CEA Advantages of JE-CEA approach
tNo formal assessment of social justice.
tMay promote policy choices that are cost-
effective, but contribute to further clustering 
of disadvantage.
tCannot provide information to highlight areas 
of negative social impacts for standard or 
novel interventions.
tDoes not systematically include certain major 
considerations of social justice relevant to 
decisions that economic evaluation informs.
t Introduce language of social justice into CEA.
t Encourage the inclusion of formal assessments 
of social justice impacts in future decision and 
policy-making.
t Provide key information surrounding 
social justice necessary for advocacy (price 
negotiations of novel drugs for resource 
limited settings).
tHighlight need for data collection activities to 
inform future formal social justice assessments.
t Present considerations of social justice 
simultaneous with those of cost-effectiveness.
For any given policy question to which CEA is applicable, the ‘enhancement’ 
added by JE-CEA adds a social justice assessment that enables decision-makers 
explicitly to consider expected impacts on the clustering of disadvantage. For 
example, using three impact levels, the social justice assessment for a given 
scenario under analysis could be either ‘Expected not to worsen…’, ‘May 
worsen…’, or ‘Expected to worsen…” the clustering of disadvantage’, as 
color-coded in Figure 6. We use the language of ‘worsening’ here because, as 
noted above, a just decision process for questions of health policy should avoid 
exacerbating the clustering of disadvantage in affected populations.27 
In the context of scaling-up novel MDR-TB regimens, our assumption is that 
successful disease treatment is the main vehicle to alleviate disease-imposed 
disadvantage. In addition, JE-CEA is distinctively concerned with helping 
policymakers to avoid making people worse off. JE-CEA is designed to support 
the comparison of therapeutic regimens in terms of their exacerbation of 
disadvantage across core dimensions of well-being – agency, association, and 
respect – while undergoing the therapeutic regimen. Our intended scope of 
application for “the clustering of disadvantage” is within the personal life 
experiences of the affected populations.26
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These assessments would be compiled by using empirical !ndings to track the 
occurrence, magnitude, and breadth of cross-cutting impacts on the three core 
dimensions of well-being (agency, association, and respect) identi!ed in the 
social justice framework developed by Bailey et al.28 For instance, empirical 
!ndings indicate that patients who are cured after MDR-TB treatment tend to 
suffer marital strife as a result of their prolonged hospitalization or public ridicule 
coming from the MDR-TB hospital. An MDR-TB cure requiring hospitalization 
might be associated with adverse impacts of moderate magnitude across 
association (social isolation) and respect (stigma).26 Such levels of a social justice 
impact could be assessed for each major type of outcome under the treatment 
regimens to be compared. 
In Figure 7 we show a hypothetical assessment with possible outcomes of cure, 
toxicity, and failure. Each outcome could have a probability and an expected 
impact on social justice informed by empirical data for both standard and novel 
MDR-TB regimens. 
Social justice assessments can be presented in parallel to a decision tree, as is 
commonly used for CEA (Figure 7). Each social justice assessment will have two 
dimensions, including a proportion of the patient population exposed to each 
outcome (length of the bar shown in Figure 6), and a level of impact on the 
clustering of disadvantage under that outcome (color of the bar). An overall 
social justice or stigma assessment can be compiled by laying the bars for each 
regimen in question alongside each other (see the bottom of Figure 7) and 
presenting summary bars for each alternative. In the hypothetical example of 
Figure 7, the summary bars indicate that, relative to the standard regimen, the 
novel regimen is favored on both dimensions of the social justice assessment (the 
proportion exposed and level of impact).26
In this simpli!ed decision analysis tree, we present how social justice assessments 
may be overlaid with the decision analysis framework corresponding to particular 
branches in the model. In a decision analysis model, a hypothetical cohort 
of patients enter at the left of the tree and progress through the branching 
structure towards the right. A probability at each branching node predicts what 
proportion of the patient cohort continues down each branch. The bar colors 
represent the average expected impact on social justice experienced across each 
branch pathway, while the length of the bars corresponds to the proportion of 
the cohort experiencing that particular social justice impact. For the overall social 
justice assessment, assessments are concatenated across each intervention arm.
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Synthesis
Decision-makers should be empowered to assess both value for money and 
impact on disadvantage, and explicitly stating any trade-offs between them. 
When they are concordant, the case for making a certain decision is bolstered. 
When they are discordant, decision-makers should evaluate the discrepancy. In 
Data to inform JE-CEA: MDR-TB patients’ lived 
experiences
To perform JE-CEA comparing MDR-TB treatment regimens in a given setting, 
empirical estimates of the impact on core dimensions of well-being are required. 
A qualitative evaluation is needed to determine if, how, and to what extent 
each regimen might worsen the clustering of disadvantage experienced by 
patients. For example, a meta-analysis of prior qualitative research on TB 
patients’ experience indicates that patient-centered barriers to TB treatment 
adherence include a lack of community, family, or household support.29 In-depth 
interviews with MDR-TB patients and their healthcare providers can be used to 
explore social isolation as well as other ways in which MDR-TB treatment may 
compromise agency, respect, and association for patients. Interviews can be used 
to compile formal social justice assessments, which are then incorporated into 
the JE-CEA decision analysis. Future work could build on qualitative !ndings to 
re!ne decision analysis by developing tools to better quantify the factors most 
likely to exacerbate disadvantage.26
Figure 7. Hypothetical, Simpli!ed Example of the Proposed Methodology Incorporating Social 
Justice 
Overall Social Justice Assessment
Std M
D
R Treatm
ent
N
ovel M
D
R Treatm
ent
Std MDR Treatment
Std MDR
Treatment
Patients with
MDR diagnosis
Novel MDR
Treatment
Toxicity, p=0.1
Cure, p=0.6
Failure, p=0.3
ICER = $X / DALY averted
Cost H, DALY H, p=0.6
Survive, p=0.4
Die, p=0.6
Survive, p=0.5
Die, p=0.5
Survive, p=0.4
Die, p=0.6
Cure, p=0.5
Toxicity, p=0.2
Survive, p=0.5
Die, p=0.5
COST A, DALY A, p=0.1
COST B, DALY B, p=0.1
COST G, DALY G, p=0.05
COST C, DALY C, p=0.5
COST D, DALY D, p=0.12
COST E, DALY E, p=0.18
COST F, DALY F, p=0.05
COST I, DALY I, p=0.12
COST J, DALY J, p=0.18
Failure, p=0.3
Novel MDR Treatment Expected not to worsenExpected to worsen
Expected to worsen May worsen
(p: probability; DALY: disability-adjusted life years; MDR: multi-drug resistant tuberculosis; ICER: incremental cost-effectiveness ratio)
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cases like the example discussed above, in which the hospitalization required by 
standard MDR-TB treatment is associated with stigma and social isolation, which 
could be averted by a novel (but high-cost) regimen requiring no hospitalization, 
the CEA component of JE-CEA (the ICER) might favor the standard regimen. 
The justice-enhanced component (social justice assessment) favors the novel 
regimen. JE-CEA would present decision-makers not only with this discrepancy, 
but also with the relevant impacts on each side. In this case, JE-CEA might 
provide the additional justi!cation needed for policymakers to implement costly 
regimens in order to improve the plight of MDR-TB patients, and ultimately for 
civil society to press for price reductions of novel MDR-TB regimens.26
Strengths and limitations of the JE-CEA approach
JE-CEA could !ll important gaps in the current approach to economic 
evaluation (Box 1). These include introducing social justice language into 
economic evaluation, encouraging awareness and inclusion of social justice 
impacts when making health-related decisions, highlighting the need for data 
collection and analysis to demonstrate how treatment regimens can exacerbate 
social disadvantage, and encouraging decision-makers to incorporate formal 
social justice assessments in key policy and resource allocation decisions. 
Additional resources and expertise would be required to compile formal social 
justice assessments across different settings. It remains unclear how far such 
assessments may be generalizable (though the same could be said about the 
economic considerations of CEA). It is important to note that social justice 
may not be the only element lacking in CEA, and evaluations should also 
include assessments of fairness, equity, or age preference. The methodology 
proposed here is a !rst attempt to include elements like social justice in a formal 
assessment of CEA. While transmission is a critical issue for MDR-TB control, 
JE-CEA relies on a decision analysis model and does not explicitly account for 
transmission.
JE-CEA methodology is currently under conceptual development. Its full 
elucidation must be borne out through empirical research and discussions with 
clinicians and policymakers. Further work will re!ne this concept by including 
empirical estimates/observations of the perceptions of social justice impacts, as 
well as quantitative efforts to appropriately balance cost-effectiveness and social 
justice considerations. The adoption of JE-CEA will require the engagement 
and education of key stakeholders as well as thoughtful dissemination across 
various settings. Being able to see social justice assessments alongside traditional 
CEA outputs leaves policymakers with dif!cult decisions, particularly in cases of 
discordance. Like traditional CEA, however, JE-CEA is not designed to replace 
the decision-making process but to provide a more complete picture that can 
be used to organize and inform deliberations. Importantly, we do not suggest 
that JE-CEA is the only way to incorporate social justice assessments into 
economic evaluation; rather, the development of JE-CEA may stimulate improved 
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approaches that could further promote the inclusion of formal social justice 
assessments into traditional CEA, policy development, and decision-making 
processes.
Conclusion 
Current prevailing methods for economic evaluation do not fully address 
social justice considerations. As a result, assessments may overlook important 
potential bene!ts in reducing clusters of disadvantage and thereby alleviating 
the patient burden. Here we propose justice-enhanced CEA as an alternative 
approach. Formal assessments of social justice can and should be undertaken in 
conjunction with CEA to provide more complete information to decision-makers. 
Otherwise, initially costly interventions (such as the rollout of novel regimens for 
MDR-TB) may never be scaled-up, and clinicians will not have access to certain 
(more expensive) treatments. Clustering of disadvantage may be worsened 
among already badly-off populations, and suf!cient pressure is never applied 
for the economics of those interventions to change. Incorporating social justice 
assessments into CEA can lead to more ethically responsible decision-making, 
ultimately creating a healthier and more just society.26
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Chapter 14
Measuring TB Stigma as part of a 
Syndemic
Ellen M.H. Mitchell, Amrita Daftary, Gill Craig, Lisa Redwood
Abstract
Mistreatment of people with TB is rooted in prejudice.1 Oppression can be 
layered, cumulative, and hard to disentangle. A syndemic stigma is when two 
or more stigmatized identities are fused in the public consciousness. It is it 
challenging to tease out the negative impact of TB stigma for the purposes of 
policy and intervention. This chapter teaches readers to measure different types 
of intersecting stigma and prejudice using validated scales. We offer practical 
guidance to address the challenges posed by syndemic stigma. A compilation of 
scales for measuring other biases is provided. We present TB/HIV stigma scales 
for when the two stigmas are interwoven. 
Objectives
1. To grasp the methodological challenges inherent in syndemic stigmas and the 
risks associated with a overly narrow approach to measurement of TB stigma. 
2. To appreciate the advantages of an intersectional approach to measurement 
of TB stigma. 
3. To appreciate the various scales available for measuring other types of 
stigma.
4. To understand the methodological implications of an intersectional approach.
Target Audience
This chapter is intended for those who are comfortable measuring TB stigma, 
and who want to ensure that any claims of causality are not confounded. The 
intended audience includes social scientists, clinicians. It is essential reading for 
M&E of!cers, TB program staff, CBO staff, activists, and those without a !rm 
foundation in the social sciences. This chapter builds upon Chapters 2, 3, and 9.
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Introduction
The concept of syndemic stigma was recently developed by medical 
anthropologists to describe disparaged characteristics, qualities, and behaviors 
that co-occur, such as being poor and having TB or using drugs and developing 
TB.2 
A syndemic is a set of intertwined and mutually enhancing epidemics involving 
disease interactions at the biological level that develop and are sustained in a 
population because of harmful social conditions and injurious social connections.3 
The syndemics model of health focuses on the biosocial complex, which 
consists of interacting, co-present, or sequential diseases and the social and 
environmental factors that promote and enhance the negative effects of disease 
interaction.4
Syndemic stigmas have been referred to as compounded, layered, or 
intersectional stigmas in the literature.5,6 These terms imply that stigma is enabled 
by structural inequalities, which leave some groups more vulnerable than others.2 
A syndemic stigma is occurs when underlying inequities cluster, which may 
compound social exclusion.7,8 Racism, xenophobia, classism, and other prejudices 
can potentiate TB stigma.9,10 
The burden of multiple disparaged characteristics and behaviors, such as being 
poor, having TB, and being malnourished, is not new, but the language may be 
unfamiliar.11
Disparaged
social
locations
e.g. poor 
Discredited
behaviors
e.g. drug use
Discredited
health issues
e.g. TB
Figure 1. Clustering of illnesses, social exclusions, and prejudices can create syndemic stigma
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Intersectionality was developed by the African American feminist Kimberlé 
Crenshaw to understanding the experiences of people facing multiple, 
simultaneous oppressions or privileges.12
Intersectionality is closely linked to the public health idea of syndemics, as both 
involve looking at all social in"uences (e.g., race, class, gender) concurrently in 
order to better understand health and behavior.13 
Intersectional or syndemic stigmas complicate and enhance our ability to 
understand the life experiences of people with TB (Figure 1). For example, 
migrants, prisoners, the homeless, people living with HIV, smokers, and persons 
dependent on tobacco, alcohol, or drugs already experience varying degrees of 
social exclusion. 
Xenophobia
Racism
Homophobia
Stigma of 
incarceration
Sexism
Stigma of 
tobacco, 
drug and 
alcohol use
Stigma of 
homelessness
Stigma of 
diabetes
Stigmatized 
occupations 
(sex work, 
morgue, lab)
HIV
stigma
TB stigma 
affecting 
people 
with TB
Figure 2. Stigmas that may impact people with TB
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Intersectionality means that we explore TB stigma with the understanding that 
its expression is likely to vary by gender, class, race, ethnicity, behavior, identity, 
and co-morbidity.12 In measuring TB stigma, other pervasive stigmas must also 
be accounted for.14–16 Failure to measure auxiliary (and possibly dominant) forms 
of exclusion may lead to an over- or under-estimation of the stigma associated 
with TB. It will also complicate efforts to reduce stigma. 
An awareness of syndemic stigma changes the way we design and measure TB 
stigma in several ways:
1. We accept that a particular person can be subjected to different forms of 
prejudice and self-stigma simultaneously. The existence of other stigmas 
must be captured.
2. We recognize that TB stigma can have a differential impact on particular 
people because TB stigma is often mediated by other stigmas. The 
magnitude, direction, and impact of other stigmas must be clari!ed.
3. We must ensure that we are measuring TB stigma, and the confounding 
potential of other stigmas must be mitigated. 
This chapter guides readers in measuring different types of intersecting stigma 
and prejudice using validated scales. This guidance will evolve as research 
continues and best practices are further articulated.17
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TB Syndemic Stigmas
Readers of this book are already familiar a disease syndemic. We recognize 
TB-HIV, TB-diabetes, TB-smoking, TB-silicosis, and TB-depression as interlinked 
and destructive syndemics that must be addressed with multi-disciplinary 
collaboration.18–23
Figure 3. The Compounding Effect of Multiple Oppressions
 Stigmas can be additive, and compound the impact of TB stigma. In most settings, TB is 
disproportionately concentrated among people and communities who are already social excluded.24 
Marginalized groups with elevated TB risk include the poor, those who are malnourished, homeless, 
drug dependent, people with HIV, sex workers, and migrant populations.24–26
In some Asian countries, TB is linked to smoking, and the stigma of smoking and lung cancer may 
marginalize people at risk for TB.27 In sub-Saharan Africa and Central Asia, people with TB may 
experience stigma due to the presumed association between TB and HIV, which is associated with 
sexual transgression, promiscuity, amorality, and death.16,28 In Europe and North America, TB is often 
rhetorically linked to poverty, ethnicity, and race, including immigrants and those living in indigenous 
communities.29 TB is more common among people deprived of liberty and homeless persons.31 
Shaming and blaming of TB patients can be related to smoking, drinking, or other discreditable 
behaviors.
It may be challenging for members of disparaged groups to discern exactly why they are being 
stereotyped, shamed, blamed, or discriminated against given their high background level of social 
exclusion and discrimination.30
TB
Stigma 
Negative
Health
Outcome
other
Stigma 
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The ethnographic literature suggests that TB stigma is not always the 
predominant form of discrimination for many affected by TB.31 Other stigmas 
may mitigate or exacerbate the effect of TB stigma.32,33 For example, anticipated 
cancer or smoking stigmas may deter smokers from seeking care for a painful 
chronic cough, or anticipated HIV stigma may inhibit some people from seeking 
TB treatment. 
Figure 4. Challenges of Attribution for People with TB Experiencing Discrimination
Multiple Stigmas
Cause Effect
Experienced
Stigmatization
Just as some attributes may compound TB stigma, socially desirable attributes 
(e.g., being wealthy or educated) may de"ect and buffer stigmatization. 
The Temporizing Effect of More Pernicious Stigmas
In some situations, stigmas can be so negative that they dwarf the impact 
of TB stigma. Individuals with heavily stigmatized co-morbidities (e.g., drug 
dependence or severe mental health issues) may prefer to self-identify as having 
TB rather than disclosure of the more discrediting condition. This behavior is 
called covering.16
In some circumstances, TB can be the more discrediting of two stigmatized 
identities.34 With widespread access to antiretroviral therapies and poor access 
to second-line TB medicines, some !nd it less stigmatizing to be treated 
for HIV than to be treated for DR-TB.35 Label avoidance, or the tendency 
to resist publicly acknowledging a stigmatized identity, can impede stigma 
measurement.36 People may under-report concealable stigmatized identities (CSI) 
or cover with another label. To minimize label avoidance, surveys need to be 
carefully phrased and should be posed by trustworthy data collectors.37
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Figure 5. Covering an DR-TB diagnosis with an HIV diagnosis
Gender Lens
Applying a gender lens is important when measuring TB stigma. Previous TB 
stigma scales have been gender blind, meaning that they failed to recognize 
that the autonomy and power of women/girls and men/boys varies in speci!c 
social, cultural, economic, and political contexts.38 The assumption that stigma 
questions are valid for all genders may have produced spurious results. Sexism as 
a mediating factor in TB stigma is gaining attention. 
Figure 4. ????
HIV
STIGMA
DR-TB
STIGMA
Preferred self-presentation
as an ART client
290
Recent studies of anticipated and internalized stigma among men in Malawi, 
Zambia, Tanzania, Lesotho, and South Africa have drawn attention to the 
powerful role of stigma in care seeking.39–44 Two studies found that women are 
more adherent to TB treatment when they perceive high levels of stigma, while 
men, on average, were less adherent.45,46 While little is known about TB stigma 
among transgender populations, lack of trust and low cultural competence has 
encumbered TB outbreak investigations.47–49
Do not mistake TB stigma for other exclusions and prejudices that may be 
equally or more detrimental.
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Other Stigmas as Latent Confounders: The Case of TB 
Stigma and Gender
In order to develop tools that accurately capture different stigmas, one must 
know which forms of prejudice coexist with TB stigma in a given setting. When 
we develop TB stigma measurement scales, we have to ensure that they have 
content validity. Other stigmas can be a latent confounding factor if we are not 
selective when choosing items for a scale.
The EMIC scale, a widely used TB stigma measurement tool, has sexual 
negotiation and marriageability questions that are profoundly gendered.42,50 
One item queries whether a TB patient has been refused sex. This is supposed 
to measure TB stigma, but it is likely confounded by gendered heteronormative 
power relations in sexual situations. Using the EMIC scale in India, Bangladesh, 
and elsewhere has led many stakeholders to conclude that women experience 
higher rates of TB stigma, in part because they are more likely to be refused sex 
than men are. When these gendered items are not included in stigma scales, the 
difference in rates of TB stigma between men and women are no longer found.51
The sampling and bias detection methods described in Chapters 3 and 9 are 
tools to assess the possible confounders of TB stigma measures in marginalized 
groups. Chapter 16 has statistical tools for detecting whether a stigma scale is 
measuring two or more different constructs.
Figure 6. Sexism as a latent confounder in an explanatory model of treatment adherence
Sexism
Gender
TB 
Treatment
Adherence
Stigma
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Practical Approaches for Measuring Syndemic Stigma 
The following are tips for overcoming the methodological challenges associated 
with measuring TB stigma in the context of other prejudiced attitudes and 
behaviors: 
tAssess local drivers and intersecting stigmas through complementary 
qualitative research (Chapter 3). 
tMeasure all relevant stigmas with validated scales. 
t Increase study sample sizes to account for the added statistical power 
necessary to permit multivariate analyses. 
tUse sampling techniques appropriate for marginalized groups (Chapter 9).
tAssess covariance and confounding when analyzing impacts of stigma. 
Validated scales for many stigmas can be used in conjunction with a TB stigma 
scale. A partial list of stigmas and prejudices that may coexist in the presence of 
TB stigma includes:
1. HIV. 
2. Alcohol and substance use and dependency.
3. Poverty.
4. Homelessness.
5. Occupation. 
6. Involvement with the criminal justice system.
7. Xenophobia/immigration status.
8. Racism.
9. Sexism/misogyny.
10. Illiteracy or lack of education.
11. Mental illness.
12. Smoking.
13. Lung cancer.
14. Hearing loss. 
Qualitative studies assessing the role of multiple stigmas affecting people with 
TB, and the social dimensions of TB stigma, are introduced in Chapter 3.
Using Vignettes to Measure Intersectional Stigmas
Vignettes can be used to tease out multiple types of prejudice, which the 
respondent may not be conscious of, when measuring intersecting stigmas by 
survey or interview.52–55 Vignettes that vary the characteristics of a person in 
a narrative can reveal biasis.52,56,57 By pairing different stigmatized conditions, 
one can see whether compounding different stigmas lessens the effects of the 
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individual stigmas, is the sum of the individual effects, or more than doubles the 
individual effects of the separate stigmas. Vignettes allow for the presentation of 
realistic patient populations and clarify their multiple stigmatized identities.
You can also use names in the narrative, which implies a particular ethnic 
background.
The Social Distance Scale by Kelly and colleagues is widely used for vignette-
based measurement.58–60 The following are the yes/no survey items after the 
vignette:
1. If you met ‘[insert name]’, would you be willing to strike up a conversation 
with him?
2. Would you attend a party where ‘A’ was present?
3. Would you attend a party where ‘A’ was preparing food?
4. Would you be willing to work in the same of!ce with ‘A’? 
5. If you were a friend of ‘A’s, would you be willing to continue friendship at 
this time?
6. If you were ‘A’s’ landlord and his lease was up in two months, would you 
renew his lease? 
7. Would you allow your children to visit ‘A’ in his home?
Figure 7. Varied characteristics of vignette subjects
Vary Skin Color
Patient
Archetype 1
Patient
Archetype 2
Patient
Archetype 3
Vary Gender
Vary Socioeconomic 
Status
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Resources for Validated Scales to Measure Stigma
It is beyond the scope of this TB Stigma Measurement Guidance to describe 
all forms of prejudice, stigma, and discrimination that co-occur with TB and 
require measurement. However, here is a list of validated scales that should be 
considered in a survey instrument. 
Stigma Scales
Stigma of HIV status
HIV Stigma scale (Berger)61
Community Perspectives Towards HIV/AIDS (Van 
Rie)62
Stigma of HIV for Healthcare Workers
Wouters HIV Stigma Scale63
Uys Stigma Scale (see Chapter 8)64
Stigma of alcohol Dependency Alcohol Use Disorders Identi!cation Test (AUDIT)65,66
Stigma of Substance Use and Dependency
Substance Abuse Self-Stigma Scale67
Stigma of Substance Abuse Scale68
Stigma of Poverty or Homelessness Attitude Toward Poverty Scale69
Stigma of Involvement with the Criminal 
Justice System
Self-Stigma of Individuals with Criminal Records Scale 
(SSICR)70
Xenophobia and Racism Racial and Ethnic Microaggression Scale (REMS)71
Sexism, Misogyny, Homophobia, and 
Transphobia
LGBT People of Color Microaggression Scale (LGBT-
PCMS)72
Sex work stigma73
Sexual stigma74
Stigma of Mental Illness
Hopkins Symptom Checklist (HSCL-25)
Mental Illness Microaggressions Scale-Perpetrator 
(MIMS-P)75
The Ryff Scales of Psychological Well-Being76,77
Patient Health Questionnaire - Nine Item (PHQ9)
Stigma of Traumatic Events Harvard Trauma Questionnaire (HTQ)78
Stigma of Chronic Illness Chronic Illness Anticipated Stigma Scale (CIASS)79
Stigma of Smoking and Lung Cancer 
Internalized Stigma of Smoking Inventory (ISSI)80
Cataldo Lung Cancer Stigma Scale81
Stigma of Diabetes Diabetes Self-Stigma Scale (SSS)82,83
Generic Discrimination Experiences of Discrimination (EOD) Index84
Stigma of Hearing Loss
Hearing Attitudes in Rehabilitation Questionnaire 
(HARQ)85
The Attitudes Toward Loss of Hearing Questionnaire 
(ALHQ; Cienkowski & Pimentel, 2001) The Hearing 
Handicap Inventory for the Elderly (HHIE)
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Special Scales for the TB/HIV Syndemic
Separating co-occurring TB and HIV stigma can be challenging.88 A variant 
colloquially referred to as the ‘new/thin TB’ has emerged, which refers to people 
with TB/HIV coinfection.88,89 When TB and HIV disease symptoms are con"ated, 
the meaning of the individual diagnoses changes.88,90 In these situations, 
measuring both TB and HIV stigma using separate scales may not fully capture 
the local construct. 
 
When two diseases are indivisible, use the validated TB/HIV stigma scales. 
In South Africa, Wouters et al. developed a scale with three statements: ‘TB is 
a sign that someone has HIV,’ ‘Someone with TB has probably also got HIV,’ 
‘TB symptoms make HIV more noticeable. Each was rated on a four-point 
Likert scale indicating strong agreement, agreement, disagreement, or strong 
disagreement. 
They also tested how interlinked the stigmas are, as de!ned by the respondent 
(the Compound Stigma by the Respondent (CS-R)). The item ‘Someone who has 
TB should feel equally guilty about it as someone who has HIV’ was used and 
rated on a four-point Likert scale. 
Finally, Wouters et al. tested how interlinked HIV and TB stigmatization was 
perceived to be by colleagues (Perceived Compound Stigma by Colleagues 
(CS-C)). They used two items on a four point Likert scale: ‘People are afraid of 
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working together with someone who has TB because they think that the person 
also has HIV’ and ‘People with TB tend to be treated badly because they may 
have HIV.’ These items had good reliability and can be used in settings with a 
high TB and HIV prevalence rate.
Survey Questionnaire Length
The survey questionnaire may be long if many scales are included. To minimize 
respondent burden, use the shortest valid scales available. The instrument can 
be sub-divided and administered over several sessions, if necessary. As with any 
study, balance feasibility and comprehensiveness. 
Statistical Challenges of Intersectional Stigma 
Measurement
Latent Pro!le Analysis (LPA), latent class analysis, and moderational analysis are 
statistical approaches to dealing with the challenges of intersectionality. This 
person-centered statistical approach assumes that stigmas are associated with 
one another. These skills are beyond the scope of this guidance, as they require a 
sophisticated grasp of statistical methods. DeVellis’s Scale Development: Theory 
and Applications offers insights on these complexities.91
If you believe that TB stigma in your setting is moderated by other stigmas, but 
you want to detect the TB stigma signal, then you will need a larger sample 
size. If necessary, consult a statistician. Chapter 9 has guidance on sampling 
considerations for measuring TB stigma among stigmatized groups.
Conclusions
TB typically affects those who are devalued in society. TB stigma does not 
exist in a vacuum; its proper measurement requires attention to the many 
other forms of prejudice that affects people with TB. This chapter discusses 
an intersectional approach to syndemic stigma measurement. Despite the 
dif!culty in differentiating types of stigma, it is possible to detect harmful 
attitudes and behaviors attributable to TB stigma versus those caused by other 
biases, fears, and prejudice. Approaching stigmas as syndemic acknowledges 
interconnectedness, without con"ating them. This is a challenge for effective TB 
stigma measurement and reduction. This topic is an emerging !eld, and guidance 
will evolve as research continues. 
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Chapter 15
Measuring the Impact of TB stigma on 
Outcomes
Ellen M.H. Mitchell, Rajita Bhavaraju, and Lisa Redwood
Abstract
Preventing suffering in people with TB is a pillar of the END TB strategy.1,2 Yet, 
some stakeholders also want to know if TB stigma interferes with treatment 
completion and recovery, or if it contributes to death, before they will dedicate 
scarce resources towards addressing it. This implies that researchers should know 
how to measure the impact of TB stigma on health outcomes, which may be 
challenging. This chapter describes methods to quantify the consequences of TB 
stigma on TB treatment adherence and survival.
Objectives
1. To describe how to determine the impact of TB stigma on adherence behaviors 
and TB mortality.
2. To convey the importance of developing and operationalizing comprehensive 
theoretical frameworks.
3. To emphasize the methodological challenges and statistical considerations 
that must be addressed when studying the impact of stigma on adherence 
behaviors and outcomes.
Target Audience
This chapter is for readers with a social and behavioral science and/or 
epidemiological background who have a basic understanding of epidemiological 
and statistical concepts, such as sampling frames, sample size, confounding, and 
regression analysis, as well as forms of qualitative data collection and analysis. 
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Introduction
Stigma’s impact is widely felt, but poorly quanti!ed. Policymakers, ministries 
of health, and country coordinating mechanisms want to know the relative 
importance of stigma among the many challenges facing TB programs.
In Chapter 13, we introduced the justice enhanced cost-effectiveness analysis, 
which looks at TB stigma as a consequence of certain choices. In this chapter, 
we look at how TB stigma can cause speci!c consequences. Here we will de!ne 
stigma-related outcomes of TB diagnosis and treatment and provide possible 
standard de!nitions for measurement. We will also look at study designs, 
including mixed methods, for measuring stigma in the context of how it may 
affect TB outcomes.
A frequent critique of the TB stigma research to date has been its narrow focus 
on personal experiences of stigma, with little attention on how these experiences 
contribute to negative health outcomes. We believe that any mistreatment, 
denial of care or basic needs, and inability to fully enjoy one’s human rights 
is reason enough to measure and intervene on stigma. The fact that stigma 
hampers health outcomes can only strengthen the resolve of some stakeholders 
to help measure and reduce stigma.
The impact of stigma on TB treatment self-ef!cacy and adherence appears 
to vary widely by context, gender, and type of TB.3–5 Much of this variance is 
attributable to the diversity in measurement criteria and use of non-standardized 
de!nitions of stigma and adherence.6 However, it is plausible that different 
people react to stigmatization in different ways. Studies in Russia, Uganda, 
and Thailand found that perceived TB stigma increased patient treatment 
adherence.7–9 However, large studies in South Africa and Pakistan found stigma 
a signi!cant barrier to adherence.10–13 Small studies of fewer than 1,000 TB 
patients typically detected no effect.14 Two studies found women were more 
adherent to TB treatment when they perceive high levels of stigma, while men 
were less adherent, particularly if they found TB treatment humiliating.9,15 
It is likely that stigma impacts people’s treatment experience in different ways. 
Studies of TB stigma in Mexico, Malawi, Zambia, Tanzania, Lesotho, and South 
Africa have drawn attention to differential impact of TB stigma on men and 
women.16–22 Two studies found women were more adherent to TB treatment 
when they perceive high levels of TB stigma, while men were less adherent, 
particularly if they found direct observation of TB treatment humiliating.9,15 
There is also clear variation of stigma’s impacts among sub-populations (e.g., 
pastoralists and drug users).23,24
How does TB stigma affect 
TB patients’ self-care, 
adherence to treatment, 
retention in care, and 
infection control practices?
How does stigma 
contribute to death and 
disability?
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Challenges 
One of the challenges in determining the impact of stigma on TB care seeking, 
adherence, and mortality is that these outcomes are attributable to a wide 
variety of factors and are often multi-causal. Stigma can occur at multiple points 
in the patient pathway, so its cumulative impact is dif!cult to quantify.25,26 
There are also many possible confounders when measuring the true impact of 
TB stigma on an undesirable outcome.25 Measuring the relative in"uence of 
stigma on downstream outcomes almost always requires a large sample and a 
comprehensive questionnaire, making it a resource-intensive endeavor for both 
researcher and respondent.26
In this chapter, we will discuss possible methods to assess the role of TB stigma 
on treatment initiation, treatment adherence, and (near) mortality.
Assessing the role of TB stigma on treatment initiation 
and adherence
TB treatment initiation and adherence are very complex behaviors that have 
many factors and mediating in"uences.27,28 A comprehensive theoretical 
framework is necessary to study stigma.
Munro et al. provide a framework based on four categories of factors (structural, 
personal, health services, and social context.) See Figure 1.11
Figure 1. Model of Factors Associated with TB Treatment Adherence (Munro et al.)
Structural Factors: incorporating 
poverty, especially costs and !nancial 
burden, gender discrimination, law
Personal Factors: incorporating 
knowledge, beliefs, and attitudes 
towards treatment, interpretations of 
illness and wellness
Social Context: incorporating 
family, community and household 
support, including stigma
Health Service Factors: incorporating 
organization of care and treatment, 
disease progress and side effects
Note: 
      suggest a bi-directional relationship between factors. For example, health service interventions directed at patients are likely to in"uence patient 
adherence behavior through the !lter of “personal factors.” Similarly, patients’ interactions with health services are likely to be in"uence by their 
knowledge, attitudes, beliefs about treatment as well as their interpretations of illness and wellness.
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Figure 2. Factors In#uencing Pediatric TB Treatment Adherence (Weaver et al.)
Notes: The central circle which contains the adherence dimensions used by WHO is surrounded by the 5 main categories of relevant interventions. 
The factors that may promote treatment adherence are shown in blue boxes and factors that may threaten treatment adherence are in gray boxes. 
Therapeutic alliance refers to relationship-building between providers and patients.
A systematic review of the qualitative literature by Munro et al. identi!ed eight 
general categories of in"uences upon adherence to TB treatment:
1. Organization of treatment and care. 
2. Interpretations of illness and wellness.
3. The !nancial burden of treatment.
4. Knowledge, attitudes, and beliefs about treatment.
5. Law and immigration. 
6. Personal characteristics.
7. Treatment side effects.
8. Family, community, and household support.29
Adherence to drug-resistant (DR)-TB treatment has similar determinants, but 
the relative importance (rank) may be signi!cantly different.30 Stigma is often a 
more potent determinant of adherence in longer MDR-TB treatment regimens. 
Additional adherence challenges among DR-TB patients include:
1. Extended periods of isolation in some settings.
2. Extended length of treatment of certain regimens.
3. Toxic side effects of speci!c drugs that create disincentives for completion. 
4. Inaccessibility of health services, such as inconvenient operating hours.31–33 
 
A recent review of TB adherence for pediatric patients by Weaver identi!ed a 
more complex set of factors in"uencing adherence.34 TB stigma is only one of 
a myriad of issues, including caregivers that need to be carefully considered as 
moderators of adherence and in"uencers on treatment outcomes, even with 
good adherence.
Therapy
Psychosocial
Health System
Health System
Care Delivery
Patient
Condition
Education
Social/Economic
Social Protection
Social stigma of condition or treatment;
inadequate therapeutic alliance; mistrust
Social support; mobilizes
community resources;
coordinated
multidisciplinary care
Patient-centered service
locations and times; tracer
systems; adherence-sensitive
staff and management process
Family education;
adherence counseling;
contracting; patient
empowerment
Low literacy; limited
education; limited
self-ef!cacy
Support for food,
transportation, housing and
daily living; lower
out-of-pocket expenses
Food insecurity; distance from
health center; limited
and/or missed income
Limited provider knowledge; inadequate
communication or engagement; complex regimens
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PEOPLE WITH TB FREQUENCY AND SEVERITY OFEXPOSURE TO STIGMATIZATION
POTENTIAL
CONFOUNDERS
OBSERVABLE
PHENOMENA
HEALTH CARE
SOCIAL NETWORK
EMPLOYMENT
COMMUNITY
CHARACTERISTICS
Gender
Age
Class 
Ethnicity/caste/race
Self-ef!cacy
Resilience
Other disparaged
identities
1.   Quality of care
2.   Access to health facility 
3.   Availability of drugs
4.   Treatment regimen (length, 
      complexity)
5.   Cost of transport, care
6.   Opportunity costs of 
      adherence (time, money)
7.   Treatment literacy/Interpretation of 
      symptom resolution
8.   Tolerability of side-effects
9.   Co-morbidities (e.g., depression, 
      addiction, HIV, hepatitis)
10. Strength of supportive social 
      network
11. Social protections (laws, safety net) 
      to buffer consequences of 
      stigmatization
12. Other prevalent forms of 
      stigmatization, discrimination
HEALTH STATUS
Type of TB (drug susceptible,
resistant)
Severity of TB
Concealability of TB
TREATMENT
ADHERENCE
TB MORTALITY
OR
RECOVERY
Figure 3. Logic Model for a Study on the Role of Stigma on Treatment Adherence and Mortality 
Figure 3 is illustrative of the range of factors that would need to be measured 
along with stigma in order to determine the relative importance of stigma as 
a barrier to TB treatment adherence.
Important methodological considerations include:
1. What is the best de!nition of adherence? The WHO’s de!nition of ‘lost to 
follow-up’ (or TB treatment non-adherence) is “a TB patient who did not 
start treatment or whose treatment was interrupted for two consecutive 
months or more.”35 
2. How will adherence to TB medication be measured? By a self-reported 
measure of how many doses were missed? This is a very subjective question 
if asked directly to the patients (e.g., highly susceptible to recall and social 
desirability bias). 
3. Stigma should be measured using a validated tuberculosis stigma 
measurement scale that has been adapted to the local context (see Chapters 
5, 7, and 10).
To study the in"uence of stigma upon retention in care with any precision, one 
must be willing and able to trace those lost to follow up. This is an energy and 
resource intensive effort, but failure to reconnect with a representative sample of 
those lost to follow up introduces bias in the study sample. Plans for such a study 
should include suf!cient time, money, and energy for tracing. 
Prospective studies may be less biased than retrospective studies because one 
can include more address and social contact variables during the enrolment 
Failure to include those 
lost to follow-up and 
those treated in the 
private sector will lead 
to underestimates of 
the importance of TB 
stigma upon TB treatment 
outcomes.9,69,70
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Figure 4. The Comparative Advantages of Retrospective and Prospective study designs
process, and therefore improve the probability of !nding those lost to follow-up 
in the future. Prospective studies also better allow for capturing key information 
in a standardized manner. Prospective studies do take longer to conduct. The 
global target is successful treatment outcomes for at least 85% of the patients.36 
A relatively small proportion of patients being lost to follow-up will jeopardize 
this goal. A case-control approach is often used when an outcome is relatively 
rare, such as loss to follow-up.
Case control studies
To evaluate the in"uence of stigma on late diagnosis or loss to follow-up, a case 
control study design can be used.28 Case control studies are an ef!cient design 
when the outcome (e.g., non-adherence) is relatively rare. The case control 
study will examine the difference in stigma between the (smaller) number of 
TB patients lost to follow-up and the (larger) number of TB patients who were 
retained in care to see differences in stigmatization among TB patients that were 
lost to follow-up (“cases”) and a sample of those that completed treatment 
(“controls”). 
To discern the in"uence of stigma, it is vital to consider relevant confounders. 
This is done by ensuring that both the case and control groups are balanced 
or matched with regard to other drivers of adherence. The confounders would 
include the known in"uences on TB treatment adherence, such as access to care, 
co-morbidities (e.g., drug and alcohol dependence), and gender, (Figure 5).37
Feasibility
1. Completedness
2. Standardization
 3. Lower bias
Retrospective study 
designs gather data 
on the past
Prospective study 
designs gather data 
about the future
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GENDER
DISTRIBUTION
SOCIO-ECONOMIC
STATUS
DISTANCE TO CARE
CO-MORBIDITIES
Adherent to
TB Treatment
GENDER
DISTRIBUTION
SOCIO-ECONOMIC
STATUS
DISTANCE TO CARE
CO-MORBIDITIES
Non-adherent to
TB Treatment
Figure 5. Matching in a Case-Control Study
Planning a study of the impact of TB stigma on treatment initiation and 
adherence
1. Establish an operational and meaningful de!nition of your adherence 
outcome of interest, e.g. loss to follow-up.
2. Assess and strategize about how (and how soon) those patients lost to follow 
up can best be found (taking into consideration outmigration, death, etc.)
3. Based on the above, chose your study design (e.g., retrospective, 
prospective, case control)
4. Theorize all the determinants of loss to follow-up in your settings (literature 
review, formative interviews with persons lost to follow-up) and build your 
conceptual framework.
5. Operationalize the framework (i.e., decide how best to measure the 
determinants of loss to follow-up).
6. Size the study (e.g., determine the sample size) based on your estimate of 
the relative importance of TB stigma upon loss to follow-up.
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Table 1. Interview Guide for Treatment Adherence among TB Patients
Challenges
One challenge to the measurement of treatment adherence is social desirability 
bias. Many people with TB are well aware of the norms regarding TB treatment 
adherence. Therefore, it can be hard to ask about it directly. Moreover, in 
planning an intervention, it is often necessary to know why and how stigma 
discourages TB treatment adherence. This favors a qualitative approach.
Table 1 offers sample interview questions that were posed to TB patient 
participants recruited at health centers. These questions we used to identify 
the drivers and facilitators of TB stigma that contributed to loss to follow up or 
treatment non-adherence.11,14 Although researchers were interested to learn 
about the role of stigma on adherence, questions about stigma, exclusion, 
discrimination, or fear were not asked outright. An indirect approach prevented 
over-in"ation of the relevance of stigma in patients’ illness experiences, and 
misrepresentation of the components and drivers of TB stigma in the study 
setting. 
Topics Sample Questions
Ice breaker How are you feeling today?
Diagnostic Journey How did you feel when you learned you have TB?
Have you had TB before? Do you feel differently this time?
How did you become a patient at that clinic? How did you choose that 
clinic?
Perceptions What did you think about TB before you became ill? What about now?
Why do you think you got TB?
Health Care Tell me about your experience at that clinic. How do you spend your time 
there? 
Think about the last few times you came to that clinic. What do you think 
about the care you have received?
How did the nurses treat you? What about the doctors? 
What have they told you about your treatment?
If you feel unwell between appointments, what do you do?
If you wanted to change something, what would it be?
Social Circumstances Tell me a little about yourself and your life.
Who do you live with? How did they respond when you became ill? 
Have any of your family members also been treated because of your illness? 
If so, how did this make you feel?
Does anyone help you with your treatment (or accompany you to the 
clinic)?
How has your life changed since you became ill?
How are you managing your expenses?
Are you working or were you working before? How has that changed?
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Coping How are you dealing with your illness?
How about the demands of treatment? How does that go?
How do you feel – Physically? Emotionally?
What do you do when you feel tired or unwell? Who do you reach out to? 
(Who do you trust and why?)
What has been the hardest thing for you over the past few months/weeks?
What are your thoughts about the future? 
Has anyone discussed with you how TB is spread? How does this make you 
feel?
Participatory Probes 
(may be inserted 
throughout to elicit 
thick descriptions)
Can you tell me what happened next?
Can you tell me the reason why?
Can you tell me more about that?
How did this make you feel?
What did you do then?
Can you give me an example?
Think back to the last week…?
How has this changed over the last few months?
*Silence and non-lexical conversational sounds such as “mhm” or “uh-huh” 
are also helpful probes
Assessing the impact of TB stigma on TB mortality
 
High TB mortality rates are increasingly understood as an indicator of many 
different problems in the health system and community. Limited awareness of 
TB in society and restricted accessibility to care and/or quality of health services 
can hamper survival. Lack of insurance or permanent employment is a risk factor 
for TB mortality.38 Evidence suggests that co-morbid TB patients (i.e., those with 
HIV, hepatitis, diabetes, etc.) are particularly vulnerable when the quality and 
timing of clinical care services are suboptimal and/or diagnosis is delayed, not 
just because TB diagnosis may be more challenging in these persons, but due to 
compounded stigma.39–41 Exploration and analysis of death among TB patients 
can lead to a clearer and speci!c understanding of why deaths have happened 
and where stigma reduction interventions are likely to make the most difference. 
Stigma can contribute to life threatening situations and loss of life directly, but 
often the contribution is more distal, and harder to capture.25,26 Most research on 
predictors of TB mortality have chosen not to measure stigma.42 It is important 
to distinguish if stigma contributes to mortality but when and how it does so, 
because it will require a different set of corrective actions to reduce it. Below are 
consequences of stigma at different points along the patient pathway.
1. Delays or deciding not to seek care for TB symptoms (see Chapter 4).
2. Delays or failure to refer or diagnose with TB.
3. Delays or failure to provide correct TB drug treatment.
4. Delays or failure to provide appropriate TB treatment supports.
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5. Delays or failure to adhere to TB treatment.
6. Delays or failure to provide appropriate care for co-morbidities.
7. Low quality of acute care provided to a severely ill TB patient.
Insights into the person’s care-seeking itinerary (and the often-long chain 
of social, economic, and clinical events) that led to his/her life-threatening 
hospital admission can help us to decide where to focus improvement efforts. 
Approaching the problem at the individual level in the context of the patient-
centered approach can lead to improvement of the whole health care system. 
Sample questions include:
tAre certain types of TB patients avoiding the health care system because they 
feel unwelcome or have experienced mistreatment? 
t Is there a problem with availability, distribution, or accessibility of TB services?
tAre TB patients seeking care early, but not being referred to trained providers?
t Is the care that TB patients receive inadequate or sub-optimal?
The journey that people follow from initial infection to recovery or death has 
critical intervention points along the way. Any potential delays and challenges 
along this itinerary, including health seeking delays, poor accessibility of services, 
dif!culties in diagnosis or initiation of treatment, or challenges in coping with the 
many consequences of illness, can contribute to a negative outcome. 
Challenges in studying stigma and TB mortality
There are several methodological challenges to understanding the relationship 
between stigma and TB mortality.
1. Stigma’s effects on mortality can be dif!cult to pinpoint as they can occur all 
along the patient-pathway.25
2. There are so many predictors of TB mortality that samples and questionnaires 
must be comprehensive.
3. Death is an uncommon outcome among people diagnosed with TB. Most 
TB deaths are from people who are not diagnosed. And many deaths 
among people diagnosed with TB are not due to TB. Therefore, sample size 
requirements can be a challenge.
4. Identifying TB deaths is a challenge among people who die without a 
diagnosis.
Conceptualizing the impact of stigma
Given that TB mortality can have dozens of contributing causes, it is important 
to have a good conceptual model (See Figure 4). Stigma can be both a proximal 
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and a distal in"uence, felt both directly and indirectly during the disease 
process.25,26,43
Accounting for confounding impact of other in#uences 
on TB mortality
As with adherence studies, parsimonious measures of all the factors are essential 
to keep the data collection instruments a reasonable size. Qualitative data 
collection can add value and help elucidate some of these measures.
Sample size considerations for a mortality study
The necessary sample size of a valid study tends to exceed 300.44 This is a 
major feasibility consideration for TB programs seeking timely information for 
policy and planning. Large samples of people who die from TB is a challenge, 
even though TB is the leading infectious cause of death in the world. Death is 
a rare outcome of TB disease among those who are diagnosed and provided 
effective treatment. The rarity of deaths among those with treated TB disease 
makes evaluating the role of stigma in TB mortality very challenging for most TB 
programs. 
 
Identi!cation of TB deaths 
It is challenging to identify people who die from TB without being diagnosed. 
Most of the established methods of identi!cation, such as verbal autopsy, do not 
work well for TB because the symptoms are non-speci!c.45,46 It is rarely practical 
to measure the impact of TB stigma on TB mortality by only interviewing families 
who have experienced a loss. Families with a TB death often dissolve, move, or 
simply do not wish to participate.47,48 
An alternative to study mortality directly: near miss 
audit
A more feasible proxy for mortality is to conduct a near miss audit, as is done 
routinely in the !elds of maternal mortality, air transport, and workplace 
safety.49–53 A near miss is de!ned, for the purposes of TB stigma assessment, 
as a person with TB in serious life threatening condition or with a high risk of 
imminent death. 
The study of emergencies often catalyses action by highlighting speci!c gaps 
in care. The use of near-miss methods in maternal health has led to concrete 
improvements and declines in maternal mortality. The use of near miss audits 
in maternal mortality led to the counter-intuitive conclusion that investing in 
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improvements in antenatal and primary care would have only marginal impact 
on maternal mortality.54,55
The methods can be used at the facility, district, state, or national levels. The 
major disadvantage of using near miss is that you will not capture the impact of 
stigma on those who never seek care.49 Thus, even with a large sample, you will 
never be able to generalize to all who were negatively impacted by stigma at the 
community level, and the study probably will exclude those most inhibited by 
stigma. There may be delays in interviewing near-miss patients due to extent of 
illness.
Figure 6. Relative Size of the Population with Acute TB Complications versus Those Who Die from 
TB
People who die from TB
People who are hospitalized
with a life threatening 
condition due to TB
People with TB
De!nitions of a TB near miss
The term “life threatening condition” needs to be strictly de!ned and agreed 
upon by all stakeholders. It is important to adopt a speci!c de!nition of near 
miss for adults and children, as severe disease manifests very differently. For 
example, oxygenation is only of limited utility in judging severity in many 
pediatric respiratory conditions.
Common measures of imminent mortality that have been used in TB mortality 
studies include:
tAcute Physiology and Chronic Health Evaluation II (APACHE II).56–61 
t Sequential Organ Failure Assessment (SOFA) scores.58,62
For low resource settings, simpler scales may be more feasible. The Tropical 
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Intensive Care Score, (TropICS) includes emergency surgery, respiratory rate, 
systolic blood pressure, Glasgow Coma Scale, and blood urea, and hemoglobin 
is fairly accurate and requires few tests. There is a 95% con!dence interval (CI), 
AUC 0.767 (0.741-0.792).61
To observe the role of stigma in TB-HIV client mortality, one could use urine 
LAM positivity as the de!nition of a TB-HIV case at high-risk for mortality.63,64 
Positive urine-lipoarabinomannan (LAM) status was strongly associated with 
mortality at 90 days (adjusted hazard ratio 4.2; 95%CI 1.50-11.75) in adult 
PLHIV in South Africa. LAM-positive PLHIV adults had a three-fold risk of death 
within 12 months (3.58 mortality hazard ratio (95% CI, 1.26-6.73). Urine LAM 
is a point of care screening tool for TB in acutely ill PLHIV.
Accounting for multiple stigmas upon TB mortality
As discussed in Chapter 14, TB stigma is unlikely to be the only stigma negatively 
affecting people at high risk of mortality. In some settings, deaths are more 
common among TB patients with multiple stigmatized co-morbidities.65 
Planning a near miss investigation
The following steps should be taken when conducting a near miss:
1. Establish the purpose of the study and which methodology to use.
2. Decide how to de!ne a near miss in the context of the chosen review. 
3. Develop a consensus on the threshold for the near-miss cases to be 
reviewed.
4. Consider how to identify eligible cases of near miss TB.
In order to analyze TB deaths and improve TB services, look at the antecedents, 
health seeking behavior, and perceptions of care provided to review the timing 
and quality of care in health facilities. Exploring the same patient’s experience 
from two different points of view can reveal much more than simply a one-
sided record review, especially when records are poorly kept, poorly designed, or 
entirely absent.
Health
Seeking
Delay
Referral
Delay
Diagnostic
Delay
Treatment
Delay
Low
Quality
of Care
Near
Miss
Figure 7. TB Stigma as a Contributor to Near Misses
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Method
Successful implementation of the TB near miss audit depends on fostering a 
climate of con!dentiality and trust. Using a non-punitive, non-threatening, 
inquisitive approach to describe and analyze the factors leading to adverse 
outcomes is essential. 
Both health care and community workers and family members should be 
assured that the sole purpose of the audit is to learn valuable lessons and to 
save lives. These reviews seek only to identify barriers to accessing and receiving 
quality care in the health care system. They must never be used for litigation, 
management sanctions, or personnel decisions.66
The combined !ndings of the Community-based Near Miss Review (CBNMR) 
and the Facility-Based Near Miss Audit (FBNMA) should be used by local 
change agents:67 This includes people with the power and commitment to 
improve health care quality and access (e.g., administrators, district leadership, 
activists). The tools are not intended strictly for use by researchers, but rather 
by multidisciplinary stakeholder teams committed to reducing mortality and 
morbidity among TB patients. The change process can be similar to the WHO 
Strategic Approach in that it is a participatory process with stakeholders who 
have diverse research, policy, clinical, and community skills.68
FHI 360 has also published international research ethics training materials 
in English, Spanish, French, and Portuguese, which can help the team to 
understand the ethical dimensions of a near-miss audit. A key principle for 
effective near miss audits is “no name, no blame, no shame.”66
https://www.fhi360.org/resource/research-ethics-training-curriculum-retc-
second-edition
For a word version of the Community-based Near Miss Review (CBNMR) and 
Facility-Based Near Miss Audit (FBNMA) tools, as well as methodology advice on 
how to carry out an audit, please refer to the Lessons from Loss manual (See also 
Appendix 1). 
https://www.challengetb.org/publications/tools/hss/Lessons_from_Loss.pdf
Conclusion
In this chapter we have outlined the key steps in measuring the consequences of 
stigma so an appropriate response can be mounted. To determine if TB stigma 
is a major contributor to non-adherence, sequelae, or mortality, a very careful 
study design and a robust sample size is required. When measuring TB stigma to 
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determine if it is a barrier to treatment, it is important to include (and control for) 
all other possible barriers to treatment adherence. 
The main advantage of studying TB stigma among near misses rather than 
among TB patient who have died (via mortality audits or case reviews) is that 
the complications of TB occur much more frequently than TB deaths, enabling a 
more appropriate sample size to be generated. 
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Appendix 1: Illustrative Instrument for Gathering Data from Families 
on Factors that In#uence Non-Adherence and Mortality
This is for co-habitants or witnesses to the care of the person with TB.
I am…………………and this is…………………. who will help me by taking notes during this 
interview. We want to have this discussion so that we can learn your ideas and opinions to improve 
the care of people with TB in the future. By listening to families, we can better understand what it 
was like for [insert name] and your family. We hope that by talking with you, we can learn how to 
avoid the challenges that you have faced.
Sometimes it is dif!cult to be open, especially when you are being asked about how other people do 
their work or when talking about sad times. However, I hope you can be open and honest with me, 
because what you have to say can help others. Your information will be combined with the interviews 
of many other families, and your names will never be used. If you feel uncomfortable, we can take a 
break and return later. You may end this interview at any point and no one will be angry with you.
Because there will be a lot of information that I will not be able to remember or write down, I would 
like to tape record this discussion. If you do not feel comfortable with that, it is OK for me to take 
notes only.
1. Community code: [__][__]
2. Date of interview: [__][__]/[__][__]/[__][__]
3. Field worker code: [__][__]
4. Relationship to the patient of respondent:
 Spouse
 Mother/father
 Brother/sister
 Son/daughter
 Other household member
 Other (specify) ______________________________
SOCIO-DEMOGRAPHIC DATA
5. Date of Birth of PWTB  [__][__]/[__][__]/[__][__]
6. Gender:  Female Male  Transgender
7. Age of the PWTB (in years)        [__][__]
8. Education level of PWTB:   Include relevant categories  [__][__]
9. Occupation of PWTB: (adapt as required) Include relevant categories  [__][__]
10. What was PWTB’s main tribe/ethnicity? Include relevant categories  [__][__]
11. What was PWTB’s religion (if any)?  Include relevant categories   [__][__]
12. PWTB’s marital status    If relevant, include categories [__][__] 
13. What do you think caused the problem that led to [insert name]’s hospitalization?
14. When did this problem start? [__][__]/[__][__]/[__][__]
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15. Why do you think the illness started when it did?
16. What do you think the sickness does to people who have it? How does it work?
17. Were there any particular reasons why [insert name] got [insert name of sickness]? 
Do not read out the list. Tick any risk factors if mentioned by the respondent:
 HIV co-infection
 Diabetes
 Child under !ve years
 Elderly 
 Pregnancy/postpartum
 Mentally ill
 Alcohol-addicted
 Drug-addicted
 Smoker
 Malnourished
 Previously treated for  
 TB
 Miner
 Factory worker
 Resident of an urban  
 slum
 Former prisoner or   
 prison staff
 Healthcare worker 
 Soldier 
 Refugee or internally  
 displaced (IDP)
 Marginalized man who  
 has sex with men
 Sex worker
 Transgender
 Migration
 Indigenous 
 Homelessness
 Orphan or vulnerable  
 child
 Other(specify):__________
 _______________________
 Not known_____________
SYMPTOMS OF TB (and HIV)
18. From the time [insert name] started feeling ill, what health complaints did he/she have, and when 
did those start? 
(Interviewer: First ask for the symptoms, then probe for the dates. Tick all options mentioned. 
DO NOT PROBE for symptoms, only for the dates! If exact date unknown: beginning of month=07, 
mid-month=15, end of month = 22, if part of the month entirely unknown =99)
Symptom Tick all options 
mentioned 
Date symptom started: 
dd/mm/yy
19. = Cough a. [__][__]/[__][__]/[__][__]
20. = Production of sputum b. [__][__]/[__][__]/[__][__]
21. = Chest pain c. [__][__]/[__][__]/[__][__]
22. = Haemoptysis (coughing blood) d. [__][__]/[__][__]/[__][__]
23. = Fever e. [__][__]/[__][__]/[__][__]
24. = Night sweats f. [__][__]/[__][__]/[__][__]
25. = Weight loss g. [__][__]/[__][__]/[__][__]
26. = Breathlessness h. [__][__]/[__][__]/[__][__]
27. = Fatigue i. [__][__]/[__][__]/[__][__]
28. = Loss of appetite j. [__][__]/[__][__]/[__][__]
29. = Headache k. [__][__]/[__][__]/[__][__]
30. = Body pains l. [__][__]/[__][__]/[__][__]
31. = Other, specify ……………………code [__][__] m. [__][__]/[__][__]/[__][__]
32. = Other, specify ……………………code [__][__] n. [__][__]/[__][__]/[__][__]
320
[Note: If the exact date is not known, probe for an estimate. This information is critical. You can often 
use community events as a reference for probing, for example, by asking if the person developed 
symptoms before or after a commonly observed event/occurrence, such as recent elections, harvest 
time, religious celebrations, rainy season, etc., and how many weeks before or after the event.]
33. In addition to the hospitalization of [insert name] has the sickness caused other problems for your 
family? 
HEALTH SEEKING BEHAVIOR
Now, I would like you to name all the persons, clinics or hospitals that [insert name] visited for care 
about [insert name]’s sickness and the investigations done at each, if any.
Repeat the questions below until all providers have been mentioned and discussed. Before moving 
on to other topics, con!rm the order of the providers attended. A provider may include any sort of 
care provider, including: shop, pharmacy, traditional healer, hospital, private clinic, or community 
health volunteer. Note: if the family member has any medical records available, and agrees that the 
interviewer can see those records, they can be used to verify the information (e.g., date of clinic 
visits, investigations done, etc.)
Provider Date of !rst visit Test(s) done
Amount spent 
(excluding 
transport)
Date sputum 
and/or 
chest X-ray 
performed
Categories:
1=hospital/health 
center/dispensary
2=private clinic, 
3=herbalist
4=pharmacy 
5=community health 
volunteer
6=lay person
7=other
If exact date 
unknown: beginning 
of month=07, mid-
month=15, end of 
month = 22 part of 
month completely 
unknown=99
Tick all answers that apply; Do NOT 
record Medical History or Physical 
Examination 
A. Cash: exact 
amount.
Can’t remember 
=99999
Free/no cash =00000
B. In-kind
1=yes
2=no 
9=don’t know
Very important
34. (full name 
of provider) 
____________
35. Category: [__]
36. [_][_]/[_][_]/
[_][_] 
dd/mm/yy
37. [_]Physical exam 
38. [_]Sputum 
39. [_]Chest X-ray
40. [_]Blood test 
41. [_]Biopsy
42. [_]Referred for test(s) 
43. [_]Other: (specify):………..
44. [_][_][_][_][_] 
45. B. [_]  
…………..…
46. Code[_],[_]
47. [_][_]/[_][_]/
[_][_] 
dd/mm/yy
48. (full name of 
provider) 
__________
49. Category: [__]
50. [_][_]/[_][_]/
[_][_] 
dd/mm/yy
51. [_]Physical exam 
52. [_]Sputum 
53. [_]Chest X-ray
54. [_]Blood test
55. [_]Referred for test(s) 
56. [_]Other: (specify):………..
57. [_][_][_][_][_] 
58. B. [_]  
…………..…
59. Code[_],[_]
60. [_][_]/[_][_]/
[_][_] 
dd/mm/yy
61. (full name of 
provider)  
__________
62. Category: [__]
63. [_][_]/[_][_]/
[_][_] 
dd/mm/yy
64. [_]Physical exam 
65. [_]Sputum 
66. [_]Chest X-ray
67. [_]Blood test 
68. [_]Referred for test(s) 
69. [_]Other: (specify):………..
70. [_][_][_][_][_]
71. B. [_] 
…………..…
72. Code[_],[_]
73. [_][_]/[_][_]/
[_][_] 
dd/mm/yy
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We are now going to talk about health facilities [insert name] he/she may have visited and how she/
he went to the facility. Please give us the exact !gures as much as possible.
A. What are the available transport means from [insert name]’s house to the facilities where [insert 
name] went for TB test and/or treatment?
B. What is the cost one way?
C. How long did it take him/her?
A. Transport Means B. Cost (one way) C. Duration
Insert relevant categories 
[e.g., bus =1, bike= 2]
Currency 1=≤10 minutes
2=10-30 minutes
3=31-59 minutes
4=1-2 hours
5=> 2 hours
99=don’t know
74. [_] 75. [_][_][_] 76. [_][_]
77. [_] 78. [_][_][_] 79. [_][_]
80. [_] 81. [_][_][_] 82. [_][_]
83. Is this facility where [insert name] was getting TB treatment the nearest to his/her residence? 
1=Yes, 0=No, 9=Don’t know  [__]
84. If no, why did [insert name] attend this facility but not the one nearest to him/her?
85. Did [insert name] consider going to the hospital earlier than he/she did? 
1=Yes, 0=No, 9=Don’t know  [__]
If yes, what were reasons that [insert name] didn’t go earlier?
Verbatim: ______________________________________________________________________________
_______________________________________________________________________________________
_______________________________________________________________________________________
_______________________________________________________________________________________
Do not read the options to the participant. Only probe by asking: “Were there any other reasons?” 
Tick all mentioned options (1=yes, 2=no, 9=don’t know)
86. Money factor (specify) [_]
87. No money for transport to facility [_]
88. No money to pay at the hospital [_]
89. Illness did not seem serious [_]
90. He/she did not know what illness s/he had [_]
91. Self-treatment effective [_]
92. TB thought to be without cure [_]
93. Natural/environmental issue- rains, snow, harvest, earthquake [_]
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94. Sought traditional/herbal remedies [_]
95. Fear of VCT/HIV testing [_]
96. Fear of hospital overnight admission [_]
97. Fear of injection [_]
98. Cause of problem was non-medical (witchcraft, curse, fate) [_]
99. Distance to health facility [_]
100. Long waiting in queues [_]
101. No one to assist in family [_]
102. Co-morbidity (e.g., drug-use, alcoholism, mental illness, etc.) [_]
103. Bad experience with health care system ………………………………………… [_]
104. Family opposition [_]
105. Child care responsibilities [_]
106. Fear of loss of employment [_]
107. Religious prohibition [_]
108. Civil strife, war, danger, crime [_]
109. How many visits to the formal health care system were made before TB was diagnosed?
For each provider, what kind of treatment was given?
Provider (See question 30 and record names in 
the same order)
Type of treatment
110.  111.  
112.  113.  
114.  115.  
116. What kind of treatment do you think [insert name] should have received? 
117. If TB treatment was provided, did [insert name] take the TB treatment every day?
 1=yes, 0=no, 3=don’t know  [__]
118. Probe: Why not?
Verbatim: ______________________________________________________________________________
_______________________________________________________________________________________
_______________________________________________________________________________________
_______________________________________________________________________________________
119. Feared side effects    1=yes, 0=no 7=n/a [__]
120. Couldn’t afford    1=yes, 0=no 7=n/a [__]
121. Didn’t want to go to clinic for DOT 1=yes, 0=no 7=n/a [__] 
122. What do you think [insert name] hoped would happen after taking this treatment?
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COMMUNITY CARE AND SUPPORT
123. Did the [insert name] receive any kind of extra   
 support from the TB program or the community to  
 help get better?
1=yes, 0=no (skip to #134), 9=I 
don’t know 
[__]
What treatment support did the PWTB receive?
124. Food support? 1=yes, 0=no 7=n/a [__]
125. Financial support? 1=yes, 0=no 7=n/a [__]
126. Micro!nance? 1=yes, 0=no 7=n/a [__]
127. Home-visits by health care provider? 1=yes, 0=no 7=n/a [__]
128. Counseling? 1=yes, 0=no 7=n/a [__]
129. Treatment reminders (SMS)? 1=yes, 0=no 7=n/a [__]
130. Transport reimbursement? 1=yes, 0=no 7=n/a [__]
131. Treatment supporter? 1=yes, 0=no 7=n/a [__]
132. Legal aid 1=yes, 0=no 7=n/a [__]
133. Other (specify) 1=yes, 0=no 7=n/a [__]
AWARENESS OF TB
134. How can a person prevent getting infected with TB? (Do not read answers out loud.) Tick all 
options mentioned.
Verbatim: ______________________________________________________________________________
_______________________________________________________________________________________
_______________________________________________________________________________________
_______________________________________________________________________________________
135. Opening the windows at home [__]
136. Covering mouth and nose when coughing or sneezing [__]
137. Avoid sharing dishes/utensils [__]
138. Purify water [__]
139. Washing hands [__]
140. Closing windows [__]
141. Abstaining from sexual contact [__]
142. Pray regularly [__]
143. Other (please explain): [__]
144. Do all people who get infected with TB eventually develop TB disease? 
 1=yes, 0=no, 9=don’t know
[__]
145. Why do some develop the disease and some do not develop the disease? 
Verbatim: _________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
How can a person who is already infected with TB reduce their risk of developing TB disease? 
(Do not read answers out loud)
146. Prayer [__]
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147. Avoid alcohol, drugs and/or smoking [__]
148. Use a bed net [__]
149. Eat healthy food [__]
150. Avoid infection with HIV [__]
151. Take antiretroviral medicines if they have HIV [__]
152. Take medicines that prevent development of TB disease (IPT) [__]
153. Avoid people who are sick [__]
154. Other (specify) [__]
What are the signs and symptoms of TB? (Do not read answers out loud)
155. Rash [__]
156. Cough that lasts longer than two weeks [__]
157. Coughing up blood [__]
158. Severe headache [__]
159. Nausea [__]
160. Weight loss [__]
161. Fever without clear cause that lasts longer than two weeks [__]
162. Chest pain [__]
163. Shortness of breath [__]
164. Night sweats that lasts longer than two weeks [__]
165. Ongoing fatigue [__]
166. Other (specify) [__]
167. With effective medicines, can TB be cured? 1=yes, 0=no, 9=don’t know [__]
168. What is needed to cure someone of TB? 
Verbatim: _________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
169. How long does it usually take to cure TB?
 1=Between 1-5 months
 2=Between 6-12 months
 3=Between 13-24 months
 9=Do not know
 7=TB has no cure
[__]
170. Once a PWTB has taken TB treatment daily for a month, are they still a risk of giving  
 the disease to other people when they cough?
[__]
171. Do you think you personally could get TB?
 1. Yes
 0. No
 9. Do not know
 4. Has (had) TB now
[__]
172. Where are the places you might go for care if you had symptoms of TB? (Please tick all   
 mentioned, but do not read)
173. Go to a public health clinic or hospital [__]
174. Go to a pharmacy [__]
175. Go to a traditional healer [__]
176. Go to a chemical seller [__]
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177. Go to a private clinic [__]
178. Go to a pastor or religious leader [__]
179. Other [__]
If you would not go to the public health clinic, what is the reason? (Please tick all that apply)
180. Not sure where to go [__]
181. Cost [__]
182. Dif!culties with transportation/distance to clinic [__]
183. Do not trust medical workers (con!dentiality) [__]
184. Do not like attitude of medical workers [__]
185. Cannot leave work (overlapping work hours with medical facility working hours) [__]
186. Do not want to !nd out that something is really wrong [__]
187. Other (please explain) [__]
Now we would like you to think about the community where you live. I will read some statements 
aloud, and ask you to judge how much you agree or disagree.
 
Strongly 
agree
Agree Disagree
Strongly 
disagree
188. Some people may not want to eat or drink 
with friends who have TB 
189. Some people feel uncomfortable about 
being near a person who has had TB 
190. Some community members will behave 
differently towards that person for the rest 
of their life 
191. Some people do not want those with TB 
playing with their children 
192. Some people keep their distance from 
people with TB 
193. Some people think that those with TB are 
disgusting
194. Some people do not want to talk to others 
with TB 
195. Some people are afraid of those with TB
196. Some people try not to touch others with TB 
197. Some people may not want to eat or drink 
with family members who have TB
198. Prefer not to have people with TB living in 
their community
199. In your opinion, what should be done to solve the TB problem in this community?
200. Who should be doing these activities? (If not speci!ed)
201. What role can the community play in solving the TB problem? (If not mentioned)
Thank the participant and tell her/him that their contribution has been very valuable. Emphasize that 
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this information will be kept con!dential and will only be used to improve the care of future patients.
Make sure to give extra time to go over some of the misconceptions that were discussed. A TB 
factsheet could be handed out, but where literacy is an issue, talking with the people further would 
be more effective. 
Remember that the household members of a TB case who has passed away are probably in need of 
TB screening themselves.
Consider bringing screening tools and equipment to offer free diagnosis and treatment.
Appendix 2: Illustrative Instrument for Gathering Data from Facilities 
on Factors that In#uence Non-Adherence and Mortality
Questions are written in normal font, interviewer instructions in Italic, instructions on skip patterns 
are underlined.
202. Facility code:        [__][__]
203. Date of audit:       [__][__]/[__][__]/[__][__]
204. Field worker code:       [__][__]
DEMOGRAPHIC AND BASIC CLINICAL DATA FROM RECORDS OR FROM CLINICAL STAFF WHO 
TENDED THE PWTB, THE TB CLINICAL RECORDS AND THE TB REGISTER
205. PWTB Initials:       [__].[__].
206. Date of birth:        [__][__]/[__][__]/[__][__]
207. Gender: Female Male  Trans
208. Age of the PWTB (in years):  (if infant, use decimal)  [__][__]
RISK FACTORS AND VULNERABLE GROUPS
209. Which (if any) risk factors did this PWTB have in his/her chart? Tick all that apply
 HIV co-infection
 Diabetes
 Child under !ve years
 Elderly 
 Pregnancy/postpartum
 Mentally ill
 Alcohol-addicted
 Drug-addicted
 Smoker
 Malnourished
 Previously treated for  
 TB
 Deep pit miner
 Factory worker
 Residence in an urban  
 slum
 Former prisoner or   
 prison staff
 Healthcare worker 
 Soldier 
 Refugee or internally  
 displaced (idp)
 Contact of a TB case
 Marginalized man who  
 has sex with men
 Sex worker
 Transgender
 Migration
 Indigenous 
 Homelessness
 Orphan or vulnerable  
 child
 Other(specify):__________
 _______________________
 Not known_____________
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TIMING OF SYMPTOMS OF TB
210. From the time this PWTB started feeling ill, what health complaints (symptoms) did he/she have, 
and approximately when did those start? 
(Interviewer: First ask for the symptoms, then probe for the dates. Tick all options mentioned. 
DO NOT PROBE for symptoms, only for the dates. If exact date unknown- !ll in: beginning of 
month=07, mid-month=15, end of month=22, if part of the month entirely unknown=99.)
Symptom Tick all options 
mentioned 
Date symptom started: 
dd/mm/yy
211. = Cough a. [__][__]/[__][__]/[__][__]
212. = Production of sputum b. [__][__]/[__][__]/[__][__]
213. = Chest pain c. [__][__]/[__][__]/[__][__]
214. = Haemoptysis (coughing blood) d. [__][__]/[__][__]/[__][__]
215. = Fever e. [__][__]/[__][__]/[__][__]
216. = Night sweats f. [__][__]/[__][__]/[__][__]
217. = Weight loss g. [__][__]/[__][__]/[__][__]
218. = Breathlessness h. [__][__]/[__][__]/[__][__]
219. = Fatigue i. [__][__]/[__][__]/[__][__]
220. = Loss of appetite j. [__][__]/[__][__]/[__][__]
221. = Headache k. [__][__]/[__][__]/[__][__]
222. = Body pains l. [__][__]/[__][__]/[__][__]
223. = Other, specify ………………code [__][__] m. [__][__]/[__][__]/[__][__]
224. = Other, specify ………………code [__][__] n. [__][__]/[__][__]/[__][__]
TB DIAGNOSIS AND MANAGEMENT
225. Date that the PWTB !rst sought medical attention for symptoms? 
09/09/99 if unknown
[__][__]/[__][__]/[__][__]
226. How many visits to the formal health care system were made 
before TB was diagnosed?
99=don’t know
[__][__]
227. Why was the TB investigation initiated? (choose 1)
1=PWTB sought care for TB symptoms 
4=Active case-!nding/screening 
2=Routine screening of an HIV+ client 
5=Other (specify): ………………………….. 
3=Referral from other health facility 99=don’t know
[__][__]
Physical exam !ndings   1=yes, 0=no, 99=don’t know [__][__]
Chest X-ray     1=yes, 0=no, 99=don’t know [__][__]
Sputum sample(s)    1=yes, 0=no, 99=don’t know [__][__]
Needle aspirate    1=yes, 0=no, 99=don’t know [__][__]
Urine LAM     1=yes, 0=no, 99=don’t know [__][__]
Other (specify, below)   1=yes, 0=no, 99=don’t know [__][__]
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Specify _______________________________________________________________________________
_____________________________________________________________________________________
_____________________________________________________________________________________
228. Was TB diagnosis con!rmed mycobacteriologically? [__][__]
229. If yes, how was TB diagnosis con!rmed? (tick all that apply) [__][__]
a. Con!rmed by smear microscopy  1=yes, 0=no, 99=don’t know
b. Con!rmed by liquid or solid culture  1=yes, 0=no, 99=don’t know
c. Con!rmed by GeneXpert/Rif  1=yes, 0=no, 99=don’t know
d. Con!rmed by urine LAM   1=yes, 0=no, 99=don’t know
[__][__]
230. Date that the TB diagnosis was made? 09/09/99 if unknown [__][__]/[__][__]/[__][__]
231. Type of TB? 
1=PTB S+, 2=PTB S-,3=EPTB 99=unknown
[__][__]
232. New or retreatment case? 
1=new, 2=relapse, 3 failure, 4= return after default, 5=other, 
99=unknown
[__][__]
233. Date when the PWTB was noti!ed of his/her TB diagnosis? 
(07/07/77 if not noti!ed, 09/09/99 if unknown)
[__][__]/[__][__]/[__][__]
234. Date when TB treatment started? [__][__]/[__][__]/[__][__]
235. If TB treatment was never started, what was the main reason? 
1=Drug stock out, 2=TX Consultations needed, 3=PWTB refusal, 
4=Early death, 5= Contraindication, 6=Not authorized to dispense 
TBTX, 7=Waiting list for TB TX, 8=Other
[__][__]
236. What were the other reasons? (if any) [__][__]
237. If TB treatment started more than 48hrs after TB diagnosis, what 
was the main reason? 
1=Drug stock out, 2=TX Consultations needed, 3=PWTB refusal, 
4=Early death, 5= Other
[__][__]
238. What were the other reasons? (if any) [__][__]
239. Did the PWTB have drug-resistant TB? 
1=yes, 0=no, 99=unknown
[__][__]
240. Which TB Treatment regimen was the PWTB following? 
1= Cat I, 2=Cat II, 3 =Other, 99=Unknown, 77=NoTX
[__][__]
241. Were sputum samples taken and examined at the appropriate 
times? (i.e., at two months and !ve months)  
1=yes, both times 0=no, 3= once only, 77=not applicable 
[__][__]
242. Was the PWTB started on retreatment regimen if the !ve months 
sputum was positive?  
1=yes, 0=no, 77=not applicable 99=don’t know
[__][__]
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243. How was TB treatment adherence?
1=Fully adherent (more than 90% of doses taken)
2=Between 70%-90% of doses taken
3=Less than 70% of doses taken
77=not applicable, treatment had just begun
99=unknown
[__][__]
244. What other PWTB factors (if any) impacted quality of TB care?
1=Language barriers, 2= Staff shortage,3= Collaboration challenges, 
4=Lack of family/supporters, 5=Other, 77=Not applicable, 99=Unknown
[__][__]
HIV DIAGNOSIS AND MANAGEMENT
245. Under what circumstances was the HIV test conducted?
1=PICT of TB PWTB, 2=VCT, 3=Part of clinical work-up, 99=Unknown, 
5=PWTB already known to be HIV+
[__] [__]
Date that a blood sample(s) was taken for HIV test [__][__]/[__][__]/[__][__]
246. What was the HIV test result?
1=HIV positive, 2=HIV negative, 3=In determinant, 88=Not tested, 
99=Missing result
[__] [__]
247. Date that the HIV diagnosis was made? 09/09/99 if unknown [__][__]/[__][__]/[__][__]
248. Date of HIV post-test counseling (09/09/99 if unknown) [__][__]/[__][__]/[__][__]
249. Was anti-retroviral therapy (ART) started in hospital or was the 
PWTB on ART when diagnosed with TB?
1=yes, 0=no (skip to #), 3=already on ART, 99=unknown
250. Date when ART was started?
07/07/77= HIV NEG
08/08/88=not tested
09/09/99= unknown
[__][__]/[__][__]/[__][__]
251. If ART was not started, what was the main reason?
1=Drug stock out, 2=TX Consultations needed, 3=PWTB refusal, 
4=Early death, 5= Contraindication, 6=Not authorized to dispense ART, 
7=Waiting list, 8=Other
[__] [__]
252. Other reasons for no ART provision to HIV+ TB PWTBs
253. How consistently was ART taken?
1=Fully adherent (at least 90% of doses taken)
2=Between 70%-90% of doses taken
3=Less than 70% of doses taken
77=No ARTs started, 99=Unknown
[__] [__]
254. Was Cotrimoxazole (CPT) started?
1=yes, 0=no, 77=not applicable: HIV NEG,
88=not tested, 99=missing
[__] [__]
255. When was Cotrimoxazole started? [__][__]/[__][__]/[__][__]
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256. If Cotrimoxazole was not started, what was the main reason?
1=Drug stockout, 2=TX Consultations needed, 3=PWTB refusal, 4=Early 
death, 5= contraindication, 6=not authorized to dispense ART, 7=waiting 
list, 8=other
[__] [__]
257. Result and date of latest CD4 count before discharge/death? 
999=if unknown (09/09/99 if unknown)  [__][__] [__]   [__][__]/[__][__]/[__][__]
258. Was HIV diagnosed before TB? [__] [__]
259. If yes, was client prescribed Isoniazid preventive therapy (IPT)? [__] [__]
260. If no, why not?
261. What other factors in"uenced HIV care?
CLINICAL CARE IN HOSPITAL
262. Date of admission to hospital? (09/09/99 if unknown) [__][__]/[__][__]/[__][__]
263. Was PWTB weighed upon admission?
1=yes, 0=no,99=unknown
[__] [__]
264. What was PWTB’s body weight at admission [__] [__]
265. CD4 count at admission (9999=if unknown [__] [__] [__] [__]
Indicate the total number of times the following tests were performed between admission and 
discharge/transfer/death?
266. Body weight measured [__] [__]
267. Respirations measured [__] [__]
268. Pulse measured [__] [__]
269. Blood pressure taken [__] [__]
270. Temperature measured [__] [__]
271. Chest sounds measured [__] [__]
272. Hemoglobin/Anemia measured [__] [__]
273. Other diagnostic blood tests [__] [__]
274. Liver function tests [__] [__]
275. Urine Tests [__] [__]
276. Chest X-ray performed [__][__]
277. How long was the largest time span between clinical assessments by 
a clinician? 
In hours
[__][__] [__]
278. Were signs of worsening condition noted? (tick yes if respiration 
rate>30/min, pulse>120/min, or temperature >39ºC, or other 
unstable vital) 
1=yes, 0=no, 99=unknown
[__][__]
279. Were actions taken to address the worsening condition? 
1=yes, 0=no, 99=unknown
[__][__]
Which actions were taken?
280. 
281. 
282. 
283.  
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284. How much time elapsed between worsening was noted and when 
action was taken? (in hours)
[__][__]
285. Were treatment complications identi!ed? 
1=yes, 0=no, 99=unknown
[__][__]
286. What treatment complications were found (if any)? (77=none) 
1=yes, 0=no, 99=unknown
[__][__]
287. In addition to TB, did the PWTB suffer from any other 
comorbidities? 
1=yes, 0=no, 99=unknown
[__][__]
288. Did PWTB receive other treatment/support beyond TB treatment? 
1=yes, 0=no, 99=unknown
[__][__]
a. IV "uids
1=yes, 0=no, 99=unknown
[__][__]
b. Corticosteroids
1=yes, 0=no, 99=unknown
[__][__]
c. Diuretics
1=yes, 0=no, 99=unknown
[__][__]
d. Bronchodilatators
1=yes, 0=no, 99=unknown
[__][__]
e. Supplementary food
1=yes, 0=no, 99=unknown
[__][__]
f. Other (describe:) 
1=yes, 0=no, 99=unknown
[__][__]
289. How long was the largest time span between clinical assessments by 
a clinician? (In hours)
[__][__] [__]
290. Were there delays in provision of medication due to stock outs? [__][__]
291. If yes, which ones? [__][__]
292. What was the length of time between when blood was drawn and 
when test results were acted upon? (in hours) 
(99=unknown, 77=not applicable if no tests or TX)
[__][__] [__]
293. Was there a need for PWTB !nancial contributions to cover the 
costs of tests and/or treatments? 
1=yes, tests only, 2= treatment only, 3= tests and treatment, 0=no, 
99=unknown, 77=not applicable
[__][__]
294. Did PWTB’s !nancial constraints contribute to delay in timely testing 
and/or treatment? 
1=yes, 0=no, 99=unknown, 77=not applicable
[__][__]
295. Was the PWTB discharged from the hospital? 
1=yes, 0=no
[__]
296. Date of hospital discharge [__][__]/ [__][__]/[__][__]
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297. What was the main reason for discharge? 
1=To receive palliative care  
2=Request of PWTB or relatives 
3=Condition allowed ambulatory treatment 
4=Transfer to another facility 
5= Other (specify)
[__]
298. What was PWTB’s weight at discharge? (in Kg) [__][__]
299. Where was the PWTB transferred?
300. Why was the PWTB transferred?
MORTALITY
301. Did the PWTB die? 
1=yes, 0=no
[__]
302. If yes, when did the PWTB die? [__][__]/[__][__]/[__][__]
303. If no, date of treatment outcome [__][__]/[__][__]/[__][__]
304. Where did the PWTB die? 
1=At home, 2=In this hospital, 3=In hospice, 4=Other health facility 
5=Other (specify)
[__]
305. What was the direct cause of death?
306. What is the source of information on cause of PWTB’s death 
1=Necropsy, 2=Verbal autopsy, 3=Clinical data, 99=Unknown, 
77=Not applicable
[__][__]
307. What was the underlying cause of death? 
1=TB, 2=Other opportunistic infection of HIV, 3=Other, 
99=Unknown, 77=Not applicable
[__][__]
308. On what basis was this determined?
309. What were the contributing causes of death?
310. Additional details that may be pertinent for performance improvement: _____________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
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Chapter 16
Stigma Scale Validation and Reporting 
of Stigma Measurement
Ellen Mitchell, Julia van den Land, and Jens Levy
Abstract
Scale validation is an important and often overlooked aspect of stigma 
measurement.  Failure to use valid stigma scales undermines efforts to measure 
and evaluate interventions to reduce stigma. This chapter breaks down stigma 
scale validation procedures into sequential steps. Psychometric testing can be 
daunting because the concepts are abstract, there is a lot of poorly de!ned 
jargon, and the mathematics are sophisticated. This chapter demysti!es scale 
development. Short, valid stigma instruments can be built following the steps 
outlined in this chapter.
Objectives
1. To explain how to develop and test stigma scales.
2. To empower researchers to validate existing scales in new settings. 
3. To guide measurement reporting.
Target Audience
This chapter is for people who need to pilot existing scales or develop their own 
stigma scales. The chapter is pitched to social scientists and epidemiologists, and 
assumes mastery of the material in the introductory chapters. 
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Introduction
There are many valid TB stigma scales available. However, a lack of validated 
tools for each type of TB stigma means that new scales occasionally must be 
developed, or an existing scale shortened. If you must validate a scale, commit 
to the whole process.1 The validation of a new tool is a formal psychometric 
technical process. 
Validation of a tool cannot be accomplished via a meeting of diverse 
stakeholders, a set of small pilots, or qualitative interviews in different settings. 
Scale development should be undertaken in partnership with researchers with 
quantitative psychology, sociology, and epidemiology backgrounds. 
It is challenging to measure stigma in a scale, so there must be a balance 
between capturing nuances and creating a usable tool. Follow the formative 
research steps in Chapters 1, 2, and 3 to identify domains and drivers before 
attempting to develop items for a scale.
Trying a broad range of items in the pilot phase helps trim the scale. Crafting 
an instrument that is as short as possible while reliable and valid is the major 
challenge of any scale development exercise.2
Stigma is a latent construct, meaning it cannot be measured directly, like 
empowerment, social deprivation, vulnerability, or intelligence. While we can’t 
see latent constructs, we can measure their manifestations. For example, people 
who stigmatize have tendency to exclude, avoid, blame, label and stereotype 
people with TB.
Steps in Scale Development and Validation
1. Phase 1: Survey Development to ensure content is valid (see chapters 1, 2, 
and 3.)  
2. Phase 2: Pilot to assess construct validity. This is an initial pilot of the 
survey to assess the psychometric characteristics of a draft scale; and its 
interpretation by end-users through cognitive interviews.
3. Phase 3: Validation to characterize the underlying structure (domains) of the 
scale, and to assess the comparative performance against other scales and 
related constructs. 
4. Phase 4: Revision. This is the removal (trimming) of scale items that do not 
perform well to get the minimum number of scale items that to capture the 
domains of stigma. 
A quality scale has eight 
features:
1. Content validity.
2. Internal consistency.
3. Criterion validity.
4. Construct validity.
5. Reproducibility 
(Agreement, 
reliability.)
6. Responsiveness.
7. No "oor and ceiling 
effects.
8. Easy to interpret. 
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The scale validation 
literature can be confusing 
because authors use 
different jargon to describe 
the same idea (e.g., 
domains, factors, and 
latent variables.) Do not 
let the lack of consistency 
be distracting. 
Phase 1: Survey Development
Selecting types and domains
This is a formative phase, using qualitative methods (in-depth interviews) to 
identify the main dimensions or domains of stigma to be measured and the 
mechanisms (drivers) by which it functions. This is covered in detail in Chapter 3. 
Developing items for a scale
Items should be relatively brief and the language simple and familiar to the 
target participants.3 Avoid double-negatives (e.g., “I am not concerned when my 
MDR-TB patient does not wear a mask” and double-barreled items which may 
measure two different constructs (e.g., “My TB-colleagues are dedicated and 
hardworking”) these create confusion.3 A clear item would be “I am concerned 
when my newly diagnosed MDR-TB patient does not wear a mask.”
Develop positive and negative items to overcome acquiescence responses (e.g., 
when respondents read only the !rst items and infer the direction of the rest.) 
Wording of survey items is particularly important because lack of attention can 
undermine the utility and validity of the TB scale.  
When you are developing a scale to pilot, you must test an instrument that is 
longer than what you want to end up with. Experts generate at least !ve draft 
items per stigma domain to pilot, so that one or two items can be trimmed 
during validation.4 
To properly validate your stigma scale, you will need to evaluate its performance 
in eight aspects. Then will it be a trustworthy re"ection of stigma.
. 
Figure 1. Eight aspects of stigma scale performance evaluation
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In the following sections we de!ne each term of the eight aspects of stigma scale 
performance, provide practical methods for ensuring it’s ful!lment, and discuss 
methods to test if your scale has the desired features. First, we will introduce 
some of the statistical methods that are commonly used to evaluate several of 
these features of scale development.
Analytic methods for survey development
Factor analysis is a statistical method of characterizing the variability of 
correlated factors to identify a set of items that belong to underlying unobserved 
constructs (domains). The goal of factor analysis is to reorganize the data and 
reduce the number of items so that your scale captures the maximum amount of 
information from the piloted items. 
The statistical approaches to be performed on your pilot data set will depend 
on how your items were chosen. The statistical aspect of scale validation can 
be confusing because the same statistical method, con!rmatory factor analysis 
(CFA), can be used for different validation tasks.
It is beyond the scope of this chapter to teach this process in a step-by-step 
manner. A statistician with clinimetric or psychometric skills should be involved in 
scale validation. We present an overview of what assessments should be made 
and why, and provide links to key educational resources for further elaboration.
A particularly useful statistic that is applied to measure internal consistency is 
Cronbach’s alpha (_) reliability coef!cient. This is the proportion of the total 
variance of a scale score that is attributable to the underlying shared variation 
that re"ects domains. 
This source of variation is distinct from random errors associated with the 
individual variables of the scale, which are uncorrelated among the different 
elements. The value of _ can fall between 0 and 1, which corresponds to 
absolutely no commonality (complete independence) between the variables in 
the scale and perfect commonality, re"ecting a redundancy among the variables 
in the scale. 
Factor analysis is therefore a valuable statistical tool for scale development to 
characterize latent constructs, such as stigma. 
Exploratory Factor Analysis
There are different kinds of factor analysis as it relates to scale development. 
Exploratory factor analysis (EFA) is factor analysis employed speci!cally to 
identify the underlying relationships between measured variables when a 
researcher has no pre-conceived hypothesis about these relationships. 
A useful statistic to 
measure internal 
consistency is Cronbach’s 
alpha (_) reliability 
coef!cient.
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This analysis is useful when the underlying construct of the domains is not 
already well characterized. In EFA, this methodology determines the number of 
factors (if any) there are among a set of variables. Exploratory factor analysis is 
therefore a data reduction methodology which notably overlaps with principle 
component analysis (PCA).
EFA involves taking a set of items and constructing a correlation matrix (for 
variables that are not on the same scale like sex and Likert scale) or a variance-
covariance matrix (for items with the same scale, e.g., a Likert scale between 
0 and 7). Operating under the assumption that there are as many factors or 
domains as there are items, a series of linear combinations of all of the items is 
generated to de!ne each factor. The statistical software starts with selecting the 
factor that explains the largest amount of variance in the sample, and assigns a 
weight to it. 
Subsequent factors or domains are successively evaluated and weighted to 
express the largest amount of variance in the sample uncorrelated with previous 
factor(s). In other words, each successive factor evaluated is uncorrelated with 
and explaining less variance than previous factors. Each factor captures a certain 
amount of the overall variance, and the factors or domains are ranked in order of 
the amount of variation they explain. 
How much variance the factor explains is measured by the eigenvalue. If a 
factorial structure exists in the data, most of the variance is explained on the 
basis of the !rst factors or domains. Thus, any factor with an eigenvalue of more 
than 1 explains more variance than a single observed variable. A factor with an 
eigenvalue of 2.3 would explain as much variance as 2.3 items. 
Principle Component Analysis vs. Exploratory Factor 
Analysis
Exploratory factor analysis and principle component analysis are similar. Both 
methods !nd the components (factors or domains) that are a linear combination 
of the original items that summarize the data based on the trade-off between 
simplicity (i.e., we want as few factors or domains as possible) and completeness 
(we want to explain the variation in the data as ef!ciently as possible). 
PCA tries to account for all the variance of all of the items, that is, PCA utilizes all 
of the variance associated with the elements with as few mutually independent 
underlying factors or domains as possible. Factor analysis, on the other hand, 
seeks to explain the independent underlying factors or domains with only as 
much variance that is shared among items, discarding the remaining as error. 
Factor analysis aims to reduce the scale to only the factors that relate to the 
latent variable that we are interested in (i.e., stigma).
. 
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Figure 2. Visualizing the differences between factor analyses
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Con!rmatory Factor Analysis 
Another kind of factor analysis relevant to scale development is con!rmatory 
factor analysis (CFA). This is a multivariate statistical methodology to verify 
that a relationship exists between observed items and their underlying latent 
constructs. The primary statistical tool used to perform CFA is structural equation 
modelling (SEM). CFA is a special case of SEM in which domains are modeled as 
covariances/correlations rather than as structural relationships (i.e., regressions). 
In other words, factors or domains are not assumed to directly cause one 
another. In comparison, other SEM methodologies specify that particular factors 
or domains are causal in nature. 
In contrast to EFA, CFA assumes you have a prior understanding of the number 
of factors or domains and what items will feed into each factor. This knowledge 
may come from published !ndings of earlier factor analyses that have been 
validated. Some of the most common uses of CFA include scale validation, 
construct validation, and evaluating measurement invariance. This is a necessary 
tool for measuring stigma.
Using existing theories or empirical research, specify an underlying ‘model’ that 
represents the relationship between your scale items and the underlying domains 
that you seek to measure. Using CFA, you will test whether the data !t your 
hypothesized domain structure or model. (See Figure 7 for an example of an 
underlying domain structure of a scale.) 
A scree plot can help you determine how many domains you have in your scale.
Several statistical tests 
determine whether the 
data !t the hypothesized 
measurement model:
t The chi-square 
test evaluates the 
difference between the 
observed and expected 
covariance matrices. 
t The comparative 
!t index (CFI) is a 
discrepancy function 
adjusted for sample size. 
t The Root Mean Square 
Error of Approximation 
(RMSEA).
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Figure 3. A Scree plot of eigenvalues
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1. Ensuring and Assessing the Content Validity of your 
Scale
Content validity is the evaluation of whether a measure fully represents the 
construct, that is, whether it measures what you want it to measure. 
Items in TB stigma measures should be understood by and be relevant for 
as many respondents as possible. The percentage of ‘missing values’ and 
respondents that use the categories ‘don’t know’ should be as low as possible. 
If questions are fully understood, it is acceptable to have less than 20% 
missing values and/or less than 20% of the respondents answer ‘do not know.’ 
The content validity of a scale can only be ensured if the scale items are 
derived from the formative !ndings of ethnographic, qualitative work (see 
Chapters 3 and17) Social validity can only be ensured via an inclusive process 
and early, meaningful engagement of the target populations (Chapter 1) 
People affected by TB have a key role to play in the development of items and 
tools. They can help make sure that the tool has content and social validity 
(i.e., is linked to the reality of their experiences).5–7 The social validity of a TB 
stigma tool depends on the technical contributions of people who know what 
TB stigma feels like.8
Content validity is assessed via cognitive interviews.
Cognitive Interviews
During the pilot, the trained research team should recruit, consent, and 
conduct the survey with cognitive interviews in national and/or local 
languages. 
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Cognitive interviews use a combination of both the think-aloud and verbal 
probing techniques to better understand how respondents interpreted the survey 
items.9 Cognitive interview sessions may be audio-taped so discourse can be 
analyzed and revisited by multiple investigators. 
 
The purposes of cognitive interviews are to:
tAssess the understandability of the individual questions to a broad range of 
interviewees – including variation in gender, work cadres, and seniority.
tAssess the interpretations of the questions by the interviewees, including the 
direction of the underlying facet or construct being measured.  In other words, 
do the questions really measure what we think they are measuring?
t Identify questions that are too vague or ambiguous as to cause analytic and 
interpretive challenges later.
tAssess the feasibility of obtaining valid data through the chosen methodology 
(e.g., administration, directed observation, or interviews) among the target 
population.
The cognitive interview guide will contain probes that try to con!rm if the items 
tap into the desired stigma domains and if they are understood. The interviewer 
tries to mentally recreate the environmental and personal context to reveal the 
cognitive process of responding to the items.9 
Ask respondents:
tHow did you decide to answer (a) question 17? Please walk me through the 
mental steps you took to get to your answer?
tWhat do you think they are really asking in question 4?
tWhat did you think of when you saw the word ‘excluded’? Can you give an 
example of excluding someone?
After each cognitive interview, detailed notes should be generated on any 
problems. Based on these results and pilot survey responses, the research team 
will reformulate survey items that are confusing.
2. Ensuring and Assessing Internal Consistency of Your 
Scale
Internal consistency reliability concerns how individual items relate to each-other. 
Here is an example of a DR-TB stigma scale with three subscales or three 
domains: fear, disgust and blame. 
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Figure 4. The Underlying structure of a TB stigma instrument
The principle statistic to evaluate the internal consistency of a scale is the 
Cronbach alpha (_) reliability coef!cient. The statistic varies between 0 and 
1 and describes the interrelatedness of items within a test. In other words, 
it re"ects how well items collectively capture the same singular construct. If 
the Cronbach’s _ increases when an item is dropped from the scale, it implies 
that the speci!c item is probably not a good !t for the scale of TB stigma. The 
Cronbach’s _ should be calculated for the whole scale and each sub-scale.
A scale with a Cronbach’s _ of >0.70 is considered minimally consistent, 
and it therefor has acceptable reliability of the scale and can be used for 
further analysis.10 Values between 0.70 and 0.80 are moderate-to-good, and 
above 0.80 good-to-very good. Conventional wisdom is that the minimum 
acceptable value is 0.70. However, _ tends to increase with more items added 
to the scale, so brief scales with Cronbach’s _ slightly lower than 0.70 may 
also be valid. The acceptable cut-off for Cronbach’s _is a function of how 
complex the construct is. Some types of TB stigma are complex constructs, and 
therefore a _ of slightly below 0.70 is not categorically disqualifying.
While a scale’s Cronbach’s _ coef!cients may be improved by excluding one 
or two items, retain topics that a TB-affected population rate as ‘important’ or 
even ‘actionable’ even if psychometrically they don’t enhance the scale. The 
item reduction process should balance content and construct reliability.
3. Ensuring and Assessing Criterion Validity (e.g., 
Congruence with a Gold Standard)
If a new stigma scale is valid, it should give similar results to well-established 
stigma measures. It is important to assess the congruence of a new scale 
with validated stigma scales (where they exist).8 For example, if you were 
developing a new scale to assess MDR-TB stigma among health care workers, 
you might consider including the Wouters TB stigma scale for HCW11,12 for 
comparison during the pilot.
TB StigmaComplex social construct:
Domains/constructs/factors sub-scales:
Items:
Fear
Q1 Q7 Q3 Q4 Q5 Q9 Q2 Q6 Q8
Disgust Blame
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Criterion validity is the correlation of the stigma score results with the results of 
a reference standard (or other representation of the construct) when both are 
applied to the same sample. The correlation with the gold standard should be 
at least 0.70 to conclude that the new tool has criterion validity.8
Figure 5. Criterion validity is the comparison of a new tool with an established one
4. Ensuring and Assessing Construct Validity
Construct validity refers to the theoretical relationship between the behavior 
of the scale and the underlying construct (stigma). In other words, it aims to 
capture the extent to which a set of items aligns with other relevant conditions 
that you believe are linked to stigma. These are consequences of stigma, such 
as depression, negative coping, self-ef!cacy, etc.  
Measurement of the external construct validity examines the relationship 
between the different subscales and relevant correlates. For example, one can 
assess whether a respondent’s internal stigmatizing attitudes are negatively 
correlated with respondent’s mental health. 
A good stigma scale should relate to patient-relevant outcomes. Measure 
conditions or constructs that you expect to co-vary with stigma.8 These might 
include health-related quality of life, burn out, depression, and negative coping 
behaviors.13,14 Self-ef!cacy, social support, and self-esteem are constructs 
expected to be inversely correlated with TB stigma, so it is strategic to 
include some validated scales that measure these constructs and to verify the 
relationship between them.13,14
If you want to develop a new scale to measure stigma in TB patients, 
assess construct validity by comparing your results with scales that measure 
constructs that you think are affected by stigma, such as:
1. The Ryff Scales of Psychological Well-Being15, 16
2. Mason TB Treatment Ef!cacy Scale17
Performance of
your draft
stigma scale
Performance of
a validated
stigma scale
When creating the item 
pool, it is handy to group 
domains (also called sub-
scales) together to ensure 
a suf!cient minimum 
number of items in each 
domain.
However, when the scale 
is eventually !nalized, the 
items should be re-ordered 
so domains are not 
clustered.
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Researchers building a scale to measure the stigma felt by health care workers 
usually test the construct validity of their new scale by correlating scores with 
the Maslach burnout inventory (MBI) scale (described in Chapter 8). Feeling 
discredited for treating patients with TB can covary with burnout.18 Terwee 
et al. state that construct validity has been established if at least 75% of the 
hypothesized relationships are borne out.8
Construct validity can be assessed two ways. Factor analysis can identify sets 
of items that are related and therefore likely to measure the same construct 
while excluding items that may be unrelated. Conduct principal component 
analysis or exploratory factory analysis to determine if your items form one 
single scale or if there are sub-scales (constructs, domains, or factors.) If 
you choose your items from existing validated measures or based on pre-
speci!ed domains, then use con!rmatory factor analysis (CFA). 
 
First, assess the internal construct validity for each scale. This ensures that 
those items that do not successfully load above > 0.40 onto the respective 
theoretical stigma domain, or those that are not measuring the same construct, 
will be removed from the scale. After deleting items that do not suf!ciently 
load onto a certain factor, the scale should display a good !t onto the factor 
and an increased internal reliability. 
Any particular item in a scale may contribute to more than one underlying 
factor (i.e., stigma domain or component). That is, the variable loads onto 
more than one factor.
For example, agreement with “TB patients make me uncomfortable” could 
load on a sub-scale of items about the fear domain and a sub-scale of items 
about disgust domain. An item that does not clearly sit in a single domain is 
not a good one for your stigma scale. 
Figure 6. Example of a relationship to assess construct validity of a scale
Psychological
Well-Being
is higher
TB Stigma
is lower
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To properly identify speci!c factors or domains (e.g., blame or shame), it 
is sometimes necessary to employ techniques called factor rotation (either 
orthogonal or oblique rotation.) It is beyond the scope of this guidance to 
teach these skills, which often require a sophisticated grasp of statistical 
methods.
After item reduction, social scientists believe there should always be a 
minimum of three items per domain in the trimmed !nal stigma scale. 
Otherwise, the scale will be “over identi!ed” when you perform a factor 
analysis.4 A model is considered identi!able if it is theoretically possible to learn 
the true relationships among the model’s underlying constructs after obtaining 
an in!nite number of observations from it. 
Models that are “identi!ed” are those where the items can cluster in a single 
perfect !t. Those that are ‘over identi!ed’ have multiple equally “right” 
Figure 7. An example of a factor structure of individual items in a scale and their relationship to 
speci!c stigma domains (components)19
Personalized
stigma
Disclosure
concerns
Concerns about
public attitudes
Negative
self-image
0.73 24. People avoid touching me if they know I 
      have HIV
29. People I care about stopped calling after 
      learning I have HIV
36. Have lost friends by telling them I have HIV
4. Telling someone I have HIV is risky
6. I work hard to keep my HIV a secret
17. I am very careful whom I tell that I have HIV
9. People with HIV are treated like outcasts
10. Most people believe that a person who has 
      HIV is dirty
20. Most are uncomfortable around someone 
      with HIV
2. I feel guilty because I have HIV
3. People’s attitudes about HIV make me feel 
    worse about myself
7. I feel I’m not as good as others because I have 
    HIV
0.93
0.88
0.88
0.86
0.77
0.78
0.81
0.77
0.74
0.84
0.75
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answers (i.e., the survey items can be sub-divided into different domains with 
equal statistical soundness). When there is more than one right answer, it can 
be hard to explain the relationships between two constructs (e.g., “TB stigma” 
and “treatment adherence”).
Phase 2 - Piloting a draft instrument 
A rigorous pilot of the draft scale assesses the performance of individual 
items as well as the psychometric properties of the sub-scales.8 A pilot phase 
should involve both quantitative and qualitative methods. The wording and 
structure of the survey instrument must re"ect the terms and framings used by 
respondents to describe their experiences and behaviors.20 
Below is an example of the structure of a stigma survey instrument that 
KNCV built to measure DR-TB Stigma among DR-TB patients. It captured 
!ve different types of stigma. Under each type of stigma, there were several 
domains, each of which was measured via several items distributed throughout 
the instrument.
DR-TB
Stigma Scale
DR-TB
self-stigma
DR-TB
perceived stigma
DR-TB
discrimination
Stigmatizing
side effects of
DR-TB treatment
Interpretation of
infection control
measures as
stigmatization
a. Self-blame (3 items)
b. Self-isolation (3 items)
c. Shame (3 items)
d. Hopelessness (3 items)
e. Self-ef!cacy (3 items)
f. Countering, 
   de"ection (3 items)
a. Danger/Fear (3 items)
b. Gossip (3 items)
c. Disgust (3 items)
d. Blame (3 items)
e. Social exclusion,
    avoidance (3 items)
f. Micro-agressions - 
   naming, shaming
   (3 items)
a. Infringement of right
    to care (2 items)
b. Infringement of right
    to privacy (2 items)
d. Infringement of 
    employment or 
    housing rights
    (2 items)
a. Mental health side
    effects (3 items)
b. Physical side effects
    (3 items)
a. Masking (as deductive
    disclosure, shame 
    (3 items)
b. Separation (as
    exclusion) (3 items)
c. Direct observation
    of treatment (as 
    distrust) (3 items)
Figure 8. Five DR-TB stigma scales with different domains per type and number of items 
(questions) per domain
5. Reproducibility (Agreement, Reliability)
Reproducibility can be broken down into two types: agreement and reliability. 
Reproducibility ensures that when a scale is used twice, for example, in pre/
post evaluation, any difference re"ects real changes and not measurement 
noise. Sometimes this is referred to as ‘test retest validity” or “longitudinal 
validity”. 
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The reproducibility of the tool should be measured by surveying a sub-sample 
twice. One or two weeks is suf!cient time gap to measure inter-individual 
reliability.8 A sub-sample of 50 people is considered suf!cient for a test-re-test 
reliability assessment.8 Bland and Altman recommend that one report it as the 
mean difference in score of repeated measures ± 1.96 x standard deviation of 
the difference.8
Reliability is most often measured using the interclass correlation (ICC) for 
agreement. Employ a weighted Cohen’s kappa for ordinal measures, and 
avoid statistics that do not account for systematic differences (e.g., Pearson’s 
correlation coef!cient.)8
6. Responsiveness
Responsiveness is the ability of a scale to measure relevant changes over time. 
A good stigma scale should be suf!ciently nuanced to measure reductions 
or increases in stigma that are the result of exposures. This is especially 
important when a scale is developed as part of a baseline in advance of a 
stigma reduction intervention. If your goal is evaluation of a stigma reduction 
intervention, we recommend gearing the items in any stigma scale toward 
inclusion of stigma domains that are susceptible to intervention. It makes little 
sense to measure TB stigma domains in great detail if they are immutable or 
beyond your locus of control. 
The responsiveness of the scale is the tools’ capacity to detect shifts that have 
occurred as a result of exposure to the intervention. An ROC (receiver operator 
curve) is often used to measure responsiveness compared to a gold standard 
and an adequate agreement is an AUC (area under the curve) of 0.70.8 If the 
pilot of the tool shows low responsiveness, then you may consider adding 
additional response categories to tease out more distinction.
Response categories
Another issue is the optimal number of response categories for an item. The 
most commonly used response formats are !ve- or seven point Likert scales 
(Table 1.) Hinkin (1995) concluded that !ve to seven response categories are 
adequate for most items.21 Respondents tend to prefer seven categories.22 The 
more categories you provide, the greater your ability to capture subtle shifts, 
which is crucial if your scale will be used as part of a baseline prior to a stigma 
reduction intervention. Ensuring enough categories increases the power of the 
scale to detect small improvements and helps prevent "oor and ceiling effects.
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Please indicate the extent of your 
agreement or disagreement with the 
following statements:
How often…? How true is…?
Strongly disagree Never Completely false
Disagree Rarely False 
Somewhat disagree Occasionally  Somewhat false
Neutral Sometimes Neutral
Somewhat agree Usually  Somewhat true
Agree Frequently True
Strongly agree All the time Completely true 
Visual analog scales (VAS), numeric rating scales, and verbal rating scales (VRS) 
of different lengths are all possible response types which may work for lower 
literacy populations. A thermometer is a commonly used visual analog scale for 
measuring attitudes.
Faces are also a commonly used visual for depicting the range and intensity of 
feelings.
Start
1
1 2
2 3 4 5 6 7 8 9 10
3 4 5 6 7 8 9 10
Start
No Pain Extreme Pain
1 2 3 4 5
Figure 9. Example of visual analog scale
Figure 10. Example of visual analog face scale to measure feelings or agreement
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7. Floor and Ceiling effects
To assess the "oor or ceiling effects (aka skewness) of the responses to your 
scale you should chart and report the distribution of scores. We would like to 
see fewer than 15% of responses in the highest or lowest category.8 If you 
have more than 15% of responses in the extremes of the scale, it suggests that 
the scale does not measure the full range of the concept well enough.
When four-point Likert scales are used, there is a possibility that 90% or more 
of the respondents are only using one category. So if an item tends to always 
evoke one of the most extreme values (1 or 5 on a 5-point scale), one could 
consider removing this item from the tool, since there is no room for variance. 
8. Interpretability (“So what?”)
A good stigma scale should have scores that predict outcomes of interest. With 
a new scale, you should aim to provide end-users with information on how to 
understand the results. Describe the mean score and standard deviations for 
subpopulations, including gender, age, and other sociodemographic groups if 
you expect the score may vary by these characteristics. If you can discern the 
minimally important difference (MID) in the scores that are linked to people’s 
relevant outcomes, describe them. Often in a new scale, it is not yet clear how 
improvements in the stigma score are linked to improvements in people’s lives. 
If major problems with the instrument are discovered during the pilot phase 
(2), the tool should be substantially revised and the pilot repeated.
Sample Size of the Pilot 
There is no scienti!c rule for calculating the sample size of the pilot, but include 
a minimum of !ve to ten respondents per item being piloted, with a minimum 
sample of 100. In the hypothetical case of the 20-item stigma scale, the 
number of respondents in the pilot would be between 100 and 200. Enough 
tools should be tested until at least 30 respondents report some stigmatizing 
attitudes or behaviors. The more respondents in the pilot the better.
Sampling Strategy
As the goal of the pilot is to identify problems, rather than making estimations 
or causal statements, do not randomly draw a sample. It is better to aim for 
diversity and ensure the sample includes those with lower than average literacy 
and numeracy, as well as those for whom respondent burden (e.g., time of 
administration) is a barrier to participation (i.e., health care providers.)
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A purposive sample is useful for the qualitative component of the pilot. At least 
one quarter should be respondents who may experience self- administration 
challenges (e.g., those with low literacy levels, elites, elderly, etc.)
Survey Interviewers
Experienced interviewers are preferred over medically quali!ed staff, as the 
latter may be too intimidating or directive in their mode of questioning. 
Moreover, families may be reluctant to be candid about items related to 
discrimination or non-compliance in the presence of senior medical staff. It 
is vital to ensure that those collecting data cannot be drawn into possibly 
controversial discussions, which may result in bias and con"ict of interest. 
Other factors in"uencing the interviewers include mobility, acceptability, and 
availability.
Interviewer Training
PATH has developed two curricula that can be adapted and used for training 
survey staff. The !rst builds skills in assuring privacy and con!dentiality for 
providers. It was intended for reproductive health care providers, but the 
main principles are applicable to interviewing on any sensitive topic, including 
stigma. Please see: 
Ensuring Privacy and Con!dentiality in Reproductive Health Services: A 
Training Module and Guide. For Service Providers
http://www.path.org/publications/!les/RH_ensuring_privacy.pdf 
The second curriculum is aimed at improving health workers’ TB 
communication and counseling skills, and some of the exercises can be used to 
strengthen data collector’s non-verbal communication skills. See: 
Interpersonal Communication and Counseling for Clients on Tuberculosis and 
HIV and AIDS. PATH, 2009: 
http://www.path.org/publications/detail.php?i=1770
Details of your formative work, your item and scale development, item 
generation and reduction, and the engagement of end-users in the pilot 
process should be fully described in your scale validation report. 
Conclusion
While it is not generally necessary to develop a new stigma scale, it is always 
necessary to pilot one. In this chapter we have de!ned the procedures for 
developing and validating a TB stigma scale. We have speci!ed the correct 
statistical approaches and provided practical examples. The steps in this 
chapter will help researchers avoid common pitfalls in stigma measurement.
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Chapter 17
Analyzing Qualitative Data
Amrita Daftary, and Gill Craig
Abstract
There are many approaches to qualitative research, which, although systematic, 
requires "exibility and an iterative approach to developing codes and themes 
derived from participants’ own words. Many researchers draw on concepts 
developed in grounded theory to analyze their data, but grounded theory 
may not be practical in non-academic settings. We offer an alternative that is 
increasingly used in policy contexts. The framework approach involves the in-
depth analysis of a subset of interviews to develop a coding framework which 
can later be applied to all transcripts. This also allows for a teamwork approach 
to analysis once the framework has been agreed upon, tried, and tested. 
Although software packages are available to help researchers store and manage 
their data, licenses are expensive and it can be time-consuming to learn. The 
framework was initially developed as a means to analyze data without software. 
In this chapter, we also discuss a variety of approaches to evaluating the quality 
of qualitative research, which includes, but is not limited to, critical appraisal 
tools. Transparency and accountability in reporting of the qualitative research 
processes are crucial, including the perspective of researchers and their role and 
investments in the research.
Objectives
1. To explain how to conduct qualitative data analysis
2. To reinforce techniques for enhancing the quality of qualitative research
Target Audience
This chapter is for everyone engaged in the qualitative exploration of stigma 
who wishes to strengthen the rigor and depth of the analysis.
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Introduction
There are many approaches to analyzing qualitative data and most begin with 
the reading of the transcripts of participants to understand their views in their 
own words. Ways in which people talk about illness, for example, can reveal a 
lot about the meanings they attach to their experiences. We brie"y discuss some 
approaches to qualitative data analysis and thereafter focus on the Framework 
method as a feasible and useful way to identify and examine the drivers and 
dimensions of TB stigma. We conclude with strategies to enhance the quality 
of qualitative data interpretations. These strategies should be adopted and 
integrated into the research process from the study outset, and not simply during 
analysis and write-up.
Analyzing qualitative data
Many researchers borrow from principles developed in grounded theory 
during their analysis, which encourages researchers to identify concepts and 
themes directly from participants’ words and/or !eld observations.38 Under 
pure grounded theory, any preconceived ideas about stigma drawn from the 
literature and presumptions about TB stigma are bracketed to allow for theory 
development (understandings of stigma drivers and dimensions) to emanate 
strictly from the data.
Grounded theory researchers accomplish this through a process of theoretical 
sampling (collecting data which helps to build a theory and prove or disprove 
it, as described in Chapter 3), and constant comparative analysis (drawing 
comparisons across and between different portions of the data, to identify 
underlying patterns or themes that may be re!ned and contextualized through 
subsequent readings of the data, discussed later in this chapter).48,62 
Grounded theory, however, can be dif!cult to practice in TB stigma studies, as 
this research will likely be informed by earlier understandings of stigma from the 
outset. Grounded theory can also be time-consuming because successive cycles 
of data collection and analysis might trigger the need for additional data and 
new interviews to build the theory. In many settings, this form of iterative data 
collection and analysis is not feasible.
Qualitative researchers may also draw on social theories around stigma from the 
literature to guide and re!ne their analysis. For researchers who have the interest 
and resources to adopt this in-depth critical approach, we recommend using the 
references in Chapter 3 to guide analytic interpretations. 
Given the resource intensiveness of these traditional approaches to qualitative 
data analysis, we recommend another approach that borrows on the basic 
principles of grounded theory which may be helpful to !eld researchers.
The qualitative analyst 
must use re#exive practice 
to ‘read between the lines’ 
and move from realist 
interpretations to in-depth 
critical interpretations
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Framework method of analysis
The Framework method of analysis is one approach to data management that 
is becoming increasingly popular in social policy research.63-65 Unlike other 
approaches, it does not have a philosophical underpinning or theoretical 
approach. It is "exible and allows for teams to work collaboratively on qualitative 
data interpretation. The stages are as follows:64
Transcription: Audio-recordings or observations are transcribed and, if 
applicable, translated. Transcripts have wide margins to allow for line numbering 
and labeling themes. The goal is to capture the content of the interview or 
focus group, including attention to emotional outbursts or conversational 
tone, but with less attention to details such as pauses or overlapping speech. 
The researcher should allocate adequate time for transcription and, if needed, 
translation.
Familiarization: The researcher becomes familiar with the data through 
successive readings of the transcripts, especially if the researcher was not directly 
involved with data collection.
Coding: The data gets sorted by breaking it down into smaller segments that can 
be paraphrased or labeled with a code. This is done by identifying the meaning 
of and asking questions about the data. Codes may re"ect comments, keywords, 
ideas or concepts, incidents, or events. Once a code has been identi!ed, it 
can be labeled with a meaningful name. The code may be open (based solely 
on ideas emerging from the data) or closed (based on ideas developed within 
literature reviews). Open coding is encouraged during initial stages to ensure 
interpretations more closely re"ect the participants’ voice.66 The researcher will 
then look for more instances of this code across different interview transcripts 
using a process of comparative analysis. 
Developing themes: Codes that describe similar concepts or ideas can then 
be grouped together to form categories or themes. Categories are groups of 
codes that re"ect similar events, ideas, or comments and help to describe the 
phenomenon under investigation. The researcher may re!ne or change the 
codes with repeated readings of the transcripts and through comparing the “!t” 
of the code in relation to other instances. An “other” code within each category 
can allow researchers to retain codes that do not !t with the emerging analytic 
framework.
Developing a thematic framework: A thematic framework is developed 
through indexing emerging themes or categories identi!ed from a subsample 
of transcripts. Depending on the number of interviews or focus groups, 
the researcher will select a smaller number on which to base their thematic 
framework. The idea is not to select the !rst few interviews, but to choose a 
“The Framework method 
walks qualitative 
researchers through 
the iterative process of 
coding, thematic analysis, 
charting, mapping and 
interpretation.”
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broad range of interviews to ensure that the framework is based on rich data 
and re"ects a wide range of experiences. If this is being done as a team, then the 
researchers should meet to compare and re!ne their codes. 
Below is an excerpt from a codebook that was developed for analyzing stigma 
domains.
Table 1. Stigma Domains Codebook
Code (Domains) De!nition Example Notes on Application
Fear of transmission Worries about becoming 
infected, precautions 
taken, beliefs about 
infectiousness.
 “We could have all 
gotten it from her.”
Do not apply to general 
fears (use peril code 
instead).
Peril/dangerousness Statements, ideas, 
notions about risks posed 
by PWTB, including 
dangers posed by 
unpredictability and 
irrationality.
“..They become crazy 
on those medicines…”
Do not apply to 
transmission fears (use 
fear of transmission 
code).
Positive stereotypes Any positive traits 
ascribed to PWTB.
“He could barely walk 
and he still came.”
Negative stereotype Any negative traits or 
assumptions about 
motives, behavior, 
feelings, intent, terms, 
connotations, or labels 
for PWTB.
“With proper DOT and 
guidance, they can get 
through the treatment, 
but unsupervised they 
will struggle.”
Do not apply to co-
morbidities.
Rhetorical link made 
to stigmatized co-
morbidity
References to PWTB 
having diabetes, HIV, 
alcohol dependency, drug 
dependency, hepatitis, 
nicotine dependence, etc.
“..They become crazy 
on those medicines…”
Blame/responsibility References to ‘fault’ or 
fault !nding, guilt, or 
attribution.
“I should have kept on 
with the pills, but it was 
too much for me.”
Applying the thematic framework: Once the framework has been developed, it 
is then applied to all the transcripts. Several iterations of this framework may be 
developed and ‘tested’ on the data. 
Charting: The data is charted into a framework matrix or spreadsheet, which 
brie"y summarizes or paraphrases the main analytical categories and connects 
these categories to excerpts or quotes from the interviews or focus groups (see 
Table 2). Line numbers can provide a quick cross-reference back to the original 
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Table 2. Example of charting using a framework approach
Experience of Stigma 1.1 Reaction of Others
1.2 Perceived Impact 
on Employment
1.3 Perceived Impact 
on Relationships
Participant 1 Worried what people 
would think (lines 23-
30).
Fear I would lose my 
job because I’m a 
healthcare worker (lines 
#).
Could not tell !ancée, 
assumption of bad 
blood (lines #).
Participant 2 Shocked because they 
thought only people who 
use drugs got TB (lines 
45-48).
Fear I wouldn’t be 
allowed into people’s 
homes (lines #).
Did tell husband but 
not children, fear of 
gossip (lines #).
Participant 3 Associations with HIV 
(lines 49-59).
Fear I wouldn’t get a 
job in the future (lines 
#).
Lonely, not able to tell 
anyone initially but 
then told friend (lines 
#).
data. Charting can be done using a spreadsheet in MS Word® or Excel® or for 
larger datasets.
The use of Computer Assisted Qualitative Data Analysis Software
Framework was developed as a ‘low tech’ approach to analyzing data, which did 
not require software. However, more recently software packages have become 
available which deal speci!cally with Framework (e.g., QSR NVivo). The license 
for such software packages can be expensive, and becoming pro!cient in the use 
of these packages requires training. The software only helps to store and manage 
the data, however. It does not perform qualitative analysis. The researcher must 
interpret the data while practicing re"exivity.
Mapping and interpretation: At this stage, the analyst is trying to move 
beyond description to analysis and interpretation. Table 3 illustrates how an 
analysis moves from !rst order coding with the use of labels (thin description), 
into second-order analysis (categories), and !nally into third order analytical 
categories (thick description). In this example, this highlights the social context of 
adherence and is a particular example of stigma and its intersection with gender 
and vulnerability. This process should be tested across different interviews to 
tease out further examples of adherence and stigma, gender (including men), 
and vulnerability.
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Table 3. Illustrative Example of Coding Qualitative Data (Craig et al., 2015.)67
Participant 1 Area 1 Clinic 1
1st order 
Coding: Labels
2nd order 
Coding: 
Categories
Line
Excerpt from an 
Interview with 
Immigrant TB 
Patients 
Notes on Process 
of Analysis
3rd Order 
Analytical 
Categories
Store and take 
medicines in 
secret
Acceptance 
of long term 
condition 
by relatives 
(diabetes)
Loss of 
housing and 
relationship
Disclosure 
to wider 
community 
Medicine 
management: 
secrecy
Acceptable 
illnesses
Anticipated 
stigma: 
material impact 
homelessness
Anticipated 
stigma: 
exposure 
Anticipated 
stigma: loss 
of access to 
social network 
(+material 
support)
1
2
3
4
5
6
7
8
9
I keep medication 
in a secret 
place and take 
medication at a 
secret time. 
The other illness 
(diabetes) they 
(relatives) know 
about it and 
accept it. 
The !rst thing 
I will lose [if 
diagnosis 
becomes common 
knowledge] is my 
accommodation 
and the 
relationship.
My situation 
could then be 
communicated 
to other [people 
from my country] 
who I rely on for 
help and support. 
Dif!culties taking 
medication as 
a guest in a 
relative’s house 
sleeping on a 
mattress on the 
"oor. No privacy. 
Nowhere to store 
or take medicines.
Diabetes has 
traditionally 
been seen as 
stigmatizing, but 
this is accepted. 
Why is this? Look 
for other examples 
of illness that is 
accepted.
Note impact 
of stigma has 
material effects in 
terms of the threat 
of homelessness.
Medication 
management 
governed by place 
x space x time, 
this challenges 
behavioral 
approaches to 
adherence.
Examples of 
anticipated/felt 
stigma, which 
will have material 
effects. Here, 
anticipated stigma 
intersects with 
gender and serves 
to potentially 
isolate through the 
loss of access to 
network and social 
capital. Stigma 
will render the 
women homeless 
and vulnerable, as 
they will be older, 
refugee woman.
Evaluating qualitative research 
There are many approaches to evaluating and enhancing the merit of a 
qualitative study. For example, Lincoln & Guba (1985)33 discuss quality in terms 
of reliability and validity, which they de!ne speci!cally in relation to qualitative 
research (see Table 4, noting that concepts used in conventional inquiry are 
not exactly re"ective of concepts applied in qualitative inquiry). Drawing on 
these principles, we recommend qualitative researchers embarking on TB stigma 
research consider the following strategies to enhance their work, from study 
conceptualization and data collection through analysis and write-up.
365
Table 4. Approaches to evaluating qualitative research (Adapted from Lincoln & Guba, 1985)
Conventional Inquiry Qualitative (Naturalistic) Inquiry Methods to Ensure Quality
Internal validity
Credibility – how true or 
trustworthy are the !ndings?
Prolonged engagement in the 
!eld; data triangulation.
External validity
Transferability – how applicable 
are the !ndings to other 
contexts?
Thick description of setting 
and/or participants.
Reliability
Dependability – are the !ndings 
consistent or can they be 
repeated?
Audit – researcher’s 
documentation of data, 
methods and decisions; 
researcher triangulation.
Objectivity
Con!rmability – are the !ndings 
re"ective of (grounded in) the 
data?
Audit and re"exivity.
Re#exivity: This is the ability of researchers to recognize their own values and 
in"uence (e.g., their own social and cultural contexts, positions in society, 
assumptions, experiences) on their research, as these might in"uence their choice 
of research topic, the questions they ask and the way in which they ask them, 
and how they observe, analyze, interpret, and represent the data.1,32,33 Being 
re"exive is not a passive task, where researchers simply surmise their values and 
assumptions, but rather an active task whereby researchers continuously check 
their assumptions. For example, they may consider alternative interpretations 
of the data, look for narratives that would challenge an identi!ed trend, and be 
transparent about their research decisions, including sampling strategy, line of 
questioning, coding framework, and focus on speci!c themes.
A common way to begin re"exive practice is for researchers to record their 
assumptions and investments in the research in a diary, and to use this data to 
further inform the context of their research. Such an approach recognizes that 
knowledge is co-constructed between researchers and participants (a notion that 
was introduced in Chapter 3), and lends itself to re"ecting on issues of power 
within research relationships and issues of difference between researchers and 
participants. For example, in enquiring about TB stigma, researchers should be 
cautious about misclassifying narratives as representative of stigma when these 
narratives may be more telling of related yet distinct social constructs, such as 
racism or sexism.
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Prolonged !eld engagement: Deep knowledge about the sociocultural norms 
and practices that prevail in a study setting is vital to enhance the credibility of 
qualitative !ndings.33,34 Researchers embarking on qualitative research into TB 
stigma should situate themselves in the !eld setting to familiarize themselves 
with local norms and practices, to ensure that their data interpretations are 
adequately informed by the context in which they were collected. In the absence 
of opportunities to directly immerse themselves in the !eld for a long period 
of time prior to data collection, researchers can consult with stakeholders and 
gatekeepers in the community (e.g., clinic managers, champion patients, and 
community leaders) to gain familiarity with the setting. They may also recruit 
local !eld staff to assist with data collection to ensure that social realities of 
the study setting guide interviews, questions, and recruitment strategies are 
acceptable, and study !ndings are not misinterpreted. 
Thick descriptions: Thick description35 refers to the depth of analysis that goes 
beyond super!cial descriptions of events or individual behaviors (thin) to include 
an analysis of the context that shapes and informs those events and behaviors 
(thick). The collection of rich, illustrative, personal stories that are meaningful 
to participants and exemplify their experiences with TB and stigma can allow 
readers to situate those narratives or observations to the cultural, geographic, 
and medical context. Thick descriptions allow for qualitative analyses to be 
transferred to similar, other contexts.33,36 When conducting interviews, focus 
groups, or observations, researchers should ask questions and record notes to 
produce a rich account of participants’ experiences, perspectives, and/or the 
social environment in which those experiences happen (e.g., in the case of 
observations).
Triangulation: Triangulation is the process of using multiple methods, data 
sources, analysts, or theoretical frameworks to arrive at a rich, robust, and 
comprehensive understanding of the research problem. Triangulation can 
validate !ndings, but is more useful to the qualitative paradigm. Triangulation 
helps researchers check and contextualize consistencies and differences in 
narratives and identify nuances.32,37 
For example, if interviews with patients and providers elicited similar 
understandings around trust, these data can support emerging ideas about 
patient-provider relationships and interaction quality. If providers, however, 
shared perspectives that contrasted those shared by patients, the researcher 
is pushed to question why these differences in perspective exist, and if they 
indicate the interview dynamic or level of rapport/trust established during 
data collection with diverse groups of participants, or if this difference re"ects 
a challenge encountered primarily by patients but not considered as relevant 
by health providers. Both situations can lend themselves to important analytic 
insights. Triangulation can also inform subsequent data collection (e.g., 
clinic observations may be probed in interviews with healthcare workers), as 
introduced in Chapter 3. 
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Negative case analysis: This is one of the most important practices in qualitative 
analysis, whereby inconsistencies in the data or unique cases that defy an 
emerging pattern are actively investigated.32 Inconsistencies can strengthen 
emerging theories, as they push qualitative researchers to identify when, how, 
and why the negative case (e.g., TB patients who perceive no stigma in a setting 
where stigma is commonplace) has deviated from the ‘norm’ (e.g., patients who 
encounter the typical expected experience with TB stigma). 
Constant comparison: The method of constant comparison is borrowed from 
grounded theory.38 It involves researchers checking for patterns within and across 
all interviews, developing categories, and identifying exceptions which refute 
those categories. Researchers may practice constant comparison by repeatedly 
reading and reviewing their data transcripts and !eld notes, and returning to the 
code-book, maps, and/or charts to alter codes, categories, and de!nitions. This 
allows categories to be re!ned and ensures that !ndings are not based on unique 
experiences, although these should also be reported. 
Audit trail: An audit trail entails documenting a clear process of analysis to 
enhance the con!rmability of qualitative interpretations.34,36 This includes 
documenting research decisions as well as implementation and analysis 
hurdles. For example, document how and when participants were recruited or 
observations were conducted, refusals or dif!culties, how data were transcribed 
and/or translated, how codes were developed (who was involved and how were 
points of discordance between coders resolved, how themes were identi!ed, 
contextualized, and re!ned, how negative cases were analyzed, how thematic 
saturation was assessed) and other research-related decisions and strategies. A 
like-minded researcher should be able to follow the documented steps and come 
up with a similar decision or interpretation.
Qualitative appraisal tools: Other approaches that aim to ensure rigor in 
qualitative research have different merits and disadvantages. Barbour (2001) 
talks about the danger of checklists replacing researcher judgment about the 
merits of particular approaches.39 The CASP approach to qualitative research 
appraisal is a common tool for appraising rigor. It involves asking ten questions 
(http://www.casp-uk.net/casp-tools-checklists). COREQ is a similar but 
lengthier 32-item checklist (https://academic.oup.com/intqhc/article-lookup/
doi/10.1093/intqhc/mzm042). Journal editors have also produced a variety of 
other checklists. The British Medical Journal (http://www.bmj.com/about-bmj/
resources-authors/article-types/research/editors-checklists) and The International 
Journal of Tuberculosis and Lung Disease (http://www.theunion.org/what-we-
do/journals/ijtld/body/IJTLD_Guidelines_for_Qualitative_Research.pdf) have 
checklists. 
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Conclusion
There are different approaches to analyzing qualitative data and evaluating the 
merits of qualitative research. In this chapter, we have provided an overview 
of one analytical approach adapted from the framework method, and offered 
strategies for !eld researchers qualitatively studying TB stigma to assess and 
enhance the quality of their work. 
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Glossary
Anticipated Stigma The fear of disparagement (fear of enacted stigma) even in the 
absence of having the mark (stigma).
Biogenic Explanations To situate the origin or cause of something in a biological or 
genetic frame, or to de!ne a phenomenon as organic. This is 
often a strategy to de"ect blame with stigmatized conditions.
Blame A common rhetorical framing and a domain of stigma. This 
is when responsibility for a health condition is attributed to a 
particular person, or when a causal attribution is constructed, 
whether or not it is plausible or evidence based.
Case Mix Adjuster A variable used to adjust for differences in respondents or 
facilities, so that meaningful comparison can be made.
Change Agent Any person within an institution that has enough social capital, 
respect, and leadership to catalyze new behaviors among the 
staff, through example, mentoring, advocacy or other means.
Change Process An effective change process is a recipe for selecting, adapting, 
implementing, and scaling up effective practices to achieve and 
sustain health results.
Cognitive interviewing A combination of both the think-aloud and verbal probing 
techniques to better understand how respondents interpreted the 
survey items (Haeger, Lambert, Kinzie, & Gieser, 2012).
Commitment to Change This is the determination to carry a process to the end. The 
change is complete when all program levels work together to 
continually produce desired results as they implement and support 
the changed practices. When stakeholders are committed to 
change, they don’t give up when they encounter barriers, nor do 
they stop when donors turn their resources toward other needs.
Construct validity This is the degree to which a scale measures what it claims, or 
purports, to be measuring. The internal consistency or reliability 
can then be measured by the Cronbach’s alpha (_) reliability 
coef!cient (values between 0.70 and 0.80 are moderate to good, 
and above 0.80 good to very good.)
Contact-interventions Interventions to increase knowledge and understanding of 
stigmatized persons through social contact.
Content Validity In psychometrics, content validity (also known as logical validity) 
refers to the extent to which a measure represents all facets of a 
given construct.
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Continuation Phase This phase requires a combination of two drugs to be taken 
for the !rst four months for new cases, and treatment with 
a combination of three drugs for re-treatment cases for !ve 
months.
Courtesy Stigma This is a type of secondary stigma. It is the vicarious social taint 
experienced by those who interact with stigmatized people.1 
Courtesy stigma may reduce the social standing of family, friends, 
and caretakers.
Cronbach’s Alpha Measure of the consistency between questions, or the reliability 
of a set of items (scales) for measuring the same concept. 
Cronbach’s alpha (_) is a reliability coef!cient, whereby values 
between 0.70 and 0.80 are moderate to good, and above 0.80 
good to very good.
Deconstruct To demystify a phenomenon by revealing its supporting structures 
and ideas.
Defaulter A stigmatizing word used to describe a TB patient who interrupts 
treatment or is not compliant with treatment. No longer used. 
Now called a “person lost to follow up”.
Destigmatization The process of countering the drivers of stigma through 
intervention to reduce discrimination, name calling, and feelings 
of blame and shame.
Design Effect A statistical concept that refers to the degree that a sample must 
be expanded to try to compensate for any variance arti!cially 
reduced by the study design.
Diagnostic Delay The time interval between !rst TB diagnostic test and the patient 
receiving the TB diagnosis, if it exceeds two days.
Dimension A group of conceptually similar items. See also domain.
Dirty work Employment that others regards as degrading or demeaning.2,3 
Professionals who serve the health or social needs of 
stigmatized persons may be vicariously tainted, and their roles 
are discredited in the professional hierarchy. A type of loss of 
prestige experienced by certain types of healthcare workers (e.g., 
addiction counselors, mental health professionals, and abortion 
providers).
Disclosure carryover When people are afraid of the reactions they would get if they 
were known to have TB in the past or present.
Discrimination A statistical concept unrelated to discrimination which refers to 
the scale’s ability to distinguish stigma from non-stigma.
Domain The sub-component or dimension of a complex social 
phenomenon. For stigmas, domains may refer to rhetorical 
framings, including labeling, stereotyping, cognitive separating 
(i.e., us versus them), emotional reactions (e.g., fear, shame, 
disgust), interpersonal discrimination (i.e., expected, believed, or 
experienced), and structural discrimination.4
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Enacted Stigma Behaviors designed to discredit or diminish. A synonym of 
discrimination.
Exit Interviews Interview conducted as a client is leaving a health service 
encounter to determine the quality of care before recall bias sets 
in.
Exclusionary sentiments The desires to exclude PWTB from full community participation, 
or deny them their rights.
Factor Analysis Detection of any hidden hypothetical variables, either for 
explorative reasons or for reduction of a large number of variables 
into a limited number of dimensions. This occurs by identifying 
‘unreliable’ items, with little in common with other items, and 
‘invalid’ items that do not discriminate between factors.
Focus Group Discussion A group discussion guided by a facilitator, during which group 
members discuss a certain topic. A focus group discussion is 
a qualitative method to obtain in-depth information on the 
concepts, perceptions, and ideas of a group.
Hawthorne Effect See reactivity (observer effect)
Health Seeking Delay A long time interval between initial symptoms and arrival at the 
!rst health care provider (more than 30 days.)
In-depth Interview An open-ended, discovery-oriented method that elucidates the 
mechanism, processes, and consequences of stigma. The goal is 
to deeply explore the respondent’s perspectives and to uncover 
unconscious associations.
Intensive Phase This phase of TB treatment consists of a combination of four 
drugs for the !rst eight weeks for new cases, and a combination 
of !ve drugs for the !rst eight weeks followed by four drugs for 
the next four weeks for re-treatment cases.
Item A question in a scale or survey instrument.
Label Avoidance Avoiding overt self-identi!cation with a stigmatized group.
Likert Scale The most widely used scale in survey research, which is often 
used in questionnaires. When responding to a Likert questionnaire 
item, respondents specify their level of agreement to a statement.
Microaggressions Subtle forms of interpersonal stigmatization or slights and 
denigration.
Negative affect Refers to emotional reactions toward PWTB (e.g., fear, shame, 
disgust, pity, hatred),
Normalization To create conditions where behaviors and attitudes appear 
normative.
Over identi!ed model A problem caused by a scale having too few items to represent a 
domain (e.g. social exclusion). An over-identi!ed matrix reduces 
the ability of statisticians to assess the correlation or covariance 
among the sub-scales (domains) in a scale.
Perceptions of dangerousness The idea that PWTB somehow represent a risk to society.
Physical Clue A marker behavior that may be used as an indicator for a 
particular behavior that is not observed directly.
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Probability-based sampling Any sampling method that uses simple random sampling, 
systematic random sampling, strati!ed random sampling, and 
cluster or area random sampling.
Protest A formal objection to negative representations of people with TB.
Psychometric Testing Testing the reliability and the validity of a questionnaire
Public Stigma Describes negative attitudes, beliefs, and behaviors held by the 
general public.
Reactivity ( Hawthorne effect, observer effect) The tendency of people who 
are observed to change their behavior as a consequence of being 
observed.
Referral Delay An excessive time interval between arrival at !rst point of care 
and !rst TB diagnostic test ( over one day.)
Re"exive Practice A way of conducting research that is self-critical. It queries the 
inherent biases of the researcher and how these may in"uence the 
study results.
Reliability Extent to which a result of a measurement corresponds with 
reality.
Scalability The extent to which a group of variables together form a reliable 
entity, so that they score consistently on a (Likert) scale.
Self-stigma Refers to the internalization of public stigma by a person 
(Corrigan et al., 2014). This internalization can lead to denial 
of symptoms and rejection of treatment, and may contribute to 
isolation from valuable social support.5
Semantic Differential is a rating scale in which users must choose between two 
opposites (e.g. TB patients are a) responsible or b) irresponsible).
Shame 
Skewness
The degree to which the dispersion of data departs from a normal 
distribution.
Social distancing When someone tries to avoid a PWTB.
Social Validity The degree to which an intervention or approach to a problem 
takes into consideration the wants, needs, and norms of the 
community in which it is implemented.
Stereotype 
Stigma
The relationship between an attribute and a stereotype that 
assigns undesirable labels, qualities, and behaviors to a person. 
Labeled individuals are devalued socially, leading to inequality 
and discrimination.6 For example, a TB patients is always assumed 
to be infectious, and therefore is labeled as dangerous, which 
justi!es behaviors and policies that create social distance (e.g., 
triage, separation).
Stigmatization The social process by which a condition affects the lives of all 
those who are impacted by it.
Structural Stigma Societal-level conditions, cultural norms, and institutional practices 
that constrain the opportunities, resources, and wellbeing of 
stigmatized populations. Hatzenbuehler and Link (2014).
Taxonomy Structure of a questionnaire of dimensions and items.
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The Stigma Complex The interrelated, heterogeneous system structures, from the 
individual to the society, and processes, from the molecular to 
the geographic and historical, that construct, label, and translate 
difference into marks.7
Topics Guide A check list with the main topics for focus group discussions or 
interviews. This keeps track of the research objectives while giving 
"exibility insight.
Treatment Carryover When people afraid of people knowing they were treated for TB 
in the past. This is the perceived need for secrecy that may linger 
after a person recovers.
Treatment Delay A long time interval between the date of a TB diagnosis and when 
TB medicine was dispensed to the patient, in excess of one day.
Triangulate A process of contrasting diverse sources of information and 
different data to identify divergent perspectives, validate key 
information, and explore disparities to yield a rich analysis of a 
situation.
Triangulation A process used to validate the data obtained in a study, usually 
involving alternative data sources or collection processes.
Validation Process of qualitative and quantitative testing of a set of items 
in a measurement tool to determine whether they collectively 
measure a complex social construct or not.
Value Claims Assertions designed to prove that some idea, action, or condition 
is good or bad, right or wrong, worthwhile or worthless, or 
appropriate or inappropriate according to certain preferences.
Varimax Rotation Rotation of the axes of factors to maximize the variance 
(variability) of the new variable (factor), while minimizing the 
variance around the new variable.
Voyeurism A unique form of verbal stigma in which acquaintances visit a 
person with TB, but not out of concern for the person or a desire 
to keep them company. Rather, visitors aim to observe how the 
person is faring to be able to report to others and generate gossip.
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